{"5bc01219f59c2fd45139b112a5405243d0e8a504": [["The idea of viruses as inert molecular entities has progressively been transformed since scientists began to discover the myriad of interactions that occur during the intracellular phase of virus life.", [["intracellular", "ANATOMY", 167, 180], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 167, 180], ["viruses", "PROBLEM", 12, 19], ["virus life", "TREATMENT", 190, 200], ["viruses", "OBSERVATION", 12, 19]]], ["Restricted by their own limited genetic repertoire, viruses need to use a number of cell factors for genome replication and morphogenesis.", [["cell", "ANATOMY", 84, 88], ["cell", "CELL", 84, 88], ["genome", "CELLULAR_COMPONENT", 101, 107], ["viruses", "PROBLEM", 52, 59], ["cell factors", "TREATMENT", 84, 96], ["genome replication", "TREATMENT", 101, 119]]], ["Identification of these factors is essential for understanding the virus morphogenetic processes that often take place in intracellular structures known as viral inclusions, virosomes or viral factories.", [["intracellular structures", "ANATOMY", 122, 146], ["virosomes", "ANATOMY", 174, 183], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 122, 135], ["virosomes", "CELLULAR_COMPONENT", 174, 183], ["these factors", "PROBLEM", 18, 31], ["the virus morphogenetic processes", "PROBLEM", 63, 96], ["viral inclusions", "PROBLEM", 156, 172], ["viral inclusions", "OBSERVATION", 156, 172], ["viral factories", "OBSERVATION", 187, 202]]], ["Viruses are generally thought to build these structures to recruit and concentrate viral and cell factors needed for replication and assembly; they are able to modify a variety of cell organelles and to create new inter-organelle contacts ( Fig. 14.1 ).", [["cell", "ANATOMY", 93, 97], ["cell organelles", "ANATOMY", 180, 195], ["inter-organelle contacts", "ANATOMY", 214, 238], ["cell", "CELL", 93, 97], ["cell organelles", "CELLULAR_COMPONENT", 180, 195], ["viral and cell factors", "PROTEIN", 83, 105], ["Viruses", "PROBLEM", 0, 7], ["concentrate viral and cell factors", "PROBLEM", 71, 105]]], ["In the mammalian cell, virus assembly can start inside the nucleus, in association with components of the secretory pathway (Golgi, endoplasmic reticulum or ER), at different points in the endocytic pathway (endosomes, multivesicular bodies or MVB) or at the plasma membrane.", [["cell", "ANATOMY", 17, 21], ["nucleus", "ANATOMY", 59, 66], ["Golgi", "ANATOMY", 125, 130], ["endoplasmic reticulum", "ANATOMY", 132, 153], ["ER", "ANATOMY", 157, 159], ["endosomes", "ANATOMY", 208, 217], ["multivesicular bodies", "ANATOMY", 219, 240], ["MVB", "ANATOMY", 244, 247], ["plasma membrane", "ANATOMY", 259, 274], ["mammalian cell", "CELL", 7, 21], ["nucleus", "CELLULAR_COMPONENT", 59, 66], ["Golgi", "CELLULAR_COMPONENT", 125, 130], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 132, 153], ["ER", "GENE_OR_GENE_PRODUCT", 157, 159], ["endosomes", "CELLULAR_COMPONENT", 208, 217], ["multivesicular bodies", "CELLULAR_COMPONENT", 219, 240], ["MVB", "CELLULAR_COMPONENT", 244, 247], ["plasma membrane", "CELLULAR_COMPONENT", 259, 274], ["ER", "PROTEIN", 157, 159], ["virus", "PROBLEM", 23, 28], ["MVB", "PROBLEM", 244, 247], ["mammalian cell", "OBSERVATION", 7, 21], ["virus", "OBSERVATION", 23, 28], ["nucleus", "ANATOMY", 59, 66], ["multivesicular bodies", "OBSERVATION", 219, 240], ["plasma membrane", "ANATOMY", 259, 274]]], ["Mitochondria and cytoskeletal elements are present in the factories built by many different viruses.", [["Mitochondria", "ANATOMY", 0, 12], ["cytoskeletal", "ANATOMY", 17, 29], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["cytoskeletal elements", "CELLULAR_COMPONENT", 17, 38], ["cytoskeletal elements", "DNA", 17, 38], ["Mitochondria and cytoskeletal elements", "PROBLEM", 0, 38], ["cytoskeletal elements", "OBSERVATION", 17, 38], ["many", "OBSERVATION_MODIFIER", 77, 81], ["different", "OBSERVATION_MODIFIER", 82, 91], ["viruses", "OBSERVATION", 92, 99]]]], "5c65e8b6062e0c128d74b5bb2fd698ab2ea42bfa": [["Research Highlights\u2022 BMI is strongly linked to risk for SARS-CoV-2 in hospital and COVID-19-related death among UK Biobank participants \u2022 These associations were stronger for individuals under 70 versus those over 70 years of age at time of pandemic \u2022 They were also stronger for non-whites (predominantly South Asians and Afro-Caribbean's), compared with whites.Research HighlightsWe recently proposed multiple mechanisms by which obesity/ectopic fat might enhance risk for severe COVID-19.", [["ectopic fat", "ANATOMY", 440, 451], ["SARS", "DISEASE", 56, 60], ["death", "DISEASE", 100, 105], ["obesity", "DISEASE", 432, 439], ["COVID", "DISEASE", 482, 487], ["COVID-19", "CHEMICAL", 482, 490], ["fat", "TISSUE", 448, 451], ["participants", "SPECIES", 123, 135], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "PROBLEM", 56, 60], ["CoV", "TEST", 61, 64], ["pandemic", "PROBLEM", 241, 249], ["obesity", "PROBLEM", 432, 439], ["ectopic fat", "PROBLEM", 440, 451], ["severe COVID", "PROBLEM", 475, 487], ["obesity", "OBSERVATION", 432, 439], ["ectopic fat", "OBSERVATION", 440, 451]]], ["1 Our work was stimulated by observations in hospital intensive care units which showed that body mass indices (BMI) above 35 or 40 were associated with poorer prognosis.", [["body", "ANATOMY", 93, 97], ["body", "ORGANISM_SUBDIVISION", 93, 97], ["body mass indices", "PROBLEM", 93, 110], ["BMI", "TEST", 112, 115], ["mass", "OBSERVATION", 98, 102]]], ["2,3 However, whether BMI is linearly associated with COVID-19-related risk in both sexes, in non-white ethnicities, and across ages, is not known.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 53, 61], ["BMI", "PROBLEM", 21, 24], ["COVID", "TEST", 53, 58], ["non-white ethnicities", "PROBLEM", 93, 114], ["non-white", "OBSERVATION_MODIFIER", 93, 102]]], ["Whether adiposity might mediate higher COVID-19-related risks, including death, in Black and other ethnic minority groups in the UK is important to understand.", [["death", "DISEASE", 73, 78], ["adiposity", "PROBLEM", 8, 17], ["death", "PROBLEM", 73, 78]]], ["To address these issues, we used UK Biobank data to examine the association between BMI and test positivity for SARS-CoV-2 infection in hospital, as well as COVID-19-related deaths.Research HighlightsOver 500,000 participants (aged 50-81 on 16 th March 2020) from the UK general population BMI was strongly associated with SARS-CoV-2 test positivity, in a broadly linear fashion (Figure 1a ), despite the model allowing for non-linear associations.", [["SARS-CoV-2 infection", "DISEASE", 112, 132], ["deaths", "DISEASE", 174, 180], ["CoV-2", "ORGANISM", 117, 122], ["participants", "SPECIES", 213, 225], ["SARS-CoV-2", "SPECIES", 112, 122], ["SARS-CoV", "SPECIES", 323, 331], ["BMI", "TEST", 84, 87], ["test positivity", "TEST", 92, 107], ["SARS", "PROBLEM", 112, 116], ["CoV", "PROBLEM", 117, 120], ["2 infection", "PROBLEM", 121, 132], ["COVID", "TEST", 157, 162], ["SARS", "TEST", 323, 327], ["CoV-2 test positivity", "TEST", 328, 349], ["infection", "OBSERVATION", 123, 132]]], ["There was a hint of a stronger gradient of risk across BMI (P interaction =0.09) in men compared with women for a positive SAR-SCoV-2 test, although no clear evidence for such interaction for COVID-19related death (Figure 1b) .", [["death", "DISEASE", 208, 213], ["men", "ORGANISM", 84, 87], ["women", "ORGANISM", 102, 107], ["men", "SPECIES", 84, 87], ["women", "SPECIES", 102, 107], ["a positive SAR", "PROBLEM", 112, 126], ["COVID", "TEST", 192, 197], ["19related death", "PROBLEM", 198, 213], ["no clear evidence for", "UNCERTAINTY", 149, 170]]], ["There was a stronger gradient (P interaction =0.03) of risk across BMI for COVID-19-related deaths but not SARS-CoV-2 test positivity in those under 70 versus 70 years or above (Figure 1c, d) .", [["deaths", "DISEASE", 92, 98], ["SARS", "DISEASE", 107, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 107, 117], ["SARS-CoV", "SPECIES", 107, 115], ["a stronger gradient", "PROBLEM", 10, 29], ["BMI", "TEST", 67, 70], ["COVID", "TEST", 75, 80], ["related deaths", "PROBLEM", 84, 98], ["SARS", "PROBLEM", 107, 111], ["CoV", "TEST", 112, 115], ["test positivity", "TEST", 118, 133], ["stronger", "OBSERVATION_MODIFIER", 12, 20], ["gradient", "OBSERVATION_MODIFIER", 21, 29]]], ["BMI was more strongly related to risk for SARS-CoV-2 test positivity (P interaction =0.010) and COVID-19-related death (P interaction =0.002) in non-whites versus whites (Figures 1e, f) .Research HighlightsOur findings have some limitations.", [["SARS", "DISEASE", 42, 46], ["death", "DISEASE", 113, 118], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["BMI", "TEST", 0, 3], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["COVID", "TEST", 96, 101], ["related death", "PROBLEM", 105, 118]]], ["Only a small proportion of overall UK Biobank participants were tested for SARS-CoV-2 but consistent findings for test positivity and COVID-19-related death provide confidence that observations are likely real.", [["SARS", "DISEASE", 75, 79], ["death", "DISEASE", 151, 156], ["UK", "GENE_OR_GENE_PRODUCT", 35, 37], ["CoV-2", "ORGANISM", 80, 85], ["participants", "SPECIES", 46, 58], ["SARS-CoV", "SPECIES", 75, 83], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83], ["test positivity", "TEST", 114, 129], ["COVID", "TEST", 134, 139], ["small", "OBSERVATION_MODIFIER", 7, 12]]], ["Total numbers of deaths were also modest at 189.", [["deaths", "DISEASE", 17, 23], ["deaths", "PROBLEM", 17, 23]]], ["Those untested, as well as those tested negative, were grouped together in the analysis on the assumption that those tested in hospital were more likely to have severe disease.", [["severe disease", "PROBLEM", 161, 175], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["disease", "OBSERVATION", 168, 175]]], ["Baseline anthropometric measures were collected a median of 10.9 (IQR 9.7-12.4) years before SARS-CoV-2 testing was conducted.", [["Baseline anthropometric measures", "TEST", 0, 32], ["IQR", "TEST", 66, 69], ["SARS", "TEST", 93, 97], ["CoV-2 testing", "TEST", 98, 111]]], ["BMI levels, however, track well over time; the rank correlation for BMI was r=0.90 in 34, 917 repeat measurements taken 8.5 years post baseline, suggesting baseline BMI values reliably estimate BMI variance.", [["BMI levels", "TEST", 0, 10], ["BMI", "TEST", 68, 71], ["repeat measurements", "TEST", 94, 113], ["baseline BMI values", "PROBLEM", 156, 175]]], ["We had modest numbers of deaths in subgroups in our analysis, requiring us to categorise race crudely as white and non-white.", [["deaths", "DISEASE", 25, 31], ["our analysis", "TEST", 48, 60], ["modest", "OBSERVATION_MODIFIER", 7, 13], ["numbers", "OBSERVATION_MODIFIER", 14, 21]]], ["Associations with deaths are therefore less reliable.", [["deaths", "DISEASE", 18, 24], ["deaths", "PROBLEM", 18, 24]]], ["Whilst we adjusted for deprivation, individuals with higher weights may have had greater exposure to the virus.", [["deprivation", "TREATMENT", 23, 34], ["higher weights", "PROBLEM", 53, 67], ["the virus", "PROBLEM", 101, 110]]], ["However, as excess fat can impair lung and metabolic function, stresses inflammatory pathways and cardiorenal systems, and promotes thrombotic responses, 1 our findings likely reflect some causal elements.", [["fat", "ANATOMY", 19, 22], ["lung", "ANATOMY", 34, 38], ["thrombotic", "DISEASE", 132, 142], ["fat", "TISSUE", 19, 22], ["lung", "ORGAN", 34, 38], ["stresses inflammatory pathways", "PROBLEM", 63, 93], ["cardiorenal systems", "TEST", 98, 117], ["lung", "ANATOMY", 34, 38], ["metabolic function", "OBSERVATION", 43, 61], ["inflammatory", "OBSERVATION_MODIFIER", 72, 84], ["cardiorenal systems", "ANATOMY", 98, 117], ["thrombotic", "OBSERVATION", 132, 142], ["likely reflect", "UNCERTAINTY", 169, 183], ["causal elements", "OBSERVATION", 189, 204]]], ["Although not formally tested, the current data suggest that BMI may be more strongly related to COVID-19 deaths than SARS-CoV-2 test positivity (Figures 1a-f) .Research HighlightsCurrently the UK government advises people with BMI>40 to be more stringent at adhering to non-pharmaceutical interventions (i.e. physical distancing, hand hygiene etc).", [["hand", "ANATOMY", 330, 334], ["deaths", "DISEASE", 105, 111], ["SARS", "DISEASE", 117, 121], ["people", "ORGANISM", 215, 221], ["hand", "ORGANISM_SUBDIVISION", 330, 334], ["people", "SPECIES", 215, 221], ["SARS-CoV", "SPECIES", 117, 125], ["BMI", "PROBLEM", 60, 63], ["COVID", "TEST", 96, 101], ["SARS", "TEST", 117, 121], ["CoV-2 test positivity", "TEST", 122, 143], ["non-pharmaceutical interventions", "TREATMENT", 270, 302]]], ["Our results suggest that there is no evidence of a threshold effect at BMI=40, and that risk associations are linear.", [["a threshold effect", "PROBLEM", 49, 67], ["BMI", "TEST", 71, 74], ["no evidence of", "UNCERTAINTY", 34, 48], ["linear", "OBSERVATION_MODIFIER", 110, 116]]], ["Moreover, our findings suggest excess fat may be a stronger risk factor for susceptibility to infection with SARS-CoV-2 and severity of resultant COVID-19, including death related to COVID-19, in non-whites compared to whites.", [["fat", "ANATOMY", 38, 41], ["infection", "DISEASE", 94, 103], ["SARS", "DISEASE", 109, 113], ["death", "DISEASE", 166, 171], ["fat", "TISSUE", 38, 41], ["SARS-CoV-2", "ORGANISM", 109, 119], ["excess fat", "PROBLEM", 31, 41], ["susceptibility to infection", "PROBLEM", 76, 103], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["resultant COVID", "PROBLEM", 136, 151], ["death", "PROBLEM", 166, 171], ["COVID", "TEST", 183, 188], ["excess fat", "OBSERVATION", 31, 41], ["infection", "OBSERVATION", 94, 103]]], ["Indeed, the gradients relating BMI to SARS-CoV-2 test positivity/COVID-19-related death in non-whites are reminiscent of the much stronger associations between BMI and diabetes associations in non-white people.", [["SARS", "DISEASE", 38, 42], ["death", "DISEASE", 82, 87], ["diabetes", "DISEASE", 168, 176], ["CoV-2", "GENE_OR_GENE_PRODUCT", 43, 48], ["people", "ORGANISM", 203, 209], ["people", "SPECIES", 203, 209], ["BMI", "TEST", 31, 34], ["SARS", "TEST", 38, 42], ["CoV", "TEST", 43, 46], ["test positivity", "TEST", 49, 64], ["COVID", "TEST", 65, 70], ["death", "PROBLEM", 82, 87]]], ["4 This suggests, but does not fully prove, metabolic factors may be pertinent to excess COVID-19 severity in non-white populations, an observation in line with our suggested role for excess (ectopic) fat in COVID-19 severity.", [["fat", "ANATOMY", 200, 203], ["fat", "TISSUE", 200, 203], ["COVID", "TEST", 88, 93], ["non-white populations", "PROBLEM", 109, 130], ["an observation", "TEST", 132, 146], ["excess (ectopic) fat", "PROBLEM", 183, 203], ["COVID", "TEST", 207, 212]]], ["1 The stronger association of BMI with COVID-19-related death in younger individuals also makes sense given BMI is less precise measure of excess fat in elderly people due to changes in muscle mass linked to unintentional weight loss.Research HighlightsWhen taken in context with other emerging data, 2,3,5 our results support the need for public health campaigns to help and support individuals across different ethnic groups who are overweight or obese to lose weight to lessen their chances of severe COVID-19.", [["fat", "ANATOMY", 146, 149], ["muscle", "ANATOMY", 186, 192], ["COVID-19", "CHEMICAL", 39, 47], ["death", "DISEASE", 56, 61], ["weight loss", "DISEASE", 222, 233], ["COVID", "DISEASE", 504, 509], ["COVID-19", "GENE_OR_GENE_PRODUCT", 39, 47], ["fat", "TISSUE", 146, 149], ["people", "ORGANISM", 161, 167], ["muscle", "ORGAN", 186, 192], ["people", "SPECIES", 161, 167], ["BMI", "TEST", 30, 33], ["COVID", "TEST", 39, 44], ["muscle mass", "PROBLEM", 186, 197], ["unintentional weight loss", "PROBLEM", 208, 233], ["public health campaigns", "TREATMENT", 340, 363], ["obese", "PROBLEM", 449, 454], ["severe COVID", "PROBLEM", 497, 509], ["muscle", "ANATOMY", 186, 192], ["mass", "OBSERVATION", 193, 197]]], ["Whilst we lack trial evidence to prove weight loss lowers risks, there are many additional benefits of weight loss, including improved cardiorespiratory fitness and quality of life.", [["weight loss", "DISEASE", 39, 50], ["weight loss", "DISEASE", 103, 114], ["weight loss lowers risks", "PROBLEM", 39, 63], ["weight loss", "PROBLEM", 103, 114]]], ["We recognise that not all individuals are able to lose weight through lifestyle changes; some may require drug therapies, if even temporarily, to help reduce weight and maybe lower risk.", [["drug therapies", "TREATMENT", 106, 120], ["lower risk", "OBSERVATION_MODIFIER", 175, 185]]]], "8cd37676d8820619b8aad968d9604dbea87bafaa": [["A case of an adenoma and an adenocarcinoma in the nasal cavity of a female Wistar rat (HsdCpb:WU) is described.", [["adenoma", "ANATOMY", 13, 20], ["adenocarcinoma", "ANATOMY", 28, 42], ["nasal cavity", "ANATOMY", 50, 62], ["adenoma", "DISEASE", 13, 20], ["adenocarcinoma", "DISEASE", 28, 42], ["adenoma", "CANCER", 13, 20], ["adenocarcinoma", "CANCER", 28, 42], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 50, 62], ["Wistar rat", "ORGANISM", 75, 85], ["HsdCpb:WU", "ORGANISM", 87, 96], ["rat", "SPECIES", 82, 85], ["an adenoma", "PROBLEM", 10, 20], ["an adenocarcinoma in the nasal cavity", "PROBLEM", 25, 62], ["adenoma", "OBSERVATION", 13, 20], ["adenocarcinoma", "OBSERVATION", 28, 42], ["nasal cavity", "ANATOMY", 50, 62]]], ["In rats, naturally occurring adenomas and adenocarcinomas of the nasal cavity are extremely rare, but these neoplasms can be induced by a variety of chemicals.", [["adenomas", "ANATOMY", 29, 37], ["adenocarcinomas", "ANATOMY", 42, 57], ["nasal cavity", "ANATOMY", 65, 77], ["neoplasms", "ANATOMY", 108, 117], ["adenomas", "DISEASE", 29, 37], ["adenocarcinomas of the nasal cavity", "DISEASE", 42, 77], ["neoplasms", "DISEASE", 108, 117], ["rats", "ORGANISM", 3, 7], ["adenomas", "CANCER", 29, 37], ["adenocarcinomas", "CANCER", 42, 57], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 65, 77], ["neoplasms", "CANCER", 108, 117], ["rats", "SPECIES", 3, 7], ["naturally occurring adenomas", "PROBLEM", 9, 37], ["adenocarcinomas of the nasal cavity", "PROBLEM", 42, 77], ["these neoplasms", "PROBLEM", 102, 117], ["naturally", "OBSERVATION_MODIFIER", 9, 18], ["occurring", "OBSERVATION_MODIFIER", 19, 28], ["adenomas", "OBSERVATION", 29, 37], ["adenocarcinomas", "OBSERVATION", 42, 57], ["nasal cavity", "ANATOMY", 65, 77], ["neoplasms", "OBSERVATION", 108, 117], ["variety", "OBSERVATION_MODIFIER", 138, 145]]]], "fa4343ce37e8834a0416e47ba7cdb52997fc1323": [["both due to a direct damage of the pancreas to ACE2 receptors, or secondary to locoregional vasculitis and thrombosis.", [["pancreas", "ANATOMY", 35, 43], ["vasculitis", "DISEASE", 92, 102], ["thrombosis", "DISEASE", 107, 117], ["pancreas", "ORGAN", 35, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["ACE2 receptors", "PROTEIN", 47, 61], ["a direct damage of the pancreas", "PROBLEM", 12, 43], ["ACE2 receptors", "PROBLEM", 47, 61], ["locoregional vasculitis", "PROBLEM", 79, 102], ["thrombosis", "PROBLEM", 107, 117], ["damage", "OBSERVATION", 21, 27], ["pancreas", "ANATOMY", 35, 43], ["locoregional vasculitis", "OBSERVATION", 79, 102], ["thrombosis", "OBSERVATION", 107, 117]]]], "3b2d14d09efcf36462304a894a721423ee6cfd72": [["IntroductionIn 2020, the coronavirus pandemic has rapidly spread around the globe, threatening health and economical systems.", [["coronavirus pandemic", "DISEASE", 25, 45], ["coronavirus", "ORGANISM", 25, 36], ["coronavirus", "SPECIES", 25, 36], ["IntroductionIn", "TREATMENT", 0, 14], ["the coronavirus pandemic", "PROBLEM", 21, 45], ["coronavirus pandemic", "OBSERVATION", 25, 45], ["rapidly", "OBSERVATION_MODIFIER", 50, 57], ["spread", "OBSERVATION_MODIFIER", 58, 64], ["globe", "ANATOMY", 76, 81]]], ["At first, many governments attempted to minimize exposure to the virus by limiting cross-border arrivals.", [["the virus", "PROBLEM", 61, 70]]], ["However, the rapid person-to-person transmission rate of the virus 1,2 required that more severe measures be taken to plummet infection frequencies.IntroductionGovernments that used lockdown to enforce social distancing varied in their policy, timing, and duration, in particular relative to the mortality rate in their country.", [["infection", "DISEASE", 126, 135], ["person", "SPECIES", 19, 25], ["person", "SPECIES", 29, 35], ["the virus", "PROBLEM", 57, 66], ["plummet infection frequencies", "PROBLEM", 118, 147], ["infection", "OBSERVATION", 126, 135]]], ["For example, Italy enforced a severe, nationwide, lockdown on March 10, when over 35,000 confirmed cases and almost 3,000 deaths had already been recorded.", [["deaths", "DISEASE", 122, 128], ["severe", "OBSERVATION_MODIFIER", 30, 36]]], ["In other countries, lockdown policies were embraced at earlier stages in attempt to prevent severe outbreaks.", [["severe outbreaks", "PROBLEM", 92, 108], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["outbreaks", "OBSERVATION", 99, 108]]], ["Israel, for instance, reached the strict lockdown on March 19 with a relatively low number of 648 confirmed cases and no deaths to that day.", [["deaths", "DISEASE", 121, 127]]], ["In contrast, several countries, such as Sweden and Japan, advocated social distancing but did not enforce a lockdown as a means of coronavirus spread prevention.IntroductionHow can social distancing be quantified?", [["coronavirus", "DISEASE", 131, 142], ["coronavirus", "ORGANISM", 131, 142], ["coronavirus", "SPECIES", 131, 142], ["coronavirus spread prevention", "TREATMENT", 131, 160]]], ["One could measure governmental regulations such as the permitted walking distance from the residence, limitations on mass gatherings, school closures, and whether people were allowed to attend their workplaces.", [["people", "ORGANISM", 163, 169], ["people", "SPECIES", 163, 169]]], ["This score was used to predict future infections depending on the intervention level.IntroductionWhile this model may be useful when governmental decisions are made, it does not reflect whether social distancing has been implemented de facto 4 .", [["infections", "DISEASE", 38, 48], ["This score", "TEST", 0, 10], ["future infections", "PROBLEM", 31, 48], ["infections", "OBSERVATION", 38, 48]]], ["Soures et al. used data collected from navigation applications on mobile cellphones together with past infection rates to predict future infection rates 5 .", [["infection", "DISEASE", 103, 112], ["infection", "DISEASE", 137, 146], ["navigation applications", "TREATMENT", 39, 62], ["mobile cellphones", "TREATMENT", 66, 83], ["past infection rates", "PROBLEM", 98, 118], ["infection rates", "PROBLEM", 137, 152], ["infection", "OBSERVATION", 103, 112]]], ["These predictions were based on a neural-network model, in which the connection between mobility data and infection rates is hard to interpret, and thus, practically, cannot be converted into tangible measures for the arms race against the disease.", [["neural", "ANATOMY", 34, 40], ["infection", "DISEASE", 106, 115], ["mobility data", "TEST", 88, 101], ["infection rates", "PROBLEM", 106, 121], ["the disease", "PROBLEM", 236, 247], ["disease", "OBSERVATION", 240, 247]]], ["It is currently unknown which aspects of the lockdown (e.g., duration, strictness, timing from onset of death cases) affect mortality rates.", [["death", "DISEASE", 104, 109], ["mortality rates", "TEST", 124, 139]]], ["Understanding the linkage between lockdown dynamics and COVID-19 death incidents is highly important for balancing between health, welfare, and economy.IntroductionHere we develop parametric models that quantify trends related to mobility and mortality and fit them to all OECD countries.", [["death", "DISEASE", 65, 70], ["parametric models", "TEST", 180, 197]]], ["Using these models, we demonstrate that the timing in which the social distancing was initiated by itself explains 62% of the COVID-19 related deaths across OECD .", [["deaths", "DISEASE", 143, 149]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint countries, excluding Japan (that was previously reported as an exception with respect to the spread of the disease, e.g., by Iwasaki and Grubaugh 6 ).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 208, 228], ["the disease", "PROBLEM", 453, 464], ["med", "ANATOMY", 99, 102], ["disease", "OBSERVATION", 457, 464]]], ["In contrast, the severity of the lockdown and its duration are not as informative for explaining mortality rates.", [["mortality rates", "TEST", 97, 112]]], ["Our analysis thus suggests that a moderate lockdown, rather than a very strict one as imposed by most countries, should be sufficient to curb COVID-19 related mortality, as long as action is taken in the appropriate time frame.ResultsFollowing the COVID-19 outbreak, Apple Inc. published daily reports regarding people movement, collected from usage of maps on mobile cellphones 7 .", [["people", "ORGANISM", 312, 318], ["people", "SPECIES", 312, 318], ["Our analysis", "TEST", 0, 12], ["a moderate lockdown", "PROBLEM", 32, 51], ["the COVID", "TEST", 244, 253], ["moderate", "OBSERVATION_MODIFIER", 34, 42], ["lockdown", "OBSERVATION", 43, 51]]], ["We used these mobility data, denoted as ( ), to quantify the actual commencement of the lockdown as a function of time in different OECD countries.", [["these mobility data", "TEST", 8, 27]]], ["We collected daily death incidents across time and overlaid them on the mobility data.", [["death", "DISEASE", 19, 24], ["the mobility data", "TEST", 68, 85]]], ["We observed that the trend of daily deaths stabilized and subsequently decreased several days after a sharp mobility drop (Fig. 1a for the United Kingdom as an example and Supplementary Fig. S1 for all OECD countries). ( ) is given as percentages relative to that recorded on January 13, that serves as the baseline; (b) An illustration of the mobility model and its free parameters: -mobility difference between routine and lockdown; -drop steepness; -drop midpoint; -mobility level during lockdown; -release day; -recovery rate, see Methods for more details.Mobility analysisThe mobility in a single country during the observed time period of the COVID-19 pandemic can generally be divided into four phases: (1) a stable phase of high mobility (with fluctuations on .", [["deaths", "DISEASE", 36, 42], ["a sharp mobility drop", "PROBLEM", 100, 121], ["Supplementary Fig", "TREATMENT", 172, 189], ["the mobility model", "TEST", 340, 358], ["its free parameters", "TEST", 363, 382], ["mobility difference", "PROBLEM", 385, 404], ["routine and lockdown", "TEST", 413, 433], ["drop steepness", "PROBLEM", 436, 450], ["drop midpoint", "PROBLEM", 453, 466], ["mobility level", "PROBLEM", 469, 483], ["Mobility analysis", "TEST", 560, 577], ["the COVID", "TEST", 645, 654], ["mobility", "OBSERVATION_MODIFIER", 581, 589], ["stable", "OBSERVATION_MODIFIER", 716, 722], ["high mobility", "OBSERVATION_MODIFIER", 732, 745]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Mobility analysisThe copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint weekends); (2) a sharp drop (suggesting social distancing has actually started); (3) a period of low mobility; and (4) a gradual incline towards a normal routine (Fig. 1) .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["Mobility analysis", "TEST", 196, 213], ["The copyright holder", "TREATMENT", 213, 233], ["a sharp drop", "PROBLEM", 370, 382], ["low mobility", "PROBLEM", 452, 464], ["a gradual incline", "PROBLEM", 474, 491], ["med", "ANATOMY", 99, 102], ["low mobility", "OBSERVATION_MODIFIER", 452, 464]]], ["Phases (1)-(3) reflect a (mirrored) logistic function and phase (4) is approximately linear.", [["Phases", "TEST", 0, 6], ["linear", "OBSERVATION_MODIFIER", 85, 91]]], ["We modeled this overall trend by assembling a logistic function and a linear one as a function of time ( , given in days):Mobility analysisThe six free parameters of this model are illustrated in Fig. 1b .", [["Mobility analysis", "TEST", 122, 139], ["free", "OBSERVATION_MODIFIER", 147, 151], ["illustrated", "OBSERVATION", 181, 192], ["Fig", "OBSERVATION_MODIFIER", 196, 199]]], ["Nevertheless, the mobility in Italy declined in a relatively gradual manner with respect to other examined countries, as the drop duration lasted 20 days.", [["mobility", "OBSERVATION_MODIFIER", 18, 26]]], ["The extent of mobility reduction in Germany (59%) was relatively low compared to other countries in which a lockdown was issued, and a gradual return to normal routine was initiated right after the lowest mobility level was reached.", [["mobility reduction", "PROBLEM", 14, 32], ["the lowest mobility level", "TEST", 194, 219], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["mobility", "OBSERVATION_MODIFIER", 14, 22], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["low", "OBSERVATION_MODIFIER", 65, 68]]], ["Even though a lockdown was not regulated in Sweden, the data and model show that social distancing indeed happened, as a drop of 29% was observed followed by a moderate return back to routine (lockdown release rate of 0.57).Mobility analysis.", [["routine (lockdown release rate", "TREATMENT", 184, 214], ["Mobility analysis", "TEST", 224, 241]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprintCOVID-19 mortalityThe accumulated number of COVID-19 deaths across time, ( ), was fitted using a logistic function, \u0302( ), to the data (see Methods).", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 389, 395], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprintCOVID", "TREATMENT", 320, 341], ["COVID", "TEST", 380, 385], ["med", "ANATOMY", 99, 102], ["accumulated", "OBSERVATION_MODIFIER", 358, 369], ["number", "OBSERVATION_MODIFIER", 370, 376]]], ["The average Pearson correlation between the observed mortality data and the fitted function, across all countries, was (all ; Supplementary Table S3;Association between mobility and mortality dataWe computed the response time of each country, , defined as the difference between the social distancing start time and the day when ten first deaths were recorded.", [["deaths", "DISEASE", 339, 345]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Italy, Japan, Spain, and the United States), indicating that social distancing started after ten COVID-19 deaths were documented (Fig. 4, Supplementary Fig. S2 ).", [["deaths", "DISEASE", 106, 112], ["S2", "PROTEIN", 157, 159]]], ["We observed a significant correlation between and the log COVID-19 Mortality Probability (Pearson ,(which was not certified by peer review)).", [["the log COVID", "TEST", 50, 63]]], ["Previous reports have discussed the abnormally low mortality rate in Japan 6 , thus, we computed the correlation excluding Japan and obtained a substantial increase in correlation ( , ).", [["the abnormally low mortality rate", "PROBLEM", 32, 65], ["increase", "OBSERVATION_MODIFIER", 156, 164]]], ["Neither the lockdown strictness nor the lockdown duration were significantly correlated with log COVID-19 Mortality Probability (Supplementary Table S5 ). .", [["log COVID", "TEST", 93, 102]]], ["The dashed vertical blue lines represent the day ten deaths were documented. represents the time difference between the orange and the blue vertical lines, defined as the response time ( is negative for Israel and positive for Japan).", [["deaths", "DISEASE", 53, 59], ["vertical blue lines", "CELL", 11, 30], ["blue vertical lines", "CELL", 135, 154], ["dashed vertical blue lines", "CELL_LINE", 4, 30], ["blue vertical lines", "CELL_LINE", 135, 154], ["The dashed vertical blue lines", "TREATMENT", 0, 30], ["the blue vertical lines", "TREATMENT", 131, 154], ["vertical", "OBSERVATION_MODIFIER", 11, 19], ["blue lines", "OBSERVATION", 20, 30], ["blue", "OBSERVATION", 135, 139], ["vertical lines", "OBSERVATION", 140, 154]]], ["The graphs for all OECD countries are given in Supplementary Fig. S2 .(which was not certified by peer review).", [["all OECD countries", "TREATMENT", 15, 33]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint Figure 4 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["A semi-logarithmic scatter plot of the COVID-19 Mortality Probability and .", [["A semi-logarithmic scatter plot", "TEST", 0, 31], ["the COVID", "TEST", 35, 44]]], ["The x axis represents , the difference between the social distancing start time and the day in which the ten first deaths were recorded for the respective country (intuitively, the response time).", [["deaths", "DISEASE", 115, 121], ["x axis", "OBSERVATION_MODIFIER", 4, 10]]], ["The y axis represents the COVID-19 Mortality Probability in a logarithmic scale.", [["the COVID", "TEST", 22, 31], ["a logarithmic scale", "TREATMENT", 60, 79]]], ["Dot sizes are proportional to population sizes.", [["sizes", "OBSERVATION_MODIFIER", 4, 9], ["proportional", "OBSERVATION_MODIFIER", 14, 26], ["population", "OBSERVATION_MODIFIER", 30, 40], ["sizes", "OBSERVATION_MODIFIER", 41, 46]]], ["The dashed line corresponds to the fitted regression, excluding Japan.", [["The dashed line", "TREATMENT", 0, 15], ["dashed line", "OBSERVATION", 4, 15]]], ["The high correlation between and the log COVID-19 Mortality Probability yielded a crucial implication, as it allowed inferring the time required for this probability to double.", [["the log COVID", "TEST", 33, 46], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint Next, we aimed to compute the time offset between mobility reduction and the decline in mortality growth rate.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["mobility reduction", "TREATMENT", 387, 405], ["the decline", "PROBLEM", 410, 421], ["mortality growth rate", "TEST", 425, 446], ["med", "ANATOMY", 99, 102]]], ["This offset serves as a proxy for the time between infection and fatality.(which was not certified by peer review)The time offset that yielded the highest correlation between ( ) and mortality growth rate was 25.75 days on average across countries (average Pearson , all except for Iceland, Latvia, and Slovakia, which had only several death incidents; Supplementary Table S6 and Supplementary Fig. S3 ).", [["infection", "DISEASE", 51, 60], ["death", "DISEASE", 336, 341], ["infection", "PROBLEM", 51, 60], ["fatality", "PROBLEM", 65, 73], ["mortality growth rate", "TEST", 183, 204], ["Supplementary Fig", "TREATMENT", 380, 397], ["infection", "OBSERVATION", 51, 60]]], ["This result highly resembles previous estimations of the time from infection to fatality 9,10 , although here it was derived from entirely different data and analysis.", [["infection", "DISEASE", 67, 76], ["infection", "PROBLEM", 67, 76], ["analysis", "TEST", 158, 166], ["infection", "OBSERVATION", 67, 76]]], ["Interestingly, this offset highly varied among the countries ( days), with exceptionally low offset in the United Kingdom (eight days) and exceptionally high offset in Finland, Hungary, and Estonia (38-39 days).", [["exceptionally low offset", "PROBLEM", 75, 99], ["low offset", "OBSERVATION_MODIFIER", 89, 99], ["high offset", "OBSERVATION", 153, 164]]], ["There was a mild correlation between the offset and COVID-19 Mortality Probability ( ), namely, the time between exposure and fatality shortens as the mortality rate grows.DiscussionIn this study, we modeled the mobility dynamics across time during the COVID-19 pandemic.DiscussionUsing this model we computed explanatory features that characterize a lockdown, and in turn, these features provided a quantitative measure for comparing the lockdown dynamics and outcome across countries.", [["a mild correlation", "PROBLEM", 10, 28], ["COVID", "TEST", 52, 57], ["the mortality rate", "TEST", 147, 165], ["this study", "TEST", 185, 195], ["the COVID", "TEST", 249, 258], ["pandemic", "PROBLEM", 262, 270], ["mild", "OBSERVATION_MODIFIER", 12, 16]]], ["We found high correlation between the response time of a country and its mortality rate.", [["its mortality rate", "TEST", 69, 87], ["high", "OBSERVATION_MODIFIER", 9, 13]]], ["In contrast, neither the lockdown duration nor the lockdown strictness were significantly associated with mortality rates (Supplementary Table S5 ).", [["the lockdown strictness", "PROBLEM", 47, 70]]], ["These results imply that a tight lockdown could have been unnecessary.DiscussionOfficial governmental regulations are possible resources for extracting features regarding the lockdown.", [["a tight lockdown", "TREATMENT", 25, 41]]], ["Such features were examined for their association with infection rates in previous studies 5, 11 .", [["infection", "DISEASE", 55, 64], ["infection rates", "PROBLEM", 55, 70], ["previous studies", "TEST", 74, 90], ["infection", "OBSERVATION", 55, 64]]], ["For example, Italy announced regional lockdowns in three phases.", [["regional", "OBSERVATION_MODIFIER", 29, 37]]], ["Initially, a lockdown was applied in Lombardy and Veneto regions on February 20.", [["a lockdown", "TREATMENT", 11, 21]]], ["However, the mobility data show that even though the initial lockdown was declared on Lombardy, mobility volumes across Italy kept .", [["the mobility data", "TEST", 9, 26]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint elevating and started to decrease only a week later.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv", "TREATMENT", 320, 327], ["med", "ANATOMY", 99, 102]]], ["In contrast, when the lockdowns on Northern Italy and later, on the entire country, were declared, a large drop in mobility usage had already taken place (Supplementary Fig. S4 ).(which was not certified by peer review)Most of the examined OECD countries complied well to the regression analysis in this study.(which was not certified by peer review)Small deviations could be explained by modest variations between countries, such as the conditions for defining a patient as a SARS-CoV-2 carrier, or by differences in mobile usage across areas.", [["SARS", "DISEASE", 477, 481], ["patient", "ORGANISM", 464, 471], ["patient", "SPECIES", 464, 471], ["a large drop in mobility usage", "PROBLEM", 99, 129], ["the regression analysis", "TEST", 272, 295], ["this study", "TEST", 299, 309], ["Small deviations", "PROBLEM", 350, 366], ["large", "OBSERVATION_MODIFIER", 101, 106], ["drop", "OBSERVATION_MODIFIER", 107, 111], ["deviations", "OBSERVATION", 356, 366], ["could be explained", "UNCERTAINTY", 367, 385], ["modest", "OBSERVATION_MODIFIER", 389, 395], ["variations", "OBSERVATION", 396, 406]]], ["Notably, different geographical areas also differ in numerous other attributes that may affect the coronavirus spread and induced mortality rates, e.g., humidity, wind speed, ethnicity, viral genotypic variation, and cultural habits.", [["coronavirus", "DISEASE", 99, 110], ["coronavirus", "ORGANISM", 99, 110], ["the coronavirus spread", "PROBLEM", 95, 117], ["viral genotypic variation", "PROBLEM", 186, 211], ["different", "OBSERVATION_MODIFIER", 9, 18], ["geographical", "OBSERVATION_MODIFIER", 19, 31], ["areas", "OBSERVATION_MODIFIER", 32, 37]]], ["One eminent example emerging from our analysis is Japan, where a relatively low mortality rate occurred even though mobility reduction took place relatively late.", [["our analysis", "TEST", 34, 46], ["a relatively low mortality rate", "PROBLEM", 63, 94], ["mobility reduction", "PROBLEM", 116, 134]]], ["The low mortality rate in Japan has previously been discussed 6 , and it should be beneficial to better understand the different trajectory of the pandemic in Japan, with respect to the Japanese governmental regulations and customs as a possible alternative to a strict lockdown.", [["The low mortality rate", "PROBLEM", 0, 22], ["a strict lockdown", "TREATMENT", 261, 278], ["low", "OBSERVATION_MODIFIER", 4, 7]]], ["Combining these features with the proposed mobility model may increase its overall accuracy.(which was not certified by peer review)The inferred high association between mobility and mortality rate led to crucial implications.(which was not certified by peer review)First, we found that the number of death incidents would double if action was taken in a delay of approximately one week.", [["death", "DISEASE", 301, 306], ["mortality rate", "TEST", 183, 197], ["high", "OBSERVATION_MODIFIER", 145, 149]]], ["Second, we inferred that the time offset from exposure to fatality is roughly 26 days, with some countries exhibiting extremely shorter time offsets and others much longer.", [["fatality", "DISEASE", 58, 66]]], ["We also observed that the correlation between this time offset and COVID-19 Mortality Probability results in .", [["COVID", "TEST", 67, 72]]], ["We hypothesize that the inverse correlation between the two may be explained by the load of high mortality on the health system, which might hamper the treatment and shorten survival time.", [["the treatment", "TREATMENT", 148, 161]]], ["The remaining variation may be explained by different treatment protocols, COVID-19 test policies, or other characteristics, and requires additional study.(which was not certified by peer review)We focused our analysis on 37 OECD countries, to concentrate on a representative group of relatively reliable reports.", [["different treatment protocols", "TREATMENT", 44, 73], ["COVID", "TEST", 75, 80], ["additional study", "TEST", 138, 154], ["our analysis", "TEST", 206, 218], ["may be explained", "UNCERTAINTY", 24, 40]]], ["Nevertheless, our results sustain when including additional non-OECD countries or when concentrating on sub regions for which sufficient data exist: the Pearson between and the log COVID-19 Mortality Probability for 58 countries was ( ; Supplementary Fig. S5) .", [["S5", "GENE_OR_GENE_PRODUCT", 256, 258], ["S5", "PROTEIN", 256, 258], ["the log COVID", "TREATMENT", 173, 186]]], ["A significant correlation ( ) was also observed when .", [["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint analyzing states within the United States ( ; Supplementary Fig. S6 ).", [["CC", "CHEMICAL", 0, 2], ["S6", "GENE_OR_GENE_PRODUCT", 402, 404], ["S6", "PROTEIN", 402, 404], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Finally, while in this study we investigated the association of lockdown and mortality, the number of confirmed cases or hospital-committed patients can also be examined.", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["this study", "TEST", 18, 28]]], ["We opted to use mortality as the outcome since it is less dependent on the number of COVID-19 tests, which widely varies among different countries.", [["mortality", "TREATMENT", 16, 25], ["COVID", "TEST", 85, 90], ["less dependent", "OBSERVATION_MODIFIER", 53, 67]]], ["Nevertheless, significant Pearson of 0.47 between and the log COVID-19 Infection Probability in OECD countries was also observed ( ; Supplementary Fig. S7 ).(which was not certified by peer review)The results of our analysis show that social distancing is a major factor in controlling COVID-19(which was not certified by peer review)spread.", [["the log COVID", "TEST", 54, 67], ["Infection", "PROBLEM", 71, 80], ["our analysis", "TEST", 212, 224], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["Infection", "OBSERVATION", 71, 80]]], ["Similar to previous studies 2, 8 , our analysis shows that if social distancing is not adopted, death incidents are doubled every 7.49 days.", [["death", "DISEASE", 96, 101], ["previous studies", "TEST", 11, 27], ["our analysis", "TEST", 35, 47]]], ["However, it also shows that a strict lockdown policy is not required.", [["a strict lockdown policy", "TREATMENT", 28, 52]]], ["Therefore, to avoid major infection outbreaks, we suggest undertaking a moderate form of a lockdown that can be tolerated by the society for longer time periods, with minimal socio-economic damage.Mobility dataMobility data, ( ), with one data point per day, , were downloaded from Apple repository on May 11, 2020 7 .", [["infection", "DISEASE", 26, 35], ["major infection outbreaks", "PROBLEM", 20, 45], ["a lockdown", "TREATMENT", 89, 99], ["minimal socio-economic damage", "PROBLEM", 167, 196], ["Mobility dataMobility data", "TEST", 197, 223], ["infection", "OBSERVATION", 26, 35]]], ["Due to the high similarity between \"walking\" and \"driving\" data (average Pearson correlation across countries , , all ) and since the \"transit\" data are incomplete, all analyses were applied using the \"driving\" data only.Mobility dataTo fit \u0302( ) to the mobility data, ( ), and receive the values of the parameters for every country, we used the Levenberg-Marquardt optimization algorithm from the SciPy module [12] [13] [14] .Mobility dataAccording to the parameters inferred from \u0302( ), we computed seven features to characterize the mobility trend in a country.", [["the mobility data", "TEST", 249, 266], ["the Levenberg", "TREATMENT", 341, 354]]], ["(1) , Social distancing start time; and (2) , Minimal mobility time point, corresponding to the times before and after the mobility drop.", [["the mobility drop", "PROBLEM", 119, 136]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020.Mortality dataThe Probability, the expected mortality ( ) was normalized by the population size for each country.Mortality dataData of population size were obtained from the World Population Review website 17 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["Mortality data", "TEST", 268, 282], ["med", "ANATOMY", 99, 102], ["size", "OBSERVATION_MODIFIER", 359, 363], ["size", "OBSERVATION_MODIFIER", 414, 418]]], ["Of note, our goal in this work was not to predict mortality rates, but rather, to find correlates with large changes in mortality patterns across countries.", [["large changes in mortality patterns", "PROBLEM", 103, 138], ["large", "OBSERVATION_MODIFIER", 103, 108]]], ["Since we correlate with the logarithm of the mortality rates, we expect that small deviations in mortality estimates will not affect our conclusions.Mortality data.", [["small deviations in mortality estimates", "PROBLEM", 77, 116], ["Mortality data", "TEST", 149, 163], ["small", "OBSERVATION_MODIFIER", 77, 82], ["deviations", "OBSERVATION", 83, 93]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprintAssociation between mortality and response timeWe define a response time, , as the difference between two time points: the social distancing start time (as inferred from \u0302( )) and the day in which ten first COVID-19 related deaths were recorded (according to ( ), see Fig. 3 ).", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 560, 566], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprintAssociation", "TREATMENT", 320, 347], ["med", "ANATOMY", 99, 102]]], ["The ten deaths threshold was set to avoid incidental fluctuations that do not reflect the mortality trend of a certain country.", [["deaths", "DISEASE", 8, 14], ["The ten deaths threshold", "PROBLEM", 0, 24], ["incidental fluctuations", "PROBLEM", 42, 65]]], ["Thresholds of five and 20 deaths led to similar results.", [["deaths", "DISEASE", 26, 32]]], ["We chose an absolute threshold rather than a relative threshold (i.e., number of death incidents normalized to population size) because the very initial dynamics of the disease is not expected to be strongly coupled with the population size.", [["death", "DISEASE", 81, 86], ["the disease", "PROBLEM", 165, 176], ["size", "OBSERVATION_MODIFIER", 122, 126], ["disease", "OBSERVATION", 169, 176], ["size", "OBSERVATION_MODIFIER", 236, 240]]], ["Furthermore, setting a relative threshold of one death per 1 million (or more) citizens is problematic for countries such as Iceland because its population size is smaller than 10 6 .", [["death", "DISEASE", 49, 54], ["size", "OBSERVATION_MODIFIER", 156, 160], ["smaller", "OBSERVATION_MODIFIER", 164, 171]]], ["However, setting a threshold of one death per 10 5 citizens is problematic for countries such as Australia because such countries would never reach the starting threshold (at the date the data were collected, Australia had a mortality rate of death cases per population size).Association between mortality and response timeWe fitted a linear regression model to these data ( Fig. 4 ; excluding Japan), i.e., between and the log COVID-19 Mortality Probability (denoted as ( )).", [["death", "DISEASE", 36, 41], ["death", "DISEASE", 243, 248], ["one death", "PROBLEM", 32, 41], ["a linear regression model", "TREATMENT", 333, 358], ["size", "OBSERVATION_MODIFIER", 270, 274]]], ["This fitting resulted in the inferredThe offset between mortality growth rate and mobility dataThe mortality growth rate measures the relative daily increase of fatalities and is defined byThe offset between mortality growth rate and mobility data) .", [["fatalities", "DISEASE", 161, 171], ["mobility data", "TEST", 82, 95], ["The mortality growth rate", "PROBLEM", 95, 120], ["mortality growth rate", "TEST", 208, 229]]], ["The optimal time offset, namely, the offset that yields the highest correlation between the declining trends of mobility ( ) and mortality growth rate ( ), is Supplementary Fig. S3 ).The offset between mortality growth rate and mobility data.", [["mortality growth rate", "TEST", 129, 150], ["mortality growth rate", "TEST", 202, 223], ["mobility data", "TEST", 228, 241]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The offset between mortality growth rate and mobility dataThe copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["mortality growth rate", "TEST", 215, 236], ["mobility data", "TEST", 241, 254], ["The copyright holder", "TREATMENT", 254, 274], ["medRxiv", "TREATMENT", 379, 386], ["med", "ANATOMY", 99, 102]]]], "4272569a0815349cd79d414f00d40876c3715f42": [["Stroke is a major cause of death and disability throughout the world (1), especially in Asia (2) .", [["Stroke", "DISEASE", 0, 6], ["death", "DISEASE", 27, 32], ["Stroke", "PROBLEM", 0, 6], ["death", "PROBLEM", 27, 32]]], ["Stroke occurs in 5.9% of COVID-19 patients, largely ischemic, but with a few hemorrhagic strokes (3, 4) .", [["Stroke", "DISEASE", 0, 6], ["hemorrhagic strokes", "DISEASE", 77, 96], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["Stroke", "PROBLEM", 0, 6], ["COVID", "TEST", 25, 30], ["largely ischemic", "PROBLEM", 44, 60], ["a few hemorrhagic strokes", "PROBLEM", 71, 96], ["ischemic", "OBSERVATION", 52, 60], ["few", "OBSERVATION_MODIFIER", 73, 76], ["hemorrhagic", "OBSERVATION_MODIFIER", 77, 88], ["strokes", "OBSERVATION", 89, 96]]], ["Among patients with COVID-19, cerebrovascular disease is associated with increased mortality and severe COVID-19 infection (5); patients with prior stroke have a more severe COVID-19 infection (6, 7) .", [["cerebrovascular", "ANATOMY", 30, 45], ["cerebrovascular disease", "DISEASE", 30, 53], ["infection", "DISEASE", 113, 122], ["stroke", "DISEASE", 148, 154], ["infection", "DISEASE", 183, 192], ["patients", "ORGANISM", 6, 14], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 30, 45], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 128, 136], ["COVID", "TEST", 20, 25], ["cerebrovascular disease", "PROBLEM", 30, 53], ["increased mortality", "PROBLEM", 73, 92], ["severe COVID-19 infection", "PROBLEM", 97, 122], ["prior stroke", "PROBLEM", 142, 154], ["a more severe COVID-19 infection", "PROBLEM", 160, 192], ["cerebrovascular", "ANATOMY", 30, 45], ["disease", "OBSERVATION", 46, 53], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["mortality", "OBSERVATION", 83, 92], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["infection", "OBSERVATION", 113, 122], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["infection", "OBSERVATION", 183, 192]]], ["While there is current interest in hypercoagulable states, vasculitis, and cardioembolism from cardiomyopathy as the mechanism for the stroke, others including large artery atherosclerosis, small artery disease, and other cardioembolic sources such as atrial fibrillation should not be forgotten (8, 9) .", [["artery", "ANATOMY", 166, 172], ["small artery", "ANATOMY", 190, 202], ["atrial", "ANATOMY", 252, 258], ["vasculitis", "DISEASE", 59, 69], ["cardioembolism", "DISEASE", 75, 89], ["cardiomyopathy", "DISEASE", 95, 109], ["stroke", "DISEASE", 135, 141], ["artery atherosclerosis", "DISEASE", 166, 188], ["small artery disease", "DISEASE", 190, 210], ["cardioembolic", "DISEASE", 222, 235], ["atrial fibrillation", "DISEASE", 252, 271], ["artery", "MULTI-TISSUE_STRUCTURE", 166, 172], ["artery", "MULTI-TISSUE_STRUCTURE", 196, 202], ["atrial", "MULTI-TISSUE_STRUCTURE", 252, 258], ["hypercoagulable states", "PROBLEM", 35, 57], ["vasculitis", "PROBLEM", 59, 69], ["cardioembolism", "PROBLEM", 75, 89], ["cardiomyopathy", "PROBLEM", 95, 109], ["the stroke", "PROBLEM", 131, 141], ["large artery atherosclerosis", "PROBLEM", 160, 188], ["small artery disease", "PROBLEM", 190, 210], ["other cardioembolic sources", "PROBLEM", 216, 243], ["atrial fibrillation", "PROBLEM", 252, 271], ["hypercoagulable states", "OBSERVATION", 35, 57], ["vasculitis", "OBSERVATION", 59, 69], ["cardioembolism", "OBSERVATION", 75, 89], ["cardiomyopathy", "OBSERVATION", 95, 109], ["stroke", "OBSERVATION", 135, 141], ["large", "OBSERVATION_MODIFIER", 160, 165], ["artery", "ANATOMY", 166, 172], ["atherosclerosis", "OBSERVATION", 173, 188], ["small", "OBSERVATION_MODIFIER", 190, 195], ["artery", "ANATOMY", 196, 202], ["disease", "OBSERVATION", 203, 210], ["cardioembolic", "OBSERVATION", 222, 235], ["atrial", "ANATOMY", 252, 258], ["fibrillation", "OBSERVATION", 259, 271]]], ["There has been a noticeable drop in the number of stroke patients arriving at Emergency Rooms (10) (11) (12) , or they come late (12, 13) , or when they are more severe (14) .", [["stroke", "DISEASE", 50, 56], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["noticeable", "OBSERVATION_MODIFIER", 17, 27], ["drop", "OBSERVATION_MODIFIER", 28, 32], ["number", "OBSERVATION_MODIFIER", 40, 46], ["stroke", "OBSERVATION", 50, 56]]], ["This could be possibly out of fear of entering an environment where there may be COVID-19 patients (15) , or due to the reduced availability of ambulances or prompt medical services due to resource diversion to managing COVID-19.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["COVID", "TEST", 81, 86], ["resource diversion", "TREATMENT", 189, 207], ["COVID", "TEST", 220, 225]]], ["All these impact on the provision of evidence-based stroke care that have been proven to reduce death, disability, and stroke recurrence (16) .INTRODUCTIONSingapore is a small tropical island city-state of 5.7 million people situated in the heart of South-East Asia.", [["heart", "ANATOMY", 241, 246], ["stroke", "DISEASE", 52, 58], ["death", "DISEASE", 96, 101], ["disability", "DISEASE", 103, 113], ["stroke", "DISEASE", 119, 125], ["people", "ORGANISM", 218, 224], ["heart", "ORGAN", 241, 246], ["people", "SPECIES", 218, 224], ["based stroke care", "TREATMENT", 46, 63], ["death", "PROBLEM", 96, 101], ["stroke recurrence", "PROBLEM", 119, 136], ["small", "OBSERVATION_MODIFIER", 170, 175], ["heart", "ANATOMY", 241, 246]]], ["Stroke is a major cause of death and disability, with an incidence of 1.8/1,000, prevalence of 3.65% among those aged above 50 years, and is among the top 10 causes of hospitalization to our acute care government-funded restructured hospitals that provide heavily subsidized care for more than 95% of acute stroke patients (17) .INTRODUCTIONThe number of people diagnosed with COVID-19 in Singapore has been rising (18).", [["Stroke", "DISEASE", 0, 6], ["death", "DISEASE", 27, 32], ["disability", "DISEASE", 37, 47], ["stroke", "DISEASE", 307, 313], ["COVID-19", "CHEMICAL", 377, 385], ["patients", "ORGANISM", 314, 322], ["people", "ORGANISM", 355, 361], ["patients", "SPECIES", 314, 322], ["people", "SPECIES", 355, 361], ["Stroke", "PROBLEM", 0, 6], ["death", "PROBLEM", 27, 32], ["acute stroke", "PROBLEM", 301, 313], ["COVID", "TEST", 377, 382], ["acute", "OBSERVATION_MODIFIER", 301, 306], ["stroke", "OBSERVATION", 307, 313], ["rising", "OBSERVATION_MODIFIER", 408, 414]]], ["The Taskforce's roles are to direct the national whole-of-government response to the novel coronavirus outbreak; coordinate the community response to protect Singaporeans and stay vigilant against the spread of the disease; and work with the international community to respond to the outbreak.", [["coronavirus", "DISEASE", 91, 102], ["coronavirus", "ORGANISM", 91, 102], ["Singaporeans", "ORGANISM", 158, 170], ["coronavirus", "SPECIES", 91, 102], ["the novel coronavirus outbreak", "PROBLEM", 81, 111], ["the disease", "PROBLEM", 211, 222], ["disease", "OBSERVATION", 215, 222]]], ["This has resulted in a seamless collaborative response, tapping on the resources of many ministries, so as to swiftly and effectively respond to the infection.INTRODUCTIONPrior to the COVID-19 pandemic, patients calling for the national ambulance service who were assessed as possibly having a stroke were transported directly to one of three thrombolysis/thrombectomy centers if they met the time windows, or, if not, to the nearest of the seven restructured hospitals or a collaborating private hospital scattered throughout the country.", [["infection", "DISEASE", 149, 158], ["stroke", "DISEASE", 294, 300], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["the infection", "PROBLEM", 145, 158], ["a stroke", "PROBLEM", 292, 300], ["three thrombolysis/thrombectomy centers", "TREATMENT", 337, 376], ["infection", "OBSERVATION", 149, 158], ["stroke", "OBSERVATION", 294, 300], ["thrombectomy", "OBSERVATION", 356, 368]]], ["The few patients who arrived via their own transportation means and who met the time windows would receive thrombolysis at whichever center they arrived at, but if they needed thrombectomy, they were then transported to one of the three thrombectomy centers; a small number of thrombectomies were performed at a few private hospitals.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["thrombolysis", "TREATMENT", 107, 119], ["thrombectomy", "TREATMENT", 176, 188], ["the three thrombectomy centers", "TREATMENT", 227, 257], ["a small number of thrombectomies", "PROBLEM", 259, 291], ["few", "OBSERVATION_MODIFIER", 4, 7], ["thrombectomy", "OBSERVATION", 176, 188], ["thrombectomy", "OBSERVATION", 237, 249], ["small", "OBSERVATION_MODIFIER", 261, 266]]], ["Intravenous thrombolysis and thrombectomy services were available 24 h a day.", [["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["Intravenous thrombolysis", "TREATMENT", 0, 24], ["thrombectomy services", "TREATMENT", 29, 50], ["thrombectomy", "OBSERVATION", 29, 41]]], ["In all hospitals, after emergent triage, patients were, where possible, neuro-imaged while still in the emergency department, before being sent to the acute stroke unit (ASU) of that hospital to be managed by a multidisciplinary stroke team.", [["stroke", "DISEASE", 157, 163], ["stroke", "DISEASE", 229, 235], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["emergent triage", "TEST", 24, 39]]], ["Those requiring in-patient rehabilitation were transferred to the rehabilitation department or to a nearby community hospital.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26]]], ["Community-based resources were available including out-patient rehabilitation, home medical and nursing and rehabilitation (19) .", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62]]], ["Stroke support was provided by the Singapore National Stroke Association (SNSA), the oldest national-level support group for stroke survivors and their carers (20, 21) .INTRODUCTIONThere have been a few publications with details on how the stroke care has been reorganized due to the COVD-19 situation.", [["Stroke", "DISEASE", 0, 6], ["Stroke", "DISEASE", 54, 60], ["stroke", "DISEASE", 125, 131], ["stroke", "DISEASE", 240, 246], ["Stroke support", "TREATMENT", 0, 14], ["stroke survivors", "TREATMENT", 125, 141]]], ["Some are hospital-based (22, 23) some only address a specific issue e.g., thrombectomy in that hospital (24) .", [["thrombectomy", "TREATMENT", 74, 86], ["thrombectomy", "OBSERVATION", 74, 86]]], ["There are no publications on stroke care re-organization at a regional or national level, to my knowledge.", [["stroke", "DISEASE", 29, 35], ["stroke care", "TREATMENT", 29, 40], ["no", "UNCERTAINTY", 10, 12], ["publications", "OBSERVATION", 13, 25]]], ["In Singapore's response to the COVID-19 epidemic, there were significant changes to the well-coordinated stroke care system, bolstered by lessons learnt from the 2002-2003 SARS-CoV-1 epidemic.", [["stroke", "DISEASE", 105, 111], ["SARS", "DISEASE", 172, 176], ["CoV-1", "ORGANISM", 177, 182], ["the COVID", "TEST", 27, 36], ["significant changes", "PROBLEM", 61, 80], ["CoV", "TEST", 177, 180]]], ["This paper aims to present these changes, and what efforts have been made to maintain the provision of high-quality care for those with acute stroke and after discharge, as well as ancillary stroke activities at a national level.", [["acute stroke", "DISEASE", 136, 148], ["stroke", "DISEASE", 191, 197], ["acute stroke", "PROBLEM", 136, 148], ["ancillary stroke activities", "PROBLEM", 181, 208]]], ["The information may be valuable to clinicians, administrators and policy makers involved in stroke care coordination beyond a single hospital, involving hospital and care networks.PRE-HOSPITALAt a national level, on calling for the public ambulance, patients are screened for possible COVID-19 infection or if they are at high risk of having COVID-19 (HrCP).", [["stroke", "DISEASE", 92, 98], ["infection", "DISEASE", 294, 303], ["COVID-19", "CHEMICAL", 342, 350], ["patients", "ORGANISM", 250, 258], ["COVID-19", "GENE_OR_GENE_PRODUCT", 342, 350], ["patients", "SPECIES", 250, 258], ["COVID-19", "SPECIES", 285, 293], ["COVID-19 infection", "PROBLEM", 285, 303], ["COVID", "TEST", 342, 347], ["infection", "OBSERVATION", 294, 303]]], ["The definition includes return from a country with high numbers of COVID-19 patients, in close contact with persons who have COVID-19 (e.g., same household as, cared for, or exposed for more than 30 min within two meters of a COVID-19 patient), or have been served a quarantine, leave of absence or stay-home order due to contact with a COVID-19 patient.", [["patients", "ORGANISM", 76, 84], ["persons", "ORGANISM", 108, 115], ["patient", "ORGANISM", 235, 242], ["patient", "ORGANISM", 346, 353], ["patients", "SPECIES", 76, 84], ["persons", "SPECIES", 108, 115], ["patient", "SPECIES", 235, 242], ["patient", "SPECIES", 346, 353]]], ["These HrCP are taken directly to the National Center for Infectious Diseases (NCID) where they are assessed and isolated for further care.", [["Infectious Diseases", "DISEASE", 57, 76], ["HrCP", "GENE_OR_GENE_PRODUCT", 6, 10], ["Infectious", "OBSERVATION", 57, 67]]], ["This policy of sending HrCP to the NCID may be reviewed if the center gets overloaded with patients.", [["HrCP", "GENE_OR_GENE_PRODUCT", 23, 27], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["overloaded", "OBSERVATION", 75, 85]]], ["There have been no noticeable delays in emergency service response timesthe public ambulance service is centrally coordinated and has adequate staff and necessary ambulances; the provision for dealing with large numbers of ambulance requests has been in place for many years, probably based on prior experiences with large disasters and tragedies causing mass casualties.", [["large disasters", "PROBLEM", 317, 332], ["mass casualties", "PROBLEM", 355, 370], ["no", "UNCERTAINTY", 16, 18], ["noticeable", "OBSERVATION_MODIFIER", 19, 29], ["delays", "OBSERVATION_MODIFIER", 30, 36], ["mass", "OBSERVATION", 355, 359]]], ["All others who meet the criteria for intravenous thrombolysis or thrombectomy are still taken to the three dedicated centers; if they do not meet the criteria, they are taken to any of the restructured hospitals, as before.", [["intravenous", "ANATOMY", 37, 48], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 48], ["intravenous thrombolysis", "TREATMENT", 37, 61], ["thrombectomy", "TREATMENT", 65, 77], ["thrombectomy", "OBSERVATION", 65, 77]]], ["Patients may still choose to use their own transportation means for getting to their preferred hospital.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["There is no practice change here.EMERGENCY ROOM, NEUROIMAGING AND HYPERACUTE THERAPIES (FIGURE 1)At a hospital level, existing stroke pathways had to be modified in each hospital to meet the needs for strict infection control.", [["stroke", "DISEASE", 127, 133], ["infection", "DISEASE", 208, 217], ["practice change", "PROBLEM", 12, 27], ["NEUROIMAGING", "TEST", 49, 61], ["existing stroke pathways", "PROBLEM", 118, 142], ["strict infection control", "TREATMENT", 201, 225], ["no", "UNCERTAINTY", 9, 11], ["practice", "OBSERVATION_MODIFIER", 12, 20], ["change", "OBSERVATION", 21, 27], ["stroke", "OBSERVATION", 127, 133], ["infection", "OBSERVATION", 208, 217]]], ["In all hospitals, on arrival at the emergency room, all cases are screened again for possible COVID-19 infection and fever; those who are HrCPs are immediately sent to NCID-again this policy may be amended.", [["infection", "DISEASE", 103, 112], ["fever", "DISEASE", 117, 122], ["COVID-19 infection", "PROBLEM", 94, 112], ["fever", "PROBLEM", 117, 122], ["infection", "OBSERVATION", 103, 112]]], ["The NCID is located next to the National Neuroscience Institute (NNI); the neurologist is able to see the stroke patient immediately.", [["stroke", "DISEASE", 106, 112], ["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120]]], ["NCID has a designated CT scan negative-pressure room that is staffed 24 h a day and used only for COVID-19 patients.", [["NCID", "CHEMICAL", 0, 4], ["patients", "ORGANISM", 107, 115], ["NCID", "DNA", 0, 4], ["patients", "SPECIES", 107, 115], ["a designated CT scan", "TEST", 9, 29]]], ["By protocol, all thrombectomy patients are prophylactically intubated and sent to a pre-specified operating theater which has negative pressure and a separate ventilation system.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["all thrombectomy", "TREATMENT", 13, 29], ["intubated", "TREATMENT", 60, 69], ["thrombectomy", "OBSERVATION", 17, 29]]], ["The NNI neurologist consults on the patient on a daily basis to collaborate on stroke patient care.", [["stroke", "DISEASE", 79, 85], ["patient", "ORGANISM", 36, 43], ["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 36, 43], ["patient", "SPECIES", 86, 93], ["stroke patient care", "TREATMENT", 79, 98]]], ["It is unlikely that acute stroke therapy was delayed by pre-triage to or subsequent management in NCID (25) .EMERGENCY ROOM, NEUROIMAGING AND HYPERACUTE THERAPIES (FIGURE 1)Those with fever or respiratory tract infection symptoms (e.g., cough, breathlessness, sore throat, runny nose) are defined as COVID-19 suspect patients (CSPs) and are evaluated separately in an area set aside for this purpose, with staff wearing PPE, and the patient in a face mask (FM).", [["respiratory tract", "ANATOMY", 193, 210], ["stroke", "DISEASE", 26, 32], ["fever", "DISEASE", 184, 189], ["respiratory tract infection", "DISEASE", 193, 220], ["cough", "DISEASE", 237, 242], ["breathlessness", "DISEASE", 244, 258], ["sore throat", "DISEASE", 260, 271], ["tract", "ORGANISM_SUBDIVISION", 205, 210], ["patients", "ORGANISM", 317, 325], ["patient", "ORGANISM", 433, 440], ["patients", "SPECIES", 317, 325], ["patient", "SPECIES", 433, 440], ["acute stroke therapy", "TREATMENT", 20, 40], ["NEUROIMAGING", "TEST", 125, 137], ["fever", "PROBLEM", 184, 189], ["respiratory tract infection symptoms", "PROBLEM", 193, 229], ["cough", "PROBLEM", 237, 242], ["breathlessness", "PROBLEM", 244, 258], ["sore throat", "PROBLEM", 260, 271], ["runny nose", "PROBLEM", 273, 283], ["COVID", "TEST", 300, 305], ["CSPs", "TEST", 327, 331], ["PPE", "TREATMENT", 420, 423], ["a face mask", "TREATMENT", 444, 455], ["unlikely that", "UNCERTAINTY", 6, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["stroke", "OBSERVATION", 26, 32], ["respiratory tract", "ANATOMY", 193, 210]]], ["Triage, assessment for urgent therapies, imaging are performed without delay for all CSPs and non-CSPs as per the hospital stroke protocol.", [["stroke", "DISEASE", 123, 129], ["assessment", "TEST", 8, 18], ["urgent therapies", "TREATMENT", 23, 39], ["imaging", "TEST", 41, 48], ["all CSPs", "TEST", 81, 89], ["non-CSPs", "TEST", 94, 102]]], ["CSPs needing hyperacute therapies are sent to a scan machine in a minimally equipped room prepared for them, and the scanning room is thoroughly disinfected after each patient; if not for hyperacute therapy, the imaging is delayed to the latter part of the day.", [["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["hyperacute therapies", "TREATMENT", 13, 33], ["hyperacute therapy", "TREATMENT", 188, 206], ["the imaging", "TEST", 208, 219]]], ["The three hospitals with the dedicated thrombolysis-thrombectomy services are able to reserve a scan room just for CSPs.", [["the dedicated thrombolysis", "TREATMENT", 25, 51], ["thrombectomy services", "TREATMENT", 52, 73], ["a scan room", "TEST", 94, 105], ["CSPs", "PROBLEM", 115, 119], ["thrombectomy", "OBSERVATION", 52, 64]]], ["Telemedicine is used where possible to reduce staff members entering this area.EMERGENCY ROOM, NEUROIMAGING AND HYPERACUTE THERAPIES (FIGURE 1)Intravenous thrombolysis commences in the scan room, if possible, for all patients.", [["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 143, 154], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["Telemedicine", "TREATMENT", 0, 12], ["NEUROIMAGING", "TEST", 95, 107], ["Intravenous thrombolysis", "TREATMENT", 143, 167]]], ["CSPs who need thrombectomy are prepared in a negative-pressure room if available, and aerosolgenerating activities are minimized.", [["thrombectomy", "TREATMENT", 14, 26], ["thrombectomy", "OBSERVATION", 14, 26]]], ["Non-CSPs are managed in the usual manner.", [["Non-CSPs", "PROBLEM", 0, 8]]], ["There is a pool of interventional radiologists and trained staff, allowing for multiple thrombectomy teams in each of the three dedicated centers, in order to cater for the eventuality that if one EVT team unfortunately encounters a confirmed COVID-19 case without adequate protection, that whole team may need to be quarantined for many days.", [["multiple thrombectomy teams", "TREATMENT", 79, 106], ["COVID", "TEST", 243, 248], ["thrombectomy", "OBSERVATION", 88, 100]]], ["Venepunctures, x-rays, neurosonology, echocardiography, arrhythmia monitoring, and rehabilitation are done within the isolation room by dedicated technicians and staff, based on the clinical need, but may be deferred until the patient has been moved to the ASU if it's less urgent.", [["arrhythmia", "DISEASE", 56, 66], ["patient", "ORGANISM", 227, 234], ["patient", "SPECIES", 227, 234], ["Venepunctures", "TEST", 0, 13], ["x-rays", "TEST", 15, 21], ["echocardiography", "TEST", 38, 54], ["arrhythmia monitoring", "TEST", 56, 77], ["rehabilitation", "TREATMENT", 83, 97]]], ["If repeat imaging is needed, the CSP is transported wearing a FM to the speciallyprepared scanner, with imaging performed in the latter part of the day whenever possible.", [["repeat imaging", "TEST", 3, 17], ["imaging", "TEST", 104, 111]]], ["Non-CSPs are managed as usual in the ASU, and have their investigations performed in the usual venues e.g., radiology department, neurosonology laboratory, cardiac laboratory ( Table 1) .", [["cardiac", "ANATOMY", 156, 163], ["their investigations", "TEST", 51, 71], ["cardiac", "ANATOMY", 156, 163]]], ["ASU daily rounds are attended only by essential members, communication is by electronic means wherever possible, as all hospitals have electronic medical records including review of imaging and laboratory test results.", [["imaging", "TEST", 182, 189], ["laboratory test", "TEST", 194, 209]]], ["Patient transfer and staff movement are minimized, with ward-based teams where possible.", [["Patient", "SPECIES", 0, 7]]], ["All hospital staff wear FM, infection control is strictly enforced especially handwashing; social distancing enforced as far as is practicable.", [["infection", "DISEASE", 28, 37], ["infection control", "TREATMENT", 28, 45], ["infection", "OBSERVATION", 28, 37]]], ["Care pathways continue to be followed.", [["Care pathways", "TREATMENT", 0, 13]]], ["Non-urgent surgeries have been postponed.EMERGENCY ROOM, NEUROIMAGING AND HYPERACUTE THERAPIES (FIGURE 1)Visitors are not allowed, except perhaps if the patient is in intensive care (one named visitor throughout hospital stay), or if caregiver training is being provided pre-discharge.", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["Non-urgent surgeries", "TREATMENT", 0, 20], ["NEUROIMAGING", "TEST", 57, 69]]], ["Doctors and nurses call the patient's family daily with updates, patients are allowed easy access to ward telephones, wi-fi is provided free where possible.", [["patient", "ORGANISM", 28, 35], ["patients", "ORGANISM", 65, 73], ["patient", "SPECIES", 28, 35], ["patients", "SPECIES", 65, 73]]], ["Hospital visits by volunteer befrienders from the SNSA have been halted, but communication over the phone may continue.EMERGENCY ROOM, NEUROIMAGING AND HYPERACUTE THERAPIES (FIGURE 1)Rehabilitation is provided as before, but with social distancing, with patients kept at least one meter apart in the gyms.", [["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 254, 262], ["NEUROIMAGING", "TEST", 135, 147]]], ["Transfers to rehabilitation units and community hospitals may be delayed by repeat screening for COVID-19 infection; mild strokes may be sent home with rehabilitation advice.POST-DISCHARGE CAREOut-patient rehabilitation centers are closed, which may increase functional limitations and hinder recovery (26) .", [["infection", "DISEASE", 106, 115], ["strokes", "DISEASE", 122, 129], ["patient", "ORGANISM", 197, 204], ["patient", "SPECIES", 197, 204], ["COVID-19", "SPECIES", 97, 105], ["repeat screening", "TEST", 76, 92], ["COVID", "TEST", 97, 102], ["infection", "PROBLEM", 106, 115], ["mild strokes", "PROBLEM", 117, 129], ["rehabilitation advice", "TREATMENT", 152, 173], ["mild", "OBSERVATION_MODIFIER", 117, 121], ["strokes", "OBSERVATION", 122, 129]]], ["Online rehabilitation services are being tried, but elderly patients are usually unable to manage the required steps, further challenged by their physical disabilities.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68]]], ["At the patient level, patients return for out-patient visits only if needed; many are fearful.", [["patient", "ORGANISM", 7, 14], ["patients", "ORGANISM", 22, 30], ["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 7, 14], ["patients", "SPECIES", 22, 30], ["patient", "SPECIES", 46, 53]]], ["Home visits by nurses are performed where necessary (e.g., to change nasogastric tubes, urine catheters and dressings).", [["urine", "ANATOMY", 88, 93], ["urine", "ORGANISM_SUBSTANCE", 88, 93], ["nasogastric tubes", "TREATMENT", 69, 86], ["urine catheters", "TREATMENT", 88, 103], ["dressings", "TREATMENT", 108, 117]]], ["Doctors call selected patients to determine progress.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["Medications are sent to the patient's home for a small fee to maintain compliance.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["Medications", "TREATMENT", 0, 11], ["a small fee", "TREATMENT", 47, 58]]], ["Teleconsultation is available but not actively taken up by elderly patients.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["Some stroke support activities by SNSA have started online e.g., exercises, aphasia therapy, but again disabled elderly who are not familiar with the use of online services may not participate.PROFESSIONAL MATTERSAll healthcare professionals are regularly recertified by their respective professional boards (e.g., Singapore Medical Council for doctors), usually by participating in continuing medical education (CME) activities (27) .", [["stroke", "DISEASE", 5, 11], ["SNSA", "CHEMICAL", 34, 38], ["aphasia", "DISEASE", 76, 83], ["Some stroke support activities", "PROBLEM", 0, 30], ["aphasia therapy", "TREATMENT", 76, 91], ["stroke", "OBSERVATION", 5, 11]]], ["But the availability of CME activities by electronic means via webinars has greatly increased; COVID-19 CMEs are popular and well-attended.", [["COVID", "TEST", 95, 100]]], ["Stroke research has been severely hampered as subjects are fearful to come to hospital, movements around the hospital is strictly controlled.", [["Stroke", "DISEASE", 0, 6], ["Stroke", "PROBLEM", 0, 6], ["severely", "OBSERVATION_MODIFIER", 25, 33]]], ["But some researchers are taking the opportunity provided by reduced out-patient work to write their previously-shelved papers.OTHER SOLUTIONSThere have been a number of publications of stroke systems of care during the COVID-19 epidemic.", [["stroke", "DISEASE", 185, 191], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["stroke systems", "TREATMENT", 185, 199], ["the COVID", "TEST", 215, 224]]], ["Pre-hospital triage, advance notice by the ambulance to the Emergency Room, adequate training and use of PPE to reduce staff infection, adequate respiratory management en-route, care in appropriately equipped hospitals, and minimizing transfers is important (28, 29) .", [["respiratory", "ANATOMY", 145, 156], ["infection", "DISEASE", 125, 134], ["PPE", "TREATMENT", 105, 108], ["staff infection", "PROBLEM", 119, 134], ["adequate respiratory management", "TREATMENT", 136, 167]]], ["Existing stroke pathways may need to be revised (23), including for endovascular therapy (30, 31) .", [["stroke", "DISEASE", 9, 15], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 80], ["Existing stroke pathways", "PROBLEM", 0, 24], ["endovascular therapy", "TREATMENT", 68, 88], ["stroke", "OBSERVATION", 9, 15]]], ["Rehabilitation should not be neglected (32, 33) .", [["Rehabilitation", "TREATMENT", 0, 14]]], ["It can be managed with stream-lined protocols, use of telemedicine/telerehabilitation, attending to COVID-19-related adverse events (such as fever and respiratory symptoms), enforcing social distancing and adequate sterilization of equipment (34, 35) .", [["respiratory", "ANATOMY", 151, 162], ["COVID-19", "CHEMICAL", 100, 108], ["fever", "DISEASE", 141, 146], ["respiratory symptoms", "DISEASE", 151, 171], ["stream-lined protocols", "TREATMENT", 23, 45], ["telemedicine/telerehabilitation", "TREATMENT", 54, 85], ["adverse events", "PROBLEM", 117, 131], ["fever", "PROBLEM", 141, 146], ["respiratory symptoms", "PROBLEM", 151, 171]]], ["While trying to provide the best of care to patients, staff safety cannot be neglected (36) .", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["A protocol specifically for the management of stroke among patients with COVID-19 may be helpful (22) and needs to be practiced (37) .", [["stroke", "DISEASE", 46, 52], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["A protocol", "TREATMENT", 0, 10], ["stroke", "PROBLEM", 46, 52], ["COVID", "TEST", 73, 78], ["stroke", "OBSERVATION", 46, 52]]], ["Guidelines and suggestions for stroke care have been proposed (39) (40) (41) (42) (43) (44) , but each center had best develop its own or tailor existing guidelines to meet and fit its needs.", [["stroke", "DISEASE", 31, 37], ["stroke care", "TREATMENT", 31, 42]]], ["Challenges for stroke care are even greater in developing countries (47) .CONCLUSIONSThe COVID-19 pandemic has posed some challenges to the provision of stroke care in Singapore.", [["stroke", "DISEASE", 15, 21], ["stroke", "DISEASE", 153, 159], ["stroke care", "TREATMENT", 15, 26], ["stroke care", "TREATMENT", 153, 164], ["greater", "OBSERVATION_MODIFIER", 36, 43]]], ["There is no overall change in pre-hospital and hyperacute stroke care policies, but CSPs are cared for in isolation; stroke support services and stroke research are majorly affected.", [["stroke", "DISEASE", 58, 64], ["stroke", "DISEASE", 117, 123], ["stroke", "DISEASE", 145, 151], ["overall change in pre-hospital and hyperacute stroke care policies", "PROBLEM", 12, 78], ["stroke support services", "TREATMENT", 117, 140], ["stroke research", "TREATMENT", 145, 160], ["no", "UNCERTAINTY", 9, 11], ["overall", "OBSERVATION_MODIFIER", 12, 19], ["change", "OBSERVATION", 20, 26], ["hyperacute", "OBSERVATION_MODIFIER", 47, 57], ["stroke", "OBSERVATION", 58, 64]]], ["Still, evidence-based stroke care is delivered in a re-organized manner, with a clear eye on infection control.", [["eye", "ANATOMY", 86, 89], ["stroke", "DISEASE", 22, 28], ["infection", "DISEASE", 93, 102], ["eye", "ORGAN", 86, 89], ["based stroke care", "PROBLEM", 16, 33], ["infection control", "TREATMENT", 93, 110], ["stroke", "OBSERVATION", 22, 28], ["eye", "ANATOMY", 86, 89], ["infection", "OBSERVATION", 93, 102]]]], "PMC7396565": [["IntroductionThe liver is considered a crucial organ of the body due to its involvement in numerous processes, such as metabolism, immunity, detoxification, nutrient storage, among others.", [["liver", "ANATOMY", 16, 21], ["organ", "ANATOMY", 46, 51], ["body", "ANATOMY", 59, 63], ["liver", "ORGAN", 16, 21], ["organ", "ORGAN", 46, 51], ["body", "ORGANISM_SUBDIVISION", 59, 63], ["liver", "ANATOMY", 16, 21], ["body", "ANATOMY", 59, 63]]], ["The liver is composed primarily of four distinct cell types, differentiated into two categories as parenchymal cells (PC, 60\u201380%) and non-parenchymal cells (NPC 20\u201340%).", [["liver", "ANATOMY", 4, 9], ["cell", "ANATOMY", 49, 53], ["parenchymal cells", "ANATOMY", 99, 116], ["PC", "ANATOMY", 118, 120], ["non-parenchymal cells", "ANATOMY", 134, 155], ["NPC", "ANATOMY", 157, 160], ["liver", "ORGAN", 4, 9], ["cell", "CELL", 49, 53], ["parenchymal cells", "CELL", 99, 116], ["PC", "CELL", 118, 120], ["non-parenchymal cells", "CELL", 134, 155], ["NPC", "CANCER", 157, 160], ["parenchymal cells", "CELL_TYPE", 99, 116], ["PC", "CELL_TYPE", 118, 120], ["non-parenchymal cells", "CELL_TYPE", 134, 155], ["NPC", "PROTEIN", 157, 160], ["parenchymal cells", "TEST", 99, 116], ["PC", "TEST", 118, 120], ["non-parenchymal cells", "TEST", 134, 155], ["NPC", "TEST", 157, 160], ["liver", "ANATOMY", 4, 9], ["four distinct", "OBSERVATION_MODIFIER", 35, 48], ["cell types", "OBSERVATION", 49, 59], ["parenchymal cells", "OBSERVATION", 99, 116], ["non-parenchymal cells", "OBSERVATION", 134, 155]]], ["The NPC population is composed of liver sinusoidal endothelial cells/LSECs (50%), Kupffer cells/KCs (20%) and stellate cells (<1%).", [["NPC", "ANATOMY", 4, 7], ["liver sinusoidal endothelial cells", "ANATOMY", 34, 68], ["LSECs", "ANATOMY", 69, 74], ["Kupffer cells", "ANATOMY", 82, 95], ["KCs", "ANATOMY", 96, 99], ["stellate cells", "ANATOMY", 110, 124], ["NPC", "CANCER", 4, 7], ["liver sinusoidal endothelial cells", "CELL", 34, 68], ["LSECs", "CELL", 69, 74], ["Kupffer cells", "CELL", 82, 95], ["KCs", "CELL", 96, 99], ["stellate cells", "CELL", 110, 124], ["NPC population", "CELL_LINE", 4, 18], ["liver sinusoidal endothelial cells", "CELL_TYPE", 34, 68], ["LSECs", "CELL_TYPE", 69, 74], ["Kupffer cells", "CELL_TYPE", 82, 95], ["KCs", "CELL_TYPE", 96, 99], ["stellate cells", "CELL_TYPE", 110, 124], ["The NPC population", "PROBLEM", 0, 18], ["liver sinusoidal endothelial cells", "TEST", 34, 68], ["LSECs", "TEST", 69, 74], ["Kupffer cells", "TEST", 82, 95], ["KCs", "TEST", 96, 99], ["stellate cells", "TEST", 110, 124], ["liver", "ANATOMY", 34, 39], ["sinusoidal", "ANATOMY_MODIFIER", 40, 50], ["endothelial cells", "OBSERVATION", 51, 68], ["LSECs", "ANATOMY", 69, 74]]], ["The remaining NPCs are composed of lymphocytes (25%) and biliary cells (5%) (Racanelli and Rehermann, 2006).", [["NPCs", "ANATOMY", 14, 18], ["lymphocytes", "ANATOMY", 35, 46], ["biliary cells", "ANATOMY", 57, 70], ["NPCs", "CELL", 14, 18], ["lymphocytes", "CELL", 35, 46], ["biliary cells", "CELL", 57, 70], ["NPCs", "CELL_TYPE", 14, 18], ["lymphocytes", "CELL_TYPE", 35, 46], ["biliary cells", "CELL_TYPE", 57, 70], ["lymphocytes", "TEST", 35, 46], ["biliary cells", "TEST", 57, 70], ["Racanelli", "TEST", 77, 86], ["NPCs", "OBSERVATION_MODIFIER", 14, 18], ["biliary cells", "ANATOMY", 57, 70]]], ["The role of hepatocytes, KCs and stellate cells in maintaining liver homeostasis is well documented.", [["hepatocytes", "ANATOMY", 12, 23], ["KCs", "ANATOMY", 25, 28], ["stellate cells", "ANATOMY", 33, 47], ["liver", "ANATOMY", 63, 68], ["hepatocytes", "CELL", 12, 23], ["KCs", "CELL", 25, 28], ["stellate cells", "CELL", 33, 47], ["liver", "ORGAN", 63, 68], ["hepatocytes", "CELL_TYPE", 12, 23], ["KCs", "CELL_TYPE", 25, 28], ["stellate cells", "CELL_TYPE", 33, 47], ["hepatocytes", "ANATOMY", 12, 23], ["stellate cells", "OBSERVATION", 33, 47], ["liver", "ANATOMY", 63, 68], ["homeostasis", "OBSERVATION", 69, 80]]], ["However, the LSEC, is the most understudied due to technical challenges in purification and culturing ex vivo.IntroductionProf.", [["technical challenges in purification", "TREATMENT", 51, 87], ["culturing ex vivo", "TEST", 92, 109], ["LSEC", "OBSERVATION", 13, 17]]], ["Eddie Wisse first proposed the ultrastructure of liver sinusoidal endothelial cells (LSEC) in 1970, which differentiated LSECs from KCs and paved the way for future study on LSECs and elucidation of their function (Wisse, 1970, 1972).", [["liver sinusoidal endothelial cells", "ANATOMY", 49, 83], ["LSEC", "ANATOMY", 85, 89], ["LSECs", "ANATOMY", 121, 126], ["KCs", "ANATOMY", 132, 135], ["LSECs", "ANATOMY", 174, 179], ["liver sinusoidal endothelial cells", "CELL", 49, 83], ["LSEC", "CELL", 85, 89], ["LSECs", "CELL", 121, 126], ["KCs", "CELL", 132, 135], ["LSECs", "CANCER", 174, 179], ["liver sinusoidal endothelial cells", "CELL_TYPE", 49, 83], ["LSEC", "CELL_TYPE", 85, 89], ["LSECs", "CELL_TYPE", 121, 126], ["KCs", "CELL_TYPE", 132, 135], ["LSECs", "CELL_TYPE", 174, 179], ["future study", "TEST", 158, 170], ["liver", "ANATOMY", 49, 54], ["sinusoidal", "ANATOMY_MODIFIER", 55, 65], ["endothelial cells", "OBSERVATION", 66, 83]]], ["A few years later, several research groups developed LSEC isolation techniques and identified their role in the uptake of various substances in vitro (Seglen, 1976; Smedsrod et al., 1984).", [["LSEC isolation techniques", "TREATMENT", 53, 78], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["In the early 1980s, LSECs were identified as a significant clearance site for blood-borne hyaluronan, which established their role as scavenger cells (Fraser et al., 1981).", [["LSECs", "ANATOMY", 20, 25], ["blood", "ANATOMY", 78, 83], ["cells", "ANATOMY", 144, 149], ["LSECs", "CELL", 20, 25], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 90, 100], ["cells", "CELL", 144, 149], ["LSECs", "CELL_TYPE", 20, 25], ["scavenger cells", "CELL_TYPE", 134, 149], ["a significant clearance site", "PROBLEM", 45, 73], ["blood-borne hyaluronan", "TREATMENT", 78, 100], ["LSECs", "ANATOMY", 20, 25]]], ["This led to an increase in interest among scientists from other discipline, such as immunology, virology, cancer, and more to further comprehend the various roles performed by LSECs.", [["cancer", "ANATOMY", 106, 112], ["LSECs", "ANATOMY", 176, 181], ["cancer", "DISEASE", 106, 112], ["cancer", "CANCER", 106, 112], ["LSECs", "CELL", 176, 181], ["LSECs", "CELL_TYPE", 176, 181], ["cancer", "PROBLEM", 106, 112], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["cancer", "OBSERVATION", 106, 112]]], ["This review focuses on the detailed description of LSEC morphology and their scavenger, adhesion and other prominent receptors that define their functional roles in the hematological and hepatic systems during health and disease.LSEC MorphologyLiver sinusoidal endothelial cells (LSECs) form the inner lining of liver sinusoidal blood vessels or capillary bed which serves as the site for mixing nutrient-rich blood from the hepatic portal vein and oxygen-rich blood from the hepatic artery (Sorensen et al., 2015).", [["LSEC", "ANATOMY", 51, 55], ["hematological", "ANATOMY", 169, 182], ["hepatic systems", "ANATOMY", 187, 202], ["LSEC MorphologyLiver sinusoidal endothelial cells", "ANATOMY", 229, 278], ["LSECs", "ANATOMY", 280, 285], ["inner lining", "ANATOMY", 296, 308], ["liver sinusoidal blood vessels", "ANATOMY", 312, 342], ["capillary bed", "ANATOMY", 346, 359], ["site", "ANATOMY", 380, 384], ["blood", "ANATOMY", 410, 415], ["hepatic portal vein", "ANATOMY", 425, 444], ["blood", "ANATOMY", 461, 466], ["hepatic artery", "ANATOMY", 476, 490], ["hematological and hepatic systems", "DISEASE", 169, 202], ["oxygen", "CHEMICAL", 449, 455], ["oxygen", "CHEMICAL", 449, 455], ["LSEC", "CANCER", 51, 55], ["hematological", "CANCER", 169, 182], ["hepatic systems", "MULTI-TISSUE_STRUCTURE", 187, 202], ["LSEC MorphologyLiver sinusoidal endothelial cells", "CELL", 229, 278], ["LSECs", "CELL", 280, 285], ["inner lining", "TISSUE", 296, 308], ["liver sinusoidal blood vessels", "MULTI-TISSUE_STRUCTURE", 312, 342], ["capillary bed", "TISSUE", 346, 359], ["blood", "ORGANISM_SUBSTANCE", 410, 415], ["hepatic portal vein", "MULTI-TISSUE_STRUCTURE", 425, 444], ["oxygen", "SIMPLE_CHEMICAL", 449, 455], ["blood", "ORGANISM_SUBSTANCE", 461, 466], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 476, 490], ["LSEC MorphologyLiver sinusoidal endothelial cells", "CELL_LINE", 229, 278], ["LSECs", "CELL_TYPE", 280, 285], ["disease", "PROBLEM", 221, 228], ["mixing nutrient", "PROBLEM", 389, 404], ["hematological", "ANATOMY", 169, 182], ["hepatic", "ANATOMY", 187, 194], ["sinusoidal endothelial cells", "OBSERVATION", 250, 278], ["inner", "ANATOMY_MODIFIER", 296, 301], ["lining", "ANATOMY_MODIFIER", 302, 308], ["liver", "ANATOMY", 312, 317], ["sinusoidal", "ANATOMY_MODIFIER", 318, 328], ["blood vessels", "ANATOMY", 329, 342], ["capillary", "ANATOMY_MODIFIER", 346, 355], ["hepatic", "ANATOMY", 425, 432], ["portal vein", "ANATOMY", 433, 444], ["oxygen", "OBSERVATION_MODIFIER", 449, 455], ["rich blood", "OBSERVATION", 456, 466], ["hepatic artery", "ANATOMY", 476, 490]]], ["Here, the LSECs assist in clearing macromolecular waste (extracellular matrix material and foreign molecules) from the blood and regulate hepatic vascularity.", [["LSECs", "ANATOMY", 10, 15], ["extracellular matrix", "ANATOMY", 57, 77], ["blood", "ANATOMY", 119, 124], ["hepatic", "ANATOMY", 138, 145], ["extracellular", "CELLULAR_COMPONENT", 57, 70], ["matrix material", "CELLULAR_COMPONENT", 71, 86], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["hepatic", "ORGAN", 138, 145], ["LSECs", "CELL_TYPE", 10, 15], ["extracellular matrix material", "TREATMENT", 57, 86], ["foreign molecules", "PROBLEM", 91, 108], ["the blood", "TEST", 115, 124], ["clearing", "OBSERVATION_MODIFIER", 26, 34], ["macromolecular waste", "OBSERVATION", 35, 55], ["extracellular matrix", "OBSERVATION_MODIFIER", 57, 77], ["foreign molecules", "OBSERVATION", 91, 108], ["blood", "ANATOMY", 119, 124], ["hepatic", "ANATOMY", 138, 145], ["vascularity", "OBSERVATION", 146, 157]]], ["Individual LSEC\u2019s are flat and very small in size, no thicker than 5 \u03bcm at the center and 0.3 \u03bcm at the periphery (Wisse, 1970, 1972; Smedsrod et al., 1988b; Falkowska-Hansen et al., 2007).", [["very small in size", "PROBLEM", 31, 49], ["LSEC", "OBSERVATION", 11, 15], ["flat", "OBSERVATION_MODIFIER", 22, 26], ["very", "OBSERVATION_MODIFIER", 31, 35], ["small", "OBSERVATION_MODIFIER", 36, 41], ["size", "OBSERVATION_MODIFIER", 45, 49], ["no", "UNCERTAINTY", 51, 53], ["thicker", "OBSERVATION_MODIFIER", 54, 61], ["0.3 \u03bcm", "OBSERVATION_MODIFIER", 90, 96], ["periphery", "ANATOMY_MODIFIER", 104, 113]]], ["Cytoplasmic projections, such as filopodia, lamellipodia, and microvilli are absent in LSECs, giving them a smooth appearance.", [["Cytoplasmic projections", "ANATOMY", 0, 23], ["filopodia", "ANATOMY", 33, 42], ["lamellipodia", "ANATOMY", 44, 56], ["microvilli", "ANATOMY", 62, 72], ["LSECs", "ANATOMY", 87, 92], ["filopodia", "CELLULAR_COMPONENT", 33, 42], ["lamellipodia", "CELLULAR_COMPONENT", 44, 56], ["microvilli", "CELLULAR_COMPONENT", 62, 72], ["LSECs", "PATHOLOGICAL_FORMATION", 87, 92], ["LSECs", "CELL_TYPE", 87, 92], ["Cytoplasmic projections", "TEST", 0, 23], ["filopodia", "OBSERVATION_MODIFIER", 33, 42], ["lamellipodia", "OBSERVATION_MODIFIER", 44, 56], ["microvilli", "ANATOMY_MODIFIER", 62, 72], ["LSECs", "ANATOMY", 87, 92], ["smooth", "OBSERVATION_MODIFIER", 108, 114]]], ["LSECs contain numerous fenestrae (small open pores) that facilitate the selective exchange of molecules between the blood and underlying stellate and hepatocytes (Wisse et al., 1985; Braet and Wisse, 2002).", [["LSECs", "ANATOMY", 0, 5], ["fenestrae", "ANATOMY", 23, 32], ["blood", "ANATOMY", 116, 121], ["stellate", "ANATOMY", 137, 145], ["hepatocytes", "ANATOMY", 150, 161], ["LSECs", "SIMPLE_CHEMICAL", 0, 5], ["fenestrae", "TISSUE", 23, 32], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["stellate", "CELL", 137, 145], ["hepatocytes", "CELL", 150, 161], ["LSECs", "CELL_TYPE", 0, 5], ["blood and underlying stellate and hepatocytes", "CELL_TYPE", 116, 161], ["numerous fenestrae (small open pores", "PROBLEM", 14, 50], ["the selective exchange of molecules", "TREATMENT", 68, 103], ["numerous", "OBSERVATION_MODIFIER", 14, 22], ["fenestrae", "OBSERVATION_MODIFIER", 23, 32], ["small", "OBSERVATION_MODIFIER", 34, 39], ["open pores", "OBSERVATION_MODIFIER", 40, 50], ["selective", "OBSERVATION_MODIFIER", 72, 81], ["blood", "ANATOMY", 116, 121], ["stellate", "OBSERVATION_MODIFIER", 137, 145], ["hepatocytes", "ANATOMY", 150, 161]]], ["Fenestrae are located in the cytoplasm of LSECs and usually are 50\u2013200 nm in diameter and organized in groups known as sieve plates (Wisse et al., 1985).", [["cytoplasm", "ANATOMY", 29, 38], ["LSECs", "ANATOMY", 42, 47], ["cytoplasm", "ORGANISM_SUBSTANCE", 29, 38], ["LSECs", "CANCER", 42, 47], ["Fenestrae", "TREATMENT", 0, 9], ["cytoplasm", "OBSERVATION_MODIFIER", 29, 38], ["LSECs", "ANATOMY", 42, 47], ["diameter", "OBSERVATION_MODIFIER", 77, 85], ["sieve plates", "OBSERVATION", 119, 131]]], ["They are also distributed individually on the surface of endothelium or organized in a labyrinth or mesh-like structure (Taira, 1994; Braet et al., 2007, 2009; Figure 1).", [["surface", "ANATOMY", 46, 53], ["endothelium", "ANATOMY", 57, 68], ["labyrinth", "ANATOMY", 87, 96], ["surface", "CELLULAR_COMPONENT", 46, 53], ["endothelium", "TISSUE", 57, 68], ["endothelium", "OBSERVATION", 57, 68], ["mesh", "OBSERVATION", 100, 104]]], ["LSECs do not have a basement membrane or basal lamina and diaphragm, permitting direct access of solutes to the perisinusoidal space or the Space of Disse.", [["LSECs", "ANATOMY", 0, 5], ["basement membrane", "ANATOMY", 20, 37], ["basal lamina", "ANATOMY", 41, 53], ["diaphragm", "ANATOMY", 58, 67], ["perisinusoidal space", "ANATOMY", 112, 132], ["basement membrane", "CELLULAR_COMPONENT", 20, 37], ["basal lamina", "CELLULAR_COMPONENT", 41, 53], ["diaphragm", "ORGAN", 58, 67], ["LSECs", "CELL_TYPE", 0, 5], ["basal", "ANATOMY_MODIFIER", 41, 46], ["lamina", "ANATOMY_MODIFIER", 47, 53], ["diaphragm", "ANATOMY", 58, 67], ["solutes", "OBSERVATION", 97, 104], ["perisinusoidal", "ANATOMY_MODIFIER", 112, 126], ["Space", "ANATOMY_MODIFIER", 140, 145], ["Disse", "OBSERVATION", 149, 154]]], ["The lack of a basal lamina has also been identified in several animals, such as chickens and bony fish (Fraser et al., 1986; Eng and Youson, 1992).", [["basal lamina", "ANATOMY", 14, 26], ["bony fish", "ANATOMY", 93, 102], ["basal lamina", "CELLULAR_COMPONENT", 14, 26], ["chickens", "ORGANISM", 80, 88], ["chickens", "SPECIES", 80, 88], ["chickens", "SPECIES", 80, 88], ["basal", "ANATOMY_MODIFIER", 14, 19], ["lamina", "ANATOMY_MODIFIER", 20, 26], ["several", "OBSERVATION_MODIFIER", 55, 62]]], ["The Space of Disse hosts the stellate cells as well as hepatocyte microvilli.", [["stellate cells", "ANATOMY", 29, 43], ["hepatocyte microvilli", "ANATOMY", 55, 76], ["stellate cells", "CELL", 29, 43], ["hepatocyte microvilli", "CELLULAR_COMPONENT", 55, 76], ["stellate cells", "CELL_TYPE", 29, 43], ["Space", "OBSERVATION_MODIFIER", 4, 9], ["Disse", "OBSERVATION", 13, 18], ["stellate cells", "OBSERVATION", 29, 43], ["hepatocyte", "ANATOMY", 55, 65], ["microvilli", "ANATOMY_MODIFIER", 66, 76]]], ["During fibrosis or chronic inflammation, activated stellate cells contribute to the deposition of extracellular matrix in the Space of Disse, forming a continuous basal membrane.", [["stellate cells", "ANATOMY", 51, 65], ["extracellular matrix", "ANATOMY", 98, 118], ["basal membrane", "ANATOMY", 163, 177], ["fibrosis", "DISEASE", 7, 15], ["inflammation", "DISEASE", 27, 39], ["stellate cells", "CELL", 51, 65], ["extracellular matrix", "CELLULAR_COMPONENT", 98, 118], ["basal membrane", "CELLULAR_COMPONENT", 163, 177], ["activated stellate cells", "CELL_TYPE", 41, 65], ["fibrosis", "PROBLEM", 7, 15], ["chronic inflammation", "PROBLEM", 19, 39], ["activated stellate cells", "PROBLEM", 41, 65], ["fibrosis", "OBSERVATION", 7, 15], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["inflammation", "OBSERVATION", 27, 39], ["stellate cells", "OBSERVATION", 51, 65], ["deposition", "OBSERVATION_MODIFIER", 84, 94], ["extracellular matrix", "OBSERVATION", 98, 118], ["Space", "ANATOMY_MODIFIER", 126, 131], ["Disse", "ANATOMY_MODIFIER", 135, 140], ["basal", "ANATOMY_MODIFIER", 163, 168], ["membrane", "ANATOMY_MODIFIER", 169, 177]]], ["This new basal lamina is mostly composed of collagen that inhibits the permeability of the Space of Disse and reduces the solute exchange between the parenchyma and blood (Han et al., 2001; Mak et al., 2012).LSEC MorphologyLSEC\u2019s are unique because of their plentiful fenestrae.", [["basal lamina", "ANATOMY", 9, 21], ["parenchyma", "ANATOMY", 150, 160], ["blood", "ANATOMY", 165, 170], ["basal lamina", "TISSUE", 9, 21], ["collagen", "GENE_OR_GENE_PRODUCT", 44, 52], ["solute", "SIMPLE_CHEMICAL", 122, 128], ["parenchyma", "TISSUE", 150, 160], ["blood", "ORGANISM_SUBSTANCE", 165, 170], ["fenestrae", "TISSUE", 268, 277], ["collagen", "PROTEIN", 44, 52], ["the solute exchange between the parenchyma", "PROBLEM", 118, 160], ["new", "OBSERVATION_MODIFIER", 5, 8], ["basal", "ANATOMY_MODIFIER", 9, 14], ["lamina", "ANATOMY_MODIFIER", 15, 21], ["mostly", "OBSERVATION_MODIFIER", 25, 31], ["collagen", "OBSERVATION", 44, 52], ["permeability", "OBSERVATION_MODIFIER", 71, 83], ["Space", "ANATOMY_MODIFIER", 91, 96], ["Disse", "OBSERVATION", 100, 105], ["solute exchange", "OBSERVATION", 122, 137], ["parenchyma", "ANATOMY", 150, 160], ["blood", "ANATOMY", 165, 170], ["plentiful", "OBSERVATION_MODIFIER", 258, 267], ["fenestrae", "OBSERVATION", 268, 277]]], ["The LSEC fenestrae can change their diameter in response to the cellular environment (Wisse et al., 1996; Braet and Wisse, 2002).", [["LSEC fenestrae", "ANATOMY", 4, 18], ["cellular", "ANATOMY", 64, 72], ["cellular", "CELL", 64, 72], ["The LSEC fenestrae", "TREATMENT", 0, 18], ["LSEC", "ANATOMY", 4, 8], ["fenestrae", "OBSERVATION", 9, 18], ["diameter", "OBSERVATION_MODIFIER", 36, 44]]], ["The mechanism for fenestral contraction and dilation was first discovered by researchers in the 1980s and is now known as a dynamic process (Monkemoller et al., 2015; Zapotoczny et al., 2019).", [["fenestral", "ANATOMY", 18, 27], ["fenestral contraction", "PROBLEM", 18, 39], ["dilation", "TREATMENT", 44, 52], ["mechanism for", "UNCERTAINTY", 4, 17], ["fenestral contraction", "OBSERVATION", 18, 39], ["dilation", "OBSERVATION", 44, 52]]], ["Fenestrae is surrounded by actin filaments, suggesting the role of cytoskeleton is central in the formation and maintenance of fenestrae.", [["filaments", "ANATOMY", 33, 42], ["cytoskeleton", "ANATOMY", 67, 79], ["fenestrae", "ANATOMY", 127, 136], ["actin", "GENE_OR_GENE_PRODUCT", 27, 32], ["filaments", "CELLULAR_COMPONENT", 33, 42], ["cytoskeleton", "CELLULAR_COMPONENT", 67, 79], ["fenestrae", "CELLULAR_COMPONENT", 127, 136], ["actin filaments", "PROTEIN", 27, 42], ["Fenestrae", "TREATMENT", 0, 9], ["actin filaments", "OBSERVATION", 27, 42], ["cytoskeleton", "OBSERVATION", 67, 79], ["central", "OBSERVATION_MODIFIER", 83, 90], ["fenestrae", "OBSERVATION", 127, 136]]], ["This idea was further supported by several researchers in the successive years as immunofluorescence microscopic study substantiated the presence of actin, myosin, microtubule and calmodulin as necessary in forming these structures (Wisse, 1970; Braet and Wisse, 2002).", [["microtubule", "ANATOMY", 164, 175], ["actin", "GENE_OR_GENE_PRODUCT", 149, 154], ["myosin", "GENE_OR_GENE_PRODUCT", 156, 162], ["microtubule", "CELLULAR_COMPONENT", 164, 175], ["calmodulin", "GENE_OR_GENE_PRODUCT", 180, 190], ["actin", "PROTEIN", 149, 154], ["myosin", "PROTEIN", 156, 162], ["microtubule", "PROTEIN", 164, 175], ["calmodulin", "PROTEIN", 180, 190], ["immunofluorescence microscopic study", "TEST", 82, 118], ["microtubule and calmodulin", "TREATMENT", 164, 190]]], ["Actin, myosin, and calmodulin influence the diameter of each pore and determine how long it persists.", [["pore", "ANATOMY", 61, 65], ["Actin", "GENE_OR_GENE_PRODUCT", 0, 5], ["myosin", "GENE_OR_GENE_PRODUCT", 7, 13], ["calmodulin", "GENE_OR_GENE_PRODUCT", 19, 29], ["Actin", "PROTEIN", 0, 5], ["myosin", "PROTEIN", 7, 13], ["calmodulin", "PROTEIN", 19, 29], ["calmodulin influence the diameter of each pore", "TREATMENT", 19, 65]]], ["Serotonin has also been found to regulate contraction of fenestrae by increasing the intracellular calcium concentration (Gatmaitan et al., 1996; Yokomori, 2008; Furrer et al., 2011).", [["fenestrae", "ANATOMY", 57, 66], ["intracellular", "ANATOMY", 85, 98], ["Serotonin", "CHEMICAL", 0, 9], ["calcium", "CHEMICAL", 99, 106], ["Serotonin", "CHEMICAL", 0, 9], ["calcium", "CHEMICAL", 99, 106], ["Serotonin", "GENE_OR_GENE_PRODUCT", 0, 9], ["fenestrae", "TISSUE", 57, 66], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 85, 98], ["calcium", "SIMPLE_CHEMICAL", 99, 106], ["Serotonin", "TREATMENT", 0, 9], ["fenestrae", "TREATMENT", 57, 66], ["contraction", "OBSERVATION_MODIFIER", 42, 53], ["fenestrae", "OBSERVATION_MODIFIER", 57, 66]]], ["Increase in the thickness of LSECs, unexpected formation of basal lamina and reduction in the number of pores is known as defenestration.", [["LSECs", "ANATOMY", 29, 34], ["basal lamina", "ANATOMY", 60, 72], ["basal lamina", "CELLULAR_COMPONENT", 60, 72], ["basal lamina", "PROBLEM", 60, 72], ["defenestration", "PROBLEM", 122, 136], ["thickness", "OBSERVATION_MODIFIER", 16, 25], ["LSECs", "OBSERVATION", 29, 34], ["basal", "ANATOMY_MODIFIER", 60, 65], ["lamina", "ANATOMY_MODIFIER", 66, 72], ["reduction", "OBSERVATION_MODIFIER", 77, 86], ["number", "OBSERVATION_MODIFIER", 94, 100], ["pores", "OBSERVATION_MODIFIER", 104, 109]]], ["Defenestration of LSECs gives rise to pseudocapillarization, a disorder evident in liver fibrosis, atherosclerosis and other aging associated diseases (Le Couteur et al., 2001, 2007).", [["LSECs", "ANATOMY", 18, 23], ["liver", "ANATOMY", 83, 88], ["pseudocapillarization", "DISEASE", 38, 59], ["disorder", "DISEASE", 63, 71], ["liver fibrosis", "DISEASE", 83, 97], ["atherosclerosis", "DISEASE", 99, 114], ["LSECs", "CELL", 18, 23], ["liver", "ORGAN", 83, 88], ["LSECs", "CELL_TYPE", 18, 23], ["pseudocapillarization", "PROBLEM", 38, 59], ["a disorder", "PROBLEM", 61, 71], ["liver fibrosis", "PROBLEM", 83, 97], ["atherosclerosis", "PROBLEM", 99, 114], ["other aging associated diseases", "PROBLEM", 119, 150], ["LSECs", "OBSERVATION", 18, 23], ["liver", "ANATOMY", 83, 88], ["fibrosis", "OBSERVATION", 89, 97], ["atherosclerosis", "OBSERVATION", 99, 114], ["Le", "ANATOMY_MODIFIER", 152, 154]]], ["Fenestrae is maintained cooperatively by hepatocytes and stellate cells mediated paracrine and autocrine signaling (DeLeve et al., 2004).", [["hepatocytes", "ANATOMY", 41, 52], ["stellate cells", "ANATOMY", 57, 71], ["hepatocytes", "CELL", 41, 52], ["stellate cells", "CELL", 57, 71], ["hepatocytes", "CELL_TYPE", 41, 52], ["stellate cells", "CELL_TYPE", 57, 71], ["Fenestrae", "TREATMENT", 0, 9], ["hepatocytes", "ANATOMY", 41, 52], ["stellate cells", "OBSERVATION", 57, 71]]], ["Vascular endothelial growth factor (VGEF), a hormone that functions in blood vessel growth, promotes paracrine signaling from hepatocytes and stellate cells stimulates autocrine signaling of nitric oxide (NO) from LSECs.", [["blood vessel", "ANATOMY", 71, 83], ["hepatocytes", "ANATOMY", 126, 137], ["stellate cells", "ANATOMY", 142, 156], ["LSECs", "ANATOMY", 214, 219], ["nitric oxide", "CHEMICAL", 191, 203], ["NO", "CHEMICAL", 205, 207], ["nitric oxide", "CHEMICAL", 191, 203], ["NO", "CHEMICAL", 205, 207], ["Vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 0, 34], ["VGEF", "GENE_OR_GENE_PRODUCT", 36, 40], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 71, 83], ["hepatocytes", "CELL", 126, 137], ["stellate cells", "CELL", 142, 156], ["nitric oxide", "SIMPLE_CHEMICAL", 191, 203], ["NO", "SIMPLE_CHEMICAL", 205, 207], ["LSECs", "PATHOLOGICAL_FORMATION", 214, 219], ["Vascular endothelial growth factor", "PROTEIN", 0, 34], ["VGEF", "PROTEIN", 36, 40], ["hepatocytes", "CELL_TYPE", 126, 137], ["stellate cells", "CELL_TYPE", 142, 156], ["LSECs", "CELL_TYPE", 214, 219], ["Vascular endothelial growth factor", "PROBLEM", 0, 34], ["blood vessel growth", "PROBLEM", 71, 90], ["stellate cells", "TEST", 142, 156], ["nitric oxide", "TREATMENT", 191, 203], ["endothelial", "ANATOMY", 9, 20], ["blood vessel", "ANATOMY", 71, 83], ["hepatocytes", "ANATOMY", 126, 137], ["LSECs", "ANATOMY", 214, 219]]], ["Animals lacking VEGF tend to exhibit increased defenestration in their LSECs, suggesting that this molecule plays a mechanistic role in either their formation or maintenance (Kus et al., 2019).LSEC MorphologyDefenestrated LSECs results in the reduction of hepatic uptake of lipoproteins and is one of the causes of hyperlipoproteinemia (Fraser et al., 2012).", [["LSECs", "ANATOMY", 71, 76], ["hepatic", "ANATOMY", 256, 263], ["hyperlipoproteinemia", "DISEASE", 315, 335], ["Animals", "ORGANISM", 0, 7], ["VEGF", "GENE_OR_GENE_PRODUCT", 16, 20], ["LSECs", "PATHOLOGICAL_FORMATION", 71, 76], ["hepatic", "ORGAN", 256, 263], ["VEGF", "PROTEIN", 16, 20], ["LSECs", "CELL_TYPE", 71, 76], ["LSEC MorphologyDefenestrated LSECs", "CELL_LINE", 193, 227], ["lipoproteins", "PROTEIN", 274, 286], ["increased defenestration in their LSECs", "PROBLEM", 37, 76], ["hepatic uptake of lipoproteins", "PROBLEM", 256, 286], ["hyperlipoproteinemia", "PROBLEM", 315, 335], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["defenestration", "OBSERVATION", 47, 61], ["LSECs", "ANATOMY", 71, 76], ["reduction", "OBSERVATION_MODIFIER", 243, 252], ["hepatic", "ANATOMY", 256, 263], ["uptake", "OBSERVATION", 264, 270], ["lipoproteins", "OBSERVATION", 274, 286], ["hyperlipoproteinemia", "OBSERVATION", 315, 335]]], ["Similarly, defenestration has also been observed to play an important role in the progression of non-alcoholic fatty liver disease (NAFLD).", [["non-alcoholic fatty liver", "ANATOMY", 97, 122], ["non-alcoholic fatty liver disease", "DISEASE", 97, 130], ["NAFLD", "DISEASE", 132, 137], ["non-alcoholic fatty", "CANCER", 97, 116], ["liver", "ORGAN", 117, 122], ["defenestration", "PROBLEM", 11, 25], ["non-alcoholic fatty liver disease", "PROBLEM", 97, 130], ["progression", "OBSERVATION_MODIFIER", 82, 93], ["non-alcoholic", "OBSERVATION_MODIFIER", 97, 110], ["fatty", "OBSERVATION", 111, 116], ["liver", "ANATOMY", 117, 122]]], ["Miyao et al. demonstrated that since LSECs are a \u201cgatekeeper\u201d for the liver parenchyma, their injury during early stages of NAFLD determines the severity of subsequent injury and progression of NAFLD (Miyao et al., 2015; Shetty et al., 2018).", [["LSECs", "ANATOMY", 37, 42], ["liver parenchyma", "ANATOMY", 70, 86], ["NAFLD", "DISEASE", 124, 129], ["NAFLD", "DISEASE", 194, 199], ["LSECs", "CELL", 37, 42], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 70, 86], ["LSECs", "CELL_TYPE", 37, 42], ["the liver parenchyma", "PROBLEM", 66, 86], ["their injury", "PROBLEM", 88, 100], ["NAFLD", "PROBLEM", 124, 129], ["subsequent injury", "PROBLEM", 157, 174], ["NAFLD", "PROBLEM", 194, 199], ["liver", "ANATOMY", 70, 75], ["parenchyma", "ANATOMY_MODIFIER", 76, 86], ["injury", "OBSERVATION", 94, 100], ["injury", "OBSERVATION", 168, 174], ["progression", "OBSERVATION_MODIFIER", 179, 190]]], ["In the past few years, some of this data has been called into question in that some have observed no difference in NAFLD and fenestration levels of LSECs and that LSECs have a more calming effect on injured hepatocytes and activated stellate cells (Kus et al., 2019).", [["LSECs", "ANATOMY", 148, 153], ["LSECs", "ANATOMY", 163, 168], ["hepatocytes", "ANATOMY", 207, 218], ["stellate cells", "ANATOMY", 233, 247], ["NAFLD", "DISEASE", 115, 120], ["LSECs", "SIMPLE_CHEMICAL", 148, 153], ["LSECs", "SIMPLE_CHEMICAL", 163, 168], ["hepatocytes", "CELL", 207, 218], ["stellate cells", "CELL", 233, 247], ["LSECs", "CELL_TYPE", 148, 153], ["LSECs", "CELL_TYPE", 163, 168], ["injured hepatocytes", "CELL_TYPE", 199, 218], ["activated stellate cells", "CELL_TYPE", 223, 247], ["difference in NAFLD", "PROBLEM", 101, 120], ["fenestration levels of LSECs", "PROBLEM", 125, 153], ["injured hepatocytes", "PROBLEM", 199, 218], ["activated stellate cells", "PROBLEM", 223, 247], ["NAFLD", "OBSERVATION", 115, 120], ["fenestration", "OBSERVATION", 125, 137], ["LSECs", "ANATOMY", 148, 153], ["hepatocytes", "ANATOMY", 207, 218], ["stellate cells", "OBSERVATION", 233, 247]]], ["This idea is reinforced in a study of autoimmune hepatitis in which human LSECs in biopsies from young people less than 20 years old were assessed for damage and the formation of a basement membrane.", [["LSECs", "ANATOMY", 74, 79], ["biopsies", "ANATOMY", 83, 91], ["basement membrane", "ANATOMY", 181, 198], ["autoimmune hepatitis", "DISEASE", 38, 58], ["human", "ORGANISM", 68, 73], ["LSECs", "CELL", 74, 79], ["biopsies", "CANCER", 83, 91], ["people", "ORGANISM", 103, 109], ["basement membrane", "CELLULAR_COMPONENT", 181, 198], ["human LSECs", "CELL_TYPE", 68, 79], ["human", "SPECIES", 68, 73], ["people", "SPECIES", 103, 109], ["human", "SPECIES", 68, 73], ["a study", "TEST", 27, 34], ["autoimmune hepatitis", "PROBLEM", 38, 58], ["biopsies", "TEST", 83, 91], ["damage", "PROBLEM", 151, 157], ["autoimmune", "OBSERVATION_MODIFIER", 38, 48], ["hepatitis", "OBSERVATION", 49, 58]]], ["Defenestration did occur in about half of the subjects, but little to no basement membrane formed in the Space of Disse suggesting that LSECs have regenerative properties and may soften the assault on the liver (Lotowska et al., 2018).", [["basement membrane", "ANATOMY", 73, 90], ["LSECs", "ANATOMY", 136, 141], ["liver", "ANATOMY", 205, 210], ["basement membrane", "CELLULAR_COMPONENT", 73, 90], ["LSECs", "CELL", 136, 141], ["liver", "ORGAN", 205, 210], ["LSECs", "CELL_TYPE", 136, 141], ["Defenestration", "PROBLEM", 0, 14], ["basement membrane", "PROBLEM", 73, 90], ["Disse", "OBSERVATION", 114, 119], ["LSECs", "OBSERVATION", 136, 141], ["regenerative", "OBSERVATION_MODIFIER", 147, 159], ["assault", "OBSERVATION", 190, 197], ["liver", "ANATOMY", 205, 210]]], ["While there was no causative relationship proven, the jury is still out on whether progressive NAFLD is associated with defenestration.LSEC MorphologyAnother salient characteristic of LSECs that differentiate them from other endothelial cells is their higher endocytic ability.", [["LSECs", "ANATOMY", 184, 189], ["endothelial cells", "ANATOMY", 225, 242], ["NAFLD", "DISEASE", 95, 100], ["LSECs", "CANCER", 184, 189], ["endothelial cells", "CELL", 225, 242], ["LSECs", "CELL_TYPE", 184, 189], ["endothelial cells", "CELL_TYPE", 225, 242], ["progressive NAFLD", "PROBLEM", 83, 100], ["defenestration", "PROBLEM", 120, 134], ["other endothelial cells", "PROBLEM", 219, 242], ["no causative", "UNCERTAINTY", 16, 28], ["progressive", "OBSERVATION_MODIFIER", 83, 94], ["NAFLD", "OBSERVATION", 95, 100], ["LSECs", "OBSERVATION", 184, 189], ["endothelial cells", "OBSERVATION", 225, 242]]], ["LSECs only make up about 3% of total liver volume, however, they contribute to about 45% of pinocytic vesicles in the liver (Blouin et al., 1977).", [["LSECs", "ANATOMY", 0, 5], ["liver", "ANATOMY", 37, 42], ["pinocytic vesicles", "ANATOMY", 92, 110], ["liver", "ANATOMY", 118, 123], ["liver", "ORGAN", 37, 42], ["pinocytic vesicles", "CELLULAR_COMPONENT", 92, 110], ["liver", "ORGAN", 118, 123], ["LSECs", "CELL_TYPE", 0, 5], ["LSECs", "TEST", 0, 5], ["total liver volume", "TEST", 31, 49], ["pinocytic vesicles in the liver", "PROBLEM", 92, 123], ["liver", "ANATOMY", 37, 42], ["volume", "OBSERVATION", 43, 49], ["pinocytic vesicles", "OBSERVATION", 92, 110], ["liver", "ANATOMY", 118, 123]]], ["A study was conducted to elucidate the mechanism of cross presentation by LSECs as a link was found between endocytosis and antigen presentation (Burgdorf et al., 2008).", [["LSECs", "ANATOMY", 74, 79], ["LSECs", "SIMPLE_CHEMICAL", 74, 79], ["LSECs", "CELL_TYPE", 74, 79], ["A study", "TEST", 0, 7]]], ["This study reported that LSECs were most efficient at internalizing circulating antigen in the blood as compared to dendritic cells (DC) or macrophages of the spleen as well as by KC and DC of the liver (Schurich et al., 2009).", [["LSECs", "ANATOMY", 25, 30], ["blood", "ANATOMY", 95, 100], ["dendritic cells", "ANATOMY", 116, 131], ["DC", "ANATOMY", 133, 135], ["macrophages", "ANATOMY", 140, 151], ["spleen", "ANATOMY", 159, 165], ["KC", "ANATOMY", 180, 182], ["DC", "ANATOMY", 187, 189], ["liver", "ANATOMY", 197, 202], ["LSECs", "SIMPLE_CHEMICAL", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["dendritic cells", "CELL", 116, 131], ["DC", "CELL", 133, 135], ["macrophages", "CELL", 140, 151], ["spleen", "ORGAN", 159, 165], ["KC", "CELL", 180, 182], ["DC", "CELL", 187, 189], ["liver", "ORGAN", 197, 202], ["LSECs", "CELL_TYPE", 25, 30], ["circulating antigen", "PROTEIN", 68, 87], ["dendritic cells", "CELL_TYPE", 116, 131], ["DC", "CELL_TYPE", 133, 135], ["macrophages", "CELL_TYPE", 140, 151], ["KC", "CELL_TYPE", 180, 182], ["DC", "CELL_TYPE", 187, 189], ["This study", "TEST", 0, 10], ["macrophages of the spleen", "PROBLEM", 140, 165], ["blood", "ANATOMY", 95, 100], ["dendritic cells", "OBSERVATION", 116, 131], ["macrophages", "OBSERVATION", 140, 151], ["spleen", "ANATOMY", 159, 165], ["liver", "ANATOMY", 197, 202]]], ["LSECs are well equipped with high affinity endocytic scavenger receptors and lysosomal activity that helps in the internalization and catabolization of a large number of waste substances (Table 1) as well as small colloidal particles (Knook and Sleyster, 1980; Juvet et al., 1997; Kawai et al., 1998; Elvevold et al., 2008a).LSEC MorphologyKjeken et al. (2001) showed that a clathrin-dependent mechanism is used by LSECs for fluid phase endocytosis.", [["LSECs", "ANATOMY", 0, 5], ["lysosomal", "ANATOMY", 77, 86], ["LSECs", "ANATOMY", 415, 420], ["fluid", "ANATOMY", 425, 430], ["LSECs", "CELL", 0, 5], ["lysosomal", "CELLULAR_COMPONENT", 77, 86], ["clathrin", "GENE_OR_GENE_PRODUCT", 375, 383], ["LSECs", "SIMPLE_CHEMICAL", 415, 420], ["LSECs", "CELL_TYPE", 0, 5], ["high affinity endocytic scavenger receptors", "PROTEIN", 29, 72], ["clathrin", "PROTEIN", 375, 383], ["LSECs", "CELL_TYPE", 415, 420], ["high affinity endocytic scavenger receptors", "TREATMENT", 29, 72], ["small colloidal particles", "PROBLEM", 208, 233], ["a clathrin-dependent mechanism", "PROBLEM", 373, 403], ["fluid phase endocytosis", "PROBLEM", 425, 448], ["lysosomal activity", "OBSERVATION", 77, 95], ["large", "OBSERVATION_MODIFIER", 154, 159], ["waste substances", "OBSERVATION", 170, 186], ["small", "OBSERVATION_MODIFIER", 208, 213], ["colloidal particles", "OBSERVATION", 214, 233], ["fluid phase", "OBSERVATION", 425, 436]]], ["Furthermore, they found that LSECs have higher expression of clathrin protein and twice the number of clathrin-coated pits as compared to KC or hepatocytes.", [["LSECs", "ANATOMY", 29, 34], ["pits", "ANATOMY", 118, 122], ["KC", "ANATOMY", 138, 140], ["hepatocytes", "ANATOMY", 144, 155], ["LSECs", "CELL", 29, 34], ["clathrin", "GENE_OR_GENE_PRODUCT", 61, 69], ["clathrin", "GENE_OR_GENE_PRODUCT", 102, 110], ["KC", "CELL", 138, 140], ["hepatocytes", "CELL", 144, 155], ["LSECs", "CELL_TYPE", 29, 34], ["clathrin protein", "PROTEIN", 61, 77], ["clathrin", "PROTEIN", 102, 110], ["KC", "CELL_LINE", 138, 140], ["hepatocytes", "CELL_TYPE", 144, 155], ["clathrin protein", "PROBLEM", 61, 77], ["coated pits", "PROBLEM", 111, 122], ["LSECs", "OBSERVATION", 29, 34], ["clathrin protein", "OBSERVATION", 61, 77], ["hepatocytes", "ANATOMY", 144, 155]]], ["Several years later, Falkowska-Hansen et al. (2007) reported an interesting finding about clathrin-coated vesicles in primary rat LSECs.", [["vesicles", "ANATOMY", 106, 114], ["LSECs", "ANATOMY", 130, 135], ["clathrin", "GENE_OR_GENE_PRODUCT", 90, 98], ["vesicles", "CELLULAR_COMPONENT", 106, 114], ["rat", "ORGANISM", 126, 129], ["LSECs", "CELL", 130, 135], ["clathrin", "PROTEIN", 90, 98], ["primary rat LSECs", "CELL_TYPE", 118, 135], ["rat", "SPECIES", 126, 129], ["rat", "SPECIES", 126, 129], ["rat LSECs", "OBSERVATION", 126, 135]]], ["They found that clathrin heavy chain (CHC) is distributed as net-like structure which was unique to primary rat LSECs.", [["LSECs", "ANATOMY", 112, 117], ["clathrin heavy chain", "GENE_OR_GENE_PRODUCT", 16, 36], ["rat", "ORGANISM", 108, 111], ["LSECs", "CELL", 112, 117], ["clathrin heavy chain", "PROTEIN", 16, 36], ["CHC", "PROTEIN", 38, 41], ["primary rat LSECs", "CELL_TYPE", 100, 117], ["rat", "SPECIES", 108, 111], ["rat", "SPECIES", 108, 111], ["clathrin heavy chain (CHC)", "PROBLEM", 16, 42], ["clathrin", "OBSERVATION_MODIFIER", 16, 24], ["heavy", "OBSERVATION_MODIFIER", 25, 30], ["chain", "OBSERVATION_MODIFIER", 31, 36], ["net", "OBSERVATION_MODIFIER", 61, 64], ["rat LSECs", "OBSERVATION", 108, 117]]], ["They also showed the co-localization of CHC with microtubules.", [["microtubules", "ANATOMY", 49, 61], ["CHC", "DISEASE", 40, 43], ["CHC", "GENE_OR_GENE_PRODUCT", 40, 43], ["microtubules", "CELLULAR_COMPONENT", 49, 61], ["CHC", "PROTEIN", 40, 43], ["microtubules", "PROTEIN", 49, 61], ["CHC", "OBSERVATION", 40, 43]]], ["Furthermore, they found that clathrin-coated vesicle (CCV) function is dependent on microtubules as disruption of microtubules resulted in dysregulation of intracellular transport as well as aberrant signaling of organelles involved in clathrin-mediated endocytosis in LSECs (Falkowska-Hansen et al., 2007).", [["microtubules", "ANATOMY", 84, 96], ["microtubules", "ANATOMY", 114, 126], ["intracellular", "ANATOMY", 156, 169], ["organelles", "ANATOMY", 213, 223], ["LSECs", "ANATOMY", 269, 274], ["clathrin-coated vesicle", "GENE_OR_GENE_PRODUCT", 29, 52], ["CCV", "GENE_OR_GENE_PRODUCT", 54, 57], ["microtubules", "CELLULAR_COMPONENT", 84, 96], ["microtubules", "CELLULAR_COMPONENT", 114, 126], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 169], ["organelles", "CELLULAR_COMPONENT", 213, 223], ["clathrin", "GENE_OR_GENE_PRODUCT", 236, 244], ["LSECs", "PATHOLOGICAL_FORMATION", 269, 274], ["clathrin", "PROTEIN", 29, 37], ["microtubules", "PROTEIN", 114, 126], ["clathrin", "PROTEIN", 236, 244], ["clathrin-coated vesicle", "PROBLEM", 29, 52], ["disruption of microtubules", "PROBLEM", 100, 126], ["dysregulation of intracellular transport", "PROBLEM", 139, 179], ["aberrant signaling of organelles", "PROBLEM", 191, 223], ["coated vesicle", "OBSERVATION", 38, 52], ["dependent", "OBSERVATION_MODIFIER", 71, 80], ["endocytosis", "OBSERVATION_MODIFIER", 254, 265], ["LSECs", "ANATOMY", 269, 274]]], ["Experiments evaluating the endocytosis capacity of primary LSECs in vitro must be performed the same day or within 24 h of purification of the LSECs.", [["LSECs", "ANATOMY", 59, 64], ["LSECs", "ANATOMY", 143, 148], ["LSECs", "CELL", 59, 64], ["LSECs", "CELL", 143, 148], ["primary LSECs", "CELL_TYPE", 51, 64], ["LSECs", "CELL_TYPE", 143, 148], ["the endocytosis capacity", "PROBLEM", 23, 47], ["primary LSECs", "OBSERVATION", 51, 64], ["LSECs", "ANATOMY", 143, 148]]], ["After this time period, endocytosis sharply decreases and ceases altogether around day 4 (Braet et al., 1994).", [["endocytosis", "PROBLEM", 24, 35], ["endocytosis", "OBSERVATION_MODIFIER", 24, 35], ["sharply", "OBSERVATION_MODIFIER", 36, 43], ["decreases", "OBSERVATION_MODIFIER", 44, 53]]], ["Interestingly, the disappearance of fenestrae takes place over the same time course (Braet et al., 2005).", [["fenestrae", "ANATOMY", 36, 45], ["disappearance", "OBSERVATION_MODIFIER", 19, 32], ["fenestrae", "OBSERVATION", 36, 45]]], ["To date, the record holder for maintaining LSECs in culture with their native endocytic capacity is the Smedsrod group using an animal-free medium which allowed endocytosis to occur out to 30 days using a pig model (Elvevold et al., 2005).", [["LSECs", "ANATOMY", 43, 48], ["LSECs", "CELL", 43, 48], ["pig", "ORGANISM", 205, 208], ["LSECs", "CELL_TYPE", 43, 48], ["pig", "SPECIES", 205, 208], ["LSECs in culture", "TEST", 43, 59], ["a pig model", "TREATMENT", 203, 214], ["LSECs", "OBSERVATION", 43, 48]]], ["It should be kept in mind that the study of endocytosis in LSECs must be performed with the freshly purified primary cells as no cell line to date expresses all of the specialized receptors nor morphological features that make these cells so dynamic.Scavenger Receptor A (SR-A) ::: Recently Established Nomenclature for Scavenger ReceptorsThe class A scavenger receptors (also known as MSR1, SR-AI, SCARA1) were first cloned by the Kreiger group (Kodama et al., 1990; Rohrer et al., 1990) and may have been involved with binding to modified low-density lipoproteins.", [["LSECs", "ANATOMY", 59, 64], ["primary cells", "ANATOMY", 109, 122], ["cell line", "ANATOMY", 129, 138], ["cells", "ANATOMY", 233, 238], ["LSECs", "CANCER", 59, 64], ["cells", "CELL", 117, 122], ["cell line", "CELL", 129, 138], ["cells", "CELL", 233, 238], ["Scavenger Receptor A", "GENE_OR_GENE_PRODUCT", 250, 270], ["SR-A", "GENE_OR_GENE_PRODUCT", 272, 276], ["class A scavenger receptors", "GENE_OR_GENE_PRODUCT", 343, 370], ["MSR1", "GENE_OR_GENE_PRODUCT", 386, 390], ["SR-AI", "GENE_OR_GENE_PRODUCT", 392, 397], ["SCARA1", "GENE_OR_GENE_PRODUCT", 399, 405], ["LSECs", "CELL_TYPE", 59, 64], ["freshly purified primary cells", "CELL_TYPE", 92, 122], ["Scavenger Receptors", "PROTEIN", 320, 339], ["class A scavenger receptors", "PROTEIN", 343, 370], ["MSR1", "PROTEIN", 386, 390], ["SR", "PROTEIN", 392, 394], ["AI", "PROTEIN", 395, 397], ["SCARA1", "PROTEIN", 399, 405], ["modified low-density lipoproteins", "PROTEIN", 532, 565], ["the study", "TEST", 31, 40], ["cell line", "TREATMENT", 129, 138], ["MSR1", "TEST", 386, 390], ["cell line", "OBSERVATION", 129, 138]]], ["Scavenger receptor-A (SR-A) is a type II trimeric integral plasma membrane receptor that is encoded on chromosome 8 in both humans and mice.", [["plasma membrane", "ANATOMY", 59, 74], ["chromosome 8", "ANATOMY", 103, 115], ["Scavenger receptor-A", "GENE_OR_GENE_PRODUCT", 0, 20], ["SR-A", "GENE_OR_GENE_PRODUCT", 22, 26], ["type II trimeric integral plasma membrane receptor", "GENE_OR_GENE_PRODUCT", 33, 83], ["chromosome 8", "CELLULAR_COMPONENT", 103, 115], ["humans", "ORGANISM", 124, 130], ["mice", "ORGANISM", 135, 139], ["Scavenger receptor-A", "PROTEIN", 0, 20], ["SR", "PROTEIN", 22, 24], ["type II trimeric integral plasma membrane receptor", "PROTEIN", 33, 83], ["chromosome 8", "DNA", 103, 115], ["humans", "SPECIES", 124, 130], ["mice", "SPECIES", 135, 139], ["humans", "SPECIES", 124, 130], ["mice", "SPECIES", 135, 139], ["Scavenger receptor", "TEST", 0, 18], ["a type II trimeric integral plasma membrane receptor", "TREATMENT", 31, 83]]], ["It is characterized by the following six domains: a transmembrane region, a spacer region, a coiled-coil region, a collagenous stretch of repeated Gly-X-P/K, an N-terminal cytoplasmic tail, and a carboxyl terminal-type specific-domain (Figure 2).", [["transmembrane", "ANATOMY", 52, 65], ["cytoplasmic", "ANATOMY", 172, 183], ["Gly", "CHEMICAL", 147, 150], ["N", "CHEMICAL", 161, 162], ["carboxyl", "CHEMICAL", 196, 204], ["transmembrane region", "PROTEIN", 52, 72], ["coiled-coil region", "PROTEIN", 93, 111], ["X", "PROTEIN", 151, 152], ["P", "PROTEIN", 153, 154], ["K", "PROTEIN", 155, 156], ["N-terminal cytoplasmic tail", "PROTEIN", 161, 188], ["carboxyl terminal-type specific-domain", "PROTEIN", 196, 234], ["Figure 2", "PROTEIN", 236, 244], ["a transmembrane region", "TREATMENT", 50, 72], ["a spacer region", "TREATMENT", 74, 89], ["a coiled-coil region", "TREATMENT", 91, 111], ["repeated Gly", "TEST", 138, 150], ["K", "TEST", 155, 156], ["spacer", "OBSERVATION_MODIFIER", 76, 82], ["collagenous", "OBSERVATION_MODIFIER", 115, 126], ["stretch", "OBSERVATION_MODIFIER", 127, 134], ["terminal", "ANATOMY_MODIFIER", 163, 171], ["cytoplasmic tail", "ANATOMY", 172, 188]]], ["Alternative splicing results in three variants of SR-A, namely SR-A1.1 and SR-A1.2 (Emi et al., 1993).", [["SR-A", "GENE_OR_GENE_PRODUCT", 50, 54], ["SR-A1.1", "GENE_OR_GENE_PRODUCT", 63, 70], ["SR-A1.2", "GENE_OR_GENE_PRODUCT", 75, 82], ["SR", "TEST", 63, 65], ["SR", "TEST", 75, 77]]], ["The structure of the three isoforms are very similar and the differences lie in their cysteine-rich carboxy terminal domain which is involved in cell adhesion and, possibly, bacterial binding (Bowdish and Gordon, 2009; Yap et al., 2015).", [["cell", "ANATOMY", 145, 149], ["cysteine", "CHEMICAL", 86, 94], ["carboxy", "CHEMICAL", 100, 107], ["cell", "CELL", 145, 149], ["cysteine-rich carboxy terminal domain", "PROTEIN", 86, 123], ["very", "OBSERVATION_MODIFIER", 40, 44], ["similar", "OBSERVATION_MODIFIER", 45, 52], ["cell adhesion", "OBSERVATION", 145, 158], ["possibly", "UNCERTAINTY", 164, 172], ["bacterial binding", "OBSERVATION", 174, 191]]], ["SR-A type-I is characterized with a cysteine rich carboxy terminal domain whereas SR-A type-II has short C-terminal domain lacking cysteine-rich site at the C-terminus (Rohrer et al., 1990).", [["cysteine", "CHEMICAL", 36, 44], ["carboxy", "CHEMICAL", 50, 57], ["C", "CHEMICAL", 105, 106], ["cysteine", "CHEMICAL", 131, 139], ["SR-A type-I", "GENE_OR_GENE_PRODUCT", 0, 11], ["SR-A type-II", "GENE_OR_GENE_PRODUCT", 82, 94], ["cysteine", "AMINO_ACID", 131, 139], ["cysteine rich carboxy terminal domain", "PROTEIN", 36, 73], ["SR-A type-II", "PROTEIN", 82, 94], ["C-terminal domain", "PROTEIN", 105, 122], ["cysteine-rich site", "PROTEIN", 131, 149], ["C-terminus", "PROTEIN", 157, 167], ["a cysteine rich carboxy terminal domain", "PROBLEM", 34, 73], ["short C-terminal domain lacking cysteine", "PROBLEM", 99, 139]]], ["SR-A type-III has a truncated cysteine-rich domain (Gough et al., 1999).", [["cysteine", "CHEMICAL", 30, 38], ["SR-A type-III", "GENE_OR_GENE_PRODUCT", 0, 13], ["cysteine", "AMINO_ACID", 30, 38], ["truncated cysteine-rich domain", "PROTEIN", 20, 50]]], ["SR-A type1/1.1 are involved in the binding of diverse macromolecules, such as acetylated and oxidized low density lipoprotein (ac/oxLDL) (Suzuki et al., 1997; Kunjathoor et al., 2002), \u03b2-amyloid fibrils (El Khoury et al., 1996), AGE products (Araki et al., 1995), molecules present on the surface of gram negative and positive bacteria, such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA) (Dunne et al., 1994).", [["surface", "ANATOMY", 289, 296], ["lipopolysaccharide", "CHEMICAL", 345, 363], ["LPS", "CHEMICAL", 365, 368], ["lipoteichoic acid", "CHEMICAL", 374, 391], ["LTA", "CHEMICAL", 393, 396], ["SR-A type1/1.1", "GENE_OR_GENE_PRODUCT", 0, 14], ["oxidized low density lipoprotein", "SIMPLE_CHEMICAL", 93, 125], ["oxLDL", "GENE_OR_GENE_PRODUCT", 130, 135], ["\u03b2-amyloid fibrils", "GENE_OR_GENE_PRODUCT", 185, 202], ["AGE", "SIMPLE_CHEMICAL", 229, 232], ["surface", "CELLULAR_COMPONENT", 289, 296], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 345, 363], ["LPS", "SIMPLE_CHEMICAL", 365, 368], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 374, 391], ["LTA", "SIMPLE_CHEMICAL", 393, 396], ["oxidized low density lipoprotein", "PROTEIN", 93, 125], ["ac", "PROTEIN", 127, 129], ["oxLDL", "PROTEIN", 130, 135], ["SR", "TEST", 0, 2], ["acetylated and oxidized low density lipoprotein (ac/oxLDL)", "TREATMENT", 78, 136], ["\u03b2-amyloid fibrils", "PROBLEM", 185, 202], ["gram", "TEST", 300, 304], ["positive bacteria", "PROBLEM", 318, 335], ["lipopolysaccharide", "TEST", 345, 363], ["LPS", "TEST", 365, 368], ["lipoteichoic acid (LTA", "TEST", 374, 396], ["positive bacteria", "OBSERVATION_MODIFIER", 318, 335]]], ["Rohrer et al. (1990) demonstrated that the fibrous coiled-coil and collagen-like domains are responsible for binding different ligands in SR-A type-1/1.1 as removal of cysteine-rich C-terminal domain in SR-A type-II did not affect its binding capacity.", [["cysteine", "CHEMICAL", 168, 176], ["SR-A type-II", "CHEMICAL", 203, 215], ["cysteine", "CHEMICAL", 168, 176], ["C", "CHEMICAL", 182, 183], ["collagen", "GENE_OR_GENE_PRODUCT", 67, 75], ["SR-A", "GENE_OR_GENE_PRODUCT", 138, 142], ["cysteine", "AMINO_ACID", 168, 176], ["SR-A type-II", "GENE_OR_GENE_PRODUCT", 203, 215], ["fibrous coiled-coil and collagen-like domains", "PROTEIN", 43, 88], ["cysteine-rich C-terminal domain", "PROTEIN", 168, 199], ["SR", "PROTEIN", 203, 205], ["the fibrous coiled-coil and collagen-like domains", "PROBLEM", 39, 88], ["binding different ligands", "PROBLEM", 109, 134], ["removal of cysteine", "TREATMENT", 157, 176], ["terminal domain", "PROBLEM", 184, 199], ["fibrous", "OBSERVATION", 43, 50]]], ["SR-A type-1.2 does not bind to SR-A type-1/1.1 ligands but it has been shown to negatively regulate the functions of SR-A type-1/1.1 in vitro (Gough et al., 1999).Scavenger Receptor A (SR-A) ::: Recently Established Nomenclature for Scavenger ReceptorsSR-A expression was once thought to be only expressed in macrophages/KCs, but recent work have shown their expression in brain microglia and astrocytes, LSECs and vascular smooth muscle cells (Nagelkerke et al., 1983; Hughes et al., 1995; Christie et al., 1996; Gough et al., 1999; Godoy et al., 2012).", [["macrophages", "ANATOMY", 309, 320], ["KCs", "ANATOMY", 321, 324], ["brain microglia", "ANATOMY", 373, 388], ["astrocytes", "ANATOMY", 393, 403], ["LSECs", "ANATOMY", 405, 410], ["vascular smooth muscle cells", "ANATOMY", 415, 443], ["SR-A type-1.2", "GENE_OR_GENE_PRODUCT", 0, 13], ["SR-A type-1/1.1 ligands", "GENE_OR_GENE_PRODUCT", 31, 54], ["SR-A type-1/1.1", "GENE_OR_GENE_PRODUCT", 117, 132], ["Scavenger Receptor A", "GENE_OR_GENE_PRODUCT", 163, 183], ["SR-A", "GENE_OR_GENE_PRODUCT", 185, 189], ["ReceptorsSR-A", "GENE_OR_GENE_PRODUCT", 243, 256], ["macrophages", "CELL", 309, 320], ["KCs", "CELL", 321, 324], ["brain microglia", "CELL", 373, 388], ["astrocytes", "CELL", 393, 403], ["LSECs", "CELL", 405, 410], ["vascular smooth muscle cells", "CELL", 415, 443], ["SR", "PROTEIN", 31, 33], ["SR", "PROTEIN", 117, 119], ["ReceptorsSR", "PROTEIN", 243, 254], ["macrophages", "CELL_TYPE", 309, 320], ["KCs", "CELL_TYPE", 321, 324], ["brain microglia", "CELL_TYPE", 373, 388], ["astrocytes", "CELL_TYPE", 393, 403], ["LSECs", "CELL_TYPE", 405, 410], ["vascular smooth muscle cells", "CELL_TYPE", 415, 443], ["A type-1/1.1 ligands", "PROBLEM", 34, 54], ["brain microglia", "ANATOMY", 373, 388], ["LSECs", "ANATOMY", 405, 410], ["vascular", "ANATOMY", 415, 423], ["smooth muscle", "ANATOMY", 424, 437]]], ["Work conducted in rats have shown that SR-A expressed on LSECs are primarily responsible for carrying out the uptake of the artificial ligand, acLDL, in liver (Nagelkerke et al., 1983).", [["LSECs", "ANATOMY", 57, 62], ["liver", "ANATOMY", 153, 158], ["rats", "ORGANISM", 18, 22], ["SR-A", "GENE_OR_GENE_PRODUCT", 39, 43], ["LSECs", "GENE_OR_GENE_PRODUCT", 57, 62], ["acLDL", "GENE_OR_GENE_PRODUCT", 143, 148], ["liver", "ORGAN", 153, 158], ["LSECs", "CELL_TYPE", 57, 62], ["acLDL", "PROTEIN", 143, 148], ["rats", "SPECIES", 18, 22], ["acLDL", "OBSERVATION_MODIFIER", 143, 148], ["liver", "ANATOMY", 153, 158]]], ["They also theorized the role of an acLDL receptor present on LSECs in the prevention of accumulation of cholesterol under normal condition, though the pathways involved remain elusive.", [["LSECs", "ANATOMY", 61, 66], ["cholesterol", "CHEMICAL", 104, 115], ["cholesterol", "CHEMICAL", 104, 115], ["acLDL receptor", "GENE_OR_GENE_PRODUCT", 35, 49], ["LSECs", "SIMPLE_CHEMICAL", 61, 66], ["cholesterol", "SIMPLE_CHEMICAL", 104, 115], ["acLDL receptor", "PROTEIN", 35, 49], ["an acLDL receptor", "TREATMENT", 32, 49], ["LSECs", "TREATMENT", 61, 66], ["normal condition", "OBSERVATION", 122, 138]]], ["Similarly, another report has demonstrated the uptake of ac/oxLDL by two scavenger receptors; an unidentified 95 kDa protein and the likely candidates, SR-A1/1.1 present on rat LSECs and KCs (De Rijke et al., 1992, 1994; De Rijke and Van Berkel, 1994).", [["LSECs", "ANATOMY", 177, 182], ["KCs", "ANATOMY", 187, 190], ["ac/oxLDL", "GENE_OR_GENE_PRODUCT", 57, 65], ["SR-A1", "GENE_OR_GENE_PRODUCT", 152, 157], ["rat", "ORGANISM", 173, 176], ["LSECs", "CELL", 177, 182], ["KCs", "CELL", 187, 190], ["ac", "PROTEIN", 57, 59], ["oxLDL", "PROTEIN", 60, 65], ["scavenger receptors", "PROTEIN", 73, 92], ["95 kDa protein", "PROTEIN", 110, 124], ["SR", "PROTEIN", 152, 154], ["A1", "PROTEIN", 155, 157], ["1.1", "PROTEIN", 158, 161], ["rat LSECs", "CELL_TYPE", 173, 182], ["KCs", "CELL_TYPE", 187, 190], ["rat", "SPECIES", 173, 176], ["rat", "SPECIES", 173, 176], ["ac/oxLDL", "TREATMENT", 57, 65], ["kDa protein", "TEST", 113, 124], ["SR", "TEST", 152, 154], ["likely", "UNCERTAINTY", 133, 139]]], ["In 1990, a commentary in Nature written by Brown and Goldstein had attempted to bring about a universal idea or theory involving the numerous ligands including LDLs that bind to a few scavenger receptors, of which SR-A was a very likely candidate (Brown and Goldstein, 1990).", [["LDLs", "SIMPLE_CHEMICAL", 160, 164], ["SR-A", "GENE_OR_GENE_PRODUCT", 214, 218], ["scavenger receptors", "PROTEIN", 184, 203]]], ["Furthermore, several studies have shown the elevated expression of SR-A in atherosclerotic lesions (Matsumoto et al., 1990) and accumulation of oxLDL, a SR-A ligand in plaques, suggesting it\u2019s putative role in atherogenesis (Hiltunen et al., 2001).", [["atherosclerotic lesions", "ANATOMY", 75, 98], ["plaques", "ANATOMY", 168, 175], ["atherosclerotic", "DISEASE", 75, 90], ["atherogenesis", "DISEASE", 210, 223], ["SR-A", "GENE_OR_GENE_PRODUCT", 67, 71], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 75, 98], ["oxLDL", "GENE_OR_GENE_PRODUCT", 144, 149], ["SR-A ligand", "GENE_OR_GENE_PRODUCT", 153, 164], ["plaques", "PATHOLOGICAL_FORMATION", 168, 175], ["SR-A", "PROTEIN", 67, 71], ["oxLDL", "PROTEIN", 144, 149], ["SR-A ligand", "PROTEIN", 153, 164], ["several studies", "TEST", 13, 28], ["the elevated expression of SR", "PROBLEM", 40, 69], ["A in atherosclerotic lesions", "PROBLEM", 70, 98], ["accumulation of oxLDL", "PROBLEM", 128, 149], ["A ligand in plaques", "PROBLEM", 156, 175], ["atherogenesis", "PROBLEM", 210, 223], ["atherosclerotic", "OBSERVATION_MODIFIER", 75, 90], ["lesions", "OBSERVATION", 91, 98], ["oxLDL", "ANATOMY", 144, 149], ["plaques", "OBSERVATION", 168, 175]]], ["SR-AI in LSEC is also involved in uptake and degradation of malondialdehydes-acetaldehyde-serum albumin (MAA), which is considered immunogenic and capable of producing inflammatory responses in the liver (Duryee et al., 2005).", [["liver", "ANATOMY", 198, 203], ["malondialdehydes-acetaldehyde", "CHEMICAL", 60, 89], ["MAA", "CHEMICAL", 105, 108], ["malondialdehydes", "CHEMICAL", 60, 76], ["acetaldehyde", "CHEMICAL", 77, 89], ["SR-AI", "GENE_OR_GENE_PRODUCT", 0, 5], ["LSEC", "CANCER", 9, 13], ["malondialdehydes", "SIMPLE_CHEMICAL", 60, 76], ["acetaldehyde-serum albumin", "SIMPLE_CHEMICAL", 77, 103], ["MAA", "SIMPLE_CHEMICAL", 105, 108], ["liver", "ORGAN", 198, 203], ["AI", "PROBLEM", 3, 5], ["malondialdehydes", "TEST", 60, 76], ["acetaldehyde", "TEST", 77, 89], ["serum albumin (MAA", "TEST", 90, 108], ["immunogenic", "PROBLEM", 131, 142], ["inflammatory responses in the liver", "PROBLEM", 168, 203], ["AI", "OBSERVATION", 3, 5], ["LSEC", "ANATOMY", 9, 13], ["inflammatory", "OBSERVATION", 168, 180], ["liver", "ANATOMY", 198, 203]]], ["It has also been observed that chronic ethanol administration diminishes the uptake of MAA by SR-A in rats.", [["ethanol", "CHEMICAL", 39, 46], ["MAA", "CHEMICAL", 87, 90], ["SR-A", "CHEMICAL", 94, 98], ["ethanol", "CHEMICAL", 39, 46], ["MAA", "CHEMICAL", 87, 90], ["ethanol", "SIMPLE_CHEMICAL", 39, 46], ["MAA", "SIMPLE_CHEMICAL", 87, 90], ["SR-A", "GENE_OR_GENE_PRODUCT", 94, 98], ["rats", "ORGANISM", 102, 106], ["rats", "SPECIES", 102, 106], ["chronic ethanol administration", "TREATMENT", 31, 61], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["ethanol", "OBSERVATION", 39, 46]]], ["This leads to the accumulation of acetaldehyde and aldehyde modified protein adducts in the circulation.", [["acetaldehyde", "CHEMICAL", 34, 46], ["aldehyde", "CHEMICAL", 51, 59], ["acetaldehyde", "CHEMICAL", 34, 46], ["aldehyde", "CHEMICAL", 51, 59], ["acetaldehyde", "SIMPLE_CHEMICAL", 34, 46], ["aldehyde", "SIMPLE_CHEMICAL", 51, 59], ["acetaldehyde and aldehyde modified protein adducts", "TREATMENT", 34, 84], ["accumulation", "OBSERVATION_MODIFIER", 18, 30], ["acetaldehyde", "OBSERVATION_MODIFIER", 34, 46], ["aldehyde modified", "OBSERVATION", 51, 68], ["protein adducts", "OBSERVATION", 69, 84], ["circulation", "OBSERVATION_MODIFIER", 92, 103]]], ["These adducts cause secretion of monocyte chemoattractant protein (MCP)-1 and macrophage inflammatory protein (MIP)-2 via hepatic stellate cells, contributing to alcoholic liver disease (Kharbanda et al., 2001).Scavenger Receptor A (SR-A) ::: Recently Established Nomenclature for Scavenger ReceptorsDespite all of the evidence that SR-A receptors were involved with the uptake and catabolism of LDLs, the use of knock-out mice in the late 1990\u2019s demonstrated that the SR-A receptors had a negligible effect on liver uptake and decay of serum acLDL (Ling et al., 1997; Van Berkel et al., 1998).", [["hepatic stellate cells", "ANATOMY", 122, 144], ["liver", "ANATOMY", 172, 177], ["liver", "ANATOMY", 511, 516], ["serum", "ANATOMY", 537, 542], ["alcoholic liver disease", "DISEASE", 162, 185], ["monocyte chemoattractant protein (MCP)-1", "GENE_OR_GENE_PRODUCT", 33, 73], ["macrophage inflammatory protein (MIP)-2", "GENE_OR_GENE_PRODUCT", 78, 117], ["hepatic stellate cells", "CELL", 122, 144], ["liver", "ORGAN", 172, 177], ["Scavenger Receptor A", "GENE_OR_GENE_PRODUCT", 211, 231], ["SR-A", "GENE_OR_GENE_PRODUCT", 233, 237], ["SR-A receptors", "GENE_OR_GENE_PRODUCT", 333, 347], ["LDLs", "SIMPLE_CHEMICAL", 396, 400], ["mice", "ORGANISM", 423, 427], ["SR-A receptors", "GENE_OR_GENE_PRODUCT", 469, 483], ["liver", "ORGAN", 511, 516], ["serum", "ORGANISM_SUBSTANCE", 537, 542], ["acLDL", "SIMPLE_CHEMICAL", 543, 548], ["monocyte chemoattractant protein (MCP)-1", "PROTEIN", 33, 73], ["macrophage inflammatory protein (MIP)-2", "PROTEIN", 78, 117], ["hepatic stellate cells", "CELL_TYPE", 122, 144], ["SR-A receptors", "PROTEIN", 333, 347], ["SR-A receptors", "PROTEIN", 469, 483], ["mice", "SPECIES", 423, 427], ["monocyte chemoattractant protein", "TEST", 33, 65], ["MCP)", "TEST", 67, 71], ["macrophage inflammatory protein (MIP)", "TEST", 78, 115], ["hepatic stellate cells", "PROBLEM", 122, 144], ["alcoholic liver disease", "PROBLEM", 162, 185], ["Scavenger ReceptorsDespite", "TREATMENT", 281, 307], ["the uptake and catabolism of LDLs", "PROBLEM", 367, 400], ["the SR", "TEST", 465, 471], ["liver uptake", "PROBLEM", 511, 523], ["serum acLDL", "TEST", 537, 548], ["hepatic", "ANATOMY", 122, 129], ["stellate cells", "OBSERVATION", 130, 144], ["alcoholic", "OBSERVATION_MODIFIER", 162, 171], ["liver", "ANATOMY", 172, 177], ["liver", "ANATOMY", 511, 516]]], ["Furthermore, SR-A1/1.1-deficient and wild type (WT) mice were compared with the liver sequestration of other non-parenchymal ligands, namely AGE, N-terminal propeptide of type III procollagen (PIIINP) and formaldehyde-treated serum albumin.", [["liver", "ANATOMY", 80, 85], ["non-parenchymal", "ANATOMY", 109, 124], ["serum", "ANATOMY", 226, 231], ["formaldehyde", "CHEMICAL", 205, 217], ["N", "CHEMICAL", 146, 147], ["formaldehyde", "CHEMICAL", 205, 217], ["SR-A1", "GENE_OR_GENE_PRODUCT", 13, 18], ["1.1", "GENE_OR_GENE_PRODUCT", 19, 22], ["wild type (WT) mice", "ORGANISM", 37, 56], ["liver", "ORGAN", 80, 85], ["AGE", "SIMPLE_CHEMICAL", 141, 144], ["type III procollagen", "GENE_OR_GENE_PRODUCT", 171, 191], ["PIIINP", "GENE_OR_GENE_PRODUCT", 193, 199], ["formaldehyde", "SIMPLE_CHEMICAL", 205, 217], ["serum", "ORGANISM_SUBSTANCE", 226, 231], ["albumin", "GENE_OR_GENE_PRODUCT", 232, 239], ["SR", "PROTEIN", 13, 15], ["A1", "PROTEIN", 16, 18], ["1.1", "PROTEIN", 19, 22], ["AGE", "PROTEIN", 141, 144], ["N-terminal propeptide", "PROTEIN", 146, 167], ["type III procollagen", "PROTEIN", 171, 191], ["PIIINP", "PROTEIN", 193, 199], ["formaldehyde-treated serum albumin", "PROTEIN", 205, 239], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 52, 56], ["Furthermore", "TEST", 0, 11], ["SR", "TEST", 13, 15], ["wild type (WT) mice", "PROBLEM", 37, 56], ["the liver sequestration of other non-parenchymal ligands", "PROBLEM", 76, 132], ["type III procollagen (PIIINP)", "TREATMENT", 171, 200], ["formaldehyde", "TREATMENT", 205, 217], ["serum albumin", "TEST", 226, 239], ["liver", "ANATOMY", 80, 85], ["sequestration", "OBSERVATION", 86, 99], ["non-parenchymal ligands", "OBSERVATION", 109, 132]]], ["The results indicated that the SR-A receptors were of minor importance for plasma clearance of these ligands and the distribution in other tissues and organs was not altered (Hansen et al., 2002).Scavenger Receptor B (SR-B) ::: Recently Established Nomenclature for Scavenger ReceptorsScavenger receptor class B type 1 (SR-B1/SCARB1) is a member of scavenger receptor B, which is located on chromosome 12 in humans and chromosome 5 in mice (Acton et al., 1994).", [["plasma", "ANATOMY", 75, 81], ["tissues", "ANATOMY", 139, 146], ["organs", "ANATOMY", 151, 157], ["chromosome 12", "ANATOMY", 391, 404], ["chromosome 5", "ANATOMY", 419, 431], ["SR-A receptors", "GENE_OR_GENE_PRODUCT", 31, 45], ["plasma", "ORGANISM_SUBSTANCE", 75, 81], ["tissues", "TISSUE", 139, 146], ["organs", "ORGAN", 151, 157], ["Scavenger Receptor B", "GENE_OR_GENE_PRODUCT", 196, 216], ["SR-B", "GENE_OR_GENE_PRODUCT", 218, 222], ["Scavenger receptor class B type 1", "GENE_OR_GENE_PRODUCT", 285, 318], ["SR-B1", "GENE_OR_GENE_PRODUCT", 320, 325], ["SCARB1", "GENE_OR_GENE_PRODUCT", 326, 332], ["scavenger receptor B", "GENE_OR_GENE_PRODUCT", 349, 369], ["chromosome 12", "CELLULAR_COMPONENT", 391, 404], ["humans", "ORGANISM", 408, 414], ["chromosome 5", "CELLULAR_COMPONENT", 419, 431], ["mice", "ORGANISM", 435, 439], ["SR-A receptors", "PROTEIN", 31, 45], ["Scavenger Receptor B", "PROTEIN", 196, 216], ["SR", "PROTEIN", 218, 220], ["SR", "PROTEIN", 320, 322], ["B1", "PROTEIN", 323, 325], ["SCARB1", "PROTEIN", 326, 332], ["scavenger receptor B", "PROTEIN", 349, 369], ["chromosome 12", "DNA", 391, 404], ["chromosome 5", "DNA", 419, 431], ["humans", "SPECIES", 408, 414], ["mice", "SPECIES", 435, 439], ["humans", "SPECIES", 408, 414], ["mice", "SPECIES", 435, 439], ["the SR", "TEST", 27, 33], ["plasma clearance of these ligands", "PROBLEM", 75, 108], ["organs", "ANATOMY", 151, 157]]], ["SR-B1 is a membrane glycoprotein consisting of two short cytoplasmic N- and C-terminal domains, two short hydrophobic membrane regions, and a highly N-glycosylated large looped extracellular domain (Krieger, 1999).", [["membrane", "ANATOMY", 11, 19], ["cytoplasmic", "ANATOMY", 57, 68], ["membrane", "ANATOMY", 118, 126], ["extracellular", "ANATOMY", 177, 190], ["N", "CHEMICAL", 69, 70], ["C", "CHEMICAL", 76, 77], ["N", "CHEMICAL", 149, 150], ["SR-B1", "GENE_OR_GENE_PRODUCT", 0, 5], ["membrane", "CELLULAR_COMPONENT", 11, 19], ["cytoplasmic", "ORGANISM_SUBSTANCE", 57, 68], ["membrane", "CELLULAR_COMPONENT", 118, 126], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 177, 190], ["SR", "PROTEIN", 0, 2], ["B1", "PROTEIN", 3, 5], ["membrane glycoprotein", "PROTEIN", 11, 32], ["cytoplasmic N- and C-terminal domains", "PROTEIN", 57, 94], ["hydrophobic membrane regions", "PROTEIN", 106, 134], ["N-glycosylated large looped extracellular domain", "PROTEIN", 149, 197], ["a membrane glycoprotein", "PROBLEM", 9, 32], ["two short cytoplasmic N", "TEST", 47, 70], ["C-terminal domains", "PROBLEM", 76, 94], ["two short hydrophobic membrane regions", "PROBLEM", 96, 134], ["a highly N-glycosylated large looped extracellular domain", "PROBLEM", 140, 197], ["large", "OBSERVATION_MODIFIER", 164, 169], ["looped", "OBSERVATION_MODIFIER", 170, 176], ["extracellular domain", "OBSERVATION", 177, 197]]], ["They exist as two isoforms, SR-B1 and-B1.1, resulting from alternative splicing (Webb et al., 1997).", [["SR-B1", "GENE_OR_GENE_PRODUCT", 28, 33], ["-B1.1", "GENE_OR_GENE_PRODUCT", 37, 42], ["SR", "PROTEIN", 28, 30], ["B1", "PROTEIN", 31, 33], ["B1.1", "PROTEIN", 38, 42], ["SR", "TEST", 28, 30]]], ["CD36 and LIMPII Analogous (CLA-1) is the human homolog of SR-B1 (Calvo and Vega, 1993).", [["CD36", "GENE_OR_GENE_PRODUCT", 0, 4], ["LIMPII Analogous (CLA-1", "GENE_OR_GENE_PRODUCT", 9, 32], ["human", "ORGANISM", 41, 46], ["SR-B1", "GENE_OR_GENE_PRODUCT", 58, 63], ["CD36", "PROTEIN", 0, 4], ["LIMPII", "PROTEIN", 9, 15], ["CLA", "PROTEIN", 27, 30], ["SR", "PROTEIN", 58, 60], ["B1", "PROTEIN", 61, 63], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["CD36", "TEST", 0, 4], ["LIMPII", "TEST", 9, 15], ["CLA", "TEST", 27, 30]]], ["Liver and steroidogenic tissues (adrenal glands, ovaries, and testis) have been shown to highly express SR-B1 (Acton et al., 1996).", [["Liver", "ANATOMY", 0, 5], ["steroidogenic tissues", "ANATOMY", 10, 31], ["adrenal glands", "ANATOMY", 33, 47], ["ovaries", "ANATOMY", 49, 56], ["testis", "ANATOMY", 62, 68], ["Liver", "ORGAN", 0, 5], ["steroidogenic tissues", "TISSUE", 10, 31], ["adrenal glands", "ORGAN", 33, 47], ["ovaries", "ORGAN", 49, 56], ["testis", "ORGAN", 62, 68], ["SR-B1", "GENE_OR_GENE_PRODUCT", 104, 109], ["SR", "PROTEIN", 104, 106], ["B1", "PROTEIN", 107, 109], ["Liver and steroidogenic tissues", "TEST", 0, 31], ["steroidogenic tissues", "OBSERVATION", 10, 31], ["adrenal glands", "ANATOMY", 33, 47], ["ovaries", "ANATOMY", 49, 56], ["testis", "ANATOMY", 62, 68]]], ["Malerod et al. (2002) were the first group to demonstrate the expression of SR-B1 in LSECs from isolated rat liver.", [["LSECs", "ANATOMY", 85, 90], ["liver", "ANATOMY", 109, 114], ["SR-B1", "GENE_OR_GENE_PRODUCT", 76, 81], ["LSECs", "CELL", 85, 90], ["rat", "ORGANISM", 105, 108], ["liver", "ORGAN", 109, 114], ["SR", "PROTEIN", 76, 78], ["B1", "PROTEIN", 79, 81], ["LSECs", "CELL_TYPE", 85, 90], ["rat", "SPECIES", 105, 108], ["rat", "SPECIES", 105, 108], ["rat", "ANATOMY_MODIFIER", 105, 108], ["liver", "ANATOMY", 109, 114]]], ["Several year later, Ganesan et al. (2016) showed the abundant expression of SR-B1 in mouse LSECs by confocal microscopy.", [["LSECs", "ANATOMY", 91, 96], ["SR-B1", "GENE_OR_GENE_PRODUCT", 76, 81], ["mouse", "ORGANISM", 85, 90], ["LSECs", "CELL", 91, 96], ["SR", "PROTEIN", 76, 78], ["B1", "PROTEIN", 79, 81], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 85, 90], ["confocal microscopy", "TEST", 100, 119]]], ["Mutational and knock-out studies have suggested an important role of the SR-B1 receptor in facilitating high density lipoprotein (HDL) uptake in liver and steroidogenic tissues, thereby, its role in atherosclerosis regulation (Acton et al., 1996; Kozarsky et al., 1997; Varban et al., 1998).", [["liver", "ANATOMY", 145, 150], ["steroidogenic tissues", "ANATOMY", 155, 176], ["atherosclerosis", "DISEASE", 199, 214], ["SR-B1 receptor", "GENE_OR_GENE_PRODUCT", 73, 87], ["high density lipoprotein", "SIMPLE_CHEMICAL", 104, 128], ["HDL", "SIMPLE_CHEMICAL", 130, 133], ["liver", "ORGAN", 145, 150], ["steroidogenic tissues", "TISSUE", 155, 176], ["SR-B1 receptor", "PROTEIN", 73, 87], ["HDL", "PROTEIN", 130, 133], ["Mutational and knock-out studies", "TEST", 0, 32], ["high density lipoprotein (HDL) uptake in liver and steroidogenic tissues", "PROBLEM", 104, 176], ["atherosclerosis regulation", "PROBLEM", 199, 225], ["high density", "OBSERVATION_MODIFIER", 104, 116], ["liver", "ANATOMY", 145, 150], ["steroidogenic tissues", "ANATOMY", 155, 176], ["atherosclerosis", "OBSERVATION", 199, 214]]], ["Other than HDL, SR-B1 also binds to oxLDL, apoptotic cells, unmodified LDL, VLDL (Kozarsky et al., 1997) as well as vitamin E (Reboul et al., 2006), carotenoids (During et al., 2005), and silica (Tsugita et al., 2017).", [["cells", "ANATOMY", 53, 58], ["vitamin E", "CHEMICAL", 116, 125], ["vitamin E", "CHEMICAL", 116, 125], ["silica", "CHEMICAL", 188, 194], ["HDL", "SIMPLE_CHEMICAL", 11, 14], ["SR-B1", "GENE_OR_GENE_PRODUCT", 16, 21], ["oxLDL", "SIMPLE_CHEMICAL", 36, 41], ["cells", "CELL", 53, 58], ["LDL", "SIMPLE_CHEMICAL", 71, 74], ["VLDL", "SIMPLE_CHEMICAL", 76, 80], ["vitamin E", "SIMPLE_CHEMICAL", 116, 125], ["carotenoids", "SIMPLE_CHEMICAL", 149, 160], ["HDL", "PROTEIN", 11, 14], ["B1", "PROTEIN", 19, 21], ["oxLDL", "PROTEIN", 36, 41], ["apoptotic cells", "CELL_TYPE", 43, 58], ["HDL", "TEST", 11, 14], ["SR", "TEST", 16, 18], ["oxLDL", "TEST", 36, 41], ["apoptotic cells", "PROBLEM", 43, 58], ["LDL", "TEST", 71, 74], ["vitamin E", "TREATMENT", 116, 125], ["oxLDL", "ANATOMY", 36, 41], ["apoptotic cells", "OBSERVATION", 43, 58], ["silica", "ANATOMY", 188, 194]]], ["The liver is the primary organ involved in LPS clearance and LSECs are a major contributor for this activity.", [["liver", "ANATOMY", 4, 9], ["organ", "ANATOMY", 25, 30], ["LSECs", "ANATOMY", 61, 66], ["LPS", "CHEMICAL", 43, 46], ["liver", "ORGAN", 4, 9], ["organ", "ORGAN", 25, 30], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["LSECs", "SIMPLE_CHEMICAL", 61, 66], ["LSECs", "CELL_TYPE", 61, 66], ["LPS clearance", "TEST", 43, 56], ["liver", "ANATOMY", 4, 9], ["LPS clearance", "OBSERVATION", 43, 56]]], ["SR-B1 may be involved with some of the LPS clearance, but as of this date, that is not very clear.", [["LPS", "CHEMICAL", 39, 42], ["SR-B1", "GENE_OR_GENE_PRODUCT", 0, 5], ["LPS", "SIMPLE_CHEMICAL", 39, 42], ["B1", "PROTEIN", 3, 5], ["the LPS clearance", "TEST", 35, 52], ["very", "OBSERVATION_MODIFIER", 87, 91], ["clear", "OBSERVATION", 92, 97]]], ["There may be a multitude of receptors or \u201cbuilt-in redundancy\u201d in this LPS clearance system so that LPS levels from the gut never get high enough to cause acute inflammation (Ganesan et al., 2016).Scavenger Receptor B (SR-B) ::: Recently Established Nomenclature for Scavenger ReceptorsCD36 is another member of the Scavenger Receptor B family, which is located on chromosome 7 and chromosome 5 in humans and mice, respectively (Cao et al., 1997).", [["gut", "ANATOMY", 120, 123], ["chromosome 7", "ANATOMY", 365, 377], ["chromosome 5", "ANATOMY", 382, 394], ["LPS", "CHEMICAL", 71, 74], ["LPS", "CHEMICAL", 100, 103], ["inflammation", "DISEASE", 161, 173], ["LPS", "SIMPLE_CHEMICAL", 71, 74], ["LPS", "SIMPLE_CHEMICAL", 100, 103], ["gut", "ORGANISM_SUBDIVISION", 120, 123], ["Scavenger Receptor B", "GENE_OR_GENE_PRODUCT", 197, 217], ["SR-B", "GENE_OR_GENE_PRODUCT", 219, 223], ["Scavenger ReceptorsCD36", "GENE_OR_GENE_PRODUCT", 267, 290], ["Scavenger Receptor B", "GENE_OR_GENE_PRODUCT", 316, 336], ["chromosome 7", "CELLULAR_COMPONENT", 365, 377], ["chromosome 5", "CELLULAR_COMPONENT", 382, 394], ["humans", "ORGANISM", 398, 404], ["mice", "ORGANISM", 409, 413], ["Scavenger Receptor B", "PROTEIN", 197, 217], ["SR", "PROTEIN", 219, 221], ["Scavenger ReceptorsCD36", "PROTEIN", 267, 290], ["Scavenger Receptor B family", "PROTEIN", 316, 343], ["chromosome 7", "DNA", 365, 377], ["chromosome 5", "DNA", 382, 394], ["humans", "SPECIES", 398, 404], ["mice", "SPECIES", 409, 413], ["humans", "SPECIES", 398, 404], ["mice", "SPECIES", 409, 413], ["this LPS clearance system", "TREATMENT", 66, 91], ["LPS levels", "TEST", 100, 110], ["acute inflammation", "PROBLEM", 155, 173], ["may be", "UNCERTAINTY", 6, 12], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["inflammation", "OBSERVATION", 161, 173]]], ["The entire extracellular domain of CD36 and SR-BI share high sequence homology, though the difference lies in their transmembrane and cytoplasmic domain sequences (Acton et al., 1996).", [["extracellular", "ANATOMY", 11, 24], ["transmembrane", "ANATOMY", 116, 129], ["cytoplasmic", "ANATOMY", 134, 145], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 24], ["CD36", "GENE_OR_GENE_PRODUCT", 35, 39], ["SR-BI", "GENE_OR_GENE_PRODUCT", 44, 49], ["transmembrane", "CELLULAR_COMPONENT", 116, 129], ["cytoplasmic", "ORGANISM_SUBSTANCE", 134, 145], ["extracellular domain", "PROTEIN", 11, 31], ["CD36", "PROTEIN", 35, 39], ["SR", "PROTEIN", 44, 46], ["BI", "PROTEIN", 47, 49], ["transmembrane and cytoplasmic domain sequences", "PROTEIN", 116, 162], ["CD36", "TEST", 35, 39], ["cytoplasmic domain sequences", "TEST", 134, 162]]], ["It is expressed on adipocytes, capillary endothelial cells, heart and skeletal muscles, and platelets (Talle et al., 1983; Tandon et al., 1989b; Abumrad et al., 1993; Greenwalt et al., 1995; Febbraio et al., 2001) and abundantly expressed on LSECs in the liver (Strauss et al., 2017).", [["adipocytes", "ANATOMY", 19, 29], ["capillary endothelial cells", "ANATOMY", 31, 58], ["heart", "ANATOMY", 60, 65], ["skeletal muscles", "ANATOMY", 70, 86], ["platelets", "ANATOMY", 92, 101], ["LSECs", "ANATOMY", 242, 247], ["liver", "ANATOMY", 255, 260], ["adipocytes", "CELL", 19, 29], ["capillary endothelial cells", "CELL", 31, 58], ["heart", "ORGAN", 60, 65], ["skeletal muscles", "TISSUE", 70, 86], ["platelets", "CELL", 92, 101], ["LSECs", "CELL", 242, 247], ["liver", "ORGAN", 255, 260], ["adipocytes", "CELL_TYPE", 19, 29], ["capillary endothelial cells", "CELL_TYPE", 31, 58], ["platelets", "CELL_TYPE", 92, 101], ["LSECs", "CELL_TYPE", 242, 247], ["capillary endothelial cells", "TEST", 31, 58], ["platelets", "TEST", 92, 101], ["adipocytes", "ANATOMY", 19, 29], ["capillary", "ANATOMY_MODIFIER", 31, 40], ["endothelial cells", "OBSERVATION", 41, 58], ["heart", "ANATOMY", 60, 65], ["skeletal muscles", "ANATOMY", 70, 86], ["platelets", "ANATOMY", 92, 101], ["LSECs", "OBSERVATION", 242, 247], ["liver", "ANATOMY", 255, 260]]], ["The role of CD36 in the metabolism of lipoprotein is well-documented (Febbraio and Silverstein, 2007; Jay and Hamilton, 2018).", [["CD36", "GENE_OR_GENE_PRODUCT", 12, 16], ["lipoprotein", "GENE_OR_GENE_PRODUCT", 38, 49], ["CD36", "PROTEIN", 12, 16]]], ["One study demonstrated the role of CD36 in the uptake of HDL by hepatic NPCs, and their CD36 knock-out mouse model resulted in a modest but significant decrease in the HDL uptake in both hepatocytes and NPCs (Brundert et al., 2011).", [["hepatic NPCs", "ANATOMY", 64, 76], ["hepatocytes", "ANATOMY", 187, 198], ["NPCs", "ANATOMY", 203, 207], ["CD36", "GENE_OR_GENE_PRODUCT", 35, 39], ["HDL", "SIMPLE_CHEMICAL", 57, 60], ["hepatic NPCs", "CELL", 64, 76], ["CD36", "GENE_OR_GENE_PRODUCT", 88, 92], ["mouse", "ORGANISM", 103, 108], ["HDL", "SIMPLE_CHEMICAL", 168, 171], ["hepatocytes", "CELL", 187, 198], ["NPCs", "CELL", 203, 207], ["CD36", "PROTEIN", 35, 39], ["HDL", "PROTEIN", 57, 60], ["hepatic NPCs", "CELL_TYPE", 64, 76], ["CD36", "PROTEIN", 88, 92], ["HDL", "PROTEIN", 168, 171], ["hepatocytes", "CELL_TYPE", 187, 198], ["NPCs", "CELL_TYPE", 203, 207], ["mouse", "SPECIES", 103, 108], ["mouse", "SPECIES", 103, 108], ["One study", "TEST", 0, 9], ["their CD36 knock", "TEST", 82, 98], ["the HDL uptake in both hepatocytes", "PROBLEM", 164, 198], ["hepatic", "ANATOMY", 64, 71], ["modest", "OBSERVATION_MODIFIER", 129, 135], ["significant", "OBSERVATION_MODIFIER", 140, 151], ["decrease", "OBSERVATION_MODIFIER", 152, 160], ["HDL uptake", "OBSERVATION", 168, 178], ["both", "ANATOMY_MODIFIER", 182, 186], ["hepatocytes", "ANATOMY", 187, 198]]], ["Similar to SR-B1, CD36 also binds to LDL, VLDL (Calvo et al., 1998), apoptotic cells (Savill et al., 1991) as well as anionic phospholipids (Rigotti et al., 1995), and collagen (Tandon et al., 1989a).", [["cells", "ANATOMY", 79, 84], ["SR-B1", "GENE_OR_GENE_PRODUCT", 11, 16], ["CD36", "GENE_OR_GENE_PRODUCT", 18, 22], ["LDL", "GENE_OR_GENE_PRODUCT", 37, 40], ["VLDL", "SIMPLE_CHEMICAL", 42, 46], ["cells", "CELL", 79, 84], ["anionic phospholipids", "SIMPLE_CHEMICAL", 118, 139], ["collagen", "GENE_OR_GENE_PRODUCT", 168, 176], ["SR", "PROTEIN", 11, 13], ["B1", "PROTEIN", 14, 16], ["CD36", "PROTEIN", 18, 22], ["LDL", "PROTEIN", 37, 40], ["apoptotic cells", "CELL_TYPE", 69, 84], ["collagen", "PROTEIN", 168, 176], ["SR", "TEST", 11, 13], ["CD36", "TEST", 18, 22], ["LDL", "TEST", 37, 40], ["VLDL", "TEST", 42, 46], ["apoptotic cells", "TEST", 69, 84], ["anionic phospholipids", "TREATMENT", 118, 139], ["LDL", "ANATOMY", 37, 40], ["VLDL", "ANATOMY", 42, 46], ["apoptotic cells", "OBSERVATION", 69, 84]]], ["Aldehyde modified proteins are likely taken up by CD36 as the SR-A KO mice had significant, but decreased uptake of these proteins (Duryee et al., 2005).", [["Aldehyde", "CHEMICAL", 0, 8], ["Aldehyde", "CHEMICAL", 0, 8], ["Aldehyde modified proteins", "GENE_OR_GENE_PRODUCT", 0, 26], ["CD36", "GENE_OR_GENE_PRODUCT", 50, 54], ["SR-A", "GENE_OR_GENE_PRODUCT", 62, 66], ["Aldehyde modified proteins", "PROTEIN", 0, 26], ["CD36", "PROTEIN", 50, 54], ["SR", "PROTEIN", 62, 64], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["Aldehyde modified proteins", "TREATMENT", 0, 26], ["the SR", "TEST", 58, 64], ["decreased uptake of these proteins", "PROBLEM", 96, 130], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["decreased", "OBSERVATION_MODIFIER", 96, 105]]], ["An earlier study showed the involvement of CD36 in the endocytosis and degradation of AGE products, implicating its role in diabetes (Ohgami et al., 2001).", [["diabetes", "DISEASE", 124, 132], ["CD36", "GENE_OR_GENE_PRODUCT", 43, 47], ["AGE", "SIMPLE_CHEMICAL", 86, 89], ["CD36", "PROTEIN", 43, 47], ["AGE products", "PROTEIN", 86, 98], ["An earlier study", "TEST", 0, 16], ["AGE products", "TREATMENT", 86, 98], ["diabetes", "PROBLEM", 124, 132]]], ["However, Nakajou et al. (2005) demonstrated that CD36 is not involved in the endocytosis of AGE proteins in LSECs, suggesting the involvement of other scavenger receptors.", [["LSECs", "ANATOMY", 108, 113], ["CD36", "GENE_OR_GENE_PRODUCT", 49, 53], ["AGE", "GENE_OR_GENE_PRODUCT", 92, 95], ["LSECs", "PATHOLOGICAL_FORMATION", 108, 113], ["CD36", "PROTEIN", 49, 53], ["AGE proteins", "PROTEIN", 92, 104], ["LSECs", "CELL_TYPE", 108, 113], ["scavenger receptors", "PROTEIN", 151, 170], ["not involved", "UNCERTAINTY", 57, 69], ["LSECs", "ANATOMY", 108, 113]]], ["This is quite plausible since \u201cAGE\u201d is a catch-all for all glycation modifications that occur involving reducing sugars and independent laboratories likely make and use their own \u201cAGE modified protein\u201d preparations.Scavenger Receptor B (SR-B) ::: Recently Established Nomenclature for Scavenger ReceptorsUpregulation of SR-B1 expression has been documented in the livers of mice fed with a high-fat diet as compared to control mice, suggesting crucial involvement of SR-B1 in NAFLD pathogenesis (Qiu et al., 2013).", [["livers", "ANATOMY", 364, 370], ["AGE", "CHEMICAL", 31, 34], ["NAFLD", "DISEASE", 476, 481], ["sugars", "CHEMICAL", 113, 119], ["AGE", "SIMPLE_CHEMICAL", 31, 34], ["sugars", "SIMPLE_CHEMICAL", 113, 119], ["AGE", "SIMPLE_CHEMICAL", 180, 183], ["Scavenger Receptor B", "GENE_OR_GENE_PRODUCT", 215, 235], ["SR-B", "GENE_OR_GENE_PRODUCT", 237, 241], ["SR-B1", "GENE_OR_GENE_PRODUCT", 320, 325], ["livers", "ORGAN", 364, 370], ["mice", "ORGANISM", 374, 378], ["mice", "ORGANISM", 427, 431], ["SR-B1", "GENE_OR_GENE_PRODUCT", 467, 472], ["Scavenger Receptor B", "PROTEIN", 215, 235], ["SR", "PROTEIN", 237, 239], ["SR", "PROTEIN", 320, 322], ["B1", "PROTEIN", 323, 325], ["mice", "SPECIES", 374, 378], ["mice", "SPECIES", 427, 431], ["mice", "SPECIES", 374, 378], ["mice", "SPECIES", 427, 431], ["all glycation modifications", "TREATMENT", 55, 82], ["reducing sugars", "PROBLEM", 104, 119], ["a high-fat diet", "TREATMENT", 388, 403], ["NAFLD pathogenesis", "PROBLEM", 476, 494], ["livers", "ANATOMY", 364, 370], ["NAFLD", "OBSERVATION", 476, 481]]], ["Translating that to humans, a similar higher SR-B1 expression was observed in type 2 diabetic patients, but no change in hepatic SR-B1 was observed in NASH and hypercholesterolemia patients, predicting only a minimal role of SR-B1 in NAFLD (Rein-Fischboeck et al., 2015).", [["hepatic", "ANATOMY", 121, 128], ["diabetic", "DISEASE", 85, 93], ["NASH", "DISEASE", 151, 155], ["hypercholesterolemia", "DISEASE", 160, 180], ["NAFLD", "DISEASE", 234, 239], ["humans", "ORGANISM", 20, 26], ["SR-B1", "GENE_OR_GENE_PRODUCT", 45, 50], ["patients", "ORGANISM", 94, 102], ["hepatic", "MULTI-TISSUE_STRUCTURE", 121, 128], ["SR-B1", "GENE_OR_GENE_PRODUCT", 129, 134], ["patients", "ORGANISM", 181, 189], ["SR-B1", "GENE_OR_GENE_PRODUCT", 225, 230], ["SR", "PROTEIN", 45, 47], ["B1", "PROTEIN", 48, 50], ["hepatic SR-B1", "PROTEIN", 121, 134], ["humans", "SPECIES", 20, 26], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 181, 189], ["humans", "SPECIES", 20, 26], ["type 2 diabetic patients", "PROBLEM", 78, 102], ["NASH", "PROBLEM", 151, 155], ["hypercholesterolemia", "PROBLEM", 160, 180], ["no", "UNCERTAINTY", 108, 110], ["hepatic", "ANATOMY", 121, 128], ["NASH", "OBSERVATION", 151, 155], ["hypercholesterolemia", "OBSERVATION", 160, 180], ["minimal", "OBSERVATION_MODIFIER", 209, 216]]], ["Patients manifesting severe alcoholic hepatitis, inflammation and oxidative stress symptoms had a correlation with a decrease of circulating paroxanase/arylesterase 1 (PON1) in the blood and stimulated alternatively activated (M2) macrophages through activation of CD36.", [["blood", "ANATOMY", 181, 186], ["macrophages", "ANATOMY", 231, 242], ["alcoholic hepatitis", "DISEASE", 28, 47], ["inflammation", "DISEASE", 49, 61], ["Patients", "ORGANISM", 0, 8], ["paroxanase/arylesterase 1", "GENE_OR_GENE_PRODUCT", 141, 166], ["PON1", "GENE_OR_GENE_PRODUCT", 168, 172], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["macrophages", "CELL", 231, 242], ["CD36", "GENE_OR_GENE_PRODUCT", 265, 269], ["paroxanase", "PROTEIN", 141, 151], ["arylesterase 1", "PROTEIN", 152, 166], ["PON1", "PROTEIN", 168, 172], ["stimulated alternatively activated (M2) macrophages", "CELL_TYPE", 191, 242], ["CD36", "PROTEIN", 265, 269], ["Patients", "SPECIES", 0, 8], ["severe alcoholic hepatitis", "PROBLEM", 21, 47], ["inflammation", "PROBLEM", 49, 61], ["oxidative stress symptoms", "PROBLEM", 66, 91], ["a decrease of circulating paroxanase/arylesterase", "PROBLEM", 115, 164], ["the blood", "TEST", 177, 186], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["alcoholic hepatitis", "OBSERVATION", 28, 47], ["inflammation", "OBSERVATION_MODIFIER", 49, 61], ["oxidative stress", "OBSERVATION", 66, 82], ["blood", "ANATOMY", 181, 186]]], ["The idea here is that activated macrophages internalize increased amounts of oxLDLs via CD36 and SRA1 and that contributes to the pathophysiology of severe alcoholic hepatitis (Maras et al., 2019).", [["macrophages", "ANATOMY", 32, 43], ["alcoholic hepatitis", "DISEASE", 156, 175], ["macrophages", "CELL", 32, 43], ["oxLDLs", "GENE_OR_GENE_PRODUCT", 77, 83], ["CD36", "GENE_OR_GENE_PRODUCT", 88, 92], ["SRA1", "GENE_OR_GENE_PRODUCT", 97, 101], ["activated macrophages", "CELL_TYPE", 22, 43], ["oxLDLs", "PROTEIN", 77, 83], ["CD36", "PROTEIN", 88, 92], ["SRA1", "PROTEIN", 97, 101], ["activated macrophages", "PROBLEM", 22, 43], ["SRA1", "TREATMENT", 97, 101], ["severe alcoholic hepatitis", "PROBLEM", 149, 175], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["alcoholic hepatitis", "OBSERVATION", 156, 175]]], ["However, none of the studies have documented the contribution of SR-B1 or CD36 expressed on LSECs in maintaining a homeostatic environment in the liver or a modulation in their expression in various diseases.Scavenger Receptor E (SR-E) ::: Recently Established Nomenclature for Scavenger ReceptorsSR-E1/LOX-1, also known as lectin-type oxidized LDL receptor or oxidized LDL receptor 1 (OLR1) is a type II transmembrane protein belonging to scavenger receptor E family.", [["LSECs", "ANATOMY", 92, 97], ["liver", "ANATOMY", 146, 151], ["SR-B1", "GENE_OR_GENE_PRODUCT", 65, 70], ["CD36", "GENE_OR_GENE_PRODUCT", 74, 78], ["LSECs", "GENE_OR_GENE_PRODUCT", 92, 97], ["liver", "ORGAN", 146, 151], ["Scavenger Receptor E", "GENE_OR_GENE_PRODUCT", 208, 228], ["SR-E", "GENE_OR_GENE_PRODUCT", 230, 234], ["ReceptorsSR-E1", "GENE_OR_GENE_PRODUCT", 288, 302], ["LOX-1", "GENE_OR_GENE_PRODUCT", 303, 308], ["lectin-type oxidized LDL receptor", "GENE_OR_GENE_PRODUCT", 324, 357], ["oxidized LDL receptor 1", "GENE_OR_GENE_PRODUCT", 361, 384], ["OLR1", "GENE_OR_GENE_PRODUCT", 386, 390], ["scavenger receptor E", "GENE_OR_GENE_PRODUCT", 440, 460], ["SR", "PROTEIN", 65, 67], ["B1", "PROTEIN", 68, 70], ["CD36", "PROTEIN", 74, 78], ["ReceptorsSR", "PROTEIN", 288, 299], ["E1", "PROTEIN", 300, 302], ["LOX-1", "PROTEIN", 303, 308], ["lectin-type oxidized LDL receptor", "PROTEIN", 324, 357], ["oxidized LDL receptor 1", "PROTEIN", 361, 384], ["OLR1", "PROTEIN", 386, 390], ["type II transmembrane protein", "PROTEIN", 397, 426], ["scavenger receptor E family", "PROTEIN", 440, 467], ["the studies", "TEST", 17, 28], ["CD36", "PROBLEM", 74, 78], ["various diseases", "PROBLEM", 191, 207], ["Scavenger ReceptorsSR", "TEST", 278, 299], ["E1/LOX", "TREATMENT", 300, 306], ["lectin-type oxidized LDL receptor", "TREATMENT", 324, 357], ["oxidized LDL receptor", "TREATMENT", 361, 382], ["a type II transmembrane protein", "TREATMENT", 395, 426], ["homeostatic environment", "OBSERVATION", 115, 138], ["liver", "ANATOMY", 146, 151], ["various", "OBSERVATION_MODIFIER", 191, 198], ["diseases", "OBSERVATION", 199, 207]]], ["It is located on chromosome 12 in humans and chromosome 6 in mice.", [["chromosome 12", "ANATOMY", 17, 30], ["chromosome 6", "ANATOMY", 45, 57], ["chromosome 12", "CELLULAR_COMPONENT", 17, 30], ["humans", "ORGANISM", 34, 40], ["chromosome 6", "CELLULAR_COMPONENT", 45, 57], ["mice", "ORGANISM", 61, 65], ["chromosome 12", "DNA", 17, 30], ["chromosome 6", "DNA", 45, 57], ["humans", "SPECIES", 34, 40], ["mice", "SPECIES", 61, 65], ["humans", "SPECIES", 34, 40], ["mice", "SPECIES", 61, 65]]], ["It consists of a transmembrane domain, a short cytoplasmic domain at the N-terminus, a connecting neck domain and a C-type lectin-like extracellular domain at the C-terminus (Sawamura et al., 1997; Park et al., 2005).", [["transmembrane", "ANATOMY", 17, 30], ["cytoplasmic", "ANATOMY", 47, 58], ["neck", "ANATOMY", 98, 102], ["extracellular", "ANATOMY", 135, 148], ["N", "CHEMICAL", 73, 74], ["cytoplasmic", "ORGANISM_SUBSTANCE", 47, 58], ["transmembrane domain", "PROTEIN", 17, 37], ["short cytoplasmic domain", "PROTEIN", 41, 65], ["N-terminus", "PROTEIN", 73, 83], ["connecting neck domain", "PROTEIN", 87, 109], ["C-type lectin-like extracellular domain", "PROTEIN", 116, 155], ["C-terminus", "PROTEIN", 163, 173], ["a transmembrane domain", "PROBLEM", 15, 37], ["a short cytoplasmic domain", "PROBLEM", 39, 65], ["a connecting neck domain", "PROBLEM", 85, 109], ["a C-type lectin", "PROBLEM", 114, 129], ["transmembrane domain", "OBSERVATION", 17, 37], ["short", "OBSERVATION_MODIFIER", 41, 46], ["terminus", "ANATOMY_MODIFIER", 75, 83], ["neck", "ANATOMY", 98, 102]]], ["Maturation of Lox-1 requires post-translational N-linked glycosylation of the extracellular domain at the C-terminus and this modification was shown to be important for binding of various ligands, intracellular transport, signaling processes, and several other biological functions (Kataoka et al., 2000).", [["extracellular", "ANATOMY", 78, 91], ["intracellular", "ANATOMY", 197, 210], ["N", "CHEMICAL", 48, 49], ["C", "CHEMICAL", 106, 107], ["Lox-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["extracellular domain", "CELLULAR_COMPONENT", 78, 98], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 197, 210], ["Lox-1", "PROTEIN", 14, 19], ["extracellular domain", "PROTEIN", 78, 98], ["C-terminus", "PROTEIN", 106, 116], ["the extracellular domain", "PROBLEM", 74, 98], ["various ligands", "PROBLEM", 180, 195], ["signaling processes", "PROBLEM", 222, 241], ["Lox", "OBSERVATION_MODIFIER", 14, 17]]], ["Mutational studies have shown the importance of conserved C-terminal residues in the lectin like domain in LOX-1 for ligand binding (Chen et al., 2001b).", [["C", "CHEMICAL", 58, 59], ["LOX-1", "GENE_OR_GENE_PRODUCT", 107, 112], ["C-terminal residues", "PROTEIN", 58, 77], ["lectin like domain", "PROTEIN", 85, 103], ["LOX", "PROTEIN", 107, 110], ["Mutational studies", "TEST", 0, 18], ["conserved C-terminal residues", "PROBLEM", 48, 77]]], ["LOX-1 is expressed by endothelial cells, macrophages, vascular smooth muscle cells, adipocytes and chondrocytes in low levels (Sawamura et al., 1997; Yoshida et al., 1998; Chui et al., 2005; Akagi et al., 2006).", [["endothelial cells", "ANATOMY", 22, 39], ["macrophages", "ANATOMY", 41, 52], ["vascular smooth muscle cells", "ANATOMY", 54, 82], ["adipocytes", "ANATOMY", 84, 94], ["chondrocytes", "ANATOMY", 99, 111], ["LOX-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["endothelial cells", "CELL", 22, 39], ["macrophages", "CELL", 41, 52], ["vascular smooth muscle cells", "CELL", 54, 82], ["adipocytes", "CELL", 84, 94], ["chondrocytes", "CELL", 99, 111], ["LOX-1", "PROTEIN", 0, 5], ["endothelial cells", "CELL_TYPE", 22, 39], ["macrophages", "CELL_TYPE", 41, 52], ["vascular smooth muscle cells", "CELL_TYPE", 54, 82], ["adipocytes", "CELL_TYPE", 84, 94], ["chondrocytes", "CELL_TYPE", 99, 111], ["vascular smooth muscle cells", "PROBLEM", 54, 82], ["adipocytes", "PROBLEM", 84, 94], ["chondrocytes in low levels", "PROBLEM", 99, 125], ["endothelial cells", "OBSERVATION", 22, 39], ["macrophages", "OBSERVATION", 41, 52], ["vascular", "ANATOMY", 54, 62], ["smooth muscle cells", "OBSERVATION", 63, 82], ["adipocytes", "ANATOMY", 84, 94], ["chondrocytes", "OBSERVATION", 99, 111], ["low levels", "OBSERVATION_MODIFIER", 115, 125]]], ["However, an increase in expression is seen by various pro-inflammatory markers, shear stress and mechanical stimuli, such as tumor necrosis factor-alpha (TNF-\u03b1), and phorbol 12-myristate 13-acetate (PMA) in vitro (Kume et al., 1998; Murase et al., 1998).", [["tumor", "DISEASE", 125, 130], ["phorbol 12-myristate 13-acetate", "CHEMICAL", 166, 197], ["PMA", "CHEMICAL", 199, 202], ["phorbol 12-myristate 13-acetate", "CHEMICAL", 166, 197], ["PMA", "CHEMICAL", 199, 202], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 125, 152], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 154, 159], ["phorbol 12-myristate 13-acetate", "SIMPLE_CHEMICAL", 166, 197], ["PMA", "SIMPLE_CHEMICAL", 199, 202], ["pro-inflammatory markers", "PROTEIN", 54, 78], ["tumor necrosis factor-alpha", "PROTEIN", 125, 152], ["TNF", "PROTEIN", 154, 157], ["an increase in expression", "PROBLEM", 9, 34], ["various pro-inflammatory markers", "TEST", 46, 78], ["shear stress", "PROBLEM", 80, 92], ["mechanical stimuli", "TEST", 97, 115], ["tumor necrosis factor", "PROBLEM", 125, 146], ["alpha (TNF", "TEST", 147, 157], ["phorbol", "TEST", 166, 173], ["myristate", "TREATMENT", 177, 186], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["pro-inflammatory markers", "OBSERVATION", 54, 78], ["mechanical stimuli", "OBSERVATION", 97, 115], ["tumor", "OBSERVATION_MODIFIER", 125, 130], ["necrosis", "OBSERVATION", 131, 139]]], ["Despite having no homology with other oxLDL binding SRs, such as SR-A and B, it is considered as the major endothelial SR for binding, uptake, and degradation of oxLDL (Sawamura et al., 1997).", [["endothelial", "ANATOMY", 107, 118], ["oxLDL", "CHEMICAL", 162, 167], ["oxLDL", "SIMPLE_CHEMICAL", 38, 43], ["SR-A", "GENE_OR_GENE_PRODUCT", 65, 69], ["B", "GENE_OR_GENE_PRODUCT", 74, 75], ["endothelial SR", "CELLULAR_COMPONENT", 107, 121], ["oxLDL", "SIMPLE_CHEMICAL", 162, 167], ["oxLDL binding SRs", "PROTEIN", 38, 55], ["SR", "PROTEIN", 65, 67], ["B", "PROTEIN", 74, 75], ["oxLDL", "PROTEIN", 162, 167], ["other oxLDL binding SRs", "PROBLEM", 32, 55]]], ["Other than oxLDL, LOX-1 is also involved in the binding with apoptotic and aged cells, C-reactive protein (CRP), bacteria, platelets and anionic phospholipids, such as phosphatidylserine and phosphatidylinositol, suggesting their role in various physiological conditions (Oka et al., 1998; Li and Mehta, 2000; Chen et al., 2001a; Shih et al., 2009).Scavenger Receptor E (SR-E) ::: Recently Established Nomenclature for Scavenger ReceptorsUnder normal conditions, LOX-1 is expressed in low amounts, in contrast to its high expression during various pathophysiological events (Ogura et al., 2009; Balzan and Lubrano, 2018).", [["cells", "ANATOMY", 80, 85], ["platelets", "ANATOMY", 123, 132], ["phosphatidylserine", "CHEMICAL", 168, 186], ["phosphatidylinositol", "CHEMICAL", 191, 211], ["phosphatidylserine", "CHEMICAL", 168, 186], ["phosphatidylinositol", "CHEMICAL", 191, 211], ["oxLDL", "SIMPLE_CHEMICAL", 11, 16], ["LOX-1", "GENE_OR_GENE_PRODUCT", 18, 23], ["cells", "CELL", 80, 85], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 87, 105], ["CRP", "GENE_OR_GENE_PRODUCT", 107, 110], ["platelets", "CELL", 123, 132], ["anionic phospholipids", "SIMPLE_CHEMICAL", 137, 158], ["phosphatidylserine", "SIMPLE_CHEMICAL", 168, 186], ["phosphatidylinositol", "SIMPLE_CHEMICAL", 191, 211], ["Scavenger Receptor E", "GENE_OR_GENE_PRODUCT", 349, 369], ["SR-E", "GENE_OR_GENE_PRODUCT", 371, 375], ["LOX-1", "GENE_OR_GENE_PRODUCT", 463, 468], ["oxLDL", "PROTEIN", 11, 16], ["LOX-1", "PROTEIN", 18, 23], ["apoptotic and aged cells", "CELL_TYPE", 61, 85], ["C-reactive protein", "PROTEIN", 87, 105], ["CRP", "PROTEIN", 107, 110], ["platelets", "CELL_TYPE", 123, 132], ["LOX", "PROTEIN", 463, 466], ["C-reactive protein", "TEST", 87, 105], ["CRP", "TEST", 107, 110], ["bacteria", "PROBLEM", 113, 121], ["platelets", "TEST", 123, 132], ["anionic phospholipids", "TEST", 137, 158], ["phosphatidylinositol", "TREATMENT", 191, 211], ["various pathophysiological events", "PROBLEM", 540, 573], ["low amounts", "OBSERVATION_MODIFIER", 485, 496]]], ["A study has documented an increased expression of LOX-1 in the aorta of hypercholesterolemic, hyperlipidemic rabbits suggesting that a Western diet may induce this receptor for the overall metabolism of lipids (Chen H. et al., 2000; Chen M. et al., 2000).", [["aorta", "ANATOMY", 63, 68], ["hypercholesterolemic", "DISEASE", 72, 92], ["hyperlipidemic", "DISEASE", 94, 108], ["LOX-1", "GENE_OR_GENE_PRODUCT", 50, 55], ["aorta", "MULTI-TISSUE_STRUCTURE", 63, 68], ["rabbits", "ORGANISM", 109, 116], ["lipids", "SIMPLE_CHEMICAL", 203, 209], ["LOX-1", "PROTEIN", 50, 55], ["rabbits", "SPECIES", 109, 116], ["A study", "TEST", 0, 7], ["an increased expression of LOX", "PROBLEM", 23, 53], ["hypercholesterolemic", "PROBLEM", 72, 92], ["hyperlipidemic rabbits", "TREATMENT", 94, 116], ["a Western diet", "TREATMENT", 133, 147], ["this receptor", "TREATMENT", 159, 172], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["expression", "OBSERVATION", 36, 46], ["LOX", "OBSERVATION_MODIFIER", 50, 53], ["aorta", "ANATOMY", 63, 68], ["hypercholesterolemic", "OBSERVATION", 72, 92], ["hyperlipidemic", "OBSERVATION", 94, 108]]], ["Another study was conducted on a hypertensive rat model using Dahl salt-sensitive and Dahl salt-resistant rats.", [["hypertensive", "DISEASE", 33, 45], ["salt", "CHEMICAL", 67, 71], ["salt", "CHEMICAL", 91, 95], ["rat", "ORGANISM", 46, 49], ["Dahl salt", "SIMPLE_CHEMICAL", 62, 71], ["Dahl salt", "SIMPLE_CHEMICAL", 86, 95], ["rats", "ORGANISM", 106, 110], ["rat", "SPECIES", 46, 49], ["rats", "SPECIES", 106, 110], ["Another study", "TEST", 0, 13], ["a hypertensive rat model", "TEST", 31, 55], ["Dahl salt", "TEST", 62, 71]]], ["Dahl salt sensitive rats develop hypertension when fed with a high salt diet and Dahl salt resistant rats show minor blood pressure changes on the same diet.", [["blood", "ANATOMY", 117, 122], ["salt", "CHEMICAL", 5, 9], ["hypertension", "DISEASE", 33, 45], ["salt", "CHEMICAL", 86, 90], ["Dahl salt", "ORGANISM", 0, 9], ["rats", "ORGANISM", 20, 24], ["rats", "ORGANISM", 101, 105], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["rats", "SPECIES", 20, 24], ["rats", "SPECIES", 101, 105], ["hypertension", "PROBLEM", 33, 45], ["a high salt diet", "TREATMENT", 60, 76], ["Dahl salt resistant rats", "TREATMENT", 81, 105], ["minor blood pressure changes", "PROBLEM", 111, 139], ["hypertension", "OBSERVATION", 33, 45], ["minor", "OBSERVATION_MODIFIER", 111, 116], ["blood pressure", "OBSERVATION", 117, 131]]], ["They reported up-regulation of LOX-1 expression in hypertensive rats, thereby, suggesting its role in hypertension and a putative target for treating atherosclerosis (Nagase et al., 1997, 1998).", [["hypertensive", "DISEASE", 51, 63], ["hypertension", "DISEASE", 102, 114], ["atherosclerosis", "DISEASE", 150, 165], ["LOX-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["rats", "ORGANISM", 64, 68], ["LOX", "PROTEIN", 31, 34], ["rats", "SPECIES", 64, 68], ["hypertensive rats", "PROBLEM", 51, 68], ["hypertension", "PROBLEM", 102, 114], ["treating atherosclerosis", "PROBLEM", 141, 165], ["hypertension", "OBSERVATION", 102, 114], ["atherosclerosis", "OBSERVATION", 150, 165]]], ["The role of LOX-1 contributes to the pathology NAFLD resulting, in part, from LSEC dysfunction.", [["LSEC", "ANATOMY", 78, 82], ["NAFLD", "DISEASE", 47, 52], ["LSEC dysfunction", "DISEASE", 78, 94], ["LOX-1", "GENE_OR_GENE_PRODUCT", 12, 17], ["LSEC", "CANCER", 78, 82], ["LOX-1", "PROTEIN", 12, 17], ["the pathology NAFLD", "PROBLEM", 33, 52], ["LSEC dysfunction", "PROBLEM", 78, 94], ["LSEC", "ANATOMY", 78, 82], ["dysfunction", "OBSERVATION", 83, 94]]], ["Zhang et al. (2014) studied the effect of human LSEC LOX-1 gene knockdown in oxLDL-induced hepatic injury.", [["hepatic", "ANATOMY", 91, 98], ["oxLDL", "CHEMICAL", 77, 82], ["hepatic injury", "DISEASE", 91, 105], ["human", "ORGANISM", 42, 47], ["LSEC", "GENE_OR_GENE_PRODUCT", 48, 52], ["LOX-1", "GENE_OR_GENE_PRODUCT", 53, 58], ["oxLDL", "SIMPLE_CHEMICAL", 77, 82], ["hepatic", "ORGAN", 91, 98], ["human LSEC LOX-1 gene", "DNA", 42, 63], ["oxLDL", "PROTEIN", 77, 82], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["human LSEC LOX", "TREATMENT", 42, 56], ["hepatic injury", "PROBLEM", 91, 105], ["hepatic", "ANATOMY", 91, 98], ["injury", "OBSERVATION", 99, 105]]], ["They found an increase in ROS production and enhanced p65 expression in oxLDL treated human LSECs.", [["LSECs", "ANATOMY", 92, 97], ["ROS", "CHEMICAL", 26, 29], ["oxLDL", "CHEMICAL", 72, 77], ["ROS", "SIMPLE_CHEMICAL", 26, 29], ["p65", "GENE_OR_GENE_PRODUCT", 54, 57], ["oxLDL", "SIMPLE_CHEMICAL", 72, 77], ["human", "ORGANISM", 86, 91], ["LSECs", "CELL", 92, 97], ["p65", "PROTEIN", 54, 57], ["oxLDL treated human LSECs", "CELL_LINE", 72, 97], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["an increase in ROS production", "PROBLEM", 11, 40], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["ROS production", "OBSERVATION", 26, 40]]], ["This effect was significantly reduced after LOX-1 siRNA treatment, suggesting the role of LOX-1 in activation of NF-kB and the ROS pathway.", [["LOX-1", "GENE_OR_GENE_PRODUCT", 44, 49], ["LOX-1", "GENE_OR_GENE_PRODUCT", 90, 95], ["NF-kB", "GENE_OR_GENE_PRODUCT", 113, 118], ["ROS", "SIMPLE_CHEMICAL", 127, 130], ["LOX", "PROTEIN", 44, 47], ["LOX-1", "PROTEIN", 90, 95], ["NF-kB", "PROTEIN", 113, 118], ["LOX-1 siRNA treatment", "TREATMENT", 44, 65], ["the ROS pathway", "TEST", 123, 138], ["significantly", "OBSERVATION_MODIFIER", 16, 29], ["reduced", "OBSERVATION_MODIFIER", 30, 37]]], ["A reduction in the expression of eNOS was found in human LSEC culture treated with oxLDL, whereas, LOX-1 siRNA treatment resulted in an enhanced expression of eNOS in this culture system.", [["LSEC culture", "ANATOMY", 57, 69], ["oxLDL", "CHEMICAL", 83, 88], ["eNOS", "GENE_OR_GENE_PRODUCT", 33, 37], ["human", "ORGANISM", 51, 56], ["LSEC culture", "CELL", 57, 69], ["oxLDL", "SIMPLE_CHEMICAL", 83, 88], ["LOX-1", "GENE_OR_GENE_PRODUCT", 99, 104], ["eNOS", "GENE_OR_GENE_PRODUCT", 159, 163], ["eNOS", "PROTEIN", 33, 37], ["human LSEC culture", "CELL_LINE", 51, 69], ["oxLDL", "PROTEIN", 83, 88], ["LOX", "PROTEIN", 99, 102], ["eNOS", "PROTEIN", 159, 163], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["A reduction", "TREATMENT", 0, 11], ["eNOS", "PROBLEM", 33, 37], ["human LSEC culture", "TEST", 51, 69], ["oxLDL", "TREATMENT", 83, 88], ["LOX-1 siRNA treatment", "TREATMENT", 99, 120], ["this culture system", "TEST", 167, 186], ["reduction", "OBSERVATION_MODIFIER", 2, 11], ["eNOS", "OBSERVATION", 33, 37], ["LSEC", "ANATOMY", 57, 61]]], ["They also reported a reduction in the number of fenestrae, diameter and porosity in ox-LDL-treated human LSEC culture and LOX-1 siRNA resulted in reversal of these effects, suggesting its role in stress related atherogenesis (Fraser et al., 1995).", [["fenestrae", "ANATOMY", 48, 57], ["LSEC culture", "ANATOMY", 105, 117], ["ox-LDL", "CHEMICAL", 84, 90], ["atherogenesis", "DISEASE", 211, 224], ["fenestrae", "TISSUE", 48, 57], ["ox-LDL", "SIMPLE_CHEMICAL", 84, 90], ["human", "ORGANISM", 99, 104], ["LSEC", "CELL", 105, 109], ["LOX-1", "GENE_OR_GENE_PRODUCT", 122, 127], ["ox-LDL-treated human LSEC culture", "CELL_LINE", 84, 117], ["LOX", "PROTEIN", 122, 125], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["fenestrae, diameter and porosity in ox", "PROBLEM", 48, 86], ["LDL", "TEST", 87, 90], ["human LSEC culture", "TEST", 99, 117], ["LOX-1 siRNA", "TREATMENT", 122, 133], ["stress related atherogenesis", "PROBLEM", 196, 224], ["reduction", "OBSERVATION_MODIFIER", 21, 30], ["fenestrae", "OBSERVATION", 48, 57], ["diameter", "OBSERVATION_MODIFIER", 59, 67], ["porosity", "OBSERVATION_MODIFIER", 72, 80], ["LSEC", "ANATOMY", 105, 109]]], ["LSEC defenestration was found to be mediated by LOX-1 by upregulating ET-1 and caveolin-1.", [["LSEC", "SIMPLE_CHEMICAL", 0, 4], ["LOX-1", "GENE_OR_GENE_PRODUCT", 48, 53], ["ET-1", "GENE_OR_GENE_PRODUCT", 70, 74], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 79, 89], ["LOX-1", "PROTEIN", 48, 53], ["ET-1", "PROTEIN", 70, 74], ["caveolin-1", "PROTEIN", 79, 89], ["LSEC defenestration", "TEST", 0, 19], ["LOX", "TEST", 48, 51]]], ["Although, the association between LOX-1, ET-1, and caveolin-1 remains unclear, oxidative stress generated due to ROS production suggests the role of LOX-1 in NASH and NAFLD pathological manifestations (Pasarin et al., 2012).", [["ROS", "CHEMICAL", 113, 116], ["NASH", "DISEASE", 158, 162], ["NAFLD", "DISEASE", 167, 172], ["LOX-1", "GENE_OR_GENE_PRODUCT", 34, 39], ["ET-1", "GENE_OR_GENE_PRODUCT", 41, 45], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 51, 61], ["ROS", "SIMPLE_CHEMICAL", 113, 116], ["LOX-1", "GENE_OR_GENE_PRODUCT", 149, 154], ["LOX", "PROTEIN", 34, 37], ["ET-1", "PROTEIN", 41, 45], ["caveolin-1", "PROTEIN", 51, 61], ["LOX-1", "PROTEIN", 149, 154], ["LOX", "TEST", 34, 37], ["oxidative stress", "PROBLEM", 79, 95], ["ROS production", "PROBLEM", 113, 127], ["NASH", "PROBLEM", 158, 162], ["NAFLD pathological manifestations", "PROBLEM", 167, 200]]], ["Along with SR-A, LOX-1 was also shown to be responsible for degradation of MAA-Alb (Duryee et al., 2005).", [["MAA", "CHEMICAL", 75, 78], ["MAA", "CHEMICAL", 75, 78], ["SR-A", "GENE_OR_GENE_PRODUCT", 11, 15], ["LOX-1", "GENE_OR_GENE_PRODUCT", 17, 22], ["MAA-Alb", "SIMPLE_CHEMICAL", 75, 82], ["SR", "PROTEIN", 11, 13], ["LOX-1", "PROTEIN", 17, 22]]], ["Furthermore, a study conducted on aortic endothelial cells reported a reduction in LOX-1 expression with aging and associated it with the progression of aging related diseases (Khaidakov et al., 2011).Scavenger Receptor E (SR-E) ::: Recently Established Nomenclature for Scavenger ReceptorsMannose receptor (MR)/CD206/SR-E3 is another member of the scavenger receptor E belonging to the C-type lectin family.", [["aortic endothelial cells", "ANATOMY", 34, 58], ["aortic endothelial cells", "CELL", 34, 58], ["LOX-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["Scavenger Receptor E", "GENE_OR_GENE_PRODUCT", 201, 221], ["SR-E", "GENE_OR_GENE_PRODUCT", 223, 227], ["Mannose receptor", "GENE_OR_GENE_PRODUCT", 290, 306], ["MR", "GENE_OR_GENE_PRODUCT", 308, 310], ["CD206", "GENE_OR_GENE_PRODUCT", 312, 317], ["SR-E3", "GENE_OR_GENE_PRODUCT", 318, 323], ["scavenger receptor E", "GENE_OR_GENE_PRODUCT", 349, 369], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 387, 400], ["aortic endothelial cells", "CELL_TYPE", 34, 58], ["LOX", "PROTEIN", 83, 86], ["Scavenger Receptors", "PROTEIN", 271, 290], ["Mannose receptor", "PROTEIN", 290, 306], ["MR", "PROTEIN", 308, 310], ["CD206", "PROTEIN", 312, 317], ["SR", "PROTEIN", 318, 320], ["E3", "PROTEIN", 321, 323], ["scavenger receptor E", "PROTEIN", 349, 369], ["C-type lectin family", "PROTEIN", 387, 407], ["a study", "TEST", 13, 20], ["aortic endothelial cells", "TREATMENT", 34, 58], ["aging related diseases", "PROBLEM", 153, 175], ["MR", "TEST", 308, 310], ["aortic endothelial", "ANATOMY", 34, 52], ["reduction", "OBSERVATION_MODIFIER", 70, 79]]], ["It is a type I integral membrane protein which is present on chromosome 10 in humans and chromosome 2 in mice.", [["membrane", "ANATOMY", 24, 32], ["chromosome 10", "ANATOMY", 61, 74], ["chromosome 2", "ANATOMY", 89, 101], ["type I integral", "GENE_OR_GENE_PRODUCT", 8, 23], ["membrane", "CELLULAR_COMPONENT", 24, 32], ["chromosome 10", "CELLULAR_COMPONENT", 61, 74], ["humans", "ORGANISM", 78, 84], ["chromosome 2", "CELLULAR_COMPONENT", 89, 101], ["mice", "ORGANISM", 105, 109], ["type I integral membrane protein", "PROTEIN", 8, 40], ["chromosome 10", "DNA", 61, 74], ["chromosome 2", "DNA", 89, 101], ["humans", "SPECIES", 78, 84], ["mice", "SPECIES", 105, 109], ["humans", "SPECIES", 78, 84], ["mice", "SPECIES", 105, 109], ["a type I integral membrane protein", "PROBLEM", 6, 40], ["membrane protein", "OBSERVATION", 24, 40]]], ["The mannose receptor is composed of an N-terminal extracellular region and a C-terminal intracellular region.", [["extracellular", "ANATOMY", 50, 63], ["intracellular", "ANATOMY", 88, 101], ["mannose", "CHEMICAL", 4, 11], ["N", "CHEMICAL", 39, 40], ["C", "CHEMICAL", 77, 78], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 4, 20], ["extracellular region", "CELLULAR_COMPONENT", 50, 70], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 88, 101], ["mannose receptor", "PROTEIN", 4, 20], ["N-terminal extracellular region", "PROTEIN", 39, 70], ["C-terminal intracellular region", "PROTEIN", 77, 108], ["The mannose receptor", "TREATMENT", 0, 20], ["a C-terminal intracellular region", "PROBLEM", 75, 108], ["mannose receptor", "OBSERVATION", 4, 20], ["terminal", "ANATOMY_MODIFIER", 41, 49], ["extracellular", "ANATOMY_MODIFIER", 50, 63], ["region", "ANATOMY_MODIFIER", 64, 70], ["terminal", "ANATOMY_MODIFIER", 79, 87], ["intracellular", "ANATOMY_MODIFIER", 88, 101], ["region", "ANATOMY_MODIFIER", 102, 108]]], ["The N-terminus is composed of three distinct domains and each domain binds to its specific ligands.", [["N", "CHEMICAL", 4, 5], ["N-terminus", "PROTEIN", 4, 14], ["-terminus", "OBSERVATION", 5, 14]]], ["First, eight consecutive C-type carbohydrate recognition domains (CRDs) that bind to terminal mannose residues, N-acetylglucosamine and L-fucose (Ezekowitz et al., 1990; Taylor et al., 1992).", [["N-acetylglucosamine", "CHEMICAL", 112, 131], ["L-fucose", "CHEMICAL", 136, 144], ["carbohydrate", "CHEMICAL", 32, 44], ["mannose", "CHEMICAL", 94, 101], ["N-acetylglucosamine", "CHEMICAL", 112, 131], ["L-fucose", "CHEMICAL", 136, 144], ["N-acetylglucosamine", "SIMPLE_CHEMICAL", 112, 131], ["L-fucose", "SIMPLE_CHEMICAL", 136, 144], ["C-type carbohydrate recognition domains", "PROTEIN", 25, 64], ["CRDs", "PROTEIN", 66, 70], ["eight consecutive C-type carbohydrate recognition domains", "TREATMENT", 7, 64], ["terminal mannose residues", "PROBLEM", 85, 110], ["acetylglucosamine", "TREATMENT", 114, 131], ["mannose residues", "OBSERVATION", 94, 110]]], ["Second, a fibronectin type-II repeat domain that binds to collagen I-IV (Martinez-Pomares et al., 2006; Napper et al., 2006).", [["fibronectin", "GENE_OR_GENE_PRODUCT", 10, 21], ["collagen I-IV", "GENE_OR_GENE_PRODUCT", 58, 71], ["fibronectin type-II repeat domain", "PROTEIN", 10, 43], ["collagen I-IV", "PROTEIN", 58, 71], ["a fibronectin type-II repeat domain", "TREATMENT", 8, 43]]], ["Third, a cysteine-rich domain at the N-terminus binds to sulfated sugars, such as GalNAc-4-sulfate and chondroitin sulfates A and B (Fiete et al., 1998).", [["cysteine", "CHEMICAL", 9, 17], ["GalNAc-4-sulfate", "CHEMICAL", 82, 98], ["chondroitin sulfates", "CHEMICAL", 103, 123], ["cysteine", "CHEMICAL", 9, 17], ["N", "CHEMICAL", 37, 38], ["sugars", "CHEMICAL", 66, 72], ["GalNAc-4-sulfate", "CHEMICAL", 82, 98], ["chondroitin sulfates A and B", "CHEMICAL", 103, 131], ["cysteine", "AMINO_ACID", 9, 17], ["sulfated sugars", "SIMPLE_CHEMICAL", 57, 72], ["GalNAc-4-sulfate", "SIMPLE_CHEMICAL", 82, 98], ["chondroitin sulfates A", "SIMPLE_CHEMICAL", 103, 125], ["B", "SIMPLE_CHEMICAL", 130, 131], ["cysteine-rich domain", "PROTEIN", 9, 29], ["N-terminus", "PROTEIN", 37, 47], ["a cysteine-rich domain", "TREATMENT", 7, 29], ["sulfated sugars", "TREATMENT", 57, 72], ["GalNAc", "TREATMENT", 82, 88], ["sulfate", "TREATMENT", 91, 98], ["chondroitin sulfates", "TREATMENT", 103, 123]]], ["Besides binding of specific ligands by their respective domains, MR is involved in the binding of numerous endogenous ligands, such as lysosomal hydrolases (Stahl et al., 1976; Elvevold et al., 2008a), tissue plasminogen activator (tPA) (Smedsrod et al., 1988a), and Procollagen type I carboxy-terminal propeptide (PICP) (Smedsrod et al., 1990).", [["carboxy", "CHEMICAL", 286, 293], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 202, 230], ["tPA", "GENE_OR_GENE_PRODUCT", 232, 235], ["Procollagen type I carboxy-terminal propeptide", "GENE_OR_GENE_PRODUCT", 267, 313], ["PICP", "GENE_OR_GENE_PRODUCT", 315, 319], ["MR", "PROTEIN", 65, 67], ["lysosomal hydrolases", "PROTEIN", 135, 155], ["tissue plasminogen activator", "PROTEIN", 202, 230], ["tPA", "PROTEIN", 232, 235], ["Procollagen type I carboxy-terminal propeptide", "PROTEIN", 267, 313], ["PICP", "PROTEIN", 315, 319], ["MR", "TEST", 65, 67], ["numerous endogenous ligands", "PROBLEM", 98, 125], ["tissue plasminogen activator (tPA", "TREATMENT", 202, 235], ["Procollagen type I carboxy-terminal propeptide (PICP)", "TREATMENT", 267, 320], ["endogenous ligands", "OBSERVATION", 107, 125]]], ["MR has been implicated in the binding of several pathogens including Candida albicans, Pneumocystis carinii, and Leishmania donovani by its cysteine-rich domain (Stahl and Ezekowitz, 1998; Gordon, 2002; Allavena et al., 2004).", [["MR", "DISEASE", 0, 2], ["Candida albicans", "DISEASE", 69, 85], ["Pneumocystis carinii", "DISEASE", 87, 107], ["cysteine", "CHEMICAL", 140, 148], ["Candida albicans", "ORGANISM", 69, 85], ["Pneumocystis carinii", "ORGANISM", 87, 107], ["Leishmania donovani", "ORGANISM", 113, 132], ["cysteine", "AMINO_ACID", 140, 148], ["MR", "PROTEIN", 0, 2], ["cysteine-rich domain", "PROTEIN", 140, 160], ["Candida albicans", "SPECIES", 69, 85], ["Pneumocystis carinii", "SPECIES", 87, 107], ["Leishmania donovani", "SPECIES", 113, 132], ["Candida albicans", "SPECIES", 69, 85], ["Pneumocystis carinii", "SPECIES", 87, 107], ["Leishmania donovani", "SPECIES", 113, 132], ["MR", "TEST", 0, 2], ["several pathogens", "PROBLEM", 41, 58], ["Candida albicans", "PROBLEM", 69, 85], ["Pneumocystis carinii", "PROBLEM", 87, 107], ["Leishmania donovani", "PROBLEM", 113, 132], ["several", "OBSERVATION_MODIFIER", 41, 48], ["pathogens", "OBSERVATION", 49, 58], ["Candida albicans", "OBSERVATION", 69, 85], ["Pneumocystis carinii", "OBSERVATION", 87, 107], ["Leishmania donovani", "OBSERVATION", 113, 132]]], ["More recent studies have reported MRs binding with influenza, herpes simplex virus as well as HIV (Milone and Fitzgerald-Bocarsly, 1998; Reading et al., 2000; Turville et al., 2002) with varying affinities.", [["influenza", "DISEASE", 51, 60], ["herpes simplex virus", "DISEASE", 62, 82], ["MRs", "GENE_OR_GENE_PRODUCT", 34, 37], ["herpes simplex virus", "ORGANISM", 62, 82], ["HIV", "ORGANISM", 94, 97], ["herpes simplex virus", "SPECIES", 62, 82], ["HIV", "SPECIES", 94, 97], ["herpes simplex virus", "SPECIES", 62, 82], ["HIV", "SPECIES", 94, 97], ["MRs binding", "PROBLEM", 34, 45], ["influenza", "PROBLEM", 51, 60], ["herpes simplex virus", "PROBLEM", 62, 82], ["varying affinities", "PROBLEM", 187, 205]]], ["The MR is expressed in most tissue macrophages, LSECs, lymph node and spleen; kidney mesangial cells, and dendritic cells subsets (Linehan et al., 1999; McGreal et al., 2004; Linehan et al., 2005).Scavenger Receptor E (SR-E) ::: Recently Established Nomenclature for Scavenger ReceptorsDue to their ability to recognize and bind with carbohydrate moieties present on the surface of pathogens, MR expressed on LSECs is involved in the clearance of denatured collagen (Malovic et al., 2007).", [["tissue macrophages", "ANATOMY", 28, 46], ["LSECs", "ANATOMY", 48, 53], ["lymph node", "ANATOMY", 55, 65], ["spleen", "ANATOMY", 70, 76], ["kidney mesangial cells", "ANATOMY", 78, 100], ["dendritic cells", "ANATOMY", 106, 121], ["surface", "ANATOMY", 371, 378], ["LSECs", "ANATOMY", 409, 414], ["carbohydrate", "CHEMICAL", 334, 346], ["tissue macrophages", "CELL", 28, 46], ["LSECs", "CELL", 48, 53], ["lymph node", "MULTI-TISSUE_STRUCTURE", 55, 65], ["spleen", "ORGAN", 70, 76], ["kidney mesangial cells", "CELL", 78, 100], ["dendritic cells", "CELL", 106, 121], ["Scavenger Receptor E", "GENE_OR_GENE_PRODUCT", 197, 217], ["SR-E", "GENE_OR_GENE_PRODUCT", 219, 223], ["surface", "CELLULAR_COMPONENT", 371, 378], ["LSECs", "GENE_OR_GENE_PRODUCT", 409, 414], ["collagen", "GENE_OR_GENE_PRODUCT", 457, 465], ["MR", "PROTEIN", 4, 6], ["macrophages", "CELL_TYPE", 35, 46], ["LSECs", "CELL_TYPE", 48, 53], ["kidney mesangial cells", "CELL_TYPE", 78, 100], ["dendritic cells subsets", "CELL_TYPE", 106, 129], ["MR", "PROTEIN", 393, 395], ["LSECs", "CELL_TYPE", 409, 414], ["collagen", "PROTEIN", 457, 465], ["The MR", "TEST", 0, 6], ["kidney mesangial cells", "PROBLEM", 78, 100], ["Scavenger ReceptorsDue", "TREATMENT", 267, 289], ["carbohydrate moieties", "TREATMENT", 334, 355], ["pathogens", "PROBLEM", 382, 391], ["most tissue", "OBSERVATION_MODIFIER", 23, 34], ["macrophages", "OBSERVATION", 35, 46], ["LSECs", "ANATOMY", 48, 53], ["lymph node", "OBSERVATION", 55, 65], ["spleen", "ANATOMY", 70, 76], ["kidney", "ANATOMY", 78, 84], ["mesangial cells", "OBSERVATION", 85, 100], ["dendritic cells", "OBSERVATION", 106, 121]]], ["This study showed a reduction in plasma clearance of radiolabeled DebColl, a heat-denatured type-1 collagen, in a MR KO mouse model in vivo.", [["plasma", "ANATOMY", 33, 39], ["DebColl", "CHEMICAL", 66, 73], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["DebColl", "SIMPLE_CHEMICAL", 66, 73], ["type-1 collagen", "GENE_OR_GENE_PRODUCT", 92, 107], ["mouse", "ORGANISM", 120, 125], ["DebColl", "PROTEIN", 66, 73], ["collagen", "PROTEIN", 99, 107], ["MR", "PROTEIN", 114, 116], ["mouse", "SPECIES", 120, 125], ["mouse", "SPECIES", 120, 125], ["This study", "TEST", 0, 10], ["plasma clearance", "TEST", 33, 49], ["radiolabeled DebColl", "TREATMENT", 53, 73], ["a heat", "TEST", 75, 81], ["reduction", "OBSERVATION_MODIFIER", 20, 29]]], ["LSECs isolated from MR KO mice were not able to internalize radiolabeled DebColl as efficiently as WT LSECs in vitro.", [["LSECs", "ANATOMY", 0, 5], ["LSECs", "ANATOMY", 102, 107], ["LSECs", "GENE_OR_GENE_PRODUCT", 0, 5], ["MR KO mice", "ORGANISM", 20, 30], ["DebColl", "GENE_OR_GENE_PRODUCT", 73, 80], ["LSECs", "CELL", 102, 107], ["LSECs", "CELL_TYPE", 0, 5], ["MR", "PROTEIN", 20, 22], ["DebColl", "PROTEIN", 73, 80], ["WT LSECs", "CELL_TYPE", 99, 107], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["LSECs", "TEST", 0, 5]]], ["Reduction in the endocytic capacity of LSECs for removing denatured collagen might contribute to the onset of pseudo-capillarization or fibrosis (Ala-Kokko et al., 1987).", [["LSECs", "ANATOMY", 39, 44], ["capillarization", "DISEASE", 117, 132], ["fibrosis", "DISEASE", 136, 144], ["LSECs", "SIMPLE_CHEMICAL", 39, 44], ["collagen", "GENE_OR_GENE_PRODUCT", 68, 76], ["LSECs", "CELL_TYPE", 39, 44], ["collagen", "PROTEIN", 68, 76], ["removing denatured collagen", "TREATMENT", 49, 76], ["pseudo-capillarization", "PROBLEM", 110, 132], ["fibrosis", "PROBLEM", 136, 144], ["endocytic capacity", "OBSERVATION", 17, 35], ["LSECs", "OBSERVATION", 39, 44], ["pseudo", "OBSERVATION", 110, 116], ["capillarization", "OBSERVATION_MODIFIER", 117, 132], ["fibrosis", "OBSERVATION", 136, 144]]], ["Subsequently, Elvevold et al. (2008a) reported the importance of MR in maintaining the high lysosomal degradation capacity using the MR knock-out model.", [["lysosomal", "ANATOMY", 92, 101], ["MR", "PROTEIN", 65, 67], ["MR", "PROTEIN", 133, 135], ["MR", "TEST", 65, 67], ["the high lysosomal degradation capacity", "PROBLEM", 83, 122], ["the MR knock", "TEST", 129, 141]]], ["They found a reduction in lysosomal enzymes in freshly isolated LSECs from MR KO mice as compared to WT.", [["lysosomal", "ANATOMY", 26, 35], ["LSECs", "ANATOMY", 64, 69], ["lysosomal enzymes", "GENE_OR_GENE_PRODUCT", 26, 43], ["LSECs", "CELL", 64, 69], ["MR KO mice", "ORGANISM", 75, 85], ["lysosomal enzymes", "PROTEIN", 26, 43], ["LSECs", "CELL_TYPE", 64, 69], ["MR", "PROTEIN", 75, 77], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["a reduction in lysosomal enzymes", "PROBLEM", 11, 43], ["WT", "TEST", 101, 103], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["lysosomal enzymes", "OBSERVATION", 26, 43], ["isolated LSECs", "OBSERVATION", 55, 69]]], ["They further examined the endocytic and intracellular degradative capacity of LSECs and reported that MR KO mice took twice as long to degrade injected radiolabeled formaldehyde-treated serum albumin (FSA) as compared to WT, though endocytic capacity remained the same for both cell types.", [["intracellular", "ANATOMY", 40, 53], ["LSECs", "ANATOMY", 78, 83], ["serum", "ANATOMY", 186, 191], ["cell", "ANATOMY", 278, 282], ["formaldehyde", "CHEMICAL", 165, 177], ["formaldehyde", "CHEMICAL", 165, 177], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["LSECs", "PATHOLOGICAL_FORMATION", 78, 83], ["MR KO mice", "ORGANISM", 102, 112], ["formaldehyde", "SIMPLE_CHEMICAL", 165, 177], ["serum", "ORGANISM_SUBSTANCE", 186, 191], ["albumin", "GENE_OR_GENE_PRODUCT", 192, 199], ["FSA", "SIMPLE_CHEMICAL", 201, 204], ["cell", "CELL", 278, 282], ["LSECs", "CELL_TYPE", 78, 83], ["MR", "PROTEIN", 102, 104], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 108, 112], ["serum albumin", "TEST", 186, 199], ["WT", "TEST", 221, 223], ["endocytic capacity", "TEST", 232, 250], ["cell types", "OBSERVATION", 278, 288]]], ["In accordance with the former, the MR KO mice contained nearly twice as much radioactivity than the WT mice 2 h-post-injection.", [["mice", "ORGANISM", 41, 45], ["mice", "ORGANISM", 103, 107], ["MR", "PROTEIN", 35, 37], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 103, 107]]], ["It was concluded that the cellular uptake of SR ligand is not hampered in MR KO mice and there is only a deficiency in the amount of lysosomal enzyme content, hence, reduced degradative capacity in MR KO mice.", [["cellular", "ANATOMY", 26, 34], ["lysosomal", "ANATOMY", 133, 142], ["cellular", "CELL", 26, 34], ["SR ligand", "GENE_OR_GENE_PRODUCT", 45, 54], ["MR KO mice", "ORGANISM", 74, 84], ["lysosomal enzyme", "GENE_OR_GENE_PRODUCT", 133, 149], ["MR KO mice", "ORGANISM", 198, 208], ["MR", "PROTEIN", 74, 76], ["lysosomal enzyme", "PROTEIN", 133, 149], ["MR", "PROTEIN", 198, 200], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 204, 208], ["the cellular uptake of SR ligand", "PROBLEM", 22, 54], ["a deficiency", "PROBLEM", 103, 115], ["lysosomal enzyme content", "PROBLEM", 133, 157], ["reduced degradative capacity", "PROBLEM", 166, 194], ["deficiency", "OBSERVATION", 105, 115], ["amount", "OBSERVATION_MODIFIER", 123, 129], ["lysosomal enzyme content", "OBSERVATION", 133, 157]]], ["This demonstrates that the MR is involved with the turnover and homeostasis of many intrinsic molecules within the mammalian organism.Scavenger Receptor E (SR-E) ::: Recently Established Nomenclature for Scavenger ReceptorsSeveral studies have shown the expression of MR on LSEC is impacted by cytokines and inflammatory stimuli.", [["LSEC", "ANATOMY", 274, 278], ["Scavenger Receptor E", "GENE_OR_GENE_PRODUCT", 134, 154], ["SR-E", "GENE_OR_GENE_PRODUCT", 156, 160], ["MR", "PROTEIN", 27, 29], ["MR", "PROTEIN", 268, 270], ["LSEC", "CELL_TYPE", 274, 278], ["cytokines", "PROTEIN", 294, 303], ["the MR", "TEST", 23, 29], ["many intrinsic molecules within the mammalian organism", "PROBLEM", 79, 133], ["Scavenger ReceptorsSeveral studies", "TEST", 204, 238], ["MR", "PROBLEM", 268, 270], ["inflammatory stimuli", "TEST", 308, 328], ["many", "OBSERVATION_MODIFIER", 79, 83], ["intrinsic molecules", "OBSERVATION", 84, 103], ["mammalian organism", "OBSERVATION", 115, 133], ["LSEC", "ANATOMY", 274, 278], ["inflammatory stimuli", "OBSERVATION", 308, 328]]], ["Asumendi et al. (1996) demonstrated the upregulation of the LSEC MR after exogenous administration of human recombinant IL-1b in the rat in vivo.", [["LSEC", "GENE_OR_GENE_PRODUCT", 60, 64], ["human", "ORGANISM", 102, 107], ["IL-1b", "GENE_OR_GENE_PRODUCT", 120, 125], ["rat", "ORGANISM", 133, 136], ["LSEC MR", "PROTEIN", 60, 67], ["human recombinant IL-1b", "PROTEIN", 102, 125], ["human", "SPECIES", 102, 107], ["rat", "SPECIES", 133, 136], ["human", "SPECIES", 102, 107], ["rat", "SPECIES", 133, 136], ["the LSEC MR", "TREATMENT", 56, 67], ["human recombinant IL", "TREATMENT", 102, 122], ["LSEC", "ANATOMY", 60, 64]]], ["IL-1b is a pro-inflammatory cytokine present in acute infections.", [["acute infections", "DISEASE", 48, 64], ["IL-1b", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-1b", "PROTEIN", 0, 5], ["pro-inflammatory cytokine", "PROTEIN", 11, 36], ["a pro-inflammatory cytokine", "TREATMENT", 9, 36], ["acute infections", "PROBLEM", 48, 64], ["pro-inflammatory cytokine", "OBSERVATION", 11, 36], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["infections", "OBSERVATION", 54, 64]]], ["A similar upregulation was observed in the LSEC MR when IL-1b was induced with LPS in the rat endogenously (Asumendi et al., 1996).", [["LSEC", "ANATOMY", 43, 47], ["LPS", "CHEMICAL", 79, 82], ["IL-1b", "GENE_OR_GENE_PRODUCT", 56, 61], ["LPS", "SIMPLE_CHEMICAL", 79, 82], ["rat", "ORGANISM", 90, 93], ["LSEC MR", "PROTEIN", 43, 50], ["IL-1b", "PROTEIN", 56, 61], ["rat", "SPECIES", 90, 93], ["rat", "SPECIES", 90, 93], ["LPS", "TREATMENT", 79, 82], ["upregulation", "OBSERVATION", 10, 22], ["LSEC", "ANATOMY", 43, 47]]], ["Similarly, enhanced MR expression by LSECs in culture when incubated with IL-10 or IL-4 with IL-13 (Liu Y. et al., 2013) acts contrary to IL-1b and is involved with the \u201ctype-II\u201d activation of the immune system.", [["LSECs", "ANATOMY", 37, 42], ["immune system", "ANATOMY", 197, 210], ["LSECs", "SIMPLE_CHEMICAL", 37, 42], ["IL-10", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-4", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL-13", "GENE_OR_GENE_PRODUCT", 93, 98], ["IL-1b", "GENE_OR_GENE_PRODUCT", 138, 143], ["MR", "PROTEIN", 20, 22], ["LSECs", "CELL_TYPE", 37, 42], ["IL-1b", "PROTEIN", 138, 143], ["culture", "TEST", 46, 53], ["IL", "TEST", 74, 76], ["IL", "TEST", 83, 85]]], ["Similarly, a study on mouse model of C26 colon carcinoma hepatic metastasis has shown that MR expression level and endocytic capacity increases with an increase in the production of IL-1b from LSECs.", [["C26 colon carcinoma hepatic", "ANATOMY", 37, 64], ["LSECs", "ANATOMY", 193, 198], ["colon carcinoma", "DISEASE", 41, 56], ["mouse", "ORGANISM", 22, 27], ["C26 colon carcinoma", "CANCER", 37, 56], ["hepatic", "ORGAN", 57, 64], ["IL-1b", "GENE_OR_GENE_PRODUCT", 182, 187], ["LSECs", "PATHOLOGICAL_FORMATION", 193, 198], ["MR", "PROTEIN", 91, 93], ["IL-1b", "PROTEIN", 182, 187], ["LSECs", "CELL_TYPE", 193, 198], ["mouse", "SPECIES", 22, 27], ["mouse", "SPECIES", 22, 27], ["a study", "TEST", 11, 18], ["C26 colon carcinoma", "PROBLEM", 37, 56], ["hepatic metastasis", "PROBLEM", 57, 75], ["MR expression level", "PROBLEM", 91, 110], ["endocytic capacity", "TEST", 115, 133], ["C26", "ANATOMY_MODIFIER", 37, 40], ["colon", "ANATOMY", 41, 46], ["carcinoma", "OBSERVATION", 47, 56], ["hepatic", "ANATOMY", 57, 64], ["metastasis", "OBSERVATION", 65, 75], ["endocytic capacity", "OBSERVATION", 115, 133], ["increases", "OBSERVATION_MODIFIER", 134, 143], ["increase", "OBSERVATION_MODIFIER", 152, 160]]], ["The increased production of IL-1b resulted from the binding of ICAM-1 expressed on LSECs with LFA-1 on C26 colon carcinoma cells (Arteta et al., 2010).", [["LSECs", "ANATOMY", 83, 88], ["C26 colon carcinoma cells", "ANATOMY", 103, 128], ["colon carcinoma", "DISEASE", 107, 122], ["IL-1b", "GENE_OR_GENE_PRODUCT", 28, 33], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 63, 69], ["LSECs", "SIMPLE_CHEMICAL", 83, 88], ["LFA-1", "GENE_OR_GENE_PRODUCT", 94, 99], ["C26 colon carcinoma cells", "CELL", 103, 128], ["IL-1b", "PROTEIN", 28, 33], ["ICAM-1", "PROTEIN", 63, 69], ["LSECs", "CELL_TYPE", 83, 88], ["LFA", "PROTEIN", 94, 97], ["C26 colon carcinoma cells", "CELL_LINE", 103, 128], ["ICAM", "TEST", 63, 67], ["LFA", "TEST", 94, 97], ["C26 colon carcinoma cells", "PROBLEM", 103, 128], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["production", "OBSERVATION_MODIFIER", 14, 24], ["C26 colon", "ANATOMY", 103, 112], ["carcinoma", "OBSERVATION", 113, 122]]], ["This activity decreased secretion of IFN-\u03b3 as well as anti-tumor cytotoxicity.", [["anti-tumor", "ANATOMY", 54, 64], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 37, 42], ["anti-tumor", "CANCER", 54, 64], ["IFN", "PROTEIN", 37, 40], ["\u03b3", "PROTEIN", 41, 42], ["IFN", "TREATMENT", 37, 40], ["anti-tumor cytotoxicity", "TREATMENT", 54, 77]]], ["This study discovered the role of MR in promoting IL-1b and ICAM-1 mediated pro-metastatic effects in the liver.Scavenger Receptor H (SR-H) ::: Recently Established Nomenclature for Scavenger ReceptorsStabilin (or FEEL/CLEVER/HARE) receptors are class H scavenger receptors.", [["liver", "ANATOMY", 106, 111], ["IL-1b", "GENE_OR_GENE_PRODUCT", 50, 55], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 60, 66], ["liver", "ORGAN", 106, 111], ["Scavenger Receptor H", "GENE_OR_GENE_PRODUCT", 112, 132], ["SR-H", "GENE_OR_GENE_PRODUCT", 134, 138], ["Scavenger ReceptorsStabilin", "GENE_OR_GENE_PRODUCT", 182, 209], ["FEEL/CLEVER/HARE) receptors", "GENE_OR_GENE_PRODUCT", 214, 241], ["class H scavenger receptors", "GENE_OR_GENE_PRODUCT", 246, 273], ["MR", "PROTEIN", 34, 36], ["IL", "PROTEIN", 50, 52], ["ICAM", "PROTEIN", 60, 64], ["Scavenger ReceptorsStabilin (or FEEL/CLEVER/HARE) receptors", "PROTEIN", 182, 241], ["class H scavenger receptors", "PROTEIN", 246, 273], ["This study", "TEST", 0, 10], ["MR", "TEST", 34, 36], ["promoting IL", "TEST", 40, 52], ["ICAM", "TEST", 60, 64], ["1 mediated pro-metastatic effects in the liver", "PROBLEM", 65, 111], ["pro-metastatic", "OBSERVATION", 76, 90], ["liver", "ANATOMY", 106, 111]]], ["They are type I transmembrane proteins consisting of 20\u201321 EGF/EGF-like domains, seven fasciclin-1 domains, an X-linked domain, a transmembrane region, and a short cytoplasmic domain (Politz et al., 2002).", [["transmembrane", "ANATOMY", 130, 143], ["cytoplasmic", "ANATOMY", 164, 175], ["EGF", "GENE_OR_GENE_PRODUCT", 59, 62], ["EGF", "GENE_OR_GENE_PRODUCT", 63, 66], ["fasciclin-1", "GENE_OR_GENE_PRODUCT", 87, 98], ["transmembrane", "CELLULAR_COMPONENT", 130, 143], ["cytoplasmic", "ORGANISM_SUBSTANCE", 164, 175], ["type I transmembrane proteins", "PROTEIN", 9, 38], ["20\u201321 EGF/EGF-like domains", "PROTEIN", 53, 79], ["fasciclin-1 domains", "PROTEIN", 87, 106], ["X-linked domain", "PROTEIN", 111, 126], ["transmembrane region", "PROTEIN", 130, 150], ["cytoplasmic domain", "PROTEIN", 164, 182], ["type I transmembrane proteins", "PROBLEM", 9, 38], ["EGF/EGF", "TEST", 59, 66], ["a transmembrane region", "PROBLEM", 128, 150], ["a short cytoplasmic domain", "PROBLEM", 156, 182]]], ["This family consists of two members; Stabilin-1 and Stabilin-2.", [["Stabilin-1", "GENE_OR_GENE_PRODUCT", 37, 47], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["Stabilin-1 and Stabilin-2", "PROTEIN", 37, 62], ["Stabilin", "TEST", 37, 45]]], ["Stabilin-1 is also known as SR-H1/MS-1/FEEL-1/CLEVER-1.", [["Stabilin-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["SR-H1", "GENE_OR_GENE_PRODUCT", 28, 33], ["MS-1", "GENE_OR_GENE_PRODUCT", 34, 38], ["FEEL-1", "GENE_OR_GENE_PRODUCT", 39, 45], ["CLEVER-1", "GENE_OR_GENE_PRODUCT", 46, 54], ["Stabilin-1", "PROTEIN", 0, 10], ["H1", "PROTEIN", 31, 33], ["FEEL", "PROTEIN", 39, 43], ["CLEVER-1", "DNA", 46, 54], ["SR", "TEST", 28, 30], ["MS", "TEST", 34, 36], ["FEEL", "TEST", 39, 43]]], ["Stabilin-2 is also known as SR-H2/FEEL-2 and HARE, which is a shorter isoform of Stabilin-2 generated by proteolytic cleavage (Goerdt et al., 1991; Weigel, 2019).", [["Stabilin-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SR-H2", "GENE_OR_GENE_PRODUCT", 28, 33], ["FEEL-2", "GENE_OR_GENE_PRODUCT", 34, 40], ["HARE", "GENE_OR_GENE_PRODUCT", 45, 49], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 81, 91], ["Stabilin-2", "PROTEIN", 0, 10], ["SR", "PROTEIN", 28, 30], ["H2", "PROTEIN", 31, 33], ["FEEL", "PROTEIN", 34, 38], ["HARE", "PROTEIN", 45, 49], ["Stabilin-2", "PROTEIN", 81, 91], ["Stabilin", "TEST", 81, 89]]], ["The main structural difference between Stabilin-1 and Stabilin-2 is the presence of 20 EGF-like domains in stabilin-2 as compared to 21 domains in stabilin-1.", [["Stabilin-1", "GENE_OR_GENE_PRODUCT", 39, 49], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["EGF", "GENE_OR_GENE_PRODUCT", 87, 90], ["stabilin-2", "GENE_OR_GENE_PRODUCT", 107, 117], ["stabilin-1", "GENE_OR_GENE_PRODUCT", 147, 157], ["Stabilin", "PROTEIN", 39, 47], ["Stabilin", "PROTEIN", 54, 62], ["EGF", "PROTEIN", 87, 90], ["stabilin-2", "DNA", 107, 117], ["21 domains", "DNA", 133, 143], ["stabilin-1", "DNA", 147, 157], ["Stabilin", "TEST", 39, 47], ["Stabilin", "TEST", 54, 62], ["20 EGF", "PROBLEM", 84, 90], ["stabilin", "TEST", 107, 115], ["stabilin", "TEST", 147, 155], ["main", "OBSERVATION_MODIFIER", 4, 8], ["structural", "OBSERVATION_MODIFIER", 9, 19], ["difference", "OBSERVATION_MODIFIER", 20, 30], ["20 EGF", "OBSERVATION_MODIFIER", 84, 90]]], ["Stabilin-1 is located on chromosome 3 and chromosome 14 in humans and mice, respectively.", [["chromosome 3", "ANATOMY", 25, 37], ["chromosome 14", "ANATOMY", 42, 55], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["chromosome 3", "CELLULAR_COMPONENT", 25, 37], ["chromosome 14", "CELLULAR_COMPONENT", 42, 55], ["humans", "ORGANISM", 59, 65], ["mice", "ORGANISM", 70, 74], ["Stabilin-1", "DNA", 0, 10], ["chromosome 3", "DNA", 25, 37], ["chromosome 14", "DNA", 42, 55], ["humans", "SPECIES", 59, 65], ["mice", "SPECIES", 70, 74], ["humans", "SPECIES", 59, 65], ["mice", "SPECIES", 70, 74], ["Stabilin", "TEST", 0, 8]]], ["Stabilin-2 is located on chromosome 12 in humans and chromosome 10 in mice, respectively.", [["chromosome 12", "ANATOMY", 25, 38], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["chromosome 12", "CELLULAR_COMPONENT", 25, 38], ["humans", "ORGANISM", 42, 48], ["chromosome 10", "CELLULAR_COMPONENT", 53, 66], ["mice", "ORGANISM", 70, 74], ["Stabilin-2", "DNA", 0, 10], ["chromosome 12", "DNA", 25, 38], ["chromosome 10", "DNA", 53, 66], ["humans", "SPECIES", 42, 48], ["mice", "SPECIES", 70, 74], ["humans", "SPECIES", 42, 48], ["mice", "SPECIES", 70, 74], ["Stabilin", "TEST", 0, 8]]], ["Their extracellular domains share 55% similar homology, but their short intracellular domains are highly diverse, which results in differential abundance in different tissues and cells (Harris and Cabral, 2019).", [["extracellular", "ANATOMY", 6, 19], ["intracellular", "ANATOMY", 72, 85], ["tissues", "ANATOMY", 167, 174], ["cells", "ANATOMY", 179, 184], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 19], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["tissues", "TISSUE", 167, 174], ["cells", "CELL", 179, 184], ["extracellular domains", "PROTEIN", 6, 27], ["short intracellular domains", "PROTEIN", 66, 93], ["their short intracellular domains", "PROBLEM", 60, 93], ["different tissues", "OBSERVATION_MODIFIER", 157, 174]]], ["Sinusoidal endothelial cells in the liver, spleen, adrenal cortex and tissue macrophages express Stabilin-1 (Goerdt et al., 1991; Kzhyshkowska et al., 2006a), whereas, the expression of stabilin-2 is abundant in the sinusoids of liver, spleen, lymph node and bone marrow (Yannariello-Brown et al., 1997; Weigel and Weigel, 2003; Qian et al., 2009).", [["Sinusoidal endothelial cells", "ANATOMY", 0, 28], ["liver", "ANATOMY", 36, 41], ["spleen", "ANATOMY", 43, 49], ["adrenal cortex", "ANATOMY", 51, 65], ["tissue macrophages", "ANATOMY", 70, 88], ["sinusoids", "ANATOMY", 216, 225], ["liver", "ANATOMY", 229, 234], ["spleen", "ANATOMY", 236, 242], ["lymph node", "ANATOMY", 244, 254], ["bone marrow", "ANATOMY", 259, 270], ["Sinusoidal endothelial cells", "CELL", 0, 28], ["liver", "ORGAN", 36, 41], ["spleen", "ORGAN", 43, 49], ["adrenal cortex", "MULTI-TISSUE_STRUCTURE", 51, 65], ["tissue macrophages", "CELL", 70, 88], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 97, 107], ["stabilin-2", "GENE_OR_GENE_PRODUCT", 186, 196], ["sinusoids", "TISSUE", 216, 225], ["liver", "ORGAN", 229, 234], ["spleen", "ORGAN", 236, 242], ["lymph node", "MULTI-TISSUE_STRUCTURE", 244, 254], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 259, 270], ["Sinusoidal endothelial cells", "CELL_TYPE", 0, 28], ["tissue macrophages", "CELL_TYPE", 70, 88], ["Stabilin", "PROTEIN", 97, 105], ["stabilin-2", "PROTEIN", 186, 196], ["Sinusoidal endothelial cells in the liver", "PROBLEM", 0, 41], ["Stabilin", "TEST", 97, 105], ["stabilin", "TEST", 186, 194], ["bone marrow", "TEST", 259, 270], ["Yannariello", "TEST", 272, 283], ["Weigel", "TEST", 304, 310], ["Weigel", "TEST", 315, 321], ["endothelial cells", "OBSERVATION", 11, 28], ["liver", "ANATOMY", 36, 41], ["spleen", "ANATOMY", 43, 49], ["adrenal", "ANATOMY", 51, 58], ["cortex", "ANATOMY_MODIFIER", 59, 65], ["tissue macrophages", "OBSERVATION", 70, 88], ["sinusoids", "ANATOMY_MODIFIER", 216, 225], ["liver", "ANATOMY", 229, 234], ["spleen", "ANATOMY", 236, 242], ["lymph node", "OBSERVATION", 244, 254], ["bone marrow", "ANATOMY", 259, 270]]], ["Both receptors are also expressed in several other tissues throughout the body at lower levels (Falkowski et al., 2003).", [["tissues", "ANATOMY", 51, 58], ["body", "ANATOMY", 74, 78], ["tissues", "TISSUE", 51, 58], ["body", "ORGANISM_SUBDIVISION", 74, 78], ["body", "ANATOMY_MODIFIER", 74, 78], ["lower", "ANATOMY_MODIFIER", 82, 87]]], ["Stabilin-1/2 are considered the primary scavenger receptors of LSECs and are responsible for the binding, uptake, and degradation of multifarious ligands, such as hyaluronan, N-terminal pro-peptide of type I procollagen (PINP) (Yannariello-Brown et al., 1997; McCourt et al., 1999), chondroitin sulfates (Harris et al., 2004), AGE (Li R. et al., 2009), oxLDLs (Li et al., 2011), SPARC (Kzhyshkowska et al., 2006b), heparin (Harris et al., 2008), von Willebrand factor-factor VIII (Swystun et al., 2018) and synthetic phosphorothioate antisense oligonucleotides (Miller et al., 2016).Scavenger Receptor H (SR-H) ::: Recently Established Nomenclature for Scavenger ReceptorsStabilin-1, and to some extent, Stabilin-2, in LSECs, are specifically involved in the uptake of oxLDL, thus playing a role in the prevention of atherogenesis (Li et al., 2011).", [["LSECs", "ANATOMY", 63, 68], ["LSECs", "ANATOMY", 719, 724], ["chondroitin sulfates", "CHEMICAL", 283, 303], ["heparin", "CHEMICAL", 415, 422], ["phosphorothioate", "CHEMICAL", 517, 533], ["oxLDL", "CHEMICAL", 769, 774], ["atherogenesis", "DISEASE", 817, 830], ["N", "CHEMICAL", 175, 176], ["chondroitin sulfates", "CHEMICAL", 283, 303], ["phosphorothioate", "CHEMICAL", 517, 533], ["Stabilin-1/2", "GENE_OR_GENE_PRODUCT", 0, 12], ["LSECs", "GENE_OR_GENE_PRODUCT", 63, 68], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 163, 173], ["type I procollagen", "GENE_OR_GENE_PRODUCT", 201, 219], ["PINP", "GENE_OR_GENE_PRODUCT", 221, 225], ["chondroitin sulfates", "SIMPLE_CHEMICAL", 283, 303], ["AGE", "SIMPLE_CHEMICAL", 327, 330], ["SPARC", "GENE_OR_GENE_PRODUCT", 379, 384], ["heparin", "SIMPLE_CHEMICAL", 415, 422], ["von Willebrand factor-factor VIII", "GENE_OR_GENE_PRODUCT", 446, 479], ["Scavenger Receptor H", "GENE_OR_GENE_PRODUCT", 583, 603], ["SR-H", "GENE_OR_GENE_PRODUCT", 605, 609], ["Scavenger ReceptorsStabilin-1", "GENE_OR_GENE_PRODUCT", 653, 682], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 704, 714], ["LSECs", "CELL", 719, 724], ["oxLDL", "GENE_OR_GENE_PRODUCT", 769, 774], ["Stabilin-1/2", "PROTEIN", 0, 12], ["LSECs", "CELL_TYPE", 63, 68], ["N-terminal pro-peptide", "PROTEIN", 175, 197], ["type I procollagen", "PROTEIN", 201, 219], ["PINP", "PROTEIN", 221, 225], ["Scavenger ReceptorsStabilin-1", "PROTEIN", 653, 682], ["Stabilin", "PROTEIN", 704, 712], ["LSECs", "CELL_TYPE", 719, 724], ["oxLDL", "PROTEIN", 769, 774], ["the binding", "PROBLEM", 93, 104], ["multifarious ligands", "PROBLEM", 133, 153], ["hyaluronan", "TEST", 163, 173], ["type I procollagen (PINP)", "TREATMENT", 201, 226], ["chondroitin sulfates", "TREATMENT", 283, 303], ["heparin", "TREATMENT", 415, 422], ["von Willebrand factor", "TEST", 446, 467], ["synthetic phosphorothioate antisense oligonucleotides", "TREATMENT", 507, 560], ["Scavenger ReceptorsStabilin", "TEST", 653, 680], ["Stabilin", "TEST", 704, 712], ["atherogenesis", "PROBLEM", 817, 830], ["LSECs", "ANATOMY", 63, 68], ["LSECs", "ANATOMY", 719, 724]]], ["The Stabilin receptors are also involved in the internalization and clearance of various macromolecules that cannot be cleared by the kidney due to size limitation for some of these macromolecules.", [["kidney", "ANATOMY", 134, 140], ["Stabilin receptors", "GENE_OR_GENE_PRODUCT", 4, 22], ["kidney", "ORGAN", 134, 140], ["Stabilin receptors", "PROTEIN", 4, 22], ["The Stabilin receptors", "TREATMENT", 0, 22], ["various macromolecules", "PROBLEM", 81, 103], ["size limitation", "PROBLEM", 148, 163], ["kidney", "ANATOMY", 134, 140], ["size", "OBSERVATION_MODIFIER", 148, 152]]], ["In 2011, it was reported that mice lacking both Stabilin-1 and Stabilin-2 did not live as long as their WT littermates due to mild perisinusoidal liver fibrosis and severe glomerular fibrosis.", [["liver", "ANATOMY", 146, 151], ["glomerular", "ANATOMY", 172, 182], ["fibrosis", "DISEASE", 152, 160], ["fibrosis", "DISEASE", 183, 191], ["mice", "ORGANISM", 30, 34], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 48, 58], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 63, 73], ["WT littermates", "ORGANISM", 104, 118], ["liver", "ORGAN", 146, 151], ["glomerular", "TISSUE", 172, 182], ["Stabilin", "PROTEIN", 48, 56], ["Stabilin", "PROTEIN", 63, 71], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["mild perisinusoidal liver fibrosis", "PROBLEM", 126, 160], ["severe glomerular fibrosis", "PROBLEM", 165, 191], ["mild", "OBSERVATION_MODIFIER", 126, 130], ["perisinusoidal", "ANATOMY_MODIFIER", 131, 145], ["liver", "ANATOMY", 146, 151], ["fibrosis", "OBSERVATION", 152, 160], ["severe", "OBSERVATION_MODIFIER", 165, 171], ["glomerular", "OBSERVATION_MODIFIER", 172, 182], ["fibrosis", "OBSERVATION", 183, 191]]], ["This study showed that both Stabilin-1 and -2 are essential for the normal clearance of extracellular matrix material, thus preserving the homeostasis of the liver as well as other distantly located organs (Schledzewski et al., 2011).", [["extracellular matrix", "ANATOMY", 88, 108], ["liver", "ANATOMY", 158, 163], ["organs", "ANATOMY", 199, 205], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 28, 38], ["-2", "GENE_OR_GENE_PRODUCT", 43, 45], ["extracellular", "CELLULAR_COMPONENT", 88, 101], ["matrix material", "CELLULAR_COMPONENT", 102, 117], ["liver", "ORGAN", 158, 163], ["organs", "ORGAN", 199, 205], ["Stabilin-1 and -2", "PROTEIN", 28, 45], ["This study", "TEST", 0, 10], ["Stabilin", "TEST", 28, 36], ["extracellular matrix material", "PROBLEM", 88, 117], ["the homeostasis of the liver", "PROBLEM", 135, 163], ["normal", "OBSERVATION", 68, 74], ["extracellular matrix material", "OBSERVATION", 88, 117], ["homeostasis", "OBSERVATION", 139, 150], ["liver", "ANATOMY", 158, 163]]], ["In humans, it is not known what occurs in Stabilin allelic insufficiency or loss of function.", [["allelic insufficiency", "DISEASE", 51, 72], ["loss of function", "DISEASE", 76, 92], ["humans", "ORGANISM", 3, 9], ["Stabilin", "GENE_OR_GENE_PRODUCT", 42, 50], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["Stabilin allelic insufficiency", "PROBLEM", 42, 72], ["loss of function", "PROBLEM", 76, 92], ["insufficiency", "OBSERVATION", 59, 72]]], ["However, in de-differentiated tissues in cases of liver cancer, loss in the expression of Stabilin-1 and -2 was seen in hepatocellular carcinoma (HCC) patients, and this loss was inversely related to patient survival.", [["tissues", "ANATOMY", 30, 37], ["liver cancer", "ANATOMY", 50, 62], ["hepatocellular carcinoma", "ANATOMY", 120, 144], ["HCC", "ANATOMY", 146, 149], ["liver cancer", "DISEASE", 50, 62], ["hepatocellular carcinoma", "DISEASE", 120, 144], ["HCC", "DISEASE", 146, 149], ["tissues", "TISSUE", 30, 37], ["liver cancer", "CANCER", 50, 62], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 90, 100], ["-2", "GENE_OR_GENE_PRODUCT", 105, 107], ["hepatocellular carcinoma", "CANCER", 120, 144], ["HCC", "CANCER", 146, 149], ["patients", "ORGANISM", 151, 159], ["patient", "ORGANISM", 200, 207], ["Stabilin-1 and -2", "PROTEIN", 90, 107], ["patients", "SPECIES", 151, 159], ["patient", "SPECIES", 200, 207], ["liver cancer", "PROBLEM", 50, 62], ["Stabilin", "TEST", 90, 98], ["hepatocellular carcinoma", "PROBLEM", 120, 144], ["this loss", "PROBLEM", 165, 174], ["liver", "ANATOMY", 50, 55], ["cancer", "OBSERVATION", 56, 62], ["loss", "OBSERVATION_MODIFIER", 64, 68], ["hepatocellular", "ANATOMY", 120, 134], ["carcinoma", "OBSERVATION", 135, 144], ["HCC", "OBSERVATION", 146, 149]]], ["Additionally, loss of Stabilin-1 and -2 as well as CD32b was also observed around the tissues surrounding the tumor in HCC patients (Geraud et al., 2013).", [["tissues", "ANATOMY", 86, 93], ["tumor", "ANATOMY", 110, 115], ["HCC", "ANATOMY", 119, 122], ["tumor", "DISEASE", 110, 115], ["HCC", "DISEASE", 119, 122], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 22, 32], ["-2", "GENE_OR_GENE_PRODUCT", 37, 39], ["CD32b", "GENE_OR_GENE_PRODUCT", 51, 56], ["tissues", "TISSUE", 86, 93], ["tumor", "CANCER", 110, 115], ["HCC", "CANCER", 119, 122], ["patients", "ORGANISM", 123, 131], ["Stabilin-1 and -2", "PROTEIN", 22, 39], ["CD32b", "PROTEIN", 51, 56], ["patients", "SPECIES", 123, 131], ["Stabilin", "TEST", 22, 30], ["the tumor", "PROBLEM", 106, 115], ["loss", "OBSERVATION_MODIFIER", 14, 18], ["tissues", "ANATOMY", 86, 93], ["tumor", "OBSERVATION", 110, 115], ["HCC", "ANATOMY", 119, 122]]], ["Conversely, another study has shown that Stabilin-1 retains its expression in the LSECs of the diseased liver and mediates transmigration of T cells, especially T regulatory cells across the endothelium in the inflamed liver.", [["LSECs", "ANATOMY", 82, 87], ["liver", "ANATOMY", 104, 109], ["T cells", "ANATOMY", 141, 148], ["T regulatory cells", "ANATOMY", 161, 179], ["endothelium", "ANATOMY", 191, 202], ["liver", "ANATOMY", 219, 224], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 41, 51], ["LSECs", "CANCER", 82, 87], ["liver", "ORGAN", 104, 109], ["T cells", "CELL", 141, 148], ["T regulatory cells", "CELL", 161, 179], ["endothelium", "TISSUE", 191, 202], ["liver", "ORGAN", 219, 224], ["Stabilin-1", "PROTEIN", 41, 51], ["LSECs", "CELL_TYPE", 82, 87], ["T cells", "CELL_TYPE", 141, 148], ["T regulatory cells", "CELL_TYPE", 161, 179], ["another study", "TEST", 12, 25], ["Stabilin", "TEST", 41, 49], ["transmigration of T cells", "PROBLEM", 123, 148], ["diseased", "OBSERVATION", 95, 103], ["liver", "ANATOMY", 104, 109], ["transmigration", "OBSERVATION_MODIFIER", 123, 137], ["T cells", "OBSERVATION", 141, 148], ["endothelium", "ANATOMY_MODIFIER", 191, 202], ["inflamed", "ANATOMY_MODIFIER", 210, 218], ["liver", "ANATOMY", 219, 224]]], ["They also found increased expression of Stabilin-1 in the vessels and sinusoids lining the tumor in HCC (Shetty et al., 2011).", [["vessels", "ANATOMY", 58, 65], ["sinusoids lining", "ANATOMY", 70, 86], ["tumor", "ANATOMY", 91, 96], ["HCC", "ANATOMY", 100, 103], ["tumor", "DISEASE", 91, 96], ["HCC", "DISEASE", 100, 103], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 40, 50], ["vessels", "TISSUE", 58, 65], ["sinusoids", "TISSUE", 70, 79], ["tumor", "CANCER", 91, 96], ["HCC", "CANCER", 100, 103], ["Stabilin-1", "PROTEIN", 40, 50], ["increased expression of Stabilin", "PROBLEM", 16, 48], ["sinusoids lining the tumor", "PROBLEM", 70, 96], ["HCC", "PROBLEM", 100, 103], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["expression", "OBSERVATION_MODIFIER", 26, 36], ["vessels", "ANATOMY", 58, 65], ["sinusoids", "ANATOMY", 70, 79], ["tumor", "OBSERVATION", 91, 96], ["HCC", "OBSERVATION", 100, 103]]], ["A survey was conducted on young and old rats to delineate Stabilin expression and endocytic capacity in LSECs in response to aging.", [["LSECs", "ANATOMY", 104, 109], ["rats", "ORGANISM", 40, 44], ["Stabilin", "GENE_OR_GENE_PRODUCT", 58, 66], ["LSECs", "CELL", 104, 109], ["Stabilin", "PROTEIN", 58, 66], ["LSECs", "CELL_TYPE", 104, 109], ["rats", "SPECIES", 40, 44], ["A survey", "TEST", 0, 8], ["endocytic capacity", "OBSERVATION", 82, 100]]], ["Their results found that there was an attenuation in the endocytic capacity of old rats, although the degradation capacity for both ages were similar.", [["rats", "ORGANISM", 83, 87], ["rats", "SPECIES", 83, 87], ["an attenuation", "PROBLEM", 35, 49], ["the degradation capacity", "PROBLEM", 98, 122], ["attenuation", "OBSERVATION_MODIFIER", 38, 49], ["endocytic", "OBSERVATION_MODIFIER", 57, 66], ["capacity", "OBSERVATION_MODIFIER", 67, 75]]], ["An increase in LSEC thickness was also observed in old age rats, which might be responsible for lower endocytic capacity (Simon-Santamaria et al., 2010).", [["LSEC", "ANATOMY", 15, 19], ["LSEC", "CANCER", 15, 19], ["rats", "ORGANISM", 59, 63], ["LSEC", "PROTEIN", 15, 19], ["rats", "SPECIES", 59, 63], ["An increase in LSEC thickness", "PROBLEM", 0, 29], ["lower endocytic capacity", "PROBLEM", 96, 120], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["LSEC thickness", "OBSERVATION", 15, 29], ["might be responsible", "UNCERTAINTY", 71, 91]]], ["Similarly, another study had documented a decrease in Stabilin-2 receptors expression on primary LSECs in an aged rat model (Maeso-Diaz et al., 2018).", [["primary LSECs", "ANATOMY", 89, 102], ["Stabilin-2 receptors", "GENE_OR_GENE_PRODUCT", 54, 74], ["LSECs", "CELL", 97, 102], ["rat", "ORGANISM", 114, 117], ["Stabilin-2 receptors", "PROTEIN", 54, 74], ["primary LSECs", "CELL_TYPE", 89, 102], ["rat", "SPECIES", 114, 117], ["rat", "SPECIES", 114, 117], ["another study", "TEST", 11, 24], ["a decrease in Stabilin", "PROBLEM", 40, 62], ["decrease", "OBSERVATION_MODIFIER", 42, 50]]], ["From these studies, we may generally conclude that aging results in reduced expression of the Stabilin receptors and disease may alter expression and function of these receptors.Scavenger Receptor H (SR-H) ::: Recently Established Nomenclature for Scavenger ReceptorsLSECs are involved in the synthesis of Factor VIII, a blood coagulation factor.", [["blood", "ANATOMY", 321, 326], ["Stabilin receptors", "GENE_OR_GENE_PRODUCT", 94, 112], ["Scavenger Receptor H", "GENE_OR_GENE_PRODUCT", 178, 198], ["SR-H", "GENE_OR_GENE_PRODUCT", 200, 204], ["Factor VIII", "GENE_OR_GENE_PRODUCT", 306, 317], ["blood", "ORGANISM_SUBSTANCE", 321, 326], ["Stabilin receptors", "PROTEIN", 94, 112], ["Scavenger ReceptorsLSECs", "PROTEIN", 248, 272], ["Factor VIII", "PROTEIN", 306, 317], ["blood coagulation factor", "PROTEIN", 321, 345], ["these studies", "TEST", 5, 18], ["the Stabilin receptors", "PROBLEM", 90, 112], ["disease", "PROBLEM", 117, 124], ["Scavenger ReceptorsLSECs", "TREATMENT", 248, 272], ["a blood coagulation factor", "PROBLEM", 319, 345]]], ["This pro-coagulant is either defective or missing in Hemophilia A patients (Powell, 2009).", [["Hemophilia A", "DISEASE", 53, 65], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["defective", "OBSERVATION", 29, 38], ["Hemophilia", "OBSERVATION", 53, 63]]], ["Do et al. (1999) first identified FVIII mRNA in purified LSECs and hepatocytes from mice and in cultured LSECs by RT-PCR.", [["LSECs", "ANATOMY", 57, 62], ["hepatocytes", "ANATOMY", 67, 78], ["LSECs", "ANATOMY", 105, 110], ["FVIII", "GENE_OR_GENE_PRODUCT", 34, 39], ["LSECs", "CELL", 57, 62], ["hepatocytes", "CELL", 67, 78], ["mice", "ORGANISM", 84, 88], ["LSECs", "CELL", 105, 110], ["FVIII mRNA", "RNA", 34, 44], ["LSECs", "CELL_TYPE", 57, 62], ["hepatocytes", "CELL_TYPE", 67, 78], ["LSECs", "CELL_TYPE", 105, 110], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["FVIII mRNA", "TEST", 34, 44], ["RT", "TEST", 114, 116], ["PCR", "TEST", 117, 120], ["FVIII", "OBSERVATION", 34, 39], ["LSECs", "ANATOMY", 57, 62], ["hepatocytes", "ANATOMY", 67, 78]]], ["They also found higher FVIII mRNA expression in LSECs quantitatively.", [["LSECs", "ANATOMY", 48, 53], ["FVIII", "GENE_OR_GENE_PRODUCT", 23, 28], ["LSECs", "PATHOLOGICAL_FORMATION", 48, 53], ["FVIII mRNA", "RNA", 23, 33], ["LSECs", "CELL_TYPE", 48, 53], ["higher", "OBSERVATION_MODIFIER", 16, 22], ["FVIII", "OBSERVATION", 23, 28], ["mRNA expression", "OBSERVATION", 29, 44]]], ["In agreement with this finding, the transplantation of LSECs isolated from FVB/N-Tie2\u2013GFP mice in a hemophilia A mouse model restored plasma level of FVIII (Follenzi et al., 2008).", [["LSECs", "ANATOMY", 55, 60], ["plasma", "ANATOMY", 134, 140], ["hemophilia", "DISEASE", 100, 110], ["LSECs", "GENE_OR_GENE_PRODUCT", 55, 60], ["Tie2", "GENE_OR_GENE_PRODUCT", 81, 85], ["GFP", "GENE_OR_GENE_PRODUCT", 86, 89], ["mouse", "ORGANISM", 113, 118], ["plasma", "ORGANISM_SUBSTANCE", 134, 140], ["FVIII", "GENE_OR_GENE_PRODUCT", 150, 155], ["LSECs", "CELL_TYPE", 55, 60], ["Tie2", "PROTEIN", 81, 85], ["FVIII", "PROTEIN", 150, 155], ["mice", "SPECIES", 90, 94], ["mouse", "SPECIES", 113, 118], ["mouse", "SPECIES", 113, 118], ["LSECs", "TEST", 55, 60], ["FVB", "TEST", 75, 78], ["a hemophilia", "PROBLEM", 98, 110], ["hemophilia", "OBSERVATION", 100, 110]]], ["An increase in plasma FVIII correlated with the proliferation of transplanted LSEC in a Hemophilia A mice model.", [["plasma", "ANATOMY", 15, 21], ["LSEC", "ANATOMY", 78, 82], ["Hemophilia", "DISEASE", 88, 98], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["FVIII", "GENE_OR_GENE_PRODUCT", 22, 27], ["LSEC", "CELL", 78, 82], ["mice", "ORGANISM", 101, 105], ["plasma FVIII", "PROTEIN", 15, 27], ["LSEC", "CELL_TYPE", 78, 82], ["mice", "SPECIES", 101, 105], ["Hemophilia A mice", "SPECIES", 88, 105], ["An increase in plasma FVIII", "PROBLEM", 0, 27], ["transplanted LSEC", "TREATMENT", 65, 82], ["a Hemophilia A mice model", "TREATMENT", 86, 111], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["plasma FVIII", "OBSERVATION", 15, 27], ["transplanted LSEC", "OBSERVATION", 65, 82], ["Hemophilia", "OBSERVATION", 88, 98]]], ["Two months after the LSEC transplantation, a bleeding experiment was performed to evaluate coagulation.", [["bleeding", "DISEASE", 45, 53], ["the LSEC transplantation", "TREATMENT", 17, 41], ["a bleeding experiment", "PROBLEM", 43, 64], ["coagulation", "TEST", 91, 102]]], ["The results showed that bleeding stopped in 15\u201320 min after a tail-cut which corrected this disorder.", [["tail", "ANATOMY", 62, 66], ["bleeding", "DISEASE", 24, 32], ["bleeding", "PROBLEM", 24, 32], ["this disorder", "PROBLEM", 87, 100], ["bleeding", "OBSERVATION", 24, 32]]], ["To take this one step further, an interesting attempt was made to transplant human fetal LSECs in uPA-NOG (or immunodeficient) mice and evaluate human FVIII plasma levels in mice (Fomin et al., 2013).", [["fetal LSECs", "ANATOMY", 83, 94], ["plasma", "ANATOMY", 157, 163], ["human", "ORGANISM", 77, 82], ["fetal LSECs", "CELL", 83, 94], ["uPA", "GENE_OR_GENE_PRODUCT", 98, 101], ["NOG", "GENE_OR_GENE_PRODUCT", 102, 105], ["mice", "ORGANISM", 127, 131], ["human", "ORGANISM", 145, 150], ["FVIII", "GENE_OR_GENE_PRODUCT", 151, 156], ["plasma", "ORGANISM_SUBSTANCE", 157, 163], ["mice", "ORGANISM", 174, 178], ["human fetal LSECs", "CELL_TYPE", 77, 94], ["uPA", "PROTEIN", 98, 101], ["FVIII", "PROTEIN", 151, 156], ["human", "SPECIES", 77, 82], ["mice", "SPECIES", 127, 131], ["human", "SPECIES", 145, 150], ["mice", "SPECIES", 174, 178], ["human", "SPECIES", 77, 82], ["mice", "SPECIES", 127, 131], ["human", "SPECIES", 145, 150], ["mice", "SPECIES", 174, 178], ["transplant human fetal LSECs", "TREATMENT", 66, 94], ["human FVIII plasma levels", "TEST", 145, 170], ["LSECs", "ANATOMY", 89, 94]]], ["Factor VIII levels were about half as high as a normal human plasma sample, but the amount far surpassed the non-transplanted controls indicating that LSECs produce FVIII in appreciable quantities.", [["plasma sample", "ANATOMY", 61, 74], ["LSECs", "ANATOMY", 151, 156], ["Factor VIII", "GENE_OR_GENE_PRODUCT", 0, 11], ["human", "ORGANISM", 55, 60], ["plasma", "ORGANISM_SUBSTANCE", 61, 67], ["LSECs", "SIMPLE_CHEMICAL", 151, 156], ["FVIII", "GENE_OR_GENE_PRODUCT", 165, 170], ["Factor VIII", "PROTEIN", 0, 11], ["LSECs", "CELL_TYPE", 151, 156], ["FVIII", "PROTEIN", 165, 170], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["Factor VIII levels", "TEST", 0, 18], ["FVIII", "OBSERVATION", 165, 170]]], ["These findings suggest a novel role of LSECs in the treatment of hemophilia A patients suffering from FVIII deficiency.", [["LSECs", "ANATOMY", 39, 44], ["hemophilia A", "DISEASE", 65, 77], ["FVIII deficiency", "DISEASE", 102, 118], ["LSECs", "SIMPLE_CHEMICAL", 39, 44], ["patients", "ORGANISM", 78, 86], ["FVIII", "GENE_OR_GENE_PRODUCT", 102, 107], ["FVIII", "PROTEIN", 102, 107], ["patients", "SPECIES", 78, 86], ["hemophilia", "PROBLEM", 65, 75], ["FVIII deficiency", "PROBLEM", 102, 118], ["LSECs", "OBSERVATION", 39, 44], ["hemophilia", "OBSERVATION", 65, 75], ["FVIII deficiency", "OBSERVATION", 102, 118]]], ["Interestingly, Stabilin-2 which is highly expressed in LSECs and in the sinusoids of spleen, also regulates the clearance rates of FVIII.", [["LSECs", "ANATOMY", 55, 60], ["sinusoids", "ANATOMY", 72, 81], ["spleen", "ANATOMY", 85, 91], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["LSECs", "CELL", 55, 60], ["sinusoids", "TISSUE", 72, 81], ["spleen", "ORGAN", 85, 91], ["FVIII", "GENE_OR_GENE_PRODUCT", 131, 136], ["Stabilin", "PROTEIN", 15, 23], ["LSECs", "CELL_TYPE", 55, 60], ["FVIII", "PROTEIN", 131, 136], ["Stabilin", "TEST", 15, 23], ["LSECs", "OBSERVATION", 55, 60], ["sinusoids", "ANATOMY_MODIFIER", 72, 81], ["spleen", "ANATOMY", 85, 91]]], ["Based on the data derived from genome wide association studies (GWAS), both Stabilin-2 and CLEC4M (see below) have been identified to affect vWF-FVIII levels in plasma. vWF or von Willebrand factor is normally found in tight physical association with FVIII in plasma (Lollar, 1991).", [["plasma", "ANATOMY", 161, 167], ["plasma", "ANATOMY", 260, 266], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 76, 86], ["CLEC4M", "GENE_OR_GENE_PRODUCT", 91, 97], ["vWF-FVIII", "GENE_OR_GENE_PRODUCT", 141, 150], ["plasma", "ORGANISM_SUBSTANCE", 161, 167], ["vWF", "GENE_OR_GENE_PRODUCT", 169, 172], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 176, 197], ["FVIII", "GENE_OR_GENE_PRODUCT", 251, 256], ["plasma", "ORGANISM_SUBSTANCE", 260, 266], ["Stabilin-2", "DNA", 76, 86], ["CLEC4M", "DNA", 91, 97], ["vWF", "PROTEIN", 141, 144], ["FVIII", "PROTEIN", 145, 150], ["vWF", "PROTEIN", 169, 172], ["von Willebrand factor", "PROTEIN", 176, 197], ["FVIII", "PROTEIN", 251, 256], ["GWAS", "TEST", 64, 68], ["Stabilin", "TEST", 76, 84], ["CLEC4M", "TEST", 91, 97], ["vWF", "TEST", 141, 144], ["FVIII levels", "TEST", 145, 157], ["von Willebrand factor", "PROBLEM", 176, 197]]], ["Using a combination of KO mice and immunofluorescence techniques, Swystun and co-workers firmly established that Stabilin-2 and CLEC4M expressed in LSECs of mice, regulates turnover of FVIII (Swystun et al., 2018, 2019).Scavenger Receptor L (SR-L) ::: Recently Established Nomenclature for Scavenger ReceptorsLRP-1 (Low-density lipoprotein receptor-related protein or CD91 or \u03b12macroglobulin receptor) is a scavenger and endocytic receptor present on the cell surface belonging to the family of low-density lipoprotein receptor (Herz et al., 1988).", [["LSECs", "ANATOMY", 148, 153], ["cell surface", "ANATOMY", 455, 467], ["KO mice", "ORGANISM", 23, 30], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 113, 123], ["CLEC4M", "GENE_OR_GENE_PRODUCT", 128, 134], ["LSECs", "GENE_OR_GENE_PRODUCT", 148, 153], ["mice", "ORGANISM", 157, 161], ["FVIII", "GENE_OR_GENE_PRODUCT", 185, 190], ["Scavenger Receptor L", "GENE_OR_GENE_PRODUCT", 220, 240], ["SR-L", "GENE_OR_GENE_PRODUCT", 242, 246], ["ReceptorsLRP-1", "GENE_OR_GENE_PRODUCT", 300, 314], ["Low-density lipoprotein receptor-related protein", "GENE_OR_GENE_PRODUCT", 316, 364], ["CD91", "GENE_OR_GENE_PRODUCT", 368, 372], ["\u03b12macroglobulin receptor", "GENE_OR_GENE_PRODUCT", 376, 400], ["cell surface", "CELLULAR_COMPONENT", 455, 467], ["low-density lipoprotein receptor", "GENE_OR_GENE_PRODUCT", 495, 527], ["Stabilin", "PROTEIN", 113, 121], ["CLEC4M", "PROTEIN", 128, 134], ["LSECs", "CELL_TYPE", 148, 153], ["FVIII", "PROTEIN", 185, 190], ["SR", "PROTEIN", 242, 244], ["Scavenger ReceptorsLRP-1", "PROTEIN", 290, 314], ["Low-density lipoprotein receptor-related protein", "PROTEIN", 316, 364], ["CD91", "PROTEIN", 368, 372], ["\u03b12macroglobulin receptor", "PROTEIN", 376, 400], ["endocytic receptor", "PROTEIN", 421, 439], ["low-density lipoprotein receptor", "PROTEIN", 495, 527], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 157, 161], ["KO mice", "TREATMENT", 23, 30], ["immunofluorescence techniques", "TEST", 35, 64], ["Scavenger ReceptorsLRP", "TEST", 290, 312], ["Low-density lipoprotein receptor", "TEST", 316, 348], ["\u03b12macroglobulin receptor", "TREATMENT", 376, 400]]], ["The structure of LRP-1 is composed of five domains (i) the ligand-binding domain (ii) the O-linked sugar domain (iii) the EGF-precursor homology domain (iv) the transmembrane domain and the intracellular domain.", [["transmembrane", "ANATOMY", 161, 174], ["intracellular", "ANATOMY", 190, 203], ["O", "CHEMICAL", 90, 91], ["sugar", "CHEMICAL", 99, 104], ["LRP-1", "GENE_OR_GENE_PRODUCT", 17, 22], ["EGF", "GENE_OR_GENE_PRODUCT", 122, 125], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 203], ["LRP", "PROTEIN", 17, 20], ["ligand-binding domain", "PROTEIN", 59, 80], ["O-linked sugar domain", "PROTEIN", 90, 111], ["EGF-precursor homology domain", "PROTEIN", 122, 151], ["transmembrane domain", "PROTEIN", 161, 181], ["intracellular domain", "PROTEIN", 190, 210], ["the EGF", "TEST", 118, 125], ["the transmembrane domain", "TEST", 157, 181], ["LRP", "OBSERVATION_MODIFIER", 17, 20], ["intracellular domain", "OBSERVATION", 190, 210]]], ["Proteolytic cleavage of LRP-1 results in alpha subunit ligand-binding domain at the N-terminus and \u00df subunit consisting of other remaining domain at the C-terminus (Lillis et al., 2008).", [["N", "CHEMICAL", 84, 85], ["C", "CHEMICAL", 153, 154], ["LRP-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["alpha subunit", "GENE_OR_GENE_PRODUCT", 41, 54], ["LRP", "PROTEIN", 24, 27], ["alpha subunit ligand-binding domain", "PROTEIN", 41, 76], ["N-terminus", "PROTEIN", 84, 94], ["\u00df subunit", "PROTEIN", 99, 108], ["C-terminus", "PROTEIN", 153, 163], ["Proteolytic cleavage of LRP", "TREATMENT", 0, 27], ["alpha subunit ligand", "PROBLEM", 41, 61], ["binding domain", "PROBLEM", 62, 76]]], ["LRP-1 binds to more than 30 ligands, such as ApoE (Hussain et al., 1999), tPA (Salama et al., 2019), a receptor-associated protein (RAP) (Prasad et al., 2016), in addition to trypsin-activated \u03b12-macroglobulin (\u03b12M\u2217), lactoferrin, Factor VIII and others (for a complete list of ligands, see Herz and Strickland, 2001).", [["LRP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ApoE", "GENE_OR_GENE_PRODUCT", 45, 49], ["tPA", "GENE_OR_GENE_PRODUCT", 74, 77], ["trypsin", "GENE_OR_GENE_PRODUCT", 175, 182], ["\u03b12-macroglobulin", "GENE_OR_GENE_PRODUCT", 193, 209], ["\u03b12M\u2217", "GENE_OR_GENE_PRODUCT", 211, 215], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 218, 229], ["Factor VIII", "GENE_OR_GENE_PRODUCT", 231, 242], ["LRP-1", "PROTEIN", 0, 5], ["ApoE", "PROTEIN", 45, 49], ["receptor-associated protein", "PROTEIN", 103, 130], ["RAP", "PROTEIN", 132, 135], ["trypsin", "PROTEIN", 175, 182], ["\u03b12", "PROTEIN", 193, 195], ["macroglobulin", "PROTEIN", 196, 209], ["\u03b12M\u2217", "PROTEIN", 211, 215], ["lactoferrin", "PROTEIN", 218, 229], ["Factor VIII", "PROTEIN", 231, 242], ["LRP", "TEST", 0, 3], ["tPA", "TREATMENT", 74, 77], ["a receptor", "TEST", 101, 111], ["trypsin", "TEST", 175, 182], ["macroglobulin", "TREATMENT", 196, 209], ["lactoferrin", "TREATMENT", 218, 229]]], ["The presence of different motifs at the cytoplasmic tail of LRP-1, such as two dileucine motifs, NPXY motifs, one YXXL motif has been suggested to be responsible for its high endocytic uptake (Li et al., 2000; Deane et al., 2008).", [["cytoplasmic tail", "ANATOMY", 40, 56], ["cytoplasmic", "ORGANISM_SUBSTANCE", 40, 51], ["LRP-1", "GENE_OR_GENE_PRODUCT", 60, 65], ["dileucine", "GENE_OR_GENE_PRODUCT", 79, 88], ["NPXY", "GENE_OR_GENE_PRODUCT", 97, 101], ["YXXL", "GENE_OR_GENE_PRODUCT", 114, 118], ["cytoplasmic tail", "PROTEIN", 40, 56], ["LRP-1", "PROTEIN", 60, 65], ["dileucine motifs", "PROTEIN", 79, 95], ["NPXY motifs", "DNA", 97, 108], ["YXXL motif", "DNA", 114, 124], ["LRP", "TEST", 60, 63], ["two dileucine motifs", "TREATMENT", 75, 95], ["NPXY motifs", "TREATMENT", 97, 108], ["different motifs", "OBSERVATION", 16, 32], ["tail", "OBSERVATION_MODIFIER", 52, 56]]], ["LRP-1 is expressed in the liver, lung, brain, intestine, and muscles (Herz et al., 1988).Scavenger Receptor L (SR-L) ::: Recently Established Nomenclature for Scavenger ReceptorsOie et al. (2011) reported the expression of LRP-1 on LSECs with immunofluorescence.", [["liver", "ANATOMY", 26, 31], ["lung", "ANATOMY", 33, 37], ["brain", "ANATOMY", 39, 44], ["intestine", "ANATOMY", 46, 55], ["muscles", "ANATOMY", 61, 68], ["LSECs", "ANATOMY", 232, 237], ["LRP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["liver", "ORGAN", 26, 31], ["lung", "ORGAN", 33, 37], ["brain", "ORGAN", 39, 44], ["intestine", "ORGAN", 46, 55], ["muscles", "ORGAN", 61, 68], ["Scavenger Receptor L", "GENE_OR_GENE_PRODUCT", 89, 109], ["SR-L", "GENE_OR_GENE_PRODUCT", 111, 115], ["LRP-1", "GENE_OR_GENE_PRODUCT", 223, 228], ["LSECs", "CELL", 232, 237], ["LRP-1", "PROTEIN", 0, 5], ["SR", "PROTEIN", 111, 113], ["LRP-1", "PROTEIN", 223, 228], ["LSECs", "CELL_TYPE", 232, 237], ["LRP", "TEST", 0, 3], ["LRP", "TEST", 223, 226], ["immunofluorescence", "TEST", 243, 261], ["liver", "ANATOMY", 26, 31], ["lung", "ANATOMY", 33, 37], ["brain", "ANATOMY", 39, 44], ["intestine", "ANATOMY", 46, 55], ["muscles", "ANATOMY", 61, 68]]], ["They showed that LRP-1 expressed in LSECs is responsible for partial hepatic clearance of RAP, an inhibitor of all known ligand interactions with LRP-1 and \u03b12M\u2217, along with other hepatic cells, suggesting the role of LSECs in lipid homeostasis.", [["LSECs", "ANATOMY", 36, 41], ["hepatic", "ANATOMY", 69, 76], ["hepatic cells", "ANATOMY", 179, 192], ["LSECs", "ANATOMY", 217, 222], ["RAP", "CHEMICAL", 90, 93], ["LRP-1", "GENE_OR_GENE_PRODUCT", 17, 22], ["LSECs", "CELL", 36, 41], ["hepatic", "ORGAN", 69, 76], ["RAP", "GENE_OR_GENE_PRODUCT", 90, 93], ["LRP-1", "GENE_OR_GENE_PRODUCT", 146, 151], ["\u03b12M\u2217", "GENE_OR_GENE_PRODUCT", 156, 160], ["hepatic cells", "CELL", 179, 192], ["LSECs", "GENE_OR_GENE_PRODUCT", 217, 222], ["lipid", "SIMPLE_CHEMICAL", 226, 231], ["LRP", "PROTEIN", 17, 20], ["LSECs", "CELL_TYPE", 36, 41], ["RAP", "PROTEIN", 90, 93], ["LRP", "PROTEIN", 146, 149], ["\u03b12M\u2217", "PROTEIN", 156, 160], ["hepatic cells", "CELL_TYPE", 179, 192], ["LRP", "TEST", 17, 20], ["partial hepatic clearance of RAP", "PROBLEM", 61, 93], ["an inhibitor", "TREATMENT", 95, 107], ["LRP", "TEST", 146, 149], ["LRP", "OBSERVATION", 17, 20], ["responsible for", "UNCERTAINTY", 45, 60], ["hepatic", "ANATOMY", 69, 76], ["clearance", "OBSERVATION", 77, 86], ["RAP", "OBSERVATION", 90, 93], ["hepatic", "ANATOMY", 179, 186], ["cells", "OBSERVATION", 187, 192], ["LSECs", "OBSERVATION", 217, 222], ["lipid homeostasis", "OBSERVATION", 226, 243]]], ["A hepatocyte-specific LRP-1 KO study showed that NAFLD disease progression is accelerated by the deficiency of LRP-1 in mice fed with a high-fat high cholesterol diet and that LSEC and KC LRP-1 were not sufficient to rescue the phenotype (Hamlin et al., 2018).", [["hepatocyte", "ANATOMY", 2, 12], ["NAFLD disease", "DISEASE", 49, 62], ["cholesterol", "CHEMICAL", 150, 161], ["cholesterol", "CHEMICAL", 150, 161], ["hepatocyte", "CELL", 2, 12], ["LRP-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["LRP-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["mice", "ORGANISM", 120, 124], ["cholesterol", "SIMPLE_CHEMICAL", 150, 161], ["LSEC", "SIMPLE_CHEMICAL", 176, 180], ["KC LRP-1", "GENE_OR_GENE_PRODUCT", 185, 193], ["LRP", "PROTEIN", 22, 25], ["LRP-1", "PROTEIN", 111, 116], ["KC", "PROTEIN", 185, 187], ["LRP", "PROTEIN", 188, 191], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 120, 124], ["A hepatocyte-specific LRP", "TEST", 0, 25], ["KO study", "TEST", 28, 36], ["NAFLD disease progression", "PROBLEM", 49, 74], ["the deficiency of LRP", "PROBLEM", 93, 114], ["a high-fat high cholesterol diet", "TREATMENT", 134, 166], ["KC LRP", "TEST", 185, 191], ["hepatocyte", "ANATOMY", 2, 12], ["NAFLD", "OBSERVATION_MODIFIER", 49, 54], ["disease", "OBSERVATION", 55, 62], ["LSEC", "ANATOMY", 176, 180]]], ["Similarly, another hepatocyte-specific LRP-1 KO study has demonstrated an increase in the accumulation of lipid in primary culture of LRP-1 KO hepatocytes due to an impairment in the lysosomal degradation capacity of auto-phagolysosomes leading to cell death (Hamlin et al., 2016).", [["hepatocyte", "ANATOMY", 19, 29], ["LRP-1 KO hepatocytes", "ANATOMY", 134, 154], ["lysosomal", "ANATOMY", 183, 192], ["auto-phagolysosomes", "ANATOMY", 217, 236], ["cell", "ANATOMY", 248, 252], ["death", "DISEASE", 253, 258], ["hepatocyte", "CELL", 19, 29], ["LRP-1", "GENE_OR_GENE_PRODUCT", 39, 44], ["lipid", "SIMPLE_CHEMICAL", 106, 111], ["LRP-1", "GENE_OR_GENE_PRODUCT", 134, 139], ["hepatocytes", "CELL", 143, 154], ["lysosomal", "CELLULAR_COMPONENT", 183, 192], ["cell", "CELL", 248, 252], ["LRP", "PROTEIN", 39, 42], ["LRP-1 KO hepatocytes", "CELL_LINE", 134, 154], ["another hepatocyte-specific LRP", "TEST", 11, 42], ["KO study", "TEST", 45, 53], ["LRP", "TEST", 134, 137], ["an impairment", "PROBLEM", 162, 175], ["the lysosomal degradation capacity", "PROBLEM", 179, 213], ["cell death", "PROBLEM", 248, 258], ["hepatocyte", "ANATOMY", 19, 29], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["accumulation of lipid", "OBSERVATION", 90, 111], ["impairment", "OBSERVATION", 165, 175], ["lysosomal degradation capacity", "OBSERVATION", 183, 213]]], ["These studies suggests severe impact of LRP-1 dysregulation on NAFLD progression.", [["NAFLD", "DISEASE", 63, 68], ["LRP-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["LRP", "PROTEIN", 40, 43], ["These studies", "TEST", 0, 13], ["severe impact of LRP", "PROBLEM", 23, 43], ["1 dysregulation", "PROBLEM", 44, 59], ["NAFLD progression", "PROBLEM", 63, 80], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["LRP", "OBSERVATION", 40, 43], ["1 dysregulation", "OBSERVATION_MODIFIER", 44, 59], ["NAFLD", "OBSERVATION_MODIFIER", 63, 68], ["progression", "OBSERVATION_MODIFIER", 69, 80]]], ["However, not much is known about the LSEC specific function of LRP-1 in various diseases and this needs to be elucidated.Fc\u03b3RIIb/CD32b ::: Other Cell Surface ReceptorsFc gamma receptors have four major classes in mice (Fc\u03b3RI-IV) and six in humans (Daeron, 1997).", [["Cell", "ANATOMY", 145, 149], ["LSEC", "CANCER", 37, 41], ["LRP-1", "GENE_OR_GENE_PRODUCT", 63, 68], ["CD32", "GENE_OR_GENE_PRODUCT", 129, 133], ["Cell Surface ReceptorsFc gamma receptors", "GENE_OR_GENE_PRODUCT", 145, 185], ["mice", "ORGANISM", 213, 217], ["Fc\u03b3RI-IV", "GENE_OR_GENE_PRODUCT", 219, 227], ["humans", "ORGANISM", 240, 246], ["LRP-1", "PROTEIN", 63, 68], ["Fc\u03b3", "PROTEIN", 121, 124], ["RIIb", "PROTEIN", 124, 128], ["CD32b", "PROTEIN", 129, 134], ["Cell Surface ReceptorsFc gamma receptors", "PROTEIN", 145, 185], ["mice", "SPECIES", 213, 217], ["humans", "SPECIES", 240, 246], ["mice", "SPECIES", 213, 217], ["humans", "SPECIES", 240, 246], ["LRP", "TEST", 63, 66], ["various diseases", "PROBLEM", 72, 88], ["mice (Fc\u03b3RI-IV)", "TREATMENT", 213, 228], ["LRP", "OBSERVATION_MODIFIER", 63, 66], ["diseases", "OBSERVATION", 80, 88], ["Surface", "OBSERVATION_MODIFIER", 150, 157]]], ["Fc gamma receptors IIb (Fc\u03b3RIIb) binds to the monomeric immunoglobulin G (IgG) Fc domain with low affinity and inhibit the response produced by activating Fc\u03b3Rs.", [["Fc gamma receptors IIb", "GENE_OR_GENE_PRODUCT", 0, 22], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 24, 31], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 56, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 74, 77], ["Fc\u03b3Rs", "GENE_OR_GENE_PRODUCT", 155, 160], ["Fc gamma receptors IIb", "PROTEIN", 0, 22], ["Fc\u03b3RIIb", "PROTEIN", 24, 31], ["monomeric immunoglobulin G (IgG) Fc domain", "PROTEIN", 46, 88], ["Fc\u03b3Rs", "PROTEIN", 155, 160], ["Fc gamma receptors", "TEST", 0, 18], ["the monomeric immunoglobulin G", "TEST", 42, 72], ["low affinity", "PROBLEM", 94, 106], ["low affinity", "OBSERVATION_MODIFIER", 94, 106]]], ["It is located on chromosome 1 in both humans and mice (Fagerberg et al., 2014; Yue et al., 2014).", [["chromosome 1", "ANATOMY", 17, 29], ["chromosome 1", "CELLULAR_COMPONENT", 17, 29], ["humans", "ORGANISM", 38, 44], ["mice", "ORGANISM", 49, 53], ["chromosome 1", "DNA", 17, 29], ["humans", "SPECIES", 38, 44], ["mice", "SPECIES", 49, 53], ["humans", "SPECIES", 38, 44], ["mice", "SPECIES", 49, 53]]], ["Fc\u03b3RIIb consists of a cytoplasmic region characterized by a 13 amino acid long YSLL sequence, also known as Immunoreceptor Tyrosine based Inhibitory motif (ITIM) and an extracellular domain (Van den Herik-Oudijk et al., 1995).", [["cytoplasmic", "ANATOMY", 22, 33], ["extracellular", "ANATOMY", 169, 182], ["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["Tyrosine", "CHEMICAL", 123, 131], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 0, 7], ["cytoplasmic", "ORGANISM_SUBSTANCE", 22, 33], ["amino acid", "AMINO_ACID", 63, 73], ["Immunoreceptor Tyrosine based Inhibitory motif", "GENE_OR_GENE_PRODUCT", 108, 154], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 169, 182], ["Fc\u03b3RIIb", "PROTEIN", 0, 7], ["cytoplasmic region", "PROTEIN", 22, 40], ["13 amino acid long YSLL sequence", "PROTEIN", 60, 92], ["Immunoreceptor Tyrosine based Inhibitory motif", "PROTEIN", 108, 154], ["ITIM", "PROTEIN", 156, 160], ["extracellular domain", "PROTEIN", 169, 189], ["a cytoplasmic region", "PROBLEM", 20, 40], ["a 13 amino acid long YSLL sequence", "TREATMENT", 58, 92], ["Immunoreceptor Tyrosine based Inhibitory motif (ITIM)", "TREATMENT", 108, 161]]], ["Alternative splicing of mRNA sequence results in two isoform namely Fc\u03b3RIIb1 and Fc\u03b3RIIb2.", [["Fc\u03b3RIIb1", "GENE_OR_GENE_PRODUCT", 68, 76], ["Fc\u03b3RIIb2", "GENE_OR_GENE_PRODUCT", 81, 89], ["mRNA sequence", "RNA", 24, 37], ["Fc\u03b3RIIb1", "PROTEIN", 68, 76], ["Fc\u03b3RIIb2", "PROTEIN", 81, 89], ["mRNA sequence", "TEST", 24, 37], ["Fc\u03b3RIIb2", "TREATMENT", 81, 89]]], ["ITIM is essential for its inhibitory function (Van den Herik-Oudijk et al., 1995).", [["ITIM", "GENE_OR_GENE_PRODUCT", 0, 4], ["ITIM", "PROTEIN", 0, 4]]], ["When immunoglobulins on the cell surface bind and crosslink these receptors, tyrosine 309 is phosphorylated.", [["cell surface", "ANATOMY", 28, 40], ["tyrosine", "CHEMICAL", 77, 85], ["tyrosine", "CHEMICAL", 77, 85], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 5, 20], ["cell surface", "CELLULAR_COMPONENT", 28, 40], ["tyrosine", "AMINO_ACID", 77, 85], ["309", "GENE_OR_GENE_PRODUCT", 86, 89], ["immunoglobulins", "PROTEIN", 5, 20], ["tyrosine 309", "PROTEIN", 77, 89], ["immunoglobulins", "TREATMENT", 5, 20], ["the cell surface bind", "TREATMENT", 24, 45], ["tyrosine", "TEST", 77, 85]]], ["Tatsushi et al. demonstrated that mutation of Tyr 309 to phenylalanine in the ITIM motif abolished its inhibitory effect of B cell activation (Amigorena et al., 1992; Muta et al., 1994).", [["B cell", "ANATOMY", 124, 130], ["Tyr 309", "CHEMICAL", 46, 53], ["phenylalanine", "CHEMICAL", 57, 70], ["Tyr", "CHEMICAL", 46, 49], ["phenylalanine", "CHEMICAL", 57, 70], ["Tyr 309", "AMINO_ACID", 46, 53], ["phenylalanine", "AMINO_ACID", 57, 70], ["ITIM", "AMINO_ACID", 78, 82], ["B cell", "CELL", 124, 130], ["ITIM motif", "PROTEIN", 78, 88], ["mutation of Tyr", "PROBLEM", 34, 49], ["phenylalanine in the ITIM motif", "TREATMENT", 57, 88], ["B cell activation", "PROBLEM", 124, 141]]], ["Daeron et al. (1993) demonstrated that a single mutation of Tyr26 to glycine at the intra-cytoplasmic domain and YSLL motif resulted in impairment of endocytosis and phagocytosis processes, suggesting that phosphorylation or dephosphorylation of tyrosine residues is important for normal function of the receptor.", [["glycine", "CHEMICAL", 69, 76], ["tyrosine", "CHEMICAL", 246, 254], ["Tyr26", "CHEMICAL", 60, 65], ["glycine", "CHEMICAL", 69, 76], ["tyrosine", "CHEMICAL", 246, 254], ["Tyr26", "GENE_OR_GENE_PRODUCT", 60, 65], ["glycine", "AMINO_ACID", 69, 76], ["tyrosine", "AMINO_ACID", 246, 254], ["Tyr26", "PROTEIN", 60, 65], ["intra-cytoplasmic domain", "PROTEIN", 84, 108], ["YSLL motif", "PROTEIN", 113, 123], ["a single mutation", "PROBLEM", 39, 56], ["Tyr26 to glycine", "TREATMENT", 60, 76], ["YSLL motif", "TREATMENT", 113, 123], ["impairment of endocytosis", "PROBLEM", 136, 161], ["phagocytosis processes", "PROBLEM", 166, 188], ["phosphorylation", "PROBLEM", 206, 221], ["dephosphorylation of tyrosine residues", "PROBLEM", 225, 263], ["endocytosis", "OBSERVATION", 150, 161], ["tyrosine residues", "OBSERVATION", 246, 263]]], ["Similarly, another study reported that single amino acid substitution of tyrosine to alanine using alanine scanning mutagenesis methods resulted in the abolition of endocytosis (Hunziker and Fumey, 1994).", [["amino acid", "CHEMICAL", 46, 56], ["tyrosine", "CHEMICAL", 73, 81], ["alanine", "CHEMICAL", 85, 92], ["alanine", "CHEMICAL", 99, 106], ["amino acid", "CHEMICAL", 46, 56], ["tyrosine", "CHEMICAL", 73, 81], ["alanine", "CHEMICAL", 85, 92], ["alanine", "CHEMICAL", 99, 106], ["amino acid", "AMINO_ACID", 46, 56], ["tyrosine", "AMINO_ACID", 73, 81], ["alanine", "AMINO_ACID", 85, 92], ["alanine", "AMINO_ACID", 99, 106], ["another study", "TEST", 11, 24], ["single amino acid substitution", "TREATMENT", 39, 69], ["tyrosine to alanine", "TREATMENT", 73, 92], ["alanine scanning mutagenesis methods", "TEST", 99, 135], ["endocytosis", "PROBLEM", 165, 176], ["endocytosis", "OBSERVATION", 165, 176]]], ["This investigation discovered that the endocytosis signaling and di-leucine-based signaling overlap so that you could not have one without the other in terms of function.", [["di-leucine", "CHEMICAL", 65, 75], ["di-leucine", "CHEMICAL", 65, 75], ["di-leucine", "SIMPLE_CHEMICAL", 65, 75], ["This investigation", "TEST", 0, 18], ["the endocytosis signaling", "PROBLEM", 35, 60]]], ["The expression of Fc\u03b3RIIb is found on the sinusoids of spleen and liver as well as in immune cells, such as B cells, dendritic cells, myeloid cells as well as leukemia and lymphoma cells (Lim et al., 2011; Tutt et al., 2015).Fc\u03b3RIIb/CD32b ::: Other Cell Surface ReceptorsFc\u03b3RIIb has been implicated in the regulation of immunoreactivity.", [["sinusoids", "ANATOMY", 42, 51], ["spleen", "ANATOMY", 55, 61], ["liver", "ANATOMY", 66, 71], ["immune cells", "ANATOMY", 86, 98], ["B cells", "ANATOMY", 108, 115], ["dendritic cells", "ANATOMY", 117, 132], ["myeloid cells", "ANATOMY", 134, 147], ["leukemia", "ANATOMY", 159, 167], ["lymphoma cells", "ANATOMY", 172, 186], ["Cell", "ANATOMY", 249, 253], ["leukemia and lymphoma", "DISEASE", 159, 180], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 18, 25], ["sinusoids", "TISSUE", 42, 51], ["spleen", "ORGAN", 55, 61], ["liver", "ORGAN", 66, 71], ["immune cells", "CELL", 86, 98], ["B cells", "CELL", 108, 115], ["dendritic cells", "CELL", 117, 132], ["myeloid cells", "CELL", 134, 147], ["leukemia", "CELL", 159, 167], ["lymphoma cells", "CELL", 172, 186], ["CD32", "GENE_OR_GENE_PRODUCT", 233, 237], ["Cell", "CELL", 249, 253], ["ReceptorsFc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 262, 278], ["Fc\u03b3RIIb", "PROTEIN", 18, 25], ["immune cells", "CELL_TYPE", 86, 98], ["B cells", "CELL_TYPE", 108, 115], ["dendritic cells", "CELL_TYPE", 117, 132], ["myeloid cells", "CELL_TYPE", 134, 147], ["leukemia and lymphoma cells", "CELL_TYPE", 159, 186], ["Fc\u03b3", "PROTEIN", 225, 228], ["RIIb", "PROTEIN", 228, 232], ["CD32b", "PROTEIN", 233, 238], ["Cell Surface ReceptorsFc\u03b3RIIb", "PROTEIN", 249, 278], ["Fc\u03b3RIIb", "TREATMENT", 18, 25], ["immune cells", "PROBLEM", 86, 98], ["B cells", "PROBLEM", 108, 115], ["dendritic cells", "PROBLEM", 117, 132], ["myeloid cells", "PROBLEM", 134, 147], ["leukemia", "PROBLEM", 159, 167], ["lymphoma cells", "PROBLEM", 172, 186], ["spleen", "ANATOMY", 55, 61], ["liver", "ANATOMY", 66, 71], ["immune cells", "OBSERVATION", 86, 98], ["B cells", "OBSERVATION", 108, 115], ["dendritic cells", "OBSERVATION", 117, 132], ["myeloid cells", "OBSERVATION", 134, 147], ["leukemia", "OBSERVATION", 159, 167], ["lymphoma cells", "OBSERVATION", 172, 186], ["Cell", "OBSERVATION", 249, 253], ["Surface", "OBSERVATION_MODIFIER", 254, 261], ["ReceptorsFc", "OBSERVATION", 262, 273]]], ["One study has reported a decrease in expression of Fc\u03b3RIIb on B cells in active systemic lupus erythematosus (SLE) patients as compared to healthy control, suggesting its protective role in SLE (Ochi and Kawabi, 1992).", [["B cells", "ANATOMY", 62, 69], ["systemic lupus erythematosus", "DISEASE", 80, 108], ["SLE", "DISEASE", 110, 113], ["SLE", "DISEASE", 190, 193], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 51, 58], ["B cells", "CELL", 62, 69], ["patients", "ORGANISM", 115, 123], ["Fc\u03b3RIIb", "PROTEIN", 51, 58], ["B cells", "CELL_TYPE", 62, 69], ["patients", "SPECIES", 115, 123], ["One study", "TEST", 0, 9], ["Fc\u03b3RIIb", "PROBLEM", 51, 58], ["B cells", "TREATMENT", 62, 69], ["active systemic lupus erythematosus", "PROBLEM", 73, 108], ["decrease", "OBSERVATION_MODIFIER", 25, 33], ["active", "OBSERVATION_MODIFIER", 73, 79], ["systemic lupus erythematosus", "OBSERVATION", 80, 108]]], ["Similarly, an increase in Fc\u03b3RIIb expression on B cells upon delivery of retroviral transduced Fc\u03b3RIIb bone in spontaneous lupus-prone mice compared to the mice that received parent retrovirus transduced bone marrow (McGaha et al., 2005).", [["B cells", "ANATOMY", 48, 55], ["Fc\u03b3RIIb bone", "ANATOMY", 95, 107], ["bone marrow", "ANATOMY", 204, 215], ["lupus", "DISEASE", 123, 128], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 26, 33], ["B cells", "CELL", 48, 55], ["retroviral", "ORGANISM", 73, 83], ["Fc\u03b3RIIb bone", "TISSUE", 95, 107], ["mice", "ORGANISM", 135, 139], ["mice", "ORGANISM", 156, 160], ["retrovirus", "ORGANISM", 182, 192], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 204, 215], ["Fc\u03b3RIIb", "PROTEIN", 26, 33], ["B cells", "CELL_TYPE", 48, 55], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 156, 160], ["an increase in Fc\u03b3RIIb expression", "PROBLEM", 11, 44], ["B cells", "PROBLEM", 48, 55], ["delivery", "TREATMENT", 61, 69], ["retroviral transduced Fc\u03b3RIIb bone", "TREATMENT", 73, 107], ["spontaneous lupus", "PROBLEM", 111, 128], ["parent retrovirus transduced bone marrow", "TREATMENT", 175, 215], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["Fc\u03b3RIIb expression", "OBSERVATION", 26, 44], ["retroviral transduced", "OBSERVATION", 73, 94], ["spontaneous", "OBSERVATION_MODIFIER", 111, 122], ["lupus", "OBSERVATION", 123, 128], ["bone marrow", "ANATOMY", 204, 215]]], ["They also found a decrease in the immune complex accumulation in the kidney as compared to control.", [["kidney", "ANATOMY", 69, 75], ["kidney", "ORGAN", 69, 75], ["a decrease in the immune complex accumulation in the kidney", "PROBLEM", 16, 75], ["decrease", "OBSERVATION_MODIFIER", 18, 26], ["immune", "OBSERVATION", 34, 40], ["complex", "OBSERVATION_MODIFIER", 41, 48], ["accumulation", "OBSERVATION", 49, 61], ["kidney", "ANATOMY", 69, 75]]], ["Besides its expression on hematopoietic cells, Fc\u03b3RIIb expression is also found exclusively on LSECs, and it is used as a marker to distinguish LSECs from other liver cell types (Mousavi et al., 2007).", [["hematopoietic cells", "ANATOMY", 26, 45], ["LSECs", "ANATOMY", 95, 100], ["LSECs", "ANATOMY", 144, 149], ["liver cell", "ANATOMY", 161, 171], ["LSECs", "DISEASE", 144, 149], ["hematopoietic cells", "CELL", 26, 45], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 47, 54], ["LSECs", "CELL", 95, 100], ["LSECs", "CELL", 144, 149], ["liver cell", "CELL", 161, 171], ["hematopoietic cells", "CELL_TYPE", 26, 45], ["RIIb", "PROTEIN", 50, 54], ["LSECs", "CELL_TYPE", 95, 100], ["LSECs", "CELL_TYPE", 144, 149], ["liver cell types", "CELL_TYPE", 161, 177], ["hematopoietic cells", "PROBLEM", 26, 45], ["expression", "OBSERVATION_MODIFIER", 12, 22], ["hematopoietic cells", "OBSERVATION", 26, 45], ["liver", "ANATOMY", 161, 166], ["cell", "OBSERVATION", 167, 171]]], ["In hepatic sinusoids, Fc\u03b3RIIb is responsible for removing small immune complexes (SIC).", [["hepatic sinusoids", "ANATOMY", 3, 20], ["hepatic sinusoids", "MULTI-TISSUE_STRUCTURE", 3, 20], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 22, 29], ["small immune complexes", "GENE_OR_GENE_PRODUCT", 58, 80], ["Fc\u03b3RIIb", "PROTEIN", 22, 29], ["small immune complexes", "PROTEIN", 58, 80], ["SIC", "PROTEIN", 82, 85], ["small immune complexes", "PROBLEM", 58, 80], ["hepatic", "ANATOMY", 3, 10], ["sinusoids", "ANATOMY_MODIFIER", 11, 20], ["responsible for", "UNCERTAINTY", 33, 48], ["small", "OBSERVATION_MODIFIER", 58, 63], ["immune complexes", "OBSERVATION", 64, 80]]], ["Ganesan et al. (2012) studied the blood clearance rate of SIC using radio iodinated SIC in WT and Fc\u03b3RIIb KO mice model.", [["blood", "ANATOMY", 34, 39], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 98, 105], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["the blood clearance rate of SIC", "TREATMENT", 30, 61], ["radio iodinated SIC in WT", "TREATMENT", 68, 93]]], ["They found an inhibition in the clearance rate of SIC in Fc\u03b3RIIb KO mice as compared to control, suggesting the involvement of LSECs Fc\u03b3RIIb in immune complex mediated diseases (Ganesan et al., 2012).Fc\u03b3RIIb/CD32b ::: Other Cell Surface ReceptorsA study conducted on NAFL and NASH biopsy specimens to assess the expression of Fc\u03b3RIIb on LSECs reported a medium negative correlation between serum collagen type IV and hyaluronan with Fc\u03b3RIIb expression (Ishikawa et al., 2019).", [["Cell", "ANATOMY", 224, 228], ["NAFL", "ANATOMY", 267, 271], ["NASH biopsy specimens", "ANATOMY", 276, 297], ["LSECs", "ANATOMY", 337, 342], ["serum", "ANATOMY", 390, 395], ["NASH", "DISEASE", 276, 280], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 57, 64], ["LSECs Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 127, 140], ["CD32", "GENE_OR_GENE_PRODUCT", 208, 212], ["Cell", "CELL", 224, 228], ["NAFL", "CELL", 267, 271], ["NASH biopsy specimens", "CANCER", 276, 297], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 326, 333], ["LSECs", "PATHOLOGICAL_FORMATION", 337, 342], ["serum", "ORGANISM_SUBSTANCE", 390, 395], ["collagen type IV", "GENE_OR_GENE_PRODUCT", 396, 412], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 417, 427], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 433, 440], ["SIC", "PROTEIN", 50, 53], ["Fc", "PROTEIN", 57, 59], ["LSECs", "PROTEIN", 127, 132], ["Fc\u03b3RIIb", "PROTEIN", 133, 140], ["Fc\u03b3", "PROTEIN", 200, 203], ["RIIb", "PROTEIN", 203, 207], ["CD32b", "PROTEIN", 208, 213], ["Fc\u03b3RIIb", "PROTEIN", 326, 333], ["LSECs", "CELL_TYPE", 337, 342], ["serum collagen type IV", "PROTEIN", 390, 412], ["Fc\u03b3", "PROTEIN", 433, 436], ["RIIb", "PROTEIN", 436, 440], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["immune complex mediated diseases", "PROBLEM", 144, 176], ["Other Cell Surface ReceptorsA study", "TEST", 218, 253], ["NAFL", "TREATMENT", 267, 271], ["NASH biopsy specimens", "TEST", 276, 297], ["serum collagen type IV", "TREATMENT", 390, 412], ["inhibition", "OBSERVATION", 14, 24], ["LSECs", "ANATOMY", 127, 132], ["Surface", "OBSERVATION_MODIFIER", 229, 236], ["LSECs", "ANATOMY", 337, 342]]], ["An increase in type IV collagen and hyaluronan contents have already been shown with NASH progression, suggesting a reduction in scavenger function of Fc\u03b3RIIb.", [["NASH", "DISEASE", 85, 89], ["type IV collagen", "GENE_OR_GENE_PRODUCT", 15, 31], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 36, 46], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 151, 158], ["type IV collagen", "PROTEIN", 15, 31], ["Fc\u03b3RIIb", "PROTEIN", 151, 158], ["An increase", "PROBLEM", 0, 11], ["type IV collagen and hyaluronan contents", "TREATMENT", 15, 55], ["NASH progression", "PROBLEM", 85, 101], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["type IV collagen", "OBSERVATION_MODIFIER", 15, 31], ["NASH", "OBSERVATION", 85, 89], ["reduction", "OBSERVATION_MODIFIER", 116, 125], ["scavenger function", "OBSERVATION", 129, 147]]], ["They also witnessed an inversely proportional relation between Fc\u03b3RIIb expression and fibrosis stages, reporting the highest expression at the initial stage of fibrosis and lowest at fibrosis stage 3.", [["fibrosis", "DISEASE", 86, 94], ["fibrosis", "DISEASE", 160, 168], ["fibrosis", "DISEASE", 183, 191], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 63, 70], ["Fc\u03b3", "PROTEIN", 63, 66], ["RIIb", "PROTEIN", 66, 70], ["fibrosis stages", "PROBLEM", 86, 101], ["fibrosis", "PROBLEM", 160, 168], ["lowest at fibrosis stage 3", "PROBLEM", 173, 199], ["fibrosis", "OBSERVATION", 86, 94], ["fibrosis", "OBSERVATION", 160, 168], ["lowest", "OBSERVATION_MODIFIER", 173, 179], ["fibrosis", "OBSERVATION", 183, 191]]], ["However, taking all of the data together across the various grades of fibrosis and NAFLD activity scores, Ishikawa and coworkers did not find a significant difference in expression level of Fc\u03b3RIIb.", [["fibrosis", "DISEASE", 70, 78], ["NAFLD", "DISEASE", 83, 88], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 190, 197], ["Fc\u03b3RIIb", "PROTEIN", 190, 197], ["fibrosis", "PROBLEM", 70, 78], ["NAFLD activity scores", "PROBLEM", 83, 104], ["fibrosis", "OBSERVATION", 70, 78]]], ["A new insight in the hepatic fibrosis study was provided by Vilar-Gomez et al. (2017) who reported platelet counts as a novel indirect biomarker for portal hypertension and advanced hepatic liver disease assessment.", [["hepatic", "ANATOMY", 21, 28], ["platelet", "ANATOMY", 99, 107], ["portal", "ANATOMY", 149, 155], ["hepatic liver", "ANATOMY", 182, 195], ["hepatic fibrosis", "DISEASE", 21, 37], ["hypertension", "DISEASE", 156, 168], ["hepatic liver disease", "DISEASE", 182, 203], ["hepatic", "ORGAN", 21, 28], ["platelet", "CELL", 99, 107], ["portal", "MULTI-TISSUE_STRUCTURE", 149, 155], ["hepatic liver", "MULTI-TISSUE_STRUCTURE", 182, 195], ["A new insight in the hepatic fibrosis study", "PROBLEM", 0, 43], ["platelet counts", "TEST", 99, 114], ["portal hypertension", "PROBLEM", 149, 168], ["advanced hepatic liver disease assessment", "PROBLEM", 173, 214], ["new", "OBSERVATION_MODIFIER", 2, 5], ["hepatic", "ANATOMY", 21, 28], ["fibrosis", "OBSERVATION", 29, 37], ["portal", "ANATOMY", 149, 155], ["hypertension", "OBSERVATION", 156, 168], ["advanced", "OBSERVATION_MODIFIER", 173, 181], ["hepatic", "ANATOMY", 182, 189], ["liver", "ANATOMY", 190, 195], ["disease", "OBSERVATION", 196, 203]]], ["They reported the inhibitory role of platelets in fibrosis.", [["platelets", "ANATOMY", 37, 46], ["fibrosis", "DISEASE", 50, 58], ["platelets", "CELL", 37, 46], ["platelets", "CELL_TYPE", 37, 46], ["fibrosis", "PROBLEM", 50, 58], ["platelets", "OBSERVATION", 37, 46], ["fibrosis", "OBSERVATION", 50, 58]]], ["In agreement with this study, Ishikawa et al. (2019) have shown a positive relationship between platelet count and Fc\u03b3RIIb expression on LSECs through regression analysis, suggesting a low platelet count in high fibrosis stage, thereby, decreased Fc\u03b3RIIb expression.", [["platelet", "ANATOMY", 96, 104], ["LSECs", "ANATOMY", 137, 142], ["platelet", "ANATOMY", 189, 197], ["fibrosis", "DISEASE", 212, 220], ["platelet", "CELL", 96, 104], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 115, 122], ["LSECs", "PATHOLOGICAL_FORMATION", 137, 142], ["platelet", "CELL", 189, 197], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 247, 254], ["RIIb", "PROTEIN", 118, 122], ["LSECs", "CELL_TYPE", 137, 142], ["Fc\u03b3", "PROTEIN", 247, 250], ["RIIb", "PROTEIN", 250, 254], ["this study", "TEST", 18, 28], ["a positive relationship", "PROBLEM", 64, 87], ["platelet count", "TEST", 96, 110], ["regression analysis", "TEST", 151, 170], ["a low platelet count", "PROBLEM", 183, 203], ["high fibrosis stage", "PROBLEM", 207, 226], ["low platelet count", "OBSERVATION", 185, 203], ["high", "OBSERVATION_MODIFIER", 207, 211], ["fibrosis", "OBSERVATION", 212, 220], ["decreased", "OBSERVATION_MODIFIER", 237, 246]]], ["For HCC, a decrease in Fc\u03b3RIIb expression is co-commitment with an increase in cancer grade similar to Stabilin-2 (Geraud et al., 2013).", [["HCC", "ANATOMY", 4, 7], ["cancer", "ANATOMY", 79, 85], ["HCC", "DISEASE", 4, 7], ["cancer", "DISEASE", 79, 85], ["HCC", "CANCER", 4, 7], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 23, 30], ["cancer", "CANCER", 79, 85], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 103, 113], ["Fc\u03b3RIIb", "PROTEIN", 23, 30], ["HCC", "PROBLEM", 4, 7], ["a decrease in Fc\u03b3RIIb expression", "PROBLEM", 9, 41], ["an increase in cancer grade", "PROBLEM", 64, 91], ["Stabilin", "TEST", 103, 111], ["HCC", "OBSERVATION", 4, 7], ["decrease", "OBSERVATION_MODIFIER", 11, 19], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["cancer", "OBSERVATION", 79, 85]]], ["A study conducted on peritumoral tissue samples of HCC patients showed that the expression of Fc\u03b3RIIb was decreased in 63% of samples taken into consideration for the study.", [["peritumoral tissue samples", "ANATOMY", 21, 47], ["HCC", "ANATOMY", 51, 54], ["samples", "ANATOMY", 126, 133], ["HCC", "DISEASE", 51, 54], ["peritumoral tissue samples", "TISSUE", 21, 47], ["HCC", "CANCER", 51, 54], ["patients", "ORGANISM", 55, 63], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 94, 101], ["samples", "CANCER", 126, 133], ["Fc\u03b3RIIb", "PROTEIN", 94, 101], ["patients", "SPECIES", 55, 63], ["A study", "TEST", 0, 7], ["peritumoral tissue samples", "TEST", 21, 47], ["Fc\u03b3RIIb", "TREATMENT", 94, 101], ["the study", "TEST", 163, 172], ["HCC", "OBSERVATION", 51, 54]]], ["A microarray analysis of these tissues found that loss of Fc\u03b3RIIb is related to significantly longer tumor-specific survival.", [["tissues", "ANATOMY", 31, 38], ["tumor", "ANATOMY", 101, 106], ["tumor", "DISEASE", 101, 106], ["tissues", "TISSUE", 31, 38], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 58, 65], ["tumor", "CANCER", 101, 106], ["Fc\u03b3RIIb", "PROTEIN", 58, 65], ["A microarray analysis", "TEST", 0, 21], ["loss of Fc\u03b3RIIb", "PROBLEM", 50, 65], ["significantly longer tumor", "PROBLEM", 80, 106], ["tumor", "OBSERVATION", 101, 106]]], ["However, in terms of the 5-yr survival rate, there was more of an impact or survival rate for Stabilin-2 (42%) than Fc\u03b3RIIb (16%).Fc\u03b3RIIb/CD32b ::: Other Cell Surface ReceptorsAnother ligand of Fc\u03b3RIIb, fibrinogen-like protein 2 (FGL2), was found to be increased in NAFLD patients demonstrating severe forms of NAFLD, suggesting a decrease in Fc\u03b3RIIb expression (Colak et al., 2011).", [["NAFLD", "DISEASE", 266, 271], ["NAFLD", "DISEASE", 311, 316], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 94, 104], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 116, 123], ["CD32", "GENE_OR_GENE_PRODUCT", 138, 142], ["Cell", "CELL", 154, 158], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 194, 201], ["fibrinogen-like protein 2", "GENE_OR_GENE_PRODUCT", 203, 228], ["FGL2", "GENE_OR_GENE_PRODUCT", 230, 234], ["patients", "ORGANISM", 272, 280], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 343, 350], ["Fc\u03b3RIIb", "PROTEIN", 116, 123], ["Fc\u03b3", "PROTEIN", 130, 133], ["RIIb", "PROTEIN", 133, 137], ["CD32b", "PROTEIN", 138, 143], ["Cell Surface Receptors", "PROTEIN", 154, 176], ["Fc\u03b3RIIb", "PROTEIN", 194, 201], ["fibrinogen-like protein 2", "PROTEIN", 203, 228], ["FGL2", "PROTEIN", 230, 234], ["Fc\u03b3", "PROTEIN", 343, 346], ["RIIb", "PROTEIN", 346, 350], ["patients", "SPECIES", 272, 280], ["survival rate", "TEST", 76, 89], ["Stabilin", "TEST", 94, 102], ["Other Cell Surface Receptors", "TEST", 148, 176], ["Fc\u03b3RIIb", "TEST", 194, 201], ["fibrinogen", "TEST", 203, 213], ["protein", "TEST", 219, 226], ["FGL2", "TEST", 230, 234], ["severe forms of NAFLD", "PROBLEM", 295, 316], ["a decrease in Fc", "PROBLEM", 329, 345], ["increased", "OBSERVATION_MODIFIER", 253, 262], ["NAFLD", "OBSERVATION", 266, 271], ["severe", "OBSERVATION_MODIFIER", 295, 301], ["NAFLD", "OBSERVATION", 311, 316], ["decrease", "OBSERVATION_MODIFIER", 331, 339], ["Fc", "OBSERVATION_MODIFIER", 343, 345]]], ["This correlation did not hold across the fibrosis stages or grades of steatosis.", [["fibrosis", "DISEASE", 41, 49], ["steatosis", "DISEASE", 70, 79], ["the fibrosis stages", "PROBLEM", 37, 56], ["steatosis", "PROBLEM", 70, 79], ["fibrosis", "OBSERVATION", 41, 49], ["steatosis", "OBSERVATION", 70, 79]]], ["Furthermore, Maeso-Diaz et al. (2018) have shown an even or slight increase in Fc\u03b3RIIb expression in the comparison of young and old LSECs, however, there is a very stark reduction in Stabilin-2, eNOS, BMP-2, Lamb1, and HGF in aged LSECs suggesting that the LSECs become vulnerable to acute or chronic injury in old age.Toll-Like Receptors ::: Other Cell Surface ReceptorsBesides scavenger receptors, LSECs express multifarious pattern recognition receptors mostly consisting of toll-like receptors (TLRs).", [["LSECs", "ANATOMY", 133, 138], ["LSECs", "ANATOMY", 232, 237], ["LSECs", "ANATOMY", 258, 263], ["LSECs", "ANATOMY", 401, 406], ["Fc\u03b3RIIb", "GENE_OR_GENE_PRODUCT", 79, 86], ["LSECs", "CELL", 133, 138], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 184, 194], ["eNOS", "GENE_OR_GENE_PRODUCT", 196, 200], ["BMP-2", "GENE_OR_GENE_PRODUCT", 202, 207], ["Lamb1", "GENE_OR_GENE_PRODUCT", 209, 214], ["HGF", "GENE_OR_GENE_PRODUCT", 220, 223], ["LSECs", "CELL", 232, 237], ["LSECs", "CELL", 258, 263], ["Toll-Like Receptors", "GENE_OR_GENE_PRODUCT", 320, 339], ["Cell", "CELL", 350, 354], ["LSECs", "GENE_OR_GENE_PRODUCT", 401, 406], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 479, 498], ["TLRs", "GENE_OR_GENE_PRODUCT", 500, 504], ["Fc\u03b3", "PROTEIN", 79, 82], ["RIIb", "PROTEIN", 82, 86], ["Stabilin", "PROTEIN", 184, 192], ["eNOS", "PROTEIN", 196, 200], ["BMP", "PROTEIN", 202, 205], ["Lamb1", "PROTEIN", 209, 214], ["HGF", "PROTEIN", 220, 223], ["LSECs", "CELL_TYPE", 258, 263], ["Toll-Like Receptors", "PROTEIN", 320, 339], ["Cell Surface ReceptorsBesides scavenger receptors", "PROTEIN", 350, 399], ["LSECs", "PROTEIN", 401, 406], ["multifarious pattern recognition receptors", "PROTEIN", 415, 457], ["toll-like receptors", "PROTEIN", 479, 498], ["TLRs", "PROTEIN", 500, 504], ["a very stark reduction", "PROBLEM", 158, 180], ["Stabilin", "TEST", 184, 192], ["eNOS", "TEST", 196, 200], ["BMP", "TEST", 202, 205], ["Lamb1", "TEST", 209, 214], ["chronic injury", "PROBLEM", 294, 308], ["Other Cell Surface ReceptorsBesides scavenger receptors", "TREATMENT", 344, 399], ["multifarious pattern recognition receptors", "PROBLEM", 415, 457], ["slight", "OBSERVATION_MODIFIER", 60, 66], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["LSECs", "ANATOMY", 133, 138], ["acute", "OBSERVATION_MODIFIER", 285, 290], ["chronic", "OBSERVATION_MODIFIER", 294, 301], ["injury", "OBSERVATION", 302, 308], ["Surface", "OBSERVATION_MODIFIER", 355, 362]]], ["TLRs are capable of recognizing pathogen-associated molecular patterns (PAMP) present on invading microbes or damage-associated molecular pattern (DAMP) originating from endogenous damaged or apoptotic cells (Kawasaki and Kawai, 2014).", [["cells", "ANATOMY", 202, 207], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 32, 70], ["PAMP", "GENE_OR_GENE_PRODUCT", 72, 76], ["damage-associated molecular pattern", "GENE_OR_GENE_PRODUCT", 110, 145], ["cells", "CELL", 202, 207], ["TLRs", "PROTEIN", 0, 4], ["pathogen-associated molecular patterns", "PROTEIN", 32, 70], ["PAMP", "PROTEIN", 72, 76], ["apoptotic cells", "CELL_TYPE", 192, 207], ["recognizing pathogen", "PROBLEM", 20, 40], ["invading microbes", "PROBLEM", 89, 106], ["damage", "PROBLEM", 110, 116], ["molecular pattern (DAMP)", "PROBLEM", 128, 152], ["apoptotic cells", "PROBLEM", 192, 207], ["molecular pattern", "OBSERVATION_MODIFIER", 128, 145], ["apoptotic cells", "OBSERVATION", 192, 207]]], ["They are type I transmembrane glycoprotein consisting of an extracellular N-terminal ligand-binding domain, single transmembrane domain, and a C-terminal cytoplasmic domain.", [["extracellular", "ANATOMY", 60, 73], ["cytoplasmic", "ANATOMY", 154, 165], ["N", "CHEMICAL", 74, 75], ["C", "CHEMICAL", 143, 144], ["cytoplasmic", "ORGANISM_SUBSTANCE", 154, 165], ["type I transmembrane glycoprotein", "PROTEIN", 9, 42], ["extracellular N-terminal ligand-binding domain", "PROTEIN", 60, 106], ["single transmembrane domain", "PROTEIN", 108, 135], ["C-terminal cytoplasmic domain", "PROTEIN", 143, 172], ["type I transmembrane glycoprotein", "PROBLEM", 9, 42], ["single transmembrane domain", "TEST", 108, 135], ["a C-terminal cytoplasmic domain", "TREATMENT", 141, 172]]], ["Ligand binding is mediated through an ectodomain characterized by leucine-rich repeats (Bell et al., 2003).", [["leucine", "CHEMICAL", 66, 73], ["leucine", "CHEMICAL", 66, 73], ["leucine", "AMINO_ACID", 66, 73], ["ectodomain", "PROTEIN", 38, 48], ["leucine-rich repeats", "PROTEIN", 66, 86]]], ["Downstream signaling is mediated by adaptor proteins associated with the Toll/IL-1 receptor (TIR) present at the cytoplasmic C-terminal domain (O\u2019Neill and Bowie, 2007).", [["cytoplasmic", "ANATOMY", 113, 124], ["C", "CHEMICAL", 125, 126], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 78, 91], ["TIR", "GENE_OR_GENE_PRODUCT", 93, 96], ["cytoplasmic", "ORGANISM_SUBSTANCE", 113, 124], ["adaptor proteins", "PROTEIN", 36, 52], ["Toll/IL-1 receptor", "PROTEIN", 73, 91], ["TIR", "PROTEIN", 93, 96], ["cytoplasmic C-terminal domain", "PROTEIN", 113, 142], ["Downstream signaling", "PROBLEM", 0, 20], ["adaptor proteins", "PROBLEM", 36, 52], ["the Toll/IL", "TREATMENT", 69, 80]]], ["TLRs form an important bridge between innate and adaptive immune response system (Werling and Jungi, 2003; Pasare and Medzhitov, 2004).", [["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLRs", "PROTEIN", 0, 4]]], ["TLRs also induce the production of pro-inflammatory and effector cytokines and aid in the activation of T-cells by upregulating co-stimulatory molecules present on antigen-presenting cells (Vasselon and Detmers, 2002).", [["T-cells", "ANATOMY", 104, 111], ["antigen-presenting cells", "ANATOMY", 164, 188], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["T-cells", "CELL", 104, 111], ["cells", "CELL", 183, 188], ["Vasselon", "CELL", 190, 198], ["TLRs", "PROTEIN", 0, 4], ["pro-inflammatory and effector cytokines", "PROTEIN", 35, 74], ["T-cells", "CELL_TYPE", 104, 111], ["co-stimulatory molecules", "PROTEIN", 128, 152], ["antigen-presenting cells", "CELL_TYPE", 164, 188], ["pro-inflammatory and effector cytokines", "PROBLEM", 35, 74], ["upregulating co-stimulatory molecules", "PROBLEM", 115, 152], ["pro-inflammatory", "OBSERVATION_MODIFIER", 35, 51]]], ["Humans express 10 TLRs (TLR 1\u201310), whereas, mice express 12 TLRs (Hopkins and Sriskandan, 2005).", [["Humans", "ORGANISM", 0, 6], ["TLRs", "GENE_OR_GENE_PRODUCT", 18, 22], ["TLR 1\u201310", "GENE_OR_GENE_PRODUCT", 24, 32], ["mice", "ORGANISM", 44, 48], ["TLRs", "GENE_OR_GENE_PRODUCT", 60, 64], ["TLRs", "PROTEIN", 18, 22], ["TLR 1\u201310", "PROTEIN", 24, 32], ["TLRs", "PROTEIN", 60, 64], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["10 TLRs", "OBSERVATION_MODIFIER", 15, 22]]], ["Of these, LSECs express seven Toll-like receptors; TLR1\u20134, 6, 8, 9.Toll-Like Receptors ::: Other Cell Surface ReceptorsUhrig et al. (2005) demonstrated a constitutive expression of TLR4 on cultured LSECs isolated from mice.", [["LSECs", "ANATOMY", 10, 15], ["Cell", "ANATOMY", 97, 101], ["LSECs", "ANATOMY", 198, 203], ["LSECs", "CELL", 10, 15], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 30, 49], ["TLR1\u20134", "GENE_OR_GENE_PRODUCT", 51, 57], ["Toll-Like Receptors", "GENE_OR_GENE_PRODUCT", 67, 86], ["TLR4", "GENE_OR_GENE_PRODUCT", 181, 185], ["LSECs", "CELL", 198, 203], ["mice", "ORGANISM", 218, 222], ["LSECs", "CELL_TYPE", 10, 15], ["Toll-like receptors", "PROTEIN", 30, 49], ["TLR1\u20134, 6, 8, 9", "PROTEIN", 51, 66], ["Toll-Like Receptors", "PROTEIN", 67, 86], ["TLR4", "PROTEIN", 181, 185], ["LSECs", "CELL_TYPE", 198, 203], ["mice", "SPECIES", 218, 222], ["mice", "SPECIES", 218, 222], ["TLR1", "TEST", 51, 55], ["Surface", "OBSERVATION_MODIFIER", 102, 109], ["TLR4", "ANATOMY", 181, 185]]], ["TLR4 binds to LPS present on gram-negative bacteria and initiates an immune response for its clearance (Poltorak et al., 1998).", [["LPS", "CHEMICAL", 14, 17], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["LPS", "GENE_OR_GENE_PRODUCT", 14, 17], ["TLR4", "PROTEIN", 0, 4], ["LPS", "TEST", 14, 17], ["gram", "TEST", 29, 33], ["bacteria", "PROBLEM", 43, 51], ["its clearance", "TEST", 89, 102], ["negative bacteria", "OBSERVATION_MODIFIER", 34, 51]]], ["In this study, cultured LSECs developed tolerance upon repetitive exposure with LPS, though this effect was not mediated by downregulation in the expression of TLR4.", [["LSECs", "ANATOMY", 24, 29], ["LPS", "CHEMICAL", 80, 83], ["LSECs", "CELL", 24, 29], ["LPS", "SIMPLE_CHEMICAL", 80, 83], ["TLR4", "GENE_OR_GENE_PRODUCT", 160, 164], ["cultured LSECs", "CELL_LINE", 15, 29], ["TLR4", "PROTEIN", 160, 164], ["this study", "TEST", 3, 13], ["LPS", "TREATMENT", 80, 83]]], ["Reduction in the activation of NF-kB was responsible for developing tolerance against LPS stimulation in LSECs.", [["LSECs", "ANATOMY", 105, 110], ["LPS", "CHEMICAL", 86, 89], ["NF-kB", "GENE_OR_GENE_PRODUCT", 31, 36], ["LPS", "SIMPLE_CHEMICAL", 86, 89], ["LSECs", "PATHOLOGICAL_FORMATION", 105, 110], ["NF-kB", "PROTEIN", 31, 36], ["LSECs", "CELL_TYPE", 105, 110], ["LPS stimulation", "TREATMENT", 86, 101]]], ["Not too long thereafter, Martin-Armas et al. (2006) showed that CpGs are taken up by TLR9 present in murine LSECs.", [["LSECs", "ANATOMY", 108, 113], ["CpGs", "CHEMICAL", 64, 68], ["TLR9", "GENE_OR_GENE_PRODUCT", 85, 89], ["murine", "ORGANISM", 101, 107], ["LSECs", "CELL", 108, 113], ["CpGs", "DNA", 64, 68], ["TLR9", "PROTEIN", 85, 89], ["murine LSECs", "CELL_TYPE", 101, 113], ["murine", "SPECIES", 101, 107]]], ["The bacterial DNA is characterized by unmethylated CpG motifs that act as a potent immune stimulator by inducing the production of cytokines from various immune cells, such as dendritic cells, macrophages, B cells and NK cells (Ashkar and Rosenthal, 2002; Dalpke et al., 2006).", [["immune cells", "ANATOMY", 154, 166], ["dendritic cells", "ANATOMY", 176, 191], ["macrophages", "ANATOMY", 193, 204], ["B cells", "ANATOMY", 206, 213], ["NK cells", "ANATOMY", 218, 226], ["CpG", "CHEMICAL", 51, 54], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["immune cells", "CELL", 154, 166], ["dendritic cells", "CELL", 176, 191], ["macrophages", "CELL", 193, 204], ["B cells", "CELL", 206, 213], ["NK cells", "CELL", 218, 226], ["Ashkar", "CELL", 228, 234], ["bacterial DNA", "DNA", 4, 17], ["unmethylated CpG motifs", "DNA", 38, 61], ["cytokines", "PROTEIN", 131, 140], ["immune cells", "CELL_TYPE", 154, 166], ["dendritic cells", "CELL_TYPE", 176, 191], ["macrophages", "CELL_TYPE", 193, 204], ["B cells", "CELL_TYPE", 206, 213], ["NK cells", "CELL_TYPE", 218, 226], ["The bacterial DNA", "PROBLEM", 0, 17], ["unmethylated CpG motifs", "TREATMENT", 38, 61], ["a potent immune stimulator", "TREATMENT", 74, 100], ["cytokines", "PROBLEM", 131, 140], ["various immune cells", "PROBLEM", 146, 166], ["dendritic cells", "PROBLEM", 176, 191], ["macrophages", "PROBLEM", 193, 204], ["bacterial DNA", "OBSERVATION", 4, 17], ["immune cells", "OBSERVATION", 154, 166], ["dendritic cells", "OBSERVATION", 176, 191], ["macrophages", "ANATOMY", 193, 204], ["B cells", "OBSERVATION", 206, 213], ["NK cells", "OBSERVATION", 218, 226]]], ["These studies reported the presence of TLR9 in murine LSECs for the first-time using RT-PCR and immunolabeling.", [["LSECs", "ANATOMY", 54, 59], ["TLR9", "GENE_OR_GENE_PRODUCT", 39, 43], ["murine", "ORGANISM", 47, 53], ["LSECs", "CELL", 54, 59], ["TLR9", "PROTEIN", 39, 43], ["murine LSECs", "CELL_TYPE", 47, 59], ["murine", "SPECIES", 47, 53], ["These studies", "TEST", 0, 13], ["RT-PCR", "TEST", 85, 91], ["immunolabeling", "PROBLEM", 96, 110], ["murine LSECs", "OBSERVATION", 47, 59]]], ["LSECs accumulate the most FITC-labeled CpG than other liver cell types shown by both in vitro and in vivo experiments.", [["LSECs", "ANATOMY", 0, 5], ["liver cell", "ANATOMY", 54, 64], ["FITC", "CHEMICAL", 26, 30], ["CpG", "CHEMICAL", 39, 42], ["LSECs", "CELL", 0, 5], ["FITC", "SIMPLE_CHEMICAL", 26, 30], ["liver cell", "CELL", 54, 64], ["LSECs", "CELL_TYPE", 0, 5], ["FITC-labeled CpG", "DNA", 26, 42], ["liver cell types", "CELL_TYPE", 54, 70], ["liver", "ANATOMY", 54, 59], ["cell types", "OBSERVATION", 60, 70]]], ["They also reported the binding of CpG to TLR9 in the endo-lysosomal compartment which activated NF-\u03baB signaling for the IL-1\u03b2 and IL-6 production.", [["-lysosomal compartment", "ANATOMY", 57, 79], ["CpG", "CHEMICAL", 34, 37], ["TLR9", "GENE_OR_GENE_PRODUCT", 41, 45], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 96, 101], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 120, 125], ["IL-6", "GENE_OR_GENE_PRODUCT", 130, 134], ["TLR9", "PROTEIN", 41, 45], ["NF-\u03baB", "PROTEIN", 96, 101], ["NF", "TEST", 96, 98], ["the IL", "TEST", 116, 122], ["IL", "TEST", 130, 132]]], ["This study suggests the role of LSECs in mediating innate immune response in the liver.", [["LSECs", "ANATOMY", 32, 37], ["liver", "ANATOMY", 81, 86], ["LSECs", "GENE_OR_GENE_PRODUCT", 32, 37], ["liver", "ORGAN", 81, 86], ["This study", "TEST", 0, 10], ["LSECs", "OBSERVATION", 32, 37], ["immune response", "OBSERVATION", 58, 73], ["liver", "ANATOMY", 81, 86]]], ["A TLR4 KO mouse study demonstrated the role of TLR4 in NAFLD by enhancing the secretion of hepatic TGF-\u00df and collagen associated with fibrosis (Sutter et al., 2016).", [["NAFLD", "DISEASE", 55, 60], ["fibrosis", "DISEASE", 134, 142], ["TLR4", "GENE_OR_GENE_PRODUCT", 2, 6], ["mouse", "ORGANISM", 10, 15], ["TLR4", "GENE_OR_GENE_PRODUCT", 47, 51], ["TGF-\u00df", "GENE_OR_GENE_PRODUCT", 99, 104], ["collagen", "GENE_OR_GENE_PRODUCT", 109, 117], ["TLR4", "PROTEIN", 2, 6], ["TLR4", "PROTEIN", 47, 51], ["hepatic TGF-\u00df", "PROTEIN", 91, 104], ["collagen", "PROTEIN", 109, 117], ["mouse", "SPECIES", 10, 15], ["mouse", "SPECIES", 10, 15], ["A TLR4 KO mouse study", "TEST", 0, 21], ["fibrosis", "PROBLEM", 134, 142], ["hepatic", "ANATOMY", 91, 98], ["TGF", "OBSERVATION", 99, 102], ["fibrosis", "OBSERVATION", 134, 142]]], ["These results strongly suggest that the chronic inflammation associated with fatty liver disease is regulated, in part, by TLR4.Toll-Like Receptors ::: Other Cell Surface ReceptorsWhat is the functional role of TLRs in response to ligands in LSECs?", [["fatty liver", "ANATOMY", 77, 88], ["Cell", "ANATOMY", 158, 162], ["LSECs", "ANATOMY", 242, 247], ["inflammation", "DISEASE", 48, 60], ["fatty liver disease", "DISEASE", 77, 96], ["liver", "ORGAN", 83, 88], ["TLR4", "GENE_OR_GENE_PRODUCT", 123, 127], ["Toll-Like Receptors", "GENE_OR_GENE_PRODUCT", 128, 147], ["Cell", "CELL", 158, 162], ["TLRs", "GENE_OR_GENE_PRODUCT", 211, 215], ["LSECs", "CELL", 242, 247], ["TLR4", "PROTEIN", 123, 127], ["Toll-Like Receptors", "PROTEIN", 128, 147], ["TLRs", "PROTEIN", 211, 215], ["LSECs", "CELL_TYPE", 242, 247], ["the chronic inflammation", "PROBLEM", 36, 60], ["fatty liver disease", "PROBLEM", 77, 96], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["inflammation", "OBSERVATION", 48, 60], ["fatty liver disease", "OBSERVATION", 77, 96], ["Surface", "OBSERVATION_MODIFIER", 163, 170]]], ["To answer this question, responses to many TLR specific agonists were evaluated in murine LSECs (Wu et al., 2010).", [["LSECs", "ANATOMY", 90, 95], ["TLR", "GENE_OR_GENE_PRODUCT", 43, 46], ["murine", "ORGANISM", 83, 89], ["LSECs", "CELL", 90, 95], ["TLR", "PROTEIN", 43, 46], ["murine", "SPECIES", 83, 89]]], ["Upon treatment with TLR specific agonists, the high mRNA expression level of TLR1,4,6,8 and moderate mRNA expression level of TLR9 were observed in murine LSEC, however, TLR5, 6, and TLR9 showed very low mRNA expression.", [["LSEC", "ANATOMY", 155, 159], ["TLR", "GENE_OR_GENE_PRODUCT", 20, 23], ["TLR1", "GENE_OR_GENE_PRODUCT", 77, 81], ["4", "GENE_OR_GENE_PRODUCT", 82, 83], [",6,8", "GENE_OR_GENE_PRODUCT", 83, 87], ["TLR9", "GENE_OR_GENE_PRODUCT", 126, 130], ["murine", "ORGANISM", 148, 154], ["LSEC", "CANCER", 155, 159], ["TLR5", "GENE_OR_GENE_PRODUCT", 170, 174], ["6", "GENE_OR_GENE_PRODUCT", 176, 177], ["TLR9", "GENE_OR_GENE_PRODUCT", 183, 187], ["TLR", "PROTEIN", 20, 23], ["TLR1", "PROTEIN", 77, 81], ["TLR9", "PROTEIN", 126, 130], ["TLR5", "PROTEIN", 170, 174], ["TLR9", "PROTEIN", 183, 187], ["murine", "SPECIES", 148, 154], ["treatment", "TREATMENT", 5, 14], ["TLR specific agonists", "TREATMENT", 20, 41], ["TLR1", "TEST", 77, 81], ["moderate mRNA expression level of TLR9", "PROBLEM", 92, 130], ["murine LSEC", "TEST", 148, 159], ["TLR5", "TEST", 170, 174], ["TLR9", "TEST", 183, 187], ["very low mRNA expression", "PROBLEM", 195, 219], ["moderate", "OBSERVATION_MODIFIER", 92, 100], ["murine LSEC", "OBSERVATION", 148, 159], ["very", "OBSERVATION_MODIFIER", 195, 199], ["low mRNA expression", "OBSERVATION", 200, 219]]], ["Contrary to mRNA expression, TLR5 and TLR6 did not show any expression at the protein level in flow cytometry.", [["TLR5", "GENE_OR_GENE_PRODUCT", 29, 33], ["TLR6", "GENE_OR_GENE_PRODUCT", 38, 42], ["TLR5", "PROTEIN", 29, 33], ["TLR6", "PROTEIN", 38, 42], ["TLR5 and TLR6", "TEST", 29, 42], ["flow cytometry", "TEST", 95, 109], ["flow cytometry", "OBSERVATION", 95, 109]]], ["They also showed that the antiviral response is produced by TLR3 in LSECs by the secretion of IFN-\u03b2.", [["LSECs", "ANATOMY", 68, 73], ["TLR3", "GENE_OR_GENE_PRODUCT", 60, 64], ["LSECs", "CELL", 68, 73], ["IFN", "GENE_OR_GENE_PRODUCT", 94, 97], ["TLR3", "PROTEIN", 60, 64], ["LSECs", "CELL_TYPE", 68, 73], ["IFN", "PROTEIN", 94, 97], ["antiviral response", "OBSERVATION", 26, 44]]], ["Furthermore, TNF-\u03b1 production was reported in LSECs treated with TLR4 agonists in high amounts and by TLR2,3 and TLR8 in a moderate amount.", [["LSECs", "ANATOMY", 46, 51], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 13, 18], ["LSECs", "SIMPLE_CHEMICAL", 46, 51], ["TLR4", "GENE_OR_GENE_PRODUCT", 65, 69], ["TLR2,3", "GENE_OR_GENE_PRODUCT", 102, 108], ["TLR8", "GENE_OR_GENE_PRODUCT", 113, 117], ["TNF", "PROTEIN", 13, 16], ["LSECs", "CELL_TYPE", 46, 51], ["TLR4", "PROTEIN", 65, 69], ["TLR2,3", "PROTEIN", 102, 108], ["TLR8", "PROTEIN", 113, 117], ["TNF", "TEST", 13, 16], ["TLR4 agonists", "TREATMENT", 65, 78], ["high amounts", "OBSERVATION_MODIFIER", 82, 94], ["moderate", "OBSERVATION_MODIFIER", 123, 131], ["amount", "OBSERVATION_MODIFIER", 132, 138]]], ["Similarly, a 4-fold and 16-fold upregulation was observed in LSECs treated with TLR4 and TLR3 agonists, respectively.", [["LSECs", "ANATOMY", 61, 66], ["LSECs", "PATHOLOGICAL_FORMATION", 61, 66], ["TLR4", "GENE_OR_GENE_PRODUCT", 80, 84], ["TLR3", "GENE_OR_GENE_PRODUCT", 89, 93], ["LSECs", "CELL_TYPE", 61, 66], ["TLR4", "PROTEIN", 80, 84], ["TLR3", "PROTEIN", 89, 93], ["a 4-fold and 16-fold upregulation", "TREATMENT", 11, 44], ["TLR4 and TLR3 agonists", "TREATMENT", 80, 102], ["4-fold", "OBSERVATION_MODIFIER", 13, 19], ["LSECs", "ANATOMY", 61, 66]]], ["LSECs were also able to upregulate MHC class II expression with TLR8 agonists as well as the proliferation of T-cells with TLR1,2 and TLR6 agonists.", [["LSECs", "ANATOMY", 0, 5], ["T-cells", "ANATOMY", 110, 117], ["LSECs", "SIMPLE_CHEMICAL", 0, 5], ["MHC class II", "GENE_OR_GENE_PRODUCT", 35, 47], ["TLR8", "GENE_OR_GENE_PRODUCT", 64, 68], ["T-cells", "CELL", 110, 117], ["TLR1,2", "GENE_OR_GENE_PRODUCT", 123, 129], ["TLR6", "GENE_OR_GENE_PRODUCT", 134, 138], ["LSECs", "CELL_TYPE", 0, 5], ["MHC class II", "PROTEIN", 35, 47], ["TLR8", "PROTEIN", 64, 68], ["T-cells", "CELL_TYPE", 110, 117], ["TLR1", "PROTEIN", 123, 127], ["TLR6", "PROTEIN", 134, 138], ["TLR8 agonists", "TREATMENT", 64, 77], ["TLR1", "TEST", 123, 127], ["TLR6 agonists", "TREATMENT", 134, 147]]], ["Additionally, LSECs were involved with the activation of CD4 and CD8 T-cells when treated with TLR1,2 and TLR6 agonists.", [["LSECs", "ANATOMY", 14, 19], ["CD4", "ANATOMY", 57, 60], ["CD8 T-cells", "ANATOMY", 65, 76], ["LSECs", "CELL", 14, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 57, 60], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["TLR1,2", "GENE_OR_GENE_PRODUCT", 95, 101], ["TLR6", "GENE_OR_GENE_PRODUCT", 106, 110], ["LSECs", "CELL_TYPE", 14, 19], ["CD4", "PROTEIN", 57, 60], ["CD8 T-cells", "CELL_TYPE", 65, 76], ["TLR1", "PROTEIN", 95, 99], ["TLR6", "PROTEIN", 106, 110], ["CD4", "TEST", 57, 60], ["TLR1,2 and TLR6 agonists", "TREATMENT", 95, 119], ["LSECs", "ANATOMY", 14, 19]]], ["These results suggest that LSECs are capable of initiating antiviral and pro-inflammatory responses by TLR3 as well as adaptive responses through TLR1,2,6 and TLR8, thereby maintaining hepatic immune response.", [["LSECs", "ANATOMY", 27, 32], ["hepatic", "ANATOMY", 185, 192], ["LSECs", "CELL", 27, 32], ["TLR3", "GENE_OR_GENE_PRODUCT", 103, 107], ["TLR1", "GENE_OR_GENE_PRODUCT", 146, 150], ["2,6", "GENE_OR_GENE_PRODUCT", 151, 154], ["TLR8", "GENE_OR_GENE_PRODUCT", 159, 163], ["hepatic", "ORGAN", 185, 192], ["LSECs", "CELL_TYPE", 27, 32], ["TLR3", "PROTEIN", 103, 107], ["TLR1", "PROTEIN", 146, 150], ["2,6", "PROTEIN", 151, 154], ["TLR8", "PROTEIN", 159, 163], ["antiviral and pro-inflammatory responses", "TREATMENT", 59, 99], ["TLR1", "TEST", 146, 150], ["TLR8", "TREATMENT", 159, 163], ["LSECs", "OBSERVATION", 27, 32], ["hepatic", "ANATOMY", 185, 192], ["immune response", "OBSERVATION", 193, 208]]], ["Similarly, the role of TLR3 stimulated the murine LSECs is reported in suppressing Hepatitis B viral replication mediated by IFN-\u00df production in vitro (Wu et al., 2007).Toll-Like Receptors ::: Other Cell Surface ReceptorsThe portal circulation continuously exposes the liver to microbial antigens and food from the gut; therefore, it possesses a piece of special machinery to maintain immune tolerance.", [["LSECs", "ANATOMY", 50, 55], ["Cell", "ANATOMY", 199, 203], ["portal", "ANATOMY", 225, 231], ["liver", "ANATOMY", 269, 274], ["gut", "ANATOMY", 315, 318], ["TLR3", "GENE_OR_GENE_PRODUCT", 23, 27], ["murine", "ORGANISM", 43, 49], ["LSECs", "GENE_OR_GENE_PRODUCT", 50, 55], ["Hepatitis B viral", "ORGANISM", 83, 100], ["IFN-\u00df", "GENE_OR_GENE_PRODUCT", 125, 130], ["Toll-Like Receptors", "GENE_OR_GENE_PRODUCT", 169, 188], ["Cell", "CELL", 199, 203], ["portal", "MULTI-TISSUE_STRUCTURE", 225, 231], ["liver", "ORGAN", 269, 274], ["gut", "ORGANISM_SUBDIVISION", 315, 318], ["TLR3", "PROTEIN", 23, 27], ["murine LSECs", "CELL_TYPE", 43, 55], ["IFN", "PROTEIN", 125, 128], ["\u00df", "PROTEIN", 129, 130], ["Toll-Like Receptors", "PROTEIN", 169, 188], ["Cell Surface Receptors", "PROTEIN", 199, 221], ["murine", "SPECIES", 43, 49], ["Hepatitis B", "SPECIES", 83, 94], ["Hepatitis B viral replication", "TREATMENT", 83, 112], ["special machinery", "TREATMENT", 355, 372], ["viral replication", "OBSERVATION", 95, 112], ["Surface Receptors", "OBSERVATION", 204, 221], ["portal circulation", "ANATOMY", 225, 243], ["liver", "ANATOMY", 269, 274], ["microbial", "OBSERVATION_MODIFIER", 278, 287], ["gut", "ANATOMY", 315, 318], ["immune tolerance", "OBSERVATION", 385, 401]]], ["Liu J. et al. (2013) reported that incubation of LSECs with palmitoyl-3-cysteine-serine-lysine-4 (P3C), a TLR2 ligand, resulted in the reversal of immune tolerance.", [["LSECs", "ANATOMY", 49, 54], ["palmitoyl-3-cysteine-serine-lysine-4", "CHEMICAL", 60, 96], ["palmitoyl-3-cysteine", "CHEMICAL", 60, 80], ["serine", "CHEMICAL", 81, 87], ["lysine", "CHEMICAL", 88, 94], ["LSECs", "SIMPLE_CHEMICAL", 49, 54], ["palmitoyl-3-cysteine-serine-lysine-4", "SIMPLE_CHEMICAL", 60, 96], ["P3C", "SIMPLE_CHEMICAL", 98, 101], ["TLR2", "GENE_OR_GENE_PRODUCT", 106, 110], ["TLR2 ligand", "PROTEIN", 106, 117], ["LSECs", "TEST", 49, 54], ["palmitoyl", "TEST", 60, 69], ["cysteine", "TREATMENT", 72, 80], ["serine-lysine", "TREATMENT", 81, 94], ["a TLR2 ligand", "TREATMENT", 104, 117], ["immune tolerance", "PROBLEM", 147, 163], ["LSECs", "ANATOMY", 49, 54], ["immune tolerance", "OBSERVATION", 147, 163]]], ["LSECs were co-cultured with stimulated T cells isolated from mice and treated with P3C.", [["LSECs", "ANATOMY", 0, 5], ["T cells", "ANATOMY", 39, 46], ["LSECs", "CELL", 0, 5], ["T cells", "CELL", 39, 46], ["mice", "ORGANISM", 61, 65], ["P3C", "SIMPLE_CHEMICAL", 83, 86], ["LSECs", "CELL_TYPE", 0, 5], ["T cells", "CELL_TYPE", 39, 46], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["stimulated T cells", "TREATMENT", 28, 46], ["P3C", "TREATMENT", 83, 86]]], ["This resulted in an increase in proliferation of T cells as well as cytokine production in co-culture as compared to T cells cultured alone.", [["T cells", "ANATOMY", 49, 56], ["T cells", "ANATOMY", 117, 124], ["T cells", "CELL", 49, 56], ["T cells", "CELL", 117, 124], ["T cells", "CELL_TYPE", 49, 56], ["cytokine", "PROTEIN", 68, 76], ["T cells", "CELL_TYPE", 117, 124], ["an increase in proliferation of T cells", "PROBLEM", 17, 56], ["cytokine production in co-culture", "PROBLEM", 68, 101], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["proliferation", "OBSERVATION_MODIFIER", 32, 45], ["T cells", "OBSERVATION", 49, 56]]], ["An increase in CD8+ effector T cell population, IL-12 production, and decrease in PD-L1 expression on LSECs was also observed in these co-culture systems.", [["CD8+ effector T cell", "ANATOMY", 15, 35], ["LSECs", "ANATOMY", 102, 107], ["CD8", "GENE_OR_GENE_PRODUCT", 15, 18], ["IL-12", "GENE_OR_GENE_PRODUCT", 48, 53], ["PD-L1", "GENE_OR_GENE_PRODUCT", 82, 87], ["LSECs", "CELL", 102, 107], ["CD8", "PROTEIN", 15, 18], ["LSECs", "CELL_TYPE", 102, 107], ["An increase in CD8+ effector T cell population", "PROBLEM", 0, 46], ["IL", "TEST", 48, 50], ["decrease in PD", "PROBLEM", 70, 84], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["CD8+ effector T cell", "OBSERVATION", 15, 35], ["decrease", "OBSERVATION_MODIFIER", 70, 78], ["L1", "ANATOMY", 85, 87], ["LSECs", "ANATOMY", 102, 107]]], ["This study outlined the role of TLRs in regulating the immunosuppressive property in LSECs.", [["LSECs", "ANATOMY", 85, 90], ["TLRs", "GENE_OR_GENE_PRODUCT", 32, 36], ["LSECs", "CELL", 85, 90], ["TLRs", "PROTEIN", 32, 36], ["LSECs", "CELL_TYPE", 85, 90], ["This study", "TEST", 0, 10]]], ["Similarly, one study has demonstrated the role of TLR2 expressed on LSECs in initiating an innate immune response toward adeno-associated viral vectors (rAAV) and efficiency of gene therapy mediated by rAAV which may be enhanced by understanding this mechanism (Hosel et al., 2012).", [["LSECs", "ANATOMY", 68, 73], ["TLR2", "GENE_OR_GENE_PRODUCT", 50, 54], ["LSECs", "GENE_OR_GENE_PRODUCT", 68, 73], ["rAAV", "ORGANISM", 153, 157], ["rAAV", "ORGANISM", 202, 206], ["TLR2", "PROTEIN", 50, 54], ["rAAV", "SPECIES", 153, 157], ["rAAV", "SPECIES", 202, 206], ["one study", "TEST", 11, 20], ["an innate immune response", "TREATMENT", 88, 113], ["adeno-associated viral vectors (rAAV", "TREATMENT", 121, 157], ["gene therapy", "TREATMENT", 177, 189], ["viral vectors", "OBSERVATION", 138, 151], ["gene therapy", "OBSERVATION", 177, 189], ["may be", "UNCERTAINTY", 213, 219]]], ["As the anatomical sieve of the liver, the LSECs are continually monitoring antigens and confer tolerance to maintain proper homeostasis.L-SIGN and LSECtin ::: Other Cell Surface ReceptorsLiver/lymph node-specific ICAM-3 grabbing non-integrin (L-SIGN)/CD299L/CLEC4M and Liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin)/CLEC4G are type II transmembrane proteins belonging to the C-type lectin family (Bashirova et al., 2001; Pohlmann et al., 2001; Gardner et al., 2003; Liu et al., 2004).", [["liver", "ANATOMY", 31, 36], ["LSECs", "ANATOMY", 42, 47], ["Cell", "ANATOMY", 165, 169], ["lymph node", "ANATOMY", 193, 203], ["Liver", "ANATOMY", 269, 274], ["L-SIGN", "CHEMICAL", 136, 142], ["LSECtin", "CHEMICAL", 147, 154], ["liver", "ORGAN", 31, 36], ["LSECs", "CANCER", 42, 47], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 136, 142], ["LSECtin", "SIMPLE_CHEMICAL", 147, 154], ["Cell", "CELL", 165, 169], ["lymph node", "MULTI-TISSUE_STRUCTURE", 193, 203], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 213, 219], ["non-integrin", "GENE_OR_GENE_PRODUCT", 229, 241], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 243, 249], ["CD299L", "GENE_OR_GENE_PRODUCT", 251, 257], ["CLEC4M", "GENE_OR_GENE_PRODUCT", 258, 264], ["Liver", "ORGAN", 269, 274], ["endothelial cell C-type lectin", "GENE_OR_GENE_PRODUCT", 301, 331], ["LSECtin", "GENE_OR_GENE_PRODUCT", 333, 340], ["CLEC4G", "GENE_OR_GENE_PRODUCT", 342, 348], ["type II transmembrane", "GENE_OR_GENE_PRODUCT", 353, 374], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 401, 414], ["LSECs", "CELL_TYPE", 42, 47], ["LSECtin", "PROTEIN", 147, 154], ["ICAM-3", "PROTEIN", 213, 219], ["non-integrin", "PROTEIN", 229, 241], ["L", "PROTEIN", 243, 244], ["SIGN", "PROTEIN", 245, 249], ["CD299L", "PROTEIN", 251, 257], ["CLEC4M", "PROTEIN", 258, 264], ["Liver and lymph node sinusoidal endothelial cell C-type lectin", "PROTEIN", 269, 331], ["LSECtin", "PROTEIN", 333, 340], ["CLEC4G", "PROTEIN", 342, 348], ["type II transmembrane proteins", "PROTEIN", 353, 383], ["C-type lectin family", "PROTEIN", 401, 421], ["Other Cell Surface", "TEST", 159, 177], ["ReceptorsLiver", "TEST", 178, 192], ["lymph node", "TEST", 193, 203], ["specific ICAM", "TEST", 204, 217], ["non-integrin", "TEST", 229, 241], ["CD299L", "TEST", 251, 257], ["CLEC4M", "PROBLEM", 258, 264], ["Liver and lymph node sinusoidal endothelial cell C-type lectin", "PROBLEM", 269, 331], ["type II transmembrane proteins", "PROBLEM", 353, 383], ["anatomical sieve", "OBSERVATION", 7, 23], ["liver", "ANATOMY", 31, 36], ["LSECs", "ANATOMY", 42, 47], ["Surface", "OBSERVATION_MODIFIER", 170, 177], ["lymph node", "OBSERVATION", 193, 203], ["Liver", "ANATOMY", 269, 274], ["lymph node sinusoidal endothelial cell", "OBSERVATION", 279, 317]]], ["These two receptors are encoded on chromosome 19 in humans (Grimwood et al., 2004).", [["chromosome 19", "ANATOMY", 35, 48], ["chromosome 19", "CELLULAR_COMPONENT", 35, 48], ["humans", "ORGANISM", 52, 58], ["chromosome 19", "DNA", 35, 48], ["humans", "SPECIES", 52, 58], ["humans", "SPECIES", 52, 58]]], ["They are characterized by an intracellular domain, a transmembrane domain, and an extracellular domain composed of a neck domain and a C-type carbohydrate recognition domain (CRD).", [["intracellular", "ANATOMY", 29, 42], ["transmembrane", "ANATOMY", 53, 66], ["extracellular", "ANATOMY", 82, 95], ["carbohydrate", "CHEMICAL", 142, 154], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["transmembrane", "CELLULAR_COMPONENT", 53, 66], ["extracellular domain", "CELLULAR_COMPONENT", 82, 102], ["intracellular domain", "PROTEIN", 29, 49], ["transmembrane domain", "PROTEIN", 53, 73], ["extracellular domain", "PROTEIN", 82, 102], ["neck domain", "PROTEIN", 117, 128], ["C-type carbohydrate recognition domain", "PROTEIN", 135, 173], ["CRD", "PROTEIN", 175, 178], ["an intracellular domain", "PROBLEM", 26, 49], ["a transmembrane domain", "PROBLEM", 51, 73], ["an extracellular domain", "PROBLEM", 79, 102], ["a neck domain", "PROBLEM", 115, 128], ["a C-type carbohydrate recognition", "TREATMENT", 133, 166], ["intracellular domain", "OBSERVATION", 29, 49], ["neck", "ANATOMY", 117, 121]]], ["Ligand binding is mediated through C-type CRD.", [["C-type CRD", "GENE_OR_GENE_PRODUCT", 35, 45], ["C-type CRD", "PROTEIN", 35, 45]]], ["L-SIGN is expressed by liver and lymph node sinusoidal endothelial and placental capillary endothelial cells (Pohlmann et al., 2001).", [["liver", "ANATOMY", 23, 28], ["lymph node sinusoidal endothelial", "ANATOMY", 33, 66], ["placental capillary endothelial cells", "ANATOMY", 71, 108], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 0, 6], ["liver", "ORGAN", 23, 28], ["lymph node sinusoidal endothelial", "CELL", 33, 66], ["placental capillary endothelial cells", "CELL", 71, 108], ["SIGN", "PROTEIN", 2, 6], ["liver and lymph node sinusoidal endothelial", "CELL_TYPE", 23, 66], ["placental capillary endothelial cells", "CELL_TYPE", 71, 108], ["placental capillary endothelial cells", "PROBLEM", 71, 108], ["liver", "ANATOMY", 23, 28], ["lymph node", "OBSERVATION", 33, 43], ["sinusoidal endothelial", "OBSERVATION", 44, 66], ["placental", "ANATOMY_MODIFIER", 71, 80], ["capillary", "ANATOMY_MODIFIER", 81, 90], ["endothelial cells", "OBSERVATION", 91, 108]]], ["Likewise, liver and lymph node sinusoidal endothelial cells specifically co-express LSECtin (Liu et al., 2004).", [["liver", "ANATOMY", 10, 15], ["lymph node sinusoidal endothelial cells", "ANATOMY", 20, 59], ["liver", "ORGAN", 10, 15], ["lymph node sinusoidal endothelial cells", "CELL", 20, 59], ["LSECtin", "GENE_OR_GENE_PRODUCT", 84, 91], ["liver and lymph node sinusoidal endothelial cells", "CELL_TYPE", 10, 59], ["liver", "ANATOMY", 10, 15], ["lymph node", "OBSERVATION", 20, 30], ["sinusoidal endothelial cells", "OBSERVATION", 31, 59]]], ["LSECtin expression is also seen on bone marrow sinusoidal endothelial cells as well as on KCs in the liver (Dominguez-Soto et al., 2009).", [["bone marrow sinusoidal endothelial cells", "ANATOMY", 35, 75], ["KCs", "ANATOMY", 90, 93], ["liver", "ANATOMY", 101, 106], ["LSECtin", "GENE_OR_GENE_PRODUCT", 0, 7], ["bone marrow sinusoidal endothelial cells", "CELL", 35, 75], ["KCs", "CELL", 90, 93], ["liver", "ORGAN", 101, 106], ["LSECtin", "PROTEIN", 0, 7], ["bone marrow sinusoidal endothelial cells", "CELL_TYPE", 35, 75], ["KCs", "CELL_TYPE", 90, 93], ["bone marrow sinusoidal endothelial cells", "PROBLEM", 35, 75], ["bone marrow", "ANATOMY", 35, 46], ["sinusoidal endothelial cells", "OBSERVATION", 47, 75], ["liver", "ANATOMY", 101, 106]]], ["L-SIGN binds to high mannose oligosaccharide (Feinberg et al., 2001), whereas, LSECtin can bind with N-acetylglucosamine, mannose, and fucose (Liu et al., 2004).", [["L-SIGN", "CHEMICAL", 0, 6], ["mannose oligosaccharide", "CHEMICAL", 21, 44], ["LSECtin", "CHEMICAL", 79, 86], ["N-acetylglucosamine", "CHEMICAL", 101, 120], ["mannose", "CHEMICAL", 122, 129], ["fucose", "CHEMICAL", 135, 141], ["L-SIGN", "CHEMICAL", 0, 6], ["mannose", "CHEMICAL", 21, 28], ["N-acetylglucosamine", "CHEMICAL", 101, 120], ["mannose", "CHEMICAL", 122, 129], ["fucose", "CHEMICAL", 135, 141], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 0, 6], ["mannose oligosaccharide", "SIMPLE_CHEMICAL", 21, 44], ["LSECtin", "SIMPLE_CHEMICAL", 79, 86], ["N-acetylglucosamine", "SIMPLE_CHEMICAL", 101, 120], ["mannose", "SIMPLE_CHEMICAL", 122, 129], ["fucose", "SIMPLE_CHEMICAL", 135, 141], ["L-SIGN", "PROTEIN", 0, 6], ["mannose", "TREATMENT", 122, 129]]], ["Since L-SIGN is expressed on placental capillary endothelium, one study has shown their possible involvement in mother to child transmission of HIV-1 virus (Boily-Larouche et al., 2012), while several other studies relating L-SIGN with HIV-1 entry remain contradictory.", [["placental capillary endothelium", "ANATOMY", 29, 60], ["HIV-1 virus", "DISEASE", 144, 155], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 6, 12], ["placental capillary endothelium", "TISSUE", 29, 60], ["HIV-1 virus", "ORGANISM", 144, 155], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 224, 230], ["HIV-1", "ORGANISM", 236, 241], ["L-SIGN", "PROTEIN", 6, 12], ["HIV-1 virus", "SPECIES", 144, 155], ["HIV-1", "SPECIES", 236, 241], ["HIV-1 virus", "SPECIES", 144, 155], ["HIV-1", "SPECIES", 236, 241], ["one study", "TEST", 62, 71], ["HIV", "PROBLEM", 144, 147], ["other studies", "TEST", 201, 214], ["HIV", "PROBLEM", 236, 239], ["placental", "ANATOMY_MODIFIER", 29, 38], ["capillary endothelium", "ANATOMY", 39, 60]]], ["L-SIGN expressed on pulmonary endothelial cells serve as the gateway for the entrance of SARS-CoV as it was able to bind HEK293T cells expressing purified soluble SARS-CoV glycoproteins (Jeffers et al., 2004).", [["pulmonary endothelial cells", "ANATOMY", 20, 47], ["HEK293T cells", "ANATOMY", 121, 134], ["SARS", "DISEASE", 89, 93], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 0, 6], ["pulmonary endothelial cells", "CELL", 20, 47], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["HEK293T cells", "CELL", 121, 134], ["SARS-CoV glycoproteins", "GENE_OR_GENE_PRODUCT", 163, 185], ["L-SIGN", "PROTEIN", 0, 6], ["pulmonary endothelial cells", "CELL_TYPE", 20, 47], ["HEK293T cells", "CELL_LINE", 121, 134], ["SARS-CoV glycoproteins", "PROTEIN", 163, 185], ["SARS-CoV", "SPECIES", 89, 97], ["pulmonary endothelial cells", "TREATMENT", 20, 47], ["SARS", "PROBLEM", 89, 93], ["CoV", "PROBLEM", 94, 97], ["purified soluble SARS", "PROBLEM", 146, 167], ["pulmonary endothelial", "ANATOMY", 20, 41]]], ["Similarly, LSECtin might also play a role in mediating SARS-CoV infection in hepatocytes (Gramberg et al., 2005).L-SIGN and LSECtin ::: Other Cell Surface ReceptorsL-SIGN has been reported to interact with glycoprotein E2 of the Hepatitis C viron (HCV) (Gardner et al., 2003).", [["hepatocytes", "ANATOMY", 77, 88], ["Cell", "ANATOMY", 142, 146], ["LSECtin", "CHEMICAL", 11, 18], ["SARS-CoV infection", "DISEASE", 55, 73], ["E2", "CHEMICAL", 219, 221], ["Hepatitis C viron", "DISEASE", 229, 246], ["L-SIGN", "CHEMICAL", 113, 119], ["LSECtin", "GENE_OR_GENE_PRODUCT", 11, 18], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["hepatocytes", "CELL", 77, 88], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 113, 119], ["Cell", "CELL", 142, 146], ["ReceptorsL-SIGN", "GENE_OR_GENE_PRODUCT", 155, 170], ["glycoprotein E2", "GENE_OR_GENE_PRODUCT", 206, 221], ["Hepatitis C viron", "ORGANISM", 229, 246], ["HCV", "ORGANISM", 248, 251], ["LSECtin", "PROTEIN", 11, 18], ["hepatocytes", "CELL_TYPE", 77, 88], ["LSECtin", "PROTEIN", 124, 131], ["ReceptorsL", "PROTEIN", 155, 165], ["SIGN", "PROTEIN", 166, 170], ["glycoprotein E2", "PROTEIN", 206, 221], ["SARS-CoV", "SPECIES", 55, 63], ["Hepatitis C viron", "SPECIES", 229, 246], ["HCV", "SPECIES", 248, 251], ["mediating SARS", "PROBLEM", 45, 59], ["CoV infection in hepatocytes", "PROBLEM", 60, 88], ["Other Cell Surface ReceptorsL", "TEST", 136, 165], ["the Hepatitis C viron", "TREATMENT", 225, 246], ["infection", "OBSERVATION", 64, 73], ["hepatocytes", "ANATOMY", 77, 88], ["Surface", "OBSERVATION_MODIFIER", 147, 154], ["Hepatitis", "OBSERVATION", 229, 238]]], ["This study has shown that L-SIGN transfected Hela cells were able to bind purified HCV-E2 protein as compared to parental HeLa cells using FACS analysis.", [["Hela cells", "ANATOMY", 45, 55], ["HeLa cells", "ANATOMY", 122, 132], ["L-SIGN", "SIMPLE_CHEMICAL", 26, 32], ["Hela cells", "CELL", 45, 55], ["HCV-E2", "GENE_OR_GENE_PRODUCT", 83, 89], ["HeLa cells", "CELL", 122, 132], ["L-SIGN transfected Hela cells", "CELL_LINE", 26, 55], ["HCV-E2 protein", "PROTEIN", 83, 97], ["parental HeLa cells", "CELL_LINE", 113, 132], ["HCV", "SPECIES", 83, 86], ["This study", "TEST", 0, 10], ["L-SIGN transfected Hela cells", "PROBLEM", 26, 55], ["HCV", "TEST", 83, 86], ["E2 protein", "TREATMENT", 87, 97], ["FACS analysis", "TEST", 139, 152], ["Hela cells", "OBSERVATION", 45, 55]]], ["Since, mannan is a ligand for L-SIGN, incubating the recombinant L-SIGN expressing HeLa cells (HeLa-L-SIGN) with mannan inhibited binding between L-SIGN and purified HCV-E2 protein.", [["HeLa cells", "ANATOMY", 83, 93], ["HeLa-L-SIGN", "ANATOMY", 95, 106], ["mannan", "SIMPLE_CHEMICAL", 7, 13], ["L-SIGN", "SIMPLE_CHEMICAL", 30, 36], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 65, 71], ["HeLa cells", "CELL", 83, 93], ["HeLa-L-SIGN", "CELL", 95, 106], ["mannan", "SIMPLE_CHEMICAL", 113, 119], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 146, 152], ["HCV-E2", "GENE_OR_GENE_PRODUCT", 166, 172], ["mannan", "PROTEIN", 7, 13], ["L-SIGN", "PROTEIN", 30, 36], ["recombinant L-SIGN expressing HeLa cells", "CELL_LINE", 53, 93], ["HeLa", "CELL_LINE", 95, 99], ["SIGN", "CELL_LINE", 102, 106], ["SIGN", "PROTEIN", 148, 152], ["purified HCV-E2 protein", "PROTEIN", 157, 180], ["HCV", "SPECIES", 166, 169], ["HeLa cells", "TEST", 83, 93], ["HeLa", "TEST", 95, 99], ["mannan inhibited binding", "PROBLEM", 113, 137], ["purified HCV", "PROBLEM", 157, 169], ["HeLa cells", "OBSERVATION", 83, 93], ["HCV", "OBSERVATION", 166, 169]]], ["They confirmed the finding by exposing the HeLa-L-SIGN cells to HCV-virion and detected the HCV genome in L-SIGN transfected Hela cells by RT-PCR and Southern blotting.", [["HeLa-L-SIGN cells", "ANATOMY", 43, 60], ["Hela cells", "ANATOMY", 125, 135], ["HeLa-L-SIGN cells", "CELL", 43, 60], ["HCV", "ORGANISM", 64, 67], ["HCV", "ORGANISM", 92, 95], ["L-SIGN", "CELL", 106, 112], ["Hela cells", "CELL", 125, 135], ["HeLa-L-SIGN cells", "CELL_LINE", 43, 60], ["HCV genome", "DNA", 92, 102], ["L-SIGN transfected Hela cells", "CELL_LINE", 106, 135], ["HCV", "SPECIES", 64, 67], ["HCV", "SPECIES", 92, 95], ["the HeLa", "TEST", 39, 47], ["HCV", "TEST", 64, 67], ["virion", "TREATMENT", 68, 74], ["the HCV genome", "PROBLEM", 88, 102], ["Hela cells", "TEST", 125, 135], ["RT", "TEST", 139, 141], ["PCR", "TEST", 142, 145], ["Southern blotting", "PROBLEM", 150, 167], ["HCV genome", "OBSERVATION", 92, 102], ["Hela cells", "OBSERVATION", 125, 135]]], ["Similarly, another group has shown the involvement of L-SIGN in facilitating the entry of HCV and passing it to nearby hepatocytes present in the liver using HCV pseudotype particles (Lozach et al., 2004).", [["hepatocytes", "ANATOMY", 119, 130], ["liver", "ANATOMY", 146, 151], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 54, 60], ["HCV", "ORGANISM", 90, 93], ["hepatocytes", "CELL", 119, 130], ["liver", "ORGAN", 146, 151], ["HCV", "ORGANISM", 158, 161], ["L-SIGN", "PROTEIN", 54, 60], ["nearby hepatocytes", "CELL_TYPE", 112, 130], ["HCV", "SPECIES", 90, 93], ["HCV", "SPECIES", 158, 161], ["HCV", "PROBLEM", 90, 93], ["HCV pseudotype particles", "TREATMENT", 158, 182], ["L", "ANATOMY_MODIFIER", 54, 55], ["HCV", "OBSERVATION", 90, 93], ["hepatocytes", "ANATOMY", 119, 130], ["liver", "ANATOMY", 146, 151], ["HCV pseudotype particles", "OBSERVATION", 158, 182]]], ["Since LSECtin and L-SIGN belongs to the same C-type lectin family and share a 32% sequence identity, Li Y. et al. (2009) demonstrated that the central domain of LSECtin binds with L-SIGN and along with the C terminal CRD domain bind with E2 glycoprotein present on HCV suggesting that LSECtin binding with L-SIGN might play a role in the HCV binding to LSECs.", [["LSECs", "ANATOMY", 353, 358], ["E2", "CHEMICAL", 238, 240], ["C", "CHEMICAL", 206, 207], ["LSECtin", "GENE_OR_GENE_PRODUCT", 6, 13], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 18, 24], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 45, 58], ["LSECtin", "GENE_OR_GENE_PRODUCT", 161, 168], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 180, 186], ["E2 glycoprotein", "GENE_OR_GENE_PRODUCT", 238, 253], ["HCV", "ORGANISM", 265, 268], ["LSECtin", "GENE_OR_GENE_PRODUCT", 285, 292], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 306, 312], ["HCV", "ORGANISM", 338, 341], ["LSECs", "CELL", 353, 358], ["LSECtin", "PROTEIN", 6, 13], ["L", "PROTEIN", 18, 19], ["SIGN", "PROTEIN", 20, 24], ["C-type lectin family", "PROTEIN", 45, 65], ["LSECtin", "PROTEIN", 161, 168], ["L-SIGN", "PROTEIN", 180, 186], ["C terminal CRD domain", "PROTEIN", 206, 227], ["E2 glycoprotein", "PROTEIN", 238, 253], ["LSECtin", "PROTEIN", 285, 292], ["SIGN", "PROTEIN", 308, 312], ["LSECs", "CELL_TYPE", 353, 358], ["HCV", "SPECIES", 265, 268], ["HCV", "SPECIES", 338, 341], ["the central domain of LSECtin binds", "PROBLEM", 139, 174], ["the C terminal CRD domain bind", "TREATMENT", 202, 232], ["E2 glycoprotein", "TREATMENT", 238, 253], ["HCV", "PROBLEM", 265, 268], ["LSECtin binding", "PROBLEM", 285, 300], ["HCV", "OBSERVATION", 338, 341]]], ["LSECtin is also involved in mediating T-cell immune response in the hepatic system (Tang et al., 2009).", [["T-cell", "ANATOMY", 38, 44], ["hepatic system", "ANATOMY", 68, 82], ["LSECtin", "GENE_OR_GENE_PRODUCT", 0, 7], ["T-cell", "CELL", 38, 44], ["hepatic system", "MULTI-TISSUE_STRUCTURE", 68, 82], ["LSECtin", "PROTEIN", 0, 7], ["hepatic", "ANATOMY", 68, 75]]], ["This study showed that LSECtin binds to CD44, a hyaluronan binding receptor, present on activated T cells, halting T-cell activation and proliferation, thereby preventing liver injury.", [["T cells", "ANATOMY", 98, 105], ["T-cell", "ANATOMY", 115, 121], ["liver", "ANATOMY", 171, 176], ["LSECtin", "CHEMICAL", 23, 30], ["liver injury", "DISEASE", 171, 183], ["LSECtin", "SIMPLE_CHEMICAL", 23, 30], ["CD44", "GENE_OR_GENE_PRODUCT", 40, 44], ["hyaluronan binding receptor", "GENE_OR_GENE_PRODUCT", 48, 75], ["T cells", "CELL", 98, 105], ["T-cell", "CELL", 115, 121], ["liver", "ORGAN", 171, 176], ["LSECtin", "PROTEIN", 23, 30], ["CD44", "PROTEIN", 40, 44], ["hyaluronan binding receptor", "PROTEIN", 48, 75], ["activated T cells", "CELL_TYPE", 88, 105], ["This study", "TEST", 0, 10], ["LSECtin binds", "PROBLEM", 23, 36], ["a hyaluronan binding receptor", "TREATMENT", 46, 75], ["activated T cells", "TREATMENT", 88, 105], ["halting T-cell activation", "TREATMENT", 107, 132], ["proliferation", "PROBLEM", 137, 150], ["liver injury", "PROBLEM", 171, 183], ["preventing", "UNCERTAINTY", 160, 170], ["liver", "ANATOMY", 171, 176], ["injury", "OBSERVATION", 177, 183]]], ["Both of these receptors bind to mannose residues, which help them in clearing pathogens from circulation (Liu et al., 2004).", [["mannose", "CHEMICAL", 32, 39], ["mannose", "SIMPLE_CHEMICAL", 32, 39], ["mannose residues", "PROBLEM", 32, 48], ["mannose residues", "OBSERVATION", 32, 48]]], ["These studies suggest that L-SIGN and LSECtin may be targeted for the treatment of HCV and inflammatory liver diseases.LYVE-1 ::: Other Cell Surface ReceptorsLymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) is a type I integral membrane glycoprotein which was firstly identified exclusively on lymph vessels responsible for sequestering hyaluronic acid in the lymph vessel endothelium (Banerji et al., 1999).", [["liver", "ANATOMY", 104, 109], ["membrane", "ANATOMY", 239, 247], ["lymph vessels", "ANATOMY", 305, 318], ["lymph vessel endothelium", "ANATOMY", 371, 395], ["L-SIGN", "CHEMICAL", 27, 33], ["LSECtin", "CHEMICAL", 38, 45], ["HCV", "DISEASE", 83, 86], ["liver diseases", "DISEASE", 104, 118], ["hyaluronic acid", "CHEMICAL", 348, 363], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 27, 33], ["LSECtin", "SIMPLE_CHEMICAL", 38, 45], ["HCV", "ORGANISM", 83, 86], ["liver", "ORGAN", 104, 109], ["Cell Surface ReceptorsLymphatic vessel endothelial hyaluronan receptor 1", "GENE_OR_GENE_PRODUCT", 136, 208], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 210, 216], ["type I integral membrane glycoprotein", "GENE_OR_GENE_PRODUCT", 223, 260], ["lymph vessels", "MULTI-TISSUE_STRUCTURE", 305, 318], ["hyaluronic acid", "SIMPLE_CHEMICAL", 348, 363], ["lymph vessel endothelium", "TISSUE", 371, 395], ["L-SIGN", "PROTEIN", 27, 33], ["Cell Surface ReceptorsLymphatic vessel endothelial hyaluronan receptor 1", "PROTEIN", 136, 208], ["LYVE", "PROTEIN", 210, 214], ["type I integral membrane glycoprotein", "PROTEIN", 223, 260], ["HCV", "SPECIES", 83, 86], ["These studies", "TEST", 0, 13], ["LSECtin", "TREATMENT", 38, 45], ["HCV", "PROBLEM", 83, 86], ["inflammatory liver diseases", "PROBLEM", 91, 118], ["LYVE", "TEST", 119, 123], ["Other Cell Surface", "TEST", 130, 148], ["vessel endothelial hyaluronan receptor", "TEST", 168, 206], ["LYVE", "TEST", 210, 214], ["a type I integral membrane glycoprotein", "PROBLEM", 221, 260], ["sequestering hyaluronic acid", "PROBLEM", 335, 363], ["HCV", "OBSERVATION", 83, 86], ["inflammatory", "OBSERVATION_MODIFIER", 91, 103], ["liver", "ANATOMY", 104, 109], ["diseases", "OBSERVATION", 110, 118], ["Cell", "ANATOMY_MODIFIER", 136, 140], ["Surface", "ANATOMY_MODIFIER", 141, 148], ["ReceptorsLymphatic", "ANATOMY_MODIFIER", 149, 167], ["vessel", "ANATOMY", 168, 174], ["endothelial", "ANATOMY_MODIFIER", 175, 186], ["lymph vessels", "OBSERVATION", 305, 318], ["hyaluronic acid", "OBSERVATION", 348, 363], ["lymph vessel", "ANATOMY", 371, 383]]], ["Similar to its homolog CD44, LYVE-1 contains a single Link module in the extracellular domain that is responsible for Hyaluronic acid (HA) binding (Day and Prestwich, 2002).", [["extracellular", "ANATOMY", 73, 86], ["Hyaluronic acid", "CHEMICAL", 118, 133], ["HA", "CHEMICAL", 135, 137], ["CD44", "GENE_OR_GENE_PRODUCT", 23, 27], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 29, 35], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 86], ["Hyaluronic acid", "SIMPLE_CHEMICAL", 118, 133], ["HA", "SIMPLE_CHEMICAL", 135, 137], ["CD44", "PROTEIN", 23, 27], ["LYVE-1", "PROTEIN", 29, 35], ["Link module", "PROTEIN", 54, 65], ["extracellular domain", "PROTEIN", 73, 93], ["its homolog CD44", "TEST", 11, 27], ["LYVE", "TEST", 29, 33], ["a single Link module in the extracellular domain", "PROBLEM", 45, 93], ["Hyaluronic acid (HA) binding", "PROBLEM", 118, 146], ["CD44", "OBSERVATION", 23, 27], ["module", "OBSERVATION", 59, 65], ["extracellular", "ANATOMY_MODIFIER", 73, 86], ["responsible for", "UNCERTAINTY", 102, 117], ["Hyaluronic acid", "OBSERVATION", 118, 133]]], ["It is present on chromosome 11 in humans and chromosome 7 in mice.", [["chromosome 11", "ANATOMY", 17, 30], ["chromosome 7", "ANATOMY", 45, 57], ["chromosome 11", "CELLULAR_COMPONENT", 17, 30], ["humans", "ORGANISM", 34, 40], ["chromosome 7", "CELLULAR_COMPONENT", 45, 57], ["mice", "ORGANISM", 61, 65], ["chromosome 11", "DNA", 17, 30], ["chromosome 7", "DNA", 45, 57], ["humans", "SPECIES", 34, 40], ["mice", "SPECIES", 61, 65], ["humans", "SPECIES", 34, 40], ["mice", "SPECIES", 61, 65]]], ["With the use of better antibodies, LYVE-1 expression was also detected in the liver, spleen, and lymph node sinusoidal endothelial cells in humans (Mouta Carreira et al., 2001; Akishima et al., 2004).", [["liver", "ANATOMY", 78, 83], ["spleen", "ANATOMY", 85, 91], ["lymph node sinusoidal endothelial cells", "ANATOMY", 97, 136], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 35, 41], ["liver", "ORGAN", 78, 83], ["spleen", "ORGAN", 85, 91], ["lymph node sinusoidal endothelial cells", "CELL", 97, 136], ["humans", "ORGANISM", 140, 146], ["LYVE", "PROTEIN", 35, 39], ["lymph node sinusoidal endothelial cells", "CELL_TYPE", 97, 136], ["humans", "SPECIES", 140, 146], ["humans", "SPECIES", 140, 146], ["LYVE", "TEST", 35, 39], ["liver", "ANATOMY", 78, 83], ["spleen", "ANATOMY", 85, 91], ["lymph node", "OBSERVATION", 97, 107], ["sinusoidal endothelial cells", "OBSERVATION", 108, 136]]], ["However, a recent study conducted in rodents has revealed their expression in the non-sinusoidal endothelium of many other organs, such as lungs, heart, and adrenal gland (Zheng et al., 2016).", [["non-sinusoidal endothelium", "ANATOMY", 82, 108], ["organs", "ANATOMY", 123, 129], ["lungs", "ANATOMY", 139, 144], ["heart", "ANATOMY", 146, 151], ["adrenal gland", "ANATOMY", 157, 170], ["non-sinusoidal endothelium", "TISSUE", 82, 108], ["organs", "ORGAN", 123, 129], ["lungs", "ORGAN", 139, 144], ["heart", "ORGAN", 146, 151], ["adrenal gland", "ORGAN", 157, 170], ["a recent study", "TEST", 9, 23], ["lungs, heart, and adrenal gland", "PROBLEM", 139, 170], ["non-sinusoidal endothelium", "ANATOMY", 82, 108], ["lungs", "ANATOMY", 139, 144], ["heart", "ANATOMY", 146, 151], ["adrenal gland", "ANATOMY", 157, 170]]], ["Once regarded as the main receptor responsible for the internalization and transport of HA in the lymph circulation, a study using LYVE-1 KO mice model revealed that it is not crucial for the metabolism of HA in the lymphatic endothelium (Gale et al., 2007).", [["lymph", "ANATOMY", 98, 103], ["lymphatic endothelium", "ANATOMY", 216, 237], ["HA", "GENE_OR_GENE_PRODUCT", 88, 90], ["lymph circulation", "MULTI-TISSUE_STRUCTURE", 98, 115], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 131, 137], ["mice", "ORGANISM", 141, 145], ["HA", "GENE_OR_GENE_PRODUCT", 206, 208], ["lymphatic endothelium", "TISSUE", 216, 237], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 141, 145], ["HA", "PROBLEM", 88, 90], ["a study", "TEST", 117, 124], ["LYVE", "TEST", 131, 135], ["HA", "PROBLEM", 206, 208], ["lymph circulation", "ANATOMY", 98, 115], ["lymphatic endothelium", "ANATOMY", 216, 237]]], ["Since HA is the only known ligand for LYVE-1, to date, and LSECs play a very important role in the degradation of HA, Mouta Carreira et al. (2001) hypothesized that LYVE-1 expression might be present on LSECs.", [["LSECs", "ANATOMY", 59, 64], ["LSECs", "ANATOMY", 203, 208], ["HA", "GENE_OR_GENE_PRODUCT", 6, 8], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 38, 44], ["LSECs", "GENE_OR_GENE_PRODUCT", 59, 64], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 165, 171], ["LSECs", "CELL", 203, 208], ["LYVE-1", "PROTEIN", 38, 44], ["LSECs", "PROTEIN", 59, 64], ["LYVE", "PROTEIN", 165, 169], ["LSECs", "CELL_TYPE", 203, 208], ["HA", "PROBLEM", 114, 116]]], ["They performed immunohistochemistry analysis and confirmed the expression of LYVE-1 on human and murine LSECs (Mouta Carreira et al., 2001).", [["LSECs", "ANATOMY", 104, 109], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 77, 83], ["human", "ORGANISM", 87, 92], ["murine", "ORGANISM", 97, 103], ["LSECs", "CELL", 104, 109], ["LYVE-1", "PROTEIN", 77, 83], ["human", "SPECIES", 87, 92], ["murine", "SPECIES", 97, 103], ["human", "SPECIES", 87, 92], ["immunohistochemistry analysis", "TEST", 15, 44], ["LYVE", "TEST", 77, 81]]], ["Since LSECs are the only LYVE-1 expressing cells in the liver, it can be used to distinguish LSEC from other liver cell types.", [["LSECs", "ANATOMY", 6, 11], ["cells", "ANATOMY", 43, 48], ["liver", "ANATOMY", 56, 61], ["LSEC", "ANATOMY", 93, 97], ["liver cell", "ANATOMY", 109, 119], ["LSEC", "DISEASE", 93, 97], ["LSECs", "CELL", 6, 11], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 25, 31], ["cells", "CELL", 43, 48], ["liver", "ORGAN", 56, 61], ["LSEC", "CANCER", 93, 97], ["liver cell", "CELL", 109, 119], ["LSECs", "CELL_TYPE", 6, 11], ["LYVE-1 expressing cells", "CELL_LINE", 25, 48], ["liver cell types", "CELL_TYPE", 109, 125], ["LSECs", "OBSERVATION", 6, 11], ["liver", "ANATOMY", 56, 61], ["LSEC", "OBSERVATION", 93, 97], ["liver", "ANATOMY", 109, 114], ["cell types", "OBSERVATION", 115, 125]]], ["Earlier studies had suggested a link between increased HA level and cirrhosis (Ichida et al., 1996).", [["cirrhosis", "DISEASE", 68, 77], ["HA", "GENE_OR_GENE_PRODUCT", 55, 57], ["Earlier studies", "TEST", 0, 15], ["a link between increased HA level", "PROBLEM", 30, 63], ["cirrhosis", "PROBLEM", 68, 77], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["HA", "OBSERVATION", 55, 57], ["cirrhosis", "OBSERVATION", 68, 77]]], ["This study showed that LSECs from the cirrhotic and HCC liver had a lower capacity to degrade HA and serum levels of HA were increased.", [["LSECs", "ANATOMY", 23, 28], ["cirrhotic", "ANATOMY", 38, 47], ["HCC liver", "ANATOMY", 52, 61], ["serum", "ANATOMY", 101, 106], ["cirrhotic", "DISEASE", 38, 47], ["HCC", "DISEASE", 52, 55], ["LSECs", "CANCER", 23, 28], ["cirrhotic", "CANCER", 38, 47], ["HCC", "CANCER", 52, 55], ["liver", "ORGAN", 56, 61], ["HA", "SIMPLE_CHEMICAL", 94, 96], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["HA", "GENE_OR_GENE_PRODUCT", 117, 119], ["LSECs", "CELL_TYPE", 23, 28], ["This study", "TEST", 0, 10], ["the cirrhotic and HCC liver", "PROBLEM", 34, 61], ["a lower capacity", "PROBLEM", 66, 82], ["serum levels", "TEST", 101, 113], ["HA", "PROBLEM", 117, 119], ["LSECs", "OBSERVATION", 23, 28], ["cirrhotic", "OBSERVATION", 38, 47], ["HCC", "OBSERVATION", 52, 55], ["liver", "ANATOMY", 56, 61], ["lower capacity", "OBSERVATION_MODIFIER", 68, 82], ["increased", "OBSERVATION_MODIFIER", 125, 134]]], ["We now know that Stabilin-2/SR-H2/HARE previously described in this article is the determining factor for HA degradation in liver (Eriksson et al., 1983; Harris et al., 2007).LYVE-1 ::: Other Cell Surface ReceptorsSimilarly, data from murine as well as a human models of HCC reported a reduction in the LYVE-1 expression in liver tumors with immunohistochemical (IHC) analysis (Geraud et al., 2013).", [["liver", "ANATOMY", 124, 129], ["Cell", "ANATOMY", 192, 196], ["HCC", "ANATOMY", 271, 274], ["liver tumors", "ANATOMY", 324, 336], ["HCC", "DISEASE", 271, 274], ["liver tumors", "DISEASE", 324, 336], ["Stabilin-2", "GENE_OR_GENE_PRODUCT", 17, 27], ["SR-H2", "GENE_OR_GENE_PRODUCT", 28, 33], ["HARE", "GENE_OR_GENE_PRODUCT", 34, 38], ["HA", "GENE_OR_GENE_PRODUCT", 106, 108], ["liver", "ORGAN", 124, 129], ["Cell", "CELL", 192, 196], ["murine", "ORGANISM", 235, 241], ["human", "ORGANISM", 255, 260], ["HCC", "CANCER", 271, 274], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 303, 309], ["liver tumors", "CANCER", 324, 336], ["Stabilin", "PROTEIN", 17, 25], ["SR", "PROTEIN", 28, 30], ["H2", "PROTEIN", 31, 33], ["HARE", "PROTEIN", 34, 38], ["LYVE", "PROTEIN", 303, 307], ["murine", "SPECIES", 235, 241], ["human", "SPECIES", 255, 260], ["human", "SPECIES", 255, 260], ["Stabilin", "TEST", 17, 25], ["H2", "PROBLEM", 31, 33], ["HA degradation in liver", "PROBLEM", 106, 129], ["LYVE", "TEST", 175, 179], ["Other Cell Surface ReceptorsSimilarly", "TEST", 186, 223], ["HCC", "PROBLEM", 271, 274], ["a reduction", "TREATMENT", 284, 295], ["the LYVE", "TEST", 299, 307], ["liver tumors", "PROBLEM", 324, 336], ["immunohistochemical (IHC) analysis", "TEST", 342, 376], ["liver", "ANATOMY", 124, 129], ["Surface", "OBSERVATION_MODIFIER", 197, 204], ["ReceptorsSimilarly", "OBSERVATION", 205, 223], ["HCC", "OBSERVATION", 271, 274], ["reduction", "OBSERVATION_MODIFIER", 286, 295], ["liver", "ANATOMY", 324, 329], ["tumors", "OBSERVATION", 330, 336]]], ["Additionally, a tissue microarray analysis of 191 HCC samples found complete loss of LYVE-1 expression in 83% of the cases as compared to control.", [["tissue", "ANATOMY", 16, 22], ["HCC samples", "ANATOMY", 50, 61], ["HCC", "DISEASE", 50, 53], ["tissue", "TISSUE", 16, 22], ["HCC samples", "CANCER", 50, 61], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 85, 91], ["LYVE-1", "DNA", 85, 91], ["a tissue microarray analysis", "TEST", 14, 42], ["HCC samples", "TEST", 50, 61], ["complete loss of LYVE", "PROBLEM", 68, 89], ["loss", "OBSERVATION_MODIFIER", 77, 81]]], ["There was also a positive correlation between LYVE-1 expression and histological grade of the individual tumor with a 47% loss in grade G1 (least) and 89% in grade G3 (most).", [["tumor", "ANATOMY", 105, 110], ["tumor", "DISEASE", 105, 110], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 46, 52], ["tumor", "CANCER", 105, 110], ["LYVE", "PROTEIN", 46, 50], ["LYVE", "TEST", 46, 50], ["the individual tumor", "PROBLEM", 90, 110], ["a 47% loss in grade G1", "PROBLEM", 116, 138], ["individual", "OBSERVATION_MODIFIER", 94, 104], ["tumor", "OBSERVATION", 105, 110], ["47% loss", "OBSERVATION_MODIFIER", 118, 126], ["grade G1", "OBSERVATION_MODIFIER", 130, 138]]], ["Furthermore, Arimoto et al. (2010) conducted an IHC experiment on frozen normal and diseased liver tissue and found decreased expression of LYVE-1 and increased vWF expression in inflamed or fibrotic liver.", [["liver tissue", "ANATOMY", 93, 105], ["fibrotic liver", "ANATOMY", 191, 205], ["liver tissue", "TISSUE", 93, 105], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 140, 146], ["vWF", "GENE_OR_GENE_PRODUCT", 161, 164], ["liver", "ORGAN", 200, 205], ["LYVE-1", "PROTEIN", 140, 146], ["vWF", "PROTEIN", 161, 164], ["diseased liver tissue", "PROBLEM", 84, 105], ["decreased expression of LYVE", "PROBLEM", 116, 144], ["increased vWF expression in inflamed or fibrotic liver", "PROBLEM", 151, 205], ["normal", "OBSERVATION", 73, 79], ["diseased", "OBSERVATION", 84, 92], ["liver", "ANATOMY", 93, 98], ["decreased", "OBSERVATION_MODIFIER", 116, 125], ["increased", "OBSERVATION_MODIFIER", 151, 160], ["vWF", "OBSERVATION", 161, 164], ["expression", "OBSERVATION_MODIFIER", 165, 175], ["inflamed", "OBSERVATION_MODIFIER", 179, 187], ["fibrotic", "OBSERVATION", 191, 199], ["liver", "ANATOMY", 200, 205]]], ["A weak negative correlation was also observed between LYVE-1 expression and fibrosis stage.", [["fibrosis", "DISEASE", 76, 84], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 54, 60], ["LYVE", "PROTEIN", 54, 58], ["fibrosis stage", "PROBLEM", 76, 90], ["weak", "OBSERVATION_MODIFIER", 2, 6], ["negative", "OBSERVATION", 7, 15], ["fibrosis", "OBSERVATION", 76, 84]]], ["An ultrastructural analysis revealed loss in LSEC fenestration and appearance of the basement membrane-like structure in the diseased liver, suggesting the onset of sinusoidal capillarization.", [["LSEC", "ANATOMY", 45, 49], ["basement membrane", "ANATOMY", 85, 102], ["liver", "ANATOMY", 134, 139], ["sinusoidal", "ANATOMY", 165, 175], ["LSEC", "PATHOLOGICAL_FORMATION", 45, 49], ["basement membrane", "CELLULAR_COMPONENT", 85, 102], ["liver", "ORGAN", 134, 139], ["An ultrastructural analysis", "TEST", 0, 27], ["loss in LSEC fenestration", "PROBLEM", 37, 62], ["the basement membrane", "TEST", 81, 102], ["sinusoidal capillarization", "PROBLEM", 165, 191], ["loss", "OBSERVATION_MODIFIER", 37, 41], ["LSEC fenestration", "OBSERVATION", 45, 62], ["basement", "OBSERVATION_MODIFIER", 85, 93], ["membrane", "OBSERVATION_MODIFIER", 94, 102], ["like structure", "OBSERVATION", 103, 117], ["diseased", "OBSERVATION", 125, 133], ["liver", "ANATOMY", 134, 139], ["sinusoidal capillarization", "OBSERVATION", 165, 191]]], ["They found a similar reduction in LYVE-1 expression in chronic viral hepatitis and virus-related cirrhosis liver tissues.", [["cirrhosis liver tissues", "ANATOMY", 97, 120], ["chronic viral hepatitis", "DISEASE", 55, 78], ["cirrhosis", "DISEASE", 97, 106], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 34, 40], ["liver tissues", "TISSUE", 107, 120], ["LYVE", "PROTEIN", 34, 38], ["a similar reduction in LYVE", "PROBLEM", 11, 38], ["chronic viral hepatitis", "PROBLEM", 55, 78], ["virus", "PROBLEM", 83, 88], ["cirrhosis liver tissues", "PROBLEM", 97, 120], ["similar", "OBSERVATION_MODIFIER", 13, 20], ["reduction", "OBSERVATION_MODIFIER", 21, 30], ["1 expression", "OBSERVATION_MODIFIER", 39, 51], ["chronic", "OBSERVATION_MODIFIER", 55, 62], ["viral hepatitis", "OBSERVATION", 63, 78], ["virus", "OBSERVATION", 83, 88], ["cirrhosis", "OBSERVATION", 97, 106], ["liver tissues", "ANATOMY", 107, 120]]], ["This study suggests the possible role of LYVE-1 in the progression of liver fibrosis.", [["liver", "ANATOMY", 70, 75], ["liver fibrosis", "DISEASE", 70, 84], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 41, 47], ["liver", "ORGAN", 70, 75], ["LYVE-1", "PROTEIN", 41, 47], ["This study", "TEST", 0, 10], ["liver fibrosis", "PROBLEM", 70, 84], ["suggests the possible", "UNCERTAINTY", 11, 32], ["progression", "OBSERVATION_MODIFIER", 55, 66], ["liver", "ANATOMY", 70, 75], ["fibrosis", "OBSERVATION", 76, 84]]], ["An increase in vWF expression with a similar decrease in LYVE-1 expression poses disturbances in microcirculation.", [["vWF", "GENE_OR_GENE_PRODUCT", 15, 18], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 57, 63], ["vWF", "PROTEIN", 15, 18], ["LYVE", "PROTEIN", 57, 61], ["An increase in vWF expression", "PROBLEM", 0, 29], ["a similar decrease in LYVE", "PROBLEM", 35, 61], ["disturbances in microcirculation", "PROBLEM", 81, 113], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["vWF expression", "OBSERVATION", 15, 29], ["similar", "OBSERVATION_MODIFIER", 37, 44], ["decrease", "OBSERVATION_MODIFIER", 45, 53]]], ["Sinusoidal capillarization results in circulatory problems and disturbs the transport of various macromolecules between blood and hepatocytes in the diseased liver state.", [["blood", "ANATOMY", 120, 125], ["hepatocytes", "ANATOMY", 130, 141], ["liver", "ANATOMY", 158, 163], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["hepatocytes", "CELL", 130, 141], ["liver", "ORGAN", 158, 163], ["hepatocytes", "CELL_TYPE", 130, 141], ["Sinusoidal capillarization", "TEST", 0, 26], ["circulatory problems", "PROBLEM", 38, 58], ["various macromolecules between blood and hepatocytes in the diseased liver state", "PROBLEM", 89, 169], ["circulatory problems", "OBSERVATION", 38, 58], ["hepatocytes", "ANATOMY", 130, 141], ["diseased", "OBSERVATION", 149, 157], ["liver", "ANATOMY", 158, 163]]], ["Given their role in hepatic disease progression, LYVE-1 and vWF may be used as a potential marker for sinusoidal capillarization.Adhesion Molecules Expressed by LSECs ::: Other Cell Surface ReceptorsAdhesion molecules play an important role in mobilizing leukocytes at the site of inflammation.", [["hepatic", "ANATOMY", 20, 27], ["sinusoidal", "ANATOMY", 102, 112], ["Cell", "ANATOMY", 177, 181], ["leukocytes", "ANATOMY", 255, 265], ["hepatic disease", "DISEASE", 20, 35], ["inflammation", "DISEASE", 281, 293], ["hepatic", "ORGAN", 20, 27], ["LYVE-1", "GENE_OR_GENE_PRODUCT", 49, 55], ["vWF", "GENE_OR_GENE_PRODUCT", 60, 63], ["Cell", "CELL", 177, 181], ["leukocytes", "CELL", 255, 265], ["LYVE-1", "PROTEIN", 49, 55], ["vWF", "PROTEIN", 60, 63], ["LSECs", "CELL_TYPE", 161, 166], ["Cell Surface ReceptorsAdhesion molecules", "PROTEIN", 177, 217], ["leukocytes", "CELL_TYPE", 255, 265], ["hepatic disease progression", "PROBLEM", 20, 47], ["LYVE", "TEST", 49, 53], ["sinusoidal capillarization", "PROBLEM", 102, 128], ["Adhesion Molecules", "PROBLEM", 129, 147], ["Other Cell Surface ReceptorsAdhesion molecules", "TREATMENT", 171, 217], ["mobilizing leukocytes", "PROBLEM", 244, 265], ["inflammation", "PROBLEM", 281, 293], ["hepatic", "ANATOMY", 20, 27], ["disease", "OBSERVATION", 28, 35], ["sinusoidal capillarization", "OBSERVATION", 102, 128], ["LSECs", "ANATOMY", 161, 166], ["Surface", "OBSERVATION_MODIFIER", 182, 189], ["mobilizing leukocytes", "OBSERVATION", 244, 265], ["inflammation", "OBSERVATION", 281, 293]]], ["This process involves several steps and carried out by a different set of adhesion molecules, such as integrins, the selectins, and Ig superfamily members (Shetty et al., 2018).", [["integrins", "GENE_OR_GENE_PRODUCT", 102, 111], ["selectins", "GENE_OR_GENE_PRODUCT", 117, 126], ["Ig", "GENE_OR_GENE_PRODUCT", 132, 134], ["adhesion molecules", "PROTEIN", 74, 92], ["integrins", "PROTEIN", 102, 111], ["selectins", "PROTEIN", 117, 126], ["Ig superfamily members", "PROTEIN", 132, 154]]], ["Each of the adhesion molecules are tightly regulated to maintain a homeostatic environment and their expression is modulated under certain diseased condition.", [["adhesion molecules", "PROTEIN", 12, 30], ["the adhesion molecules", "PROBLEM", 8, 30], ["adhesion molecules", "OBSERVATION", 12, 30]]], ["Unlike capillary and microvascular endothelial cells, LSECs express few integrins.", [["capillary", "ANATOMY", 7, 16], ["microvascular endothelial cells", "ANATOMY", 21, 52], ["LSECs", "ANATOMY", 54, 59], ["capillary", "CELL", 7, 16], ["microvascular endothelial cells", "CELL", 21, 52], ["LSECs", "CELL", 54, 59], ["integrins", "GENE_OR_GENE_PRODUCT", 72, 81], ["capillary and microvascular endothelial cells", "CELL_TYPE", 7, 52], ["LSECs", "CELL_TYPE", 54, 59], ["integrins", "PROTEIN", 72, 81], ["capillary and microvascular endothelial cells", "PROBLEM", 7, 52], ["capillary", "ANATOMY_MODIFIER", 7, 16], ["microvascular endothelial cells", "OBSERVATION", 21, 52], ["few", "OBSERVATION_MODIFIER", 68, 71], ["integrins", "OBSERVATION_MODIFIER", 72, 81]]], ["Integrins are heterodimers consisting of alpha and beta subunits mediating cell-extracellular matrix adhesion (Bokel and Brown, 2002).", [["cell", "ANATOMY", 75, 79], ["extracellular matrix", "ANATOMY", 80, 100], ["Integrins", "GENE_OR_GENE_PRODUCT", 0, 9], ["alpha and beta subunits", "GENE_OR_GENE_PRODUCT", 41, 64], ["cell", "CELL", 75, 79], ["extracellular matrix", "CELLULAR_COMPONENT", 80, 100], ["Integrins", "PROTEIN", 0, 9], ["heterodimers", "PROTEIN", 14, 26], ["alpha and beta subunits", "PROTEIN", 41, 64], ["heterodimers", "TREATMENT", 14, 26], ["alpha and beta subunits mediating cell-extracellular matrix adhesion", "TREATMENT", 41, 109], ["heterodimers", "OBSERVATION", 14, 26], ["alpha", "OBSERVATION_MODIFIER", 41, 46], ["cell", "OBSERVATION_MODIFIER", 75, 79], ["extracellular matrix adhesion", "OBSERVATION", 80, 109]]], ["Couvelard et al. (1993) evaluated the expression of different cell-matrix adhesion proteins in LSECs and found that LSECs express only \u03b11\u00df1 and \u03b15\u00df1 under normal condition whereas, \u03b1V\u00df3 and \u03b1IIb\u00df3 in low and variable levels. \u03b15\u00df1 acts as fibronectin receptor (Schaffner et al., 2013), whereas, \u03b11\u00df1 binds to collagen (Eble et al., 1993). \u03b1V\u03b23 binds to vitronectin (Horton, 1997) as well as fibronectin (Van Agthoven et al., 2014) and \u03b1IIb\u00df3 binds to fibrinogen (Wippler et al., 1994).", [["cell", "ANATOMY", 62, 66], ["LSECs", "ANATOMY", 95, 100], ["LSECs", "ANATOMY", 116, 121], ["cell", "CELL", 62, 66], ["LSECs", "CELL", 95, 100], ["LSECs", "CELL", 116, 121], ["\u03b11\u00df1", "GENE_OR_GENE_PRODUCT", 135, 139], ["\u03b15\u00df1", "GENE_OR_GENE_PRODUCT", 144, 148], ["\u03b1V\u00df3", "GENE_OR_GENE_PRODUCT", 181, 185], ["\u03b1IIb\u00df3", "GENE_OR_GENE_PRODUCT", 190, 196], ["\u03b15\u00df1", "GENE_OR_GENE_PRODUCT", 225, 229], ["fibronectin receptor", "GENE_OR_GENE_PRODUCT", 238, 258], ["\u03b11\u00df1", "GENE_OR_GENE_PRODUCT", 294, 298], ["collagen", "GENE_OR_GENE_PRODUCT", 308, 316], ["\u03b1V\u03b23", "GENE_OR_GENE_PRODUCT", 338, 342], ["vitronectin", "GENE_OR_GENE_PRODUCT", 352, 363], ["fibronectin", "GENE_OR_GENE_PRODUCT", 390, 401], ["\u03b1IIb\u00df3", "GENE_OR_GENE_PRODUCT", 434, 440], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 450, 460], ["cell-matrix adhesion proteins", "PROTEIN", 62, 91], ["LSECs", "CELL_TYPE", 95, 100], ["LSECs", "CELL_TYPE", 116, 121], ["\u03b11\u00df1", "PROTEIN", 135, 139], ["\u03b15\u00df1", "PROTEIN", 144, 148], ["\u03b1V\u00df3", "PROTEIN", 181, 185], ["\u03b1IIb\u00df3", "PROTEIN", 190, 196], ["\u03b15\u00df1", "PROTEIN", 225, 229], ["fibronectin receptor", "PROTEIN", 238, 258], ["\u03b11\u00df1", "PROTEIN", 294, 298], ["collagen", "PROTEIN", 308, 316], ["\u03b1V\u03b23", "PROTEIN", 338, 342], ["vitronectin", "PROTEIN", 352, 363], ["fibronectin", "PROTEIN", 390, 401], ["2014", "PROTEIN", 424, 428], ["\u03b1IIb\u00df3", "PROTEIN", 434, 440], ["fibrinogen", "PROTEIN", 450, 460], ["different cell-matrix adhesion proteins", "TREATMENT", 52, 91], ["LSECs", "TEST", 116, 121], ["V", "TEST", 182, 183], ["fibrinogen", "TEST", 450, 460], ["LSECs", "ANATOMY", 95, 100], ["normal", "OBSERVATION", 155, 161]]], ["Furthermore, they found a strong enhanced expression of \u03b11\u00df1 and \u03b15\u00df1 as well as \u03b1V\u00df3 and \u03b1IIb\u00df3 in cirrhotic liver that were faintly expressed in normal liver.", [["liver", "ANATOMY", 110, 115], ["liver", "ANATOMY", 154, 159], ["\u03b11\u00df1", "GENE_OR_GENE_PRODUCT", 56, 60], ["\u03b15\u00df1", "GENE_OR_GENE_PRODUCT", 65, 69], ["\u03b1V\u00df3", "GENE_OR_GENE_PRODUCT", 81, 85], ["\u03b1IIb\u00df3", "GENE_OR_GENE_PRODUCT", 90, 96], ["liver", "ORGAN", 110, 115], ["liver", "ORGAN", 154, 159], ["\u03b11\u00df1", "PROTEIN", 56, 60], ["\u03b15\u00df1", "PROTEIN", 65, 69], ["\u03b1V\u00df3", "DNA", 81, 85], ["\u03b1IIb\u00df3", "DNA", 90, 96], ["cirrhotic liver", "PROBLEM", 100, 115], ["strong", "OBSERVATION_MODIFIER", 26, 32], ["enhanced", "OBSERVATION_MODIFIER", 33, 41], ["expression", "OBSERVATION", 42, 52], ["cirrhotic", "OBSERVATION", 100, 109], ["liver", "ANATOMY", 110, 115], ["normal", "OBSERVATION", 147, 153], ["liver", "ANATOMY", 154, 159]]], ["In addition, other integrins (\u03b16\u00df1, \u03b16\u00df4, \u03b12\u00df1, and \u03b13\u00df1) that did not show any expression in normal liver, and showed an increased expression in cirrhotic liver, suggesting their contribution to capillarization.", [["liver", "ANATOMY", 101, 106], ["liver", "ANATOMY", 156, 161], ["capillarization", "DISEASE", 196, 211], ["integrins", "GENE_OR_GENE_PRODUCT", 19, 28], ["\u03b16\u00df1", "GENE_OR_GENE_PRODUCT", 30, 34], ["\u03b16\u00df4", "GENE_OR_GENE_PRODUCT", 36, 40], ["\u03b12\u00df1", "GENE_OR_GENE_PRODUCT", 42, 46], ["\u03b13\u00df1", "GENE_OR_GENE_PRODUCT", 52, 56], ["liver", "ORGAN", 101, 106], ["liver", "ORGAN", 156, 161], ["integrins", "PROTEIN", 19, 28], ["\u03b16\u00df1", "PROTEIN", 30, 34], ["\u03b16\u00df4", "PROTEIN", 36, 40], ["\u03b12\u00df1", "PROTEIN", 42, 46], ["\u03b13\u00df1", "PROTEIN", 52, 56], ["other integrins", "TEST", 13, 28], ["\u03b1", "TEST", 36, 37], ["an increased expression in cirrhotic liver", "PROBLEM", 119, 161], ["normal", "OBSERVATION", 94, 100], ["liver", "ANATOMY", 101, 106], ["increased", "OBSERVATION_MODIFIER", 122, 131], ["expression", "OBSERVATION", 132, 142], ["cirrhotic", "OBSERVATION", 146, 155], ["liver", "ANATOMY", 156, 161], ["suggesting their contribution to", "UNCERTAINTY", 163, 195], ["capillarization", "OBSERVATION", 196, 211]]], ["These integrins bind to laminin, an important component of the basal lamina of the extracellular matrix (Languino et al., 1989; Felch et al., 1992; Lee et al., 1992; Chang et al., 1995).", [["basal lamina", "ANATOMY", 63, 75], ["extracellular matrix", "ANATOMY", 83, 103], ["integrins", "GENE_OR_GENE_PRODUCT", 6, 15], ["laminin", "GENE_OR_GENE_PRODUCT", 24, 31], ["basal lamina", "CELLULAR_COMPONENT", 63, 75], ["extracellular matrix", "CELLULAR_COMPONENT", 83, 103], ["integrins", "PROTEIN", 6, 15], ["laminin", "PROTEIN", 24, 31], ["laminin", "TREATMENT", 24, 31], ["basal", "ANATOMY_MODIFIER", 63, 68], ["lamina", "ANATOMY_MODIFIER", 69, 75], ["extracellular matrix", "ANATOMY", 83, 103]]], ["Several studies have documented an increased deposition of collagen IV, fibronectin and laminin in LSEC basement membranes during liver fibrosis and inflammation (Walsh et al., 2000; Xu et al., 2003; Mak and Mei, 2017), suggesting a possible role of these integrins in inflammation and fibrosis.Adhesion Molecules Expressed by LSECs ::: Other Cell Surface ReceptorsSimilar to microvascular endothelial cells, the LSEC Ig-superfamily of adhesion molecules is composed of ICAM-1 (Intercellular adhesion molecule-1), ICAM-2 (Intercellular adhesion molecule-2), VCAM-1 (Vascular cell-adhesion molecule) and PECAM-1 (Platelet endothelial cell adhesion molecule/CD31).", [["LSEC basement membranes", "ANATOMY", 99, 122], ["liver", "ANATOMY", 130, 135], ["Cell", "ANATOMY", 343, 347], ["microvascular endothelial cells", "ANATOMY", 376, 407], ["fibrosis", "DISEASE", 136, 144], ["inflammation", "DISEASE", 149, 161], ["inflammation", "DISEASE", 269, 281], ["fibrosis", "DISEASE", 286, 294], ["collagen IV", "GENE_OR_GENE_PRODUCT", 59, 70], ["fibronectin", "GENE_OR_GENE_PRODUCT", 72, 83], ["laminin", "GENE_OR_GENE_PRODUCT", 88, 95], ["LSEC", "CELLULAR_COMPONENT", 99, 103], ["basement membranes", "CELLULAR_COMPONENT", 104, 122], ["liver", "ORGAN", 130, 135], ["integrins", "GENE_OR_GENE_PRODUCT", 256, 265], ["Cell", "CELL", 343, 347], ["microvascular endothelial cells", "CELL", 376, 407], ["LSEC Ig", "GENE_OR_GENE_PRODUCT", 413, 420], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 470, 476], ["Intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 478, 511], ["ICAM-2", "GENE_OR_GENE_PRODUCT", 514, 520], ["Intercellular adhesion molecule-2", "GENE_OR_GENE_PRODUCT", 522, 555], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 558, 564], ["Vascular cell-adhesion molecule", "GENE_OR_GENE_PRODUCT", 566, 597], ["PECAM-1", "GENE_OR_GENE_PRODUCT", 603, 610], ["Platelet endothelial cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 612, 655], ["CD31", "GENE_OR_GENE_PRODUCT", 656, 660], ["collagen IV", "PROTEIN", 59, 70], ["fibronectin", "PROTEIN", 72, 83], ["laminin", "PROTEIN", 88, 95], ["integrins", "PROTEIN", 256, 265], ["LSECs", "CELL_TYPE", 327, 332], ["microvascular endothelial cells", "CELL_TYPE", 376, 407], ["LSEC Ig-superfamily", "PROTEIN", 413, 432], ["adhesion molecules", "PROTEIN", 436, 454], ["ICAM-1", "PROTEIN", 470, 476], ["Intercellular adhesion molecule-1", "PROTEIN", 478, 511], ["ICAM-2", "PROTEIN", 514, 520], ["Intercellular adhesion molecule-2", "PROTEIN", 522, 555], ["VCAM-1", "PROTEIN", 558, 564], ["Vascular cell-adhesion molecule", "PROTEIN", 566, 597], ["PECAM-1", "PROTEIN", 603, 610], ["Platelet endothelial cell adhesion molecule", "PROTEIN", 612, 655], ["CD31", "PROTEIN", 656, 660], ["Several studies", "TEST", 0, 15], ["collagen IV", "TREATMENT", 59, 70], ["fibronectin and laminin in LSEC basement membranes", "TREATMENT", 72, 122], ["liver fibrosis", "PROBLEM", 130, 144], ["inflammation", "PROBLEM", 149, 161], ["inflammation", "PROBLEM", 269, 281], ["fibrosis", "PROBLEM", 286, 294], ["Adhesion Molecules", "PROBLEM", 295, 313], ["Other Cell Surface", "TEST", 337, 355], ["microvascular endothelial cells", "TEST", 376, 407], ["the LSEC Ig", "TEST", 409, 420], ["adhesion molecules", "PROBLEM", 436, 454], ["ICAM", "TEST", 470, 474], ["Intercellular adhesion molecule", "TEST", 478, 509], ["ICAM", "TEST", 514, 518], ["Intercellular adhesion molecule", "TEST", 522, 553], ["VCAM", "TEST", 558, 562], ["Vascular cell-adhesion molecule", "TEST", 566, 597], ["PECAM", "TEST", 603, 608], ["Platelet endothelial cell adhesion molecule", "TREATMENT", 612, 655], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["deposition", "OBSERVATION", 45, 55], ["LSEC", "ANATOMY", 99, 103], ["basement", "ANATOMY_MODIFIER", 104, 112], ["liver", "ANATOMY", 130, 135], ["fibrosis", "OBSERVATION", 136, 144], ["inflammation", "OBSERVATION", 149, 161], ["integrins", "OBSERVATION", 256, 265], ["inflammation", "OBSERVATION", 269, 281], ["fibrosis", "OBSERVATION", 286, 294], ["LSECs", "ANATOMY", 327, 332], ["Surface", "ANATOMY_MODIFIER", 348, 355], ["microvascular endothelial cells", "OBSERVATION", 376, 407], ["adhesion molecules", "OBSERVATION", 436, 454], ["Vascular cell", "ANATOMY", 566, 579], ["PECAM", "ANATOMY", 603, 608], ["endothelial cell adhesion", "OBSERVATION", 621, 646]]], ["VCAM-1 is an adhesion molecule that helps in mediating leukocyte-trans-endothelial migration.", [["leukocyte", "ANATOMY", 55, 64], ["endothelial", "ANATOMY", 71, 82], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 0, 6], ["leukocyte", "CELL", 55, 64], ["endothelial", "CELL", 71, 82], ["VCAM", "PROTEIN", 0, 4], ["adhesion molecule", "PROTEIN", 13, 30], ["VCAM", "TEST", 0, 4], ["an adhesion molecule", "PROBLEM", 10, 30], ["trans-endothelial migration", "TREATMENT", 65, 92], ["adhesion molecule", "OBSERVATION", 13, 30], ["leukocyte", "ANATOMY", 55, 64], ["endothelial", "ANATOMY", 71, 82], ["migration", "OBSERVATION", 83, 92]]], ["VCAM-1 expression is absent in normal liver, but is strongly enhanced under inflammatory conditions (Volpes et al., 1992).", [["liver", "ANATOMY", 38, 43], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 0, 6], ["liver", "ORGAN", 38, 43], ["VCAM", "PROTEIN", 0, 4], ["VCAM", "TEST", 0, 4], ["absent", "OBSERVATION", 21, 27], ["normal", "OBSERVATION", 31, 37], ["liver", "ANATOMY", 38, 43], ["enhanced", "OBSERVATION_MODIFIER", 61, 69], ["inflammatory", "OBSERVATION_MODIFIER", 76, 88]]], ["LSECs constitutively express ICAM-1 along with hepatocytes, KCs and HSCs (Gulubova, 2005; Yin et al., 2007).", [["LSECs", "ANATOMY", 0, 5], ["hepatocytes", "ANATOMY", 47, 58], ["KCs", "ANATOMY", 60, 63], ["HSCs", "ANATOMY", 68, 72], ["LSECs", "CELL", 0, 5], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 29, 35], ["hepatocytes", "CELL", 47, 58], ["KCs", "CELL", 60, 63], ["HSCs", "CELL", 68, 72], ["LSECs", "CELL_TYPE", 0, 5], ["ICAM-1", "PROTEIN", 29, 35], ["hepatocytes", "CELL_TYPE", 47, 58], ["KCs", "CELL_TYPE", 60, 63], ["HSCs", "CELL_TYPE", 68, 72], ["ICAM", "TEST", 29, 33], ["hepatocytes", "ANATOMY", 47, 58], ["KCs", "ANATOMY", 60, 63], ["HSCs", "ANATOMY", 68, 72]]], ["The expression of ICAM-1 in LSECs is found to be upregulated by several inflammatory cytokines, such as TNF-\u03b1, IL-1\u03b2, or IFN-\u03b3 (Gangopadhyay et al., 1998; Oudar et al., 1998).", [["LSECs", "ANATOMY", 28, 33], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 18, 24], ["LSECs", "CANCER", 28, 33], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 104, 109], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 111, 116], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 121, 126], ["ICAM-1", "PROTEIN", 18, 24], ["LSECs", "CELL_TYPE", 28, 33], ["inflammatory cytokines", "PROTEIN", 72, 94], ["TNF", "PROTEIN", 104, 107], ["IL-1\u03b2", "PROTEIN", 111, 116], ["IFN", "PROTEIN", 121, 124], ["ICAM", "TEST", 18, 22], ["several inflammatory cytokines", "PROBLEM", 64, 94], ["TNF", "TEST", 104, 107], ["IL", "TEST", 111, 113], ["LSECs", "ANATOMY", 28, 33], ["found to be", "UNCERTAINTY", 37, 48], ["several", "OBSERVATION_MODIFIER", 64, 71], ["inflammatory cytokines", "OBSERVATION", 72, 94]]], ["A study was conducted on various endothelial cells isolated from the liver after transplantation rejection (Steinhoff et al., 1993).", [["endothelial cells", "ANATOMY", 33, 50], ["liver", "ANATOMY", 69, 74], ["endothelial cells", "CELL", 33, 50], ["liver", "ORGAN", 69, 74], ["endothelial cells", "CELL_TYPE", 33, 50], ["A study", "TEST", 0, 7], ["various endothelial cells", "TREATMENT", 25, 50], ["transplantation rejection", "TREATMENT", 81, 106], ["liver", "ANATOMY", 69, 74], ["transplantation rejection", "OBSERVATION", 81, 106]]], ["In LSECs, weak expression of ICAM-1 and ICAM-2 was observed under normal conditions.", [["LSECs", "ANATOMY", 3, 8], ["LSECs", "CELL", 3, 8], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 29, 35], ["ICAM-2", "GENE_OR_GENE_PRODUCT", 40, 46], ["LSECs", "CELL_TYPE", 3, 8], ["ICAM-1", "PROTEIN", 29, 35], ["ICAM", "PROTEIN", 40, 44], ["ICAM", "TEST", 29, 33], ["ICAM", "TEST", 40, 44], ["LSECs", "ANATOMY", 3, 8], ["weak", "OBSERVATION_MODIFIER", 10, 14], ["normal conditions", "OBSERVATION", 66, 83]]], ["However, an elevated expression of ICAM-1 and ICAM-2 in LSECs were observed in chronic rejection as well as sepsis or viral infection cases.", [["LSECs", "ANATOMY", 56, 61], ["sepsis", "DISEASE", 108, 114], ["viral infection", "DISEASE", 118, 133], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 35, 41], ["ICAM-2", "GENE_OR_GENE_PRODUCT", 46, 52], ["LSECs", "PATHOLOGICAL_FORMATION", 56, 61], ["ICAM-1", "PROTEIN", 35, 41], ["ICAM-2", "PROTEIN", 46, 52], ["an elevated expression", "PROBLEM", 9, 31], ["ICAM", "TEST", 35, 39], ["ICAM", "TEST", 46, 50], ["chronic rejection", "PROBLEM", 79, 96], ["sepsis", "PROBLEM", 108, 114], ["viral infection cases", "PROBLEM", 118, 139], ["elevated", "OBSERVATION_MODIFIER", 12, 20], ["LSECs", "ANATOMY", 56, 61], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["rejection", "OBSERVATION", 87, 96], ["sepsis", "OBSERVATION", 108, 114], ["viral", "OBSERVATION_MODIFIER", 118, 123], ["infection", "OBSERVATION", 124, 133]]], ["VCAM-1 was also shown to be partially upregulated in LSECs of irreversible and chronic rejection conditions.", [["LSECs", "ANATOMY", 53, 58], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 0, 6], ["VCAM", "PROTEIN", 0, 4], ["VCAM", "TEST", 0, 4], ["irreversible and chronic rejection conditions", "PROBLEM", 62, 107], ["upregulated", "OBSERVATION", 38, 49], ["LSECs", "OBSERVATION", 53, 58], ["irreversible", "OBSERVATION_MODIFIER", 62, 74], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["rejection", "OBSERVATION", 87, 96]]], ["This study reflected the clinical relevance of sinusoidal endothelial adhesion molecules during liver transplantation.Adhesion Molecules Expressed by LSECs ::: Other Cell Surface ReceptorsLFA-1 (Lymphocyte Function Associated-1) belongs to the integrin family and is present on lymphocytes and leukocytes.", [["sinusoidal endothelial", "ANATOMY", 47, 69], ["liver", "ANATOMY", 96, 101], ["lymphocytes", "ANATOMY", 278, 289], ["leukocytes", "ANATOMY", 294, 304], ["sinusoidal endothelial adhesion molecules", "GENE_OR_GENE_PRODUCT", 47, 88], ["liver", "ORGAN", 96, 101], ["ReceptorsLFA-1 (Lymphocyte Function Associated-1", "GENE_OR_GENE_PRODUCT", 179, 227], ["integrin", "GENE_OR_GENE_PRODUCT", 244, 252], ["lymphocytes", "CELL", 278, 289], ["leukocytes", "CELL", 294, 304], ["sinusoidal endothelial adhesion molecules", "PROTEIN", 47, 88], ["LSECs", "CELL_TYPE", 150, 155], ["Cell Surface ReceptorsLFA-1", "PROTEIN", 166, 193], ["Lymphocyte Function Associated-1", "PROTEIN", 195, 227], ["integrin family", "PROTEIN", 244, 259], ["lymphocytes", "CELL_TYPE", 278, 289], ["leukocytes", "CELL_TYPE", 294, 304], ["This study", "TEST", 0, 10], ["sinusoidal endothelial adhesion molecules", "TREATMENT", 47, 88], ["liver transplantation", "TREATMENT", 96, 117], ["Adhesion Molecules", "PROBLEM", 118, 136], ["Other Cell Surface ReceptorsLFA", "TEST", 160, 191], ["Lymphocyte Function", "TEST", 195, 214], ["lymphocytes", "TEST", 278, 289], ["leukocytes", "TEST", 294, 304], ["sinusoidal endothelial", "OBSERVATION", 47, 69], ["adhesion molecules", "OBSERVATION", 70, 88], ["liver", "ANATOMY", 96, 101], ["transplantation", "OBSERVATION", 102, 117], ["LSECs", "ANATOMY", 150, 155], ["Surface", "OBSERVATION_MODIFIER", 171, 178], ["leukocytes", "ANATOMY", 294, 304]]], ["It is an important component in the extravasation process mediating leukocyte and lymphocyte entry into the tissues from the bloodstream (Mitroulis et al., 2015; Walling and Kim, 2018).", [["leukocyte", "ANATOMY", 68, 77], ["lymphocyte", "ANATOMY", 82, 92], ["tissues", "ANATOMY", 108, 115], ["bloodstream", "ANATOMY", 125, 136], ["leukocyte", "CELL", 68, 77], ["lymphocyte", "CELL", 82, 92], ["tissues", "TISSUE", 108, 115], ["the extravasation process", "TREATMENT", 32, 57], ["important", "OBSERVATION_MODIFIER", 9, 18], ["component", "OBSERVATION_MODIFIER", 19, 28], ["extravasation", "OBSERVATION", 36, 49], ["leukocyte", "ANATOMY", 68, 77], ["tissues", "ANATOMY", 108, 115], ["bloodstream", "ANATOMY", 125, 136]]], ["Binding of ICAM-1 expressed on LSECs to its ligand, LFA-1, expressed in pro-inflammatory cells mediates the migration of cells across the sinusoidal lining (Wong et al., 1997).", [["pro-inflammatory cells", "ANATOMY", 72, 94], ["cells", "ANATOMY", 121, 126], ["sinusoidal lining", "ANATOMY", 138, 155], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 11, 17], ["LSECs", "GENE_OR_GENE_PRODUCT", 31, 36], ["LFA-1", "GENE_OR_GENE_PRODUCT", 52, 57], ["cells", "CELL", 89, 94], ["cells", "CELL", 121, 126], ["sinusoidal lining", "TISSUE", 138, 155], ["ICAM-1", "PROTEIN", 11, 17], ["LSECs", "PROTEIN", 31, 36], ["LFA-1", "PROTEIN", 52, 57], ["pro-inflammatory cells", "CELL_TYPE", 72, 94], ["Binding of ICAM", "TEST", 0, 15], ["LFA", "TEST", 52, 55], ["ligand", "ANATOMY", 44, 50], ["pro-inflammatory cells", "OBSERVATION", 72, 94], ["migration", "OBSERVATION_MODIFIER", 108, 117], ["sinusoidal lining", "ANATOMY", 138, 155]]], ["This was one of the first studies to determine that Selectins, expressed on continuous vascular endothelium, are not an essential component for leukocyte transmigration into inflamed tissue of the liver.", [["vascular endothelium", "ANATOMY", 87, 107], ["leukocyte", "ANATOMY", 144, 153], ["tissue", "ANATOMY", 183, 189], ["liver", "ANATOMY", 197, 202], ["Selectins", "GENE_OR_GENE_PRODUCT", 52, 61], ["vascular endothelium", "TISSUE", 87, 107], ["leukocyte", "CELL", 144, 153], ["tissue", "TISSUE", 183, 189], ["liver", "ORGAN", 197, 202], ["Selectins", "PROTEIN", 52, 61], ["the first studies", "TEST", 16, 33], ["leukocyte transmigration into inflamed tissue of the liver", "PROBLEM", 144, 202], ["Selectins", "OBSERVATION", 52, 61], ["vascular endothelium", "ANATOMY", 87, 107], ["leukocyte transmigration", "OBSERVATION", 144, 168], ["inflamed tissue", "OBSERVATION", 174, 189], ["liver", "ANATOMY", 197, 202]]], ["Similarly, a co-culture study conducted with LSECs and C26 tumor cells showed that LSECs expressing ICAM-1 mediate tumor migration (Benedicto et al., 2019).", [["LSECs", "ANATOMY", 45, 50], ["C26 tumor cells", "ANATOMY", 55, 70], ["LSECs", "ANATOMY", 83, 88], ["tumor", "ANATOMY", 115, 120], ["tumor", "DISEASE", 59, 64], ["tumor", "DISEASE", 115, 120], ["LSECs", "CELL", 45, 50], ["C26 tumor cells", "CELL", 55, 70], ["LSECs", "CELL", 83, 88], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 100, 106], ["tumor", "CANCER", 115, 120], ["LSECs", "CELL_TYPE", 45, 50], ["C26 tumor cells", "CELL_LINE", 55, 70], ["LSECs", "CELL_TYPE", 83, 88], ["ICAM-1", "PROTEIN", 100, 106], ["a co-culture study", "TEST", 11, 29], ["LSECs and C26 tumor cells", "TEST", 45, 70], ["LSECs", "TEST", 83, 88], ["ICAM", "TEST", 100, 104], ["tumor migration", "PROBLEM", 115, 130], ["C26", "ANATOMY", 55, 58], ["tumor", "OBSERVATION", 115, 120]]], ["They also found an increase in the inflammatory IL-1\u03b2, IL-6, TNF-\u03b1, and PGE2 in the co-culture as compare to LSECs cultured alone.", [["LSECs", "ANATOMY", 109, 114], ["PGE2", "CHEMICAL", 72, 76], ["PGE2", "CHEMICAL", 72, 76], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 48, 53], ["IL-6", "GENE_OR_GENE_PRODUCT", 55, 59], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 61, 66], ["PGE2", "SIMPLE_CHEMICAL", 72, 76], ["LSECs", "CELL", 109, 114], ["TNF", "PROTEIN", 61, 64], ["LSECs", "CELL_TYPE", 109, 114], ["an increase", "PROBLEM", 16, 27], ["the inflammatory IL", "TEST", 31, 50], ["IL", "TEST", 55, 57], ["TNF", "TEST", 61, 64], ["PGE2 in the co-culture", "PROBLEM", 72, 94], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["inflammatory", "OBSERVATION_MODIFIER", 35, 47]]], ["Interrupting the interaction between ICAM-1 and LFA-1 expressed on LSECs and C26, respectively, reduced the secretion of observed inflammatory molecules.", [["LSECs", "ANATOMY", 67, 72], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 37, 43], ["LFA-1", "GENE_OR_GENE_PRODUCT", 48, 53], ["LSECs", "CELL", 67, 72], ["C26", "CANCER", 77, 80], ["ICAM-1", "PROTEIN", 37, 43], ["LFA-1", "PROTEIN", 48, 53], ["LSECs", "CELL_TYPE", 67, 72], ["inflammatory molecules", "PROTEIN", 130, 152], ["ICAM", "TEST", 37, 41], ["LFA", "TEST", 48, 51], ["observed inflammatory molecules", "PROBLEM", 121, 152], ["LFA", "ANATOMY", 48, 51], ["LSECs", "ANATOMY", 67, 72], ["C26", "ANATOMY", 77, 80], ["inflammatory molecules", "OBSERVATION", 130, 152]]], ["This suggests the role of ICAM-1 and LFA-1 interaction in providing an inflammatory microenvironment suitable for colonization of tumor cells in the liver.Adhesion Molecules Expressed by LSECs ::: Other Cell Surface ReceptorsAnother Ig superfamily adhesion molecule is PECAM-1 (CD31) (Newman et al., 1990).", [["tumor cells", "ANATOMY", 130, 141], ["liver", "ANATOMY", 149, 154], ["tumor", "DISEASE", 130, 135], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 26, 32], ["LFA-1", "GENE_OR_GENE_PRODUCT", 37, 42], ["tumor cells", "CELL", 130, 141], ["liver", "ORGAN", 149, 154], ["Cell Surface ReceptorsAnother Ig superfamily adhesion molecule", "GENE_OR_GENE_PRODUCT", 203, 265], ["PECAM-1", "GENE_OR_GENE_PRODUCT", 269, 276], ["CD31", "GENE_OR_GENE_PRODUCT", 278, 282], ["ICAM", "PROTEIN", 26, 30], ["LFA", "PROTEIN", 37, 40], ["tumor cells", "CELL_TYPE", 130, 141], ["LSECs", "CELL_TYPE", 187, 192], ["Cell Surface ReceptorsAnother Ig superfamily adhesion molecule", "PROTEIN", 203, 265], ["PECAM-1", "PROTEIN", 269, 276], ["CD31", "PROTEIN", 278, 282], ["ICAM", "TEST", 26, 30], ["LFA", "TEST", 37, 40], ["an inflammatory microenvironment", "TREATMENT", 68, 100], ["colonization of tumor cells in the liver", "PROBLEM", 114, 154], ["Adhesion Molecules", "PROBLEM", 155, 173], ["Other Cell Surface", "TEST", 197, 215], ["PECAM", "TEST", 269, 274], ["inflammatory", "OBSERVATION", 71, 83], ["tumor", "OBSERVATION", 130, 135], ["liver", "ANATOMY", 149, 154], ["LSECs", "ANATOMY", 187, 192], ["Surface", "OBSERVATION_MODIFIER", 208, 215], ["adhesion molecule", "OBSERVATION", 248, 265]]], ["It is an adhesion molecule located at the cellular side and is involved in mediating endothelial cell-cell adhesion.", [["cellular", "ANATOMY", 42, 50], ["endothelial cell", "ANATOMY", 85, 101], ["cell", "ANATOMY", 102, 106], ["cellular side", "CELLULAR_COMPONENT", 42, 55], ["endothelial", "CELL", 85, 96], ["cell", "CELL", 102, 106], ["adhesion molecule", "PROTEIN", 9, 26], ["an adhesion molecule", "PROBLEM", 6, 26], ["adhesion molecule", "OBSERVATION", 9, 26], ["endothelial cell-cell adhesion", "OBSERVATION", 85, 115]]], ["CD31 is also responsible for carrying out leukocyte and monocyte trans-endothelial migration (Albelda et al., 1991).", [["leukocyte", "ANATOMY", 42, 51], ["monocyte", "ANATOMY", 56, 64], ["endothelial", "ANATOMY", 71, 82], ["CD31", "GENE_OR_GENE_PRODUCT", 0, 4], ["leukocyte", "CELL", 42, 51], ["monocyte", "CELL", 56, 64], ["endothelial", "CELL", 71, 82], ["CD31", "PROTEIN", 0, 4], ["CD31", "TEST", 0, 4], ["leukocyte", "TEST", 42, 51], ["responsible for", "UNCERTAINTY", 13, 28], ["endothelial", "ANATOMY", 71, 82]]], ["Whether LSECs express CD31 or not has long been debated and remains cryptic (Couvelard et al., 1993; DeLeve et al., 2004; Elvevold et al., 2008b).", [["LSECs", "ANATOMY", 8, 13], ["LSECs", "CELL", 8, 13], ["CD31", "GENE_OR_GENE_PRODUCT", 22, 26], ["LSECs", "CELL_TYPE", 8, 13], ["CD31", "PROTEIN", 22, 26], ["CD31", "OBSERVATION", 22, 26]]], ["An upregulation in CD31 expression has been shown during the capillarization of LSECs in cirrhotic human liver (Couvelard et al., 1993).", [["LSECs", "ANATOMY", 80, 85], ["liver", "ANATOMY", 105, 110], ["cirrhotic human liver", "DISEASE", 89, 110], ["CD31", "GENE_OR_GENE_PRODUCT", 19, 23], ["LSECs", "PATHOLOGICAL_FORMATION", 80, 85], ["human", "ORGANISM", 99, 104], ["liver", "ORGAN", 105, 110], ["CD31", "PROTEIN", 19, 23], ["LSECs", "CELL_TYPE", 80, 85], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["upregulation", "OBSERVATION_MODIFIER", 3, 15], ["CD31 expression", "OBSERVATION", 19, 34], ["LSECs", "OBSERVATION", 80, 85], ["cirrhotic", "OBSERVATION", 89, 98], ["liver", "ANATOMY", 105, 110]]], ["Also, its enhanced expression is detected in LSECs during focal nodular hyperplasia (Scoazec et al., 1995).", [["LSECs", "ANATOMY", 45, 50], ["focal nodular hyperplasia", "ANATOMY", 58, 83], ["LSECs", "CELL", 45, 50], ["nodular hyperplasia", "PATHOLOGICAL_FORMATION", 64, 83], ["LSECs", "CELL_TYPE", 45, 50], ["focal nodular hyperplasia", "PROBLEM", 58, 83], ["enhanced", "OBSERVATION_MODIFIER", 10, 18], ["expression", "OBSERVATION_MODIFIER", 19, 29], ["LSECs", "ANATOMY", 45, 50], ["focal", "OBSERVATION_MODIFIER", 58, 63], ["nodular", "OBSERVATION_MODIFIER", 64, 71], ["hyperplasia", "OBSERVATION", 72, 83]]], ["Likewise, enhanced expression of CD31 has been related to the non-fenestrated and de-differentiated state of LSECs (DeLeve et al., 2006).", [["LSECs", "ANATOMY", 109, 114], ["CD31", "GENE_OR_GENE_PRODUCT", 33, 37], ["LSECs", "CELL", 109, 114], ["CD31", "PROTEIN", 33, 37], ["CD31", "PROBLEM", 33, 37], ["CD31", "OBSERVATION", 33, 37], ["LSECs", "ANATOMY", 109, 114]]], ["Neubauer et al. (2000b) for the first time showed the expression of CD31 on LSECs and found no observable difference in CD31 expression under normal conditions and carbon tetrachloride-induced (CCl4) liver fibrosis.", [["LSECs", "ANATOMY", 76, 81], ["liver", "ANATOMY", 200, 205], ["carbon tetrachloride", "CHEMICAL", 164, 184], ["CCl4", "CHEMICAL", 194, 198], ["fibrosis", "DISEASE", 206, 214], ["carbon tetrachloride", "CHEMICAL", 164, 184], ["CCl4", "CHEMICAL", 194, 198], ["CD31", "GENE_OR_GENE_PRODUCT", 68, 72], ["LSECs", "CELL", 76, 81], ["CD31", "GENE_OR_GENE_PRODUCT", 120, 124], ["carbon tetrachloride", "SIMPLE_CHEMICAL", 164, 184], ["CCl4", "SIMPLE_CHEMICAL", 194, 198], ["liver", "ORGAN", 200, 205], ["CD31", "PROTEIN", 68, 72], ["LSECs", "CELL_TYPE", 76, 81], ["CD31", "PROTEIN", 120, 124], ["carbon tetrachloride", "TEST", 164, 184], ["liver fibrosis", "PROBLEM", 200, 214], ["CD31", "OBSERVATION", 68, 72], ["no observable", "UNCERTAINTY", 92, 105], ["normal conditions", "OBSERVATION", 142, 159], ["CCl4", "ANATOMY", 194, 198], ["liver", "ANATOMY", 200, 205], ["fibrosis", "OBSERVATION", 206, 214]]], ["However, another study by the same authors demonstrated a constitutive expression of CD31 on LSECs, whereas, a decrease of CD31 was observed after CCl4 administration mediated by TNF-\u03b1 in vitro.", [["LSECs", "ANATOMY", 93, 98], ["CCl4", "CHEMICAL", 147, 151], ["CCl4", "CHEMICAL", 147, 151], ["CD31", "GENE_OR_GENE_PRODUCT", 85, 89], ["LSECs", "PATHOLOGICAL_FORMATION", 93, 98], ["CD31", "GENE_OR_GENE_PRODUCT", 123, 127], ["CCl4", "SIMPLE_CHEMICAL", 147, 151], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 179, 184], ["CD31", "PROTEIN", 85, 89], ["LSECs", "CELL_TYPE", 93, 98], ["CD31", "PROTEIN", 123, 127], ["TNF", "PROTEIN", 179, 182], ["another study", "TEST", 9, 22], ["a decrease of CD31", "PROBLEM", 109, 127], ["CCl4 administration", "TREATMENT", 147, 166], ["TNF", "TEST", 179, 182], ["CD31", "OBSERVATION", 85, 89], ["decrease", "OBSERVATION_MODIFIER", 111, 119], ["CD31", "OBSERVATION", 123, 127]]], ["They hypothesized that reduced CD31 expression might aid in more desirable mononuclear cell transmigration (Neubauer et al., 2000a).", [["mononuclear cell", "ANATOMY", 75, 91], ["CD31", "GENE_OR_GENE_PRODUCT", 31, 35], ["mononuclear cell", "CELL", 75, 91], ["CD31", "PROTEIN", 31, 35], ["reduced CD31 expression", "PROBLEM", 23, 46], ["reduced", "OBSERVATION_MODIFIER", 23, 30], ["CD31", "OBSERVATION", 31, 35], ["mononuclear cell transmigration", "OBSERVATION", 75, 106]]], ["Clearly, the on-going debate for the expression of CD31 on LSECs needs to be resolved and it should never be used as a marker for rodent LSEC purification.Perspectives and ConclusionThe past 35 years have proven to be a treasure-trove of discovery of the unique sinusoidal endothelium in liver.", [["LSECs", "ANATOMY", 59, 64], ["sinusoidal endothelium", "ANATOMY", 262, 284], ["liver", "ANATOMY", 288, 293], ["CD31", "GENE_OR_GENE_PRODUCT", 51, 55], ["LSECs", "CANCER", 59, 64], ["sinusoidal endothelium", "TISSUE", 262, 284], ["liver", "ORGAN", 288, 293], ["CD31", "PROTEIN", 51, 55], ["LSECs", "CELL_TYPE", 59, 64], ["CD31 on LSECs", "PROBLEM", 51, 64], ["rodent LSEC purification", "TREATMENT", 130, 154], ["the unique sinusoidal endothelium in liver", "PROBLEM", 251, 293], ["CD31", "OBSERVATION", 51, 55], ["sinusoidal endothelium", "OBSERVATION", 262, 284], ["liver", "ANATOMY", 288, 293]]], ["Advancements in their purification from rats and mice have enabled researchers to assess their physiological and biological role in normal and diseased phenotypes.", [["rats", "ORGANISM", 40, 44], ["mice", "ORGANISM", 49, 53], ["rats", "SPECIES", 40, 44], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["diseased phenotypes", "OBSERVATION", 143, 162]]], ["Starting with the efforts of Seglen (1976) in the early 1970s and culminating to the current date, the procedure of dissociating the liver with collagenase-based enzyme mixtures have been very similar.", [["liver", "ANATOMY", 133, 138], ["liver", "ORGAN", 133, 138], ["collagenase", "GENE_OR_GENE_PRODUCT", 144, 155], ["collagenase", "PROTEIN", 144, 155], ["the procedure", "TREATMENT", 99, 112], ["collagenase-based enzyme mixtures", "TREATMENT", 144, 177], ["liver", "ANATOMY", 133, 138], ["very", "OBSERVATION_MODIFIER", 188, 192], ["similar", "OBSERVATION_MODIFIER", 193, 200]]], ["The final steps in purification have involved differential centrifugation, fluorescent-activated cell sorting, and magnetic-activated cell sorting or a combination of these methods.", [["cell", "ANATOMY", 97, 101], ["cell", "ANATOMY", 134, 138], ["cell", "CELL", 97, 101], ["cell", "CELL", 134, 138], ["differential centrifugation", "TEST", 46, 73], ["activated cell sorting", "TEST", 87, 109], ["these methods", "TREATMENT", 167, 180]]], ["A recent review on these techniques may be found in Meyer et al. (2016).Perspectives and ConclusionThe anatomical shape and position of LSECs make them uniquely optimal for sequestering macromolecular materials from the blood.", [["blood", "ANATOMY", 220, 225], ["LSECs", "SIMPLE_CHEMICAL", 136, 141], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["these techniques", "TEST", 19, 35], ["sequestering macromolecular materials", "PROBLEM", 173, 210], ["the blood", "TEST", 216, 225], ["anatomical shape", "OBSERVATION", 103, 119], ["position", "OBSERVATION_MODIFIER", 124, 132], ["LSECs", "OBSERVATION", 136, 141], ["macromolecular materials", "OBSERVATION", 186, 210], ["blood", "ANATOMY", 220, 225]]], ["In this position, they act as \u201cguardians\u201d of the liver expressing numerous scavenger receptors and constantly monitoring the antigenic profile of the blood.", [["liver", "ANATOMY", 49, 54], ["blood", "ANATOMY", 150, 155], ["liver", "ORGAN", 49, 54], ["blood", "ORGANISM_SUBSTANCE", 150, 155], ["scavenger receptors", "PROTEIN", 75, 94], ["numerous scavenger receptors", "TREATMENT", 66, 94], ["liver", "ANATOMY", 49, 54], ["blood", "ANATOMY", 150, 155]]], ["As the liver is bathed in portal vein blood which drains the GI tract, there are many food and bacterial antigens flowing through in which LSECs play a major role in cleaning up and tempering other immune cells within the liver.", [["liver", "ANATOMY", 7, 12], ["portal vein blood", "ANATOMY", 26, 43], ["GI tract", "ANATOMY", 61, 69], ["LSECs", "ANATOMY", 139, 144], ["immune cells", "ANATOMY", 198, 210], ["liver", "ANATOMY", 222, 227], ["liver", "ORGAN", 7, 12], ["portal vein", "MULTI-TISSUE_STRUCTURE", 26, 37], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["GI tract", "ORGANISM_SUBDIVISION", 61, 69], ["LSECs", "GENE_OR_GENE_PRODUCT", 139, 144], ["immune cells", "CELL", 198, 210], ["liver", "ORGAN", 222, 227], ["LSECs", "CELL_TYPE", 139, 144], ["immune cells", "CELL_TYPE", 198, 210], ["bacterial antigens flowing", "PROBLEM", 95, 121], ["liver", "ANATOMY", 7, 12], ["bathed", "OBSERVATION", 16, 22], ["portal vein", "ANATOMY", 26, 37], ["drains", "OBSERVATION", 50, 56], ["GI tract", "ANATOMY", 61, 69], ["many", "OBSERVATION_MODIFIER", 81, 85], ["food", "OBSERVATION", 86, 90], ["bacterial antigens flowing", "OBSERVATION", 95, 121], ["immune cells", "OBSERVATION", 198, 210], ["liver", "ANATOMY", 222, 227]]], ["Table 1 of this manuscript outlined many of the exogenous and endogenous ligands for all of these receptors.", [["the exogenous and endogenous ligands", "TREATMENT", 44, 80]]], ["Redundancy in binding of multiple ligands shared by several receptors suggest the importance of physiological homeostasis with regards to external material coming into contact with blood and internal tissues.", [["blood", "ANATOMY", 181, 186], ["tissues", "ANATOMY", 200, 207], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["internal tissues", "TISSUE", 191, 207], ["Redundancy in binding of multiple ligands", "PROBLEM", 0, 41], ["physiological homeostasis", "PROBLEM", 96, 121], ["external material", "TREATMENT", 138, 155], ["multiple", "OBSERVATION_MODIFIER", 25, 33], ["ligands", "OBSERVATION", 34, 41], ["internal tissues", "ANATOMY", 191, 207]]], ["What is not known so much is the biochemistry of how these receptors are taking up multiple ligands at the same time or which amino acids/domains are interacting with each ligand.", [["amino acids", "CHEMICAL", 126, 137], ["amino acids", "CHEMICAL", 126, 137], ["amino acids", "AMINO_ACID", 126, 137], ["amino acids/domains", "PROTEIN", 126, 145], ["amino acids/domains", "TREATMENT", 126, 145]]], ["With an understanding of receptor-ligand interactions, pharmacological agents may be made to enhance or block these interactions according to required circumstances in the patient.Author ContributionsEP wrote the manuscript.", [["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 172, 179], ["receptor-ligand interactions", "TREATMENT", 25, 53], ["pharmacological agents", "TREATMENT", 55, 77]]], ["EH edited and organized the manuscript with some brief writing in various sections.", [["sections", "ANATOMY", 74, 82]]]], "PMC7534588": [["Quel est l\u2019impact de la tuberculose sur la mortalit\u00e9 par COVID-19?La m\u00e9ta-analyse de Gao et al. [8], portant seulement sur deux \u00e9tudes chinoises, regroupant 234 patients, ne retrouvait pas d\u2019association significative entre la TB et la mortalit\u00e9 li\u00e9e au COVID-19 (OR = 1,40; IC95 %: 0,10\u201318,93; p= 0,80).", [["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["au COVID", "TEST", 250, 258], ["p", "TEST", 294, 295]]], ["Aux Philippines, Sy et al. [9] ont men\u00e9 la premi\u00e8re \u00e9tude longitudinale (entre le 17 mai 2020 et le 15 juin 2020), chez 530 patients ayant la COVID-19 (valid\u00e9 par un test virologique par RT-PCR positif).", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["ont men\u00e9 la", "TEST", 31, 42], ["chez", "TEST", 115, 119], ["la COVID", "TEST", 139, 147], ["valid\u00e9 par un test virologique par RT", "TREATMENT", 152, 189]]], ["Les auteurs constataient chez les patients ayant une TB active ou des ant\u00e9c\u00e9dents de TB, une augmentation du risque de mortalit\u00e9 li\u00e9e \u00e0 la COVID-19.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["Les auteurs constataient chez les patients ayant une TB active ou des ant\u00e9c\u00e9dents de TB, une augmentation du risque de mortalit\u00e9 li\u00e9e \u00e0 la COVID-19", "SPECIES", 0, 147], ["la COVID", "TEST", 136, 144]]], ["Comparativement aux patients COVID-19 indemnes de TB (actuelle ou ancienne), il \u00e9tait not\u00e9 une association positive entre la pr\u00e9sence d\u2019une TB active ou d\u2019ant\u00e9c\u00e9dents de TB et le risque de d\u00e9c\u00e8s par COVID-19 (RR = 2,17; IC95 %: 1,4\u20133,37; p= 0,001).", [["TB", "DISEASE", 50, 52], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["COVID", "TEST", 29, 34], ["COVID", "TEST", 199, 204], ["RR", "TEST", 209, 211], ["IC95", "TEST", 220, 224], ["p", "TEST", 238, 239]]], ["Le m\u00eame constat \u00e9tait fait dans le sous-groupe des patients COVID-19 hospitalis\u00e9s (RR = 2,25; IC95 %: 1,35\u20133,75; p= 0,002).", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Le m\u00eame constat \u00e9tait fait dans le sous-groupe des patients COVID-19 hospitalis\u00e9s", "SPECIES", 0, 81], ["COVID", "TEST", 60, 65], ["RR", "TEST", 83, 85], ["IC95", "TEST", 94, 98], ["p", "TEST", 113, 114]]], ["Enfin, le d\u00e9lai moyen entre le moment du diagnostic de COVID-19 et le d\u00e9c\u00e8s \u00e9tait plus court chez patients ayant une TB active ou des ant\u00e9c\u00e9dents de TB (p= 0,0031).", [["TB", "DISEASE", 149, 151], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["Enfin", "TEST", 0, 5], ["COVID", "TEST", 55, 60], ["et le d\u00e9c\u00e8s \u00e9tait", "TREATMENT", 64, 81]]], ["Toutefois, dans cette \u00e9tude, le statut s\u00e9rologique pour le VIH n\u2019\u00e9tait pas document\u00e9 et la dur\u00e9e du suivi \u00e9tait courte (1 mois).Quel est la r\u00e9percussion de la COVID-19\u00a0sur la mortalit\u00e9 par tuberculose?Plusieurs \u00e9tudes de mod\u00e9lisation ont permis d\u2019estimer l\u2019impact de la COVID-19 sur la mortalit\u00e9 par TB.", [["TB", "DISEASE", 300, 302], ["Plusieurs", "TEST", 201, 210]]], ["En Inde, Husain et al. [10], se basant sur un rapport de Stop-TB partnership[11] pr\u00e9disent un exc\u00e8s de cas de TB non diagnostiqu\u00e9s et/ou non trait\u00e9s li\u00e9 au risque accru de transmission au sein d\u2019un m\u00eame foyer, avec pour chaque mois de confinement, un exc\u00e8s de 232 665 cas de TB ainsi que de 11 663 cas de TB multi-r\u00e9sistante (MDR-TB) et de 71 290 d\u00e9c\u00e8s par TB.", [["MDR-TB", "DISEASE", 326, 332], ["TB", "DISEASE", 357, 359]]], ["Le travail de Glaziou [12] rapporte que l\u2019OMS a envisag\u00e9 plusieurs degr\u00e9s de diminution de d\u00e9tection des cas de TB (diminution li\u00e9e aux mesures visant \u00e0 limiter la propagation du virus).", [["TB", "DISEASE", 112, 114], ["li\u00e9e aux mesures visant \u00e0 limiter la propagation du virus", "SPECIES", 127, 184], ["Le travail de Glaziou", "TREATMENT", 0, 21], ["a envisag\u00e9 plusieurs degr\u00e9s", "PROBLEM", 46, 73], ["diminution li\u00e9e aux mesures", "TREATMENT", 116, 143]]], ["Si la d\u00e9tection des cas de TB diminuait de 25 % sur une p\u00e9riode de 3 mois, une augmentation de 13 % de la mortalit\u00e9 par TB est pr\u00e9dite (soit 190 000 d\u00e9c\u00e8s suppl\u00e9mentaires, comparativement \u00e0 la p\u00e9riode pr\u00e9c\u00e9dant la COVID-19), avec un nombre total de d\u00e9c\u00e8s par TB en 2020 de 1,66 million (comparable \u00e0 celui de 2015).", [["Si la d\u00e9tection des cas", "TREATMENT", 0, 23], ["une augmentation", "TREATMENT", 75, 91], ["la COVID", "TEST", 211, 219]]], ["Si le taux de d\u00e9tection des cas de TB diminuait de 50 % en 3 mois, le nombre total de d\u00e9c\u00e8s par TB en 2020 atteindrait 1,85 million, c\u2019est \u00e0 dire celui de l\u2019ann\u00e9e 2012.", [["Si le taux de d\u00e9tection des cas", "TREATMENT", 0, 31]]], ["Pour leur part, Hogan et al. [13] ont r\u00e9alis\u00e9 une \u00e9tude de mod\u00e9lisation, avec une projection sur les 5 prochaines ann\u00e9es, pour les pays \u00e0 revenus moyens ou faibles ayant une forte incidence de tuberculose.", [["tuberculose", "CHEMICAL", 193, 204]]], ["Le facteur principal en \u00e9tait le retard du diagnostic et du traitement des nouveaux cas de TB, li\u00e9 \u00e0 la diminution de l\u2019acc\u00e8s aux soins en raison des mesures de lutte contre la COVID-19.", [["Le facteur principal", "PROBLEM", 0, 20], ["et du traitement des", "TREATMENT", 54, 74]]], ["McQuaid et al. [14] ont utilis\u00e9 un mod\u00e8le math\u00e9matique int\u00e9grant diff\u00e9rents param\u00e8tres relatifs au patient et \u00e0 la tuberculose, adapt\u00e9 aux donn\u00e9es \u00e9pid\u00e9miologiques de la Chine, de l\u2019Inde et d\u2019Afrique du Sud afin d\u2019\u00e9valuer l\u2019impact des mesures associ\u00e9es \u00e0 l\u2019\u00e9pid\u00e9mie de COVID-19 (diminution des contacts sociaux d\u2019une part et de l\u2019acc\u00e8s et de la disponibilit\u00e9 des services de soin de la TB d\u2019autre part).", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["ont utilis\u00e9 un mod\u00e8le", "TREATMENT", 20, 41], ["et \u00e0 la tuberculose", "TREATMENT", 107, 126], ["d\u2019\u00e9valuer l\u2019impact des", "TREATMENT", 212, 234]]], ["Ce travail met en \u00e9vidence que chaque effet b\u00e9n\u00e9fique sur la mortalit\u00e9 par TB li\u00e9 \u00e0 la distanciation sociale est largement mis en d\u00e9faut par la diminution de l\u2019acc\u00e8s aux soins et au traitement de la TB.", [["Ce", "CHEMICAL", 0, 2], ["TB", "DISEASE", 199, 201], ["Ce travail", "TREATMENT", 0, 10], ["effet", "TEST", 38, 43], ["li\u00e9", "TEST", 78, 81]]], ["Toutefois, avec le pire sc\u00e9nario correspond \u00e0 une faible diminution des contacts sociaux et \u00e0 une restriction importante de l\u2019acc\u00e8s aux soins, l\u2019augmentation estim\u00e9e du nombre de d\u00e9c\u00e8s par TB entre 2020 et 2024 est alors de 23 516 (Chine), 149 448 (Inde) et 28 631 (Afrique du Sud), soit une augmentation globale de 8 \u00e0 14 % des cas de d\u00e9c\u00e8s par TB pour ces 3 pays au cours de la m\u00eame p\u00e9riode.", [["soit une augmentation globale de", "TREATMENT", 283, 315]]], ["Concernant la Chine, Chen et Zhang [15] sont moins pessimistes par rapport aux pr\u00e9dictions math\u00e9matiques \u00e0 long terme de McQuaid et al. [14] en arguant de l\u2019efficacit\u00e9 des mesures pr\u00e9ventives prises contre la COVID-19 associ\u00e9es \u00e0 l\u2019exp\u00e9rience acquise dans la lutte contre la TB au cours de la pand\u00e9mie.Quel est la r\u00e9percussion de la COVID-19\u00a0sur la mortalit\u00e9 par tuberculose?En conclusion, il est urgent de lutter contre la pand\u00e9mie de COVID-19 mais il convient de mener simultan\u00e9ment le combat contre l\u2019\u00e9pid\u00e9mie de tuberculose.", [["tuberculose", "CHEMICAL", 516, 527], ["en arguant de l\u2019efficacit\u00e9 des mesures", "TREATMENT", 141, 179], ["contre la COVID", "TEST", 199, 214]]], ["Les \u00e9tudes soulignent l\u2019importance d\u2019envisager le d\u00e9pistage et la prise en charge de ses deux infections qui sont causes de mortalit\u00e9, justifiant une commune implication sanitaire.", [["infections", "DISEASE", 94, 104]]], ["L\u2019\u00e9tude pakistanaise de Malik et al. [16] d\u00e9crit une approche innovante bas\u00e9e sur la conception d\u2019un d\u00e9pistage radiologique utilisant un dispositif existant (camion \u00e9quip\u00e9 d\u2019un appareil de radiographie pulmonaire) pilot\u00e9 \u00e0 distance par un syst\u00e8me vocal et utilisant un logiciel d\u2019intelligence artificielle: (AI)-based Infinity software[17] et associant un algorithme capable de d\u00e9tecter de nombreuses anomalies radiographiques pulmonaires en proposant une \u00e9valuation du risque de TB et de pneumonie li\u00e9e \u00e0 la COVID-19.", [["L\u2019\u00e9tude pakistanaise", "TREATMENT", 0, 20], ["d\u00e9crit une approche innovante", "TREATMENT", 42, 71], ["camion \u00e9quip\u00e9 d\u2019un appareil de radiographie pulmonaire", "TREATMENT", 158, 212], ["nombreuses anomalies", "PROBLEM", 390, 410], ["pulmonaires", "TEST", 427, 438], ["la COVID", "TEST", 506, 514]]], ["Au-del\u00e0, de ce progr\u00e8s, la pr\u00e9vention et les soins continus aux personnes, restent les cl\u00e9s du succ\u00e8s contre toutes les pand\u00e9mies autant qu\u2019ils requi\u00e8rent l\u2019implication de chaque professionnel de sant\u00e9 au premier rang desquels se comptent les pneumologues.D\u00e9claration de liens d\u2019int\u00e9r\u00eatsLes auteurs d\u00e9clarent ne pas avoir de liens d\u2019int\u00e9r\u00eats.", [["Au-del\u00e0", "CHEMICAL", 0, 7], ["Au", "CHEMICAL", 0, 2]]]], "PMC7432533": [["We read with great interest the article by Thorarinsdottir et al. [1] that compared biofilm formation on three endotracheal tube (ETT) types with the finding that biofilm formation was reduced in silicone and noble-metal coated ETTs compared to uncoated ETTs.", [["biofilm", "ANATOMY", 84, 91], ["biofilm", "ANATOMY", 163, 170], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 111, 128], ["noble-metal coated ETTs", "SIMPLE_CHEMICAL", 209, 232], ["three endotracheal tube (ETT", "TREATMENT", 105, 133], ["biofilm formation", "PROBLEM", 163, 180], ["silicone and noble-metal coated ETTs", "TREATMENT", 196, 232], ["endotracheal tube", "OBSERVATION", 111, 128], ["biofilm", "OBSERVATION", 163, 170], ["uncoated ETTs", "OBSERVATION", 245, 258]]], ["Their findings have significant implications during the current pandemic given the prolonged intubation times of COVID-19 patients and many develop superimposed pneumonias during their hospital course.", [["pneumonias", "DISEASE", 161, 171], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["the prolonged intubation", "TREATMENT", 79, 103], ["superimposed pneumonias", "PROBLEM", 148, 171], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["superimposed", "OBSERVATION_MODIFIER", 148, 160], ["pneumonias", "OBSERVATION", 161, 171]]], ["It is intriguing that simply changing the ETT\u2019s coating may have significant implications in this patient population with already limited pulmonary reserve that is unable to tolerate additional insults to their lung from a ventilator-associated pneumonia (VAP).", [["pulmonary", "ANATOMY", 138, 147], ["lung", "ANATOMY", 211, 215], ["pneumonia", "DISEASE", 245, 254], ["VAP", "DISEASE", 256, 259], ["patient", "ORGANISM", 98, 105], ["pulmonary", "ORGAN", 138, 147], ["lung", "ORGAN", 211, 215], ["patient", "SPECIES", 98, 105], ["the ETT\u2019s coating", "TREATMENT", 38, 55], ["already limited pulmonary reserve", "PROBLEM", 122, 155], ["a ventilator-associated pneumonia", "PROBLEM", 221, 254], ["VAP", "PROBLEM", 256, 259], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["pulmonary", "ANATOMY", 138, 147], ["reserve", "OBSERVATION", 148, 155], ["lung", "ANATOMY", 211, 215], ["ventilator", "OBSERVATION", 223, 233], ["pneumonia", "OBSERVATION", 245, 254]]], ["However, given the prolonged intubation times of COVID-19 patients, it is likely that the ETT biofilm burden will be substantial no matter which surface coating is utilized.", [["biofilm", "ANATOMY", 94, 101], ["surface", "ANATOMY", 145, 152], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["the ETT biofilm burden", "PROBLEM", 86, 108], ["is likely", "UNCERTAINTY", 71, 80], ["surface", "OBSERVATION_MODIFIER", 145, 152]]], ["Here, we discuss other strategies to reduce the incidence of VAP.", [["VAP", "DISEASE", 61, 64], ["other strategies", "TREATMENT", 17, 33], ["VAP", "PROBLEM", 61, 64], ["VAP", "OBSERVATION", 61, 64]]]], "6988e4ed7471a80fb5d2d4398f77b46acc06ab55": [["Berufs-, Wettbewerbs-und AusbildungsrechtAnonymus: werben verboten.", [["Berufs", "SIMPLE_CHEMICAL", 0, 6], ["werben verboten", "CELL", 51, 66], ["Berufs", "TEST", 0, 6]]], ["\"Botox\" hat auf der Homepage nichts zu suchen.Berufs-, Wettbewerbs-und Ausbildungsrecht\u00c4rztekammer ahndet Verst\u00f6\u00dfe gegen Heilmittelwerbegesetz.", [["Berufs", "SIMPLE_CHEMICAL", 46, 52], ["Botox", "TREATMENT", 1, 6], ["Berufs", "TEST", 46, 52], ["Wettbewerbs", "TEST", 55, 66]]]]}